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Abstract
cAMP is a ubiquitous second messenger that is pivotal in controlling a wide 
array of cellular functions. The sole means to inactivate cAMP is to degrade it into 5’- 
AMP through the action of cyclic nucleotide phosphodiesterases (PDEs). It is now 
well appreciated that cAMP hydrolysis by PDEs is as important as its synthesis by 
adenylyl cyclases to achieve cAMP homeostasis in cells. The cAMP-specific 
phosphodiesterase-4 (PDE4) is encoded by four different genes (PDE4A, PDE4B, 
PDE4C and PDE4D), which generate over 16 different isoforms by alternative 5’ 
mRNA splicing. This process gives rise to PDE4 isoforms with unique N-terminal 
region, complete or truncated UCR1AJCR2 modules, a central catalytic domain and 
an extreme C-terminal region. This plethora o f PDE4 isoforms, complete with distinct 
N-terminal targeting domains and particular regulatory properties, confers 
compartmentalized action on cAMP signaling in various cell types. Understanding the 
distinct molecular mechanisms and functional outcomes of modification and 
sequestration of specific PDE4 isofoims can be expected to aid the development of 
more selective PDE4 inhibitor-based therapeutics.
I have assessed the involvement of PDE4 isoenzymes in the P2 -adrenergic 
receptor (PzAR) desensitization process in Chapter 3. It has been previously shown 
that agonist-activated P2 ARS can recruit PDE4 isoforms in complex with p-arrestins 
and, in particular, PDE4D5 whereupon they undergo a dual desensitization. Using the 
PDE4-selective inhibitor rolipram or siRNA-mediated knockdown of PDE4B and 
PDE4D, I determined a new facet of PDE4-mediated process in the early stage of 
P2 AR desensitization. In HEKB2 cells (stably overexpressing P2 ARS) that have been 
pretreated with either rolipram or with siRNA to PDE4B and PDE4D, PKA 
phosphorylated GRK2 was accelerated in response to treatment with the p-agonist 
isoprenaline, as was isoprenaline-induced membrane translocation of GRK2, 
phosphorylation of the P2 AR by GRK2, membrane translocation of p- 
aiTestins/PDE4D complex and internalization of P2 ARS, in comparison with the cells 
that were only challenged with isoprenaline. In the absence of isoprenaline, rolipram- 
induced inhibition of PDE4 activity in HEKB2 cells also stimulated the 
phosphorylation of GRK2 by PKA, with consequential effects on GRK2 membrane
IV
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recruitment and GRK2 phosphorylation of P2 AR. These results collectively suggest 
that PDE4 plays a fundamental role in influencing P2 AR functioning by gating for the 
ability of PKA to phosphorylate GRK2 in resting cells and thereby regulating the 
degree of feedback thiough this system in stimulated cells. This provides a finely 
tuned adaptive response for preventing inappropriate activation of GRK thi'ough 
fluctuations in the basal levels of cAMP in resting/unstimulated cells.
In Chapter 4 and 5 of this thesis, I analyzed the potential post-translational 
modification on one PDE4 isoform, namely PDE4D5. I have used site-directed 
mutagenesis to show that the ubi qui tin-interacting motif (UIM) can confer the ability 
of PDE4D5 to undergo ubiquitination in response to extracellular stimuli. 
Furthennore, this ubiquitination was shown to be mediated by the E3 ligase Mdm2 
that is brought in close proximity to PDE4D by the associated p-arrestin. My data 
shows that only a small subset of PDE4D5, namely that to which p-anestins bind, is 
susceptible to ubiquitination. Using epitode-tagged ubiquitin mutants that can block 
specific type o f ubiquitin chain formation, I detennined the K48-linked polyubiquitin 
chain as the predominant form in conjugation to PDE4D5. This finding, together with 
the observation that PDE4D5 can interact with two subunits of 19S regulatory 
complex, suggests that ubiquitination can target PDE4D5 to 26S proteasome for 
degradation. Having compared the kinetics of PDE4D5 ubiquitination and its 
association with p-arrestins, I concluded that ubiquitination alters the ability of 
PDE4D5 to bind p-arrestins. I proposed that the time-dependent ubiquitination of 
PDE4D5 may serve to facilitate P2 AR desensitization.
In Chapter 5, I investigated another post-translational modification, namely 
sumoylation, on PDE4D5. From in vitro sumoylation studies it showed that a 
subpopulation of PDE4D5 exists in a sumo-conjugated state. I confirmed this 
modification in vivo, by showing that immunoprecipitated wild type PDE4D5, but not 
a PDE4D5 SUMO K site mutant, could be conjugated with SUMO-1 as tested by 
immunoblotting. Sequential immunoprécipitation analyses showed that the 
established binding partners of PDE4D5, namely P-aiTestin, ERK2, and AKAP18Ô, 
preferentially interact with sumoylated forms of PDE4D5. This was further confirmed 
when comparing the association of these proteins with the wild type PDE4D5 and
SUMO K mutated PDE4D5, respectively, by co-immunoprecipitation. All these data 
indicate that SUMO modification of PDE4D5 serves to enhance its binding to signal 
scaffolding proteins in vivo.
I further investigated protein-protein interactions involving PDE4D5 in 
Chapter 6. Overlay studies were earned out with PDE4D5 peptide aiTay libraries. 
These showed that p-arrestin and SUMO E2 enzyme Ubc9 interact at distinct sites 
within the unique N-terminal region of PDE4D5 and at overlapping sites within the 
conserved PDE4 catalytic domain. Also that ERK2 binds this overlapping site within 
the conserved PDE4 catalytic domain. Screening scanning alanine substitution peptide 
array libraries revealed a common docking site on PDE4D5 catalytic domain for p- 
aiTestin, Ubc9 and ERK2, suggesting that these signaling scaffold proteins might 
interact with PDE4D5 in a mutually exclusive manner and compete to sequester 
distinct ‘pools’ of PDE4D5.
The above studies collectively suggest that sequestration of cAMP specific 
phosphodiesterase PDE4D5 in different signaling complex by distinct signaling 
scaffold proteins ensures the fidelity and efficiency in activating PDE4D5 post- 
translational modification and signaling.
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Chapter 1
General Introduction
î1. General Introduction 
1.1 Cyclic nucleotide signalling pathways
Two types of cyclic nucleotides exist, cyclic adenosine 3’,5’-monophosphate 
(cAMP) and cGMP. The amplitude and duration of cAMP and cGMP signals are 
controlled by their rates of synthesis by adenylyl and guanylyl cyclases, respectively, 
and their degradation by 3’,5’-cyclic nucleotide phosphodiesterases (PDEs). While 
some PDEs hydrolyse only cAMP or cGMP, others hydrolyse both. Major differences 
between phosphodiesterases are observed in substrate affinity, turnover of substrate 
and inliibitor sensitivity.
1.1.1 The cAMP signalling pathway
Cyclic adenosine 3 ’ ,5 ’-monophosphate (cAMP) is one of the oldest 
signalling molecules known (Tasken and Aandahl 2004; Beavo and Brunton 2002; 
Scott et al. 2000). This ubiquitous second messenger of hormone action is produced 
from ATP by adenylyl cyclases at the plasma membrane (Cooper 2003) and is 
degi'aded solely through the action of phosphodiesterases to 5’AMP (Houslay and 
Adams 2003). In cells, cAMP controls metabolism, cytoskeleton function, gene 
expression, muscle contraction and memory (Dumaz N. and Marais R. 2005; Tasken 
and Aandahl 2004; Beavo and Brunton 2002; Scott et al. 2000). It is also involved in 
regulating inflammation (Asiiwathan et al. 2004; Steiner and Branco 2003; Castro et 
al. 2004; Moore and Willoughby 1995). cAMP-dependent protein kinase holoenzyme 
(PKA), cyclic nucleotide gated ion channels (CNGCs) and exchange proteins 
regulated by cAMP (EPACs) are tlu'ee major but different effectors of cAMP and 
mediate distinct cAMP signalling pathways in many cells and tissues (Baillie et al.
2005) (Figure 1.1). Every focal point along each cAMP signalling pathway has the 
potential to be integrated with some other specific signalling proteins, which is 
achieved not only temporally, but also spatially. This leads to a more complexed 
signalling cross-talk than was at first appreciated (Dumaz and Marais 2005; Houslay 
and Baillie 2003; Tasken and Aandahl 2003).
1.1.2 G-proteins and G-protein coupled receptors
1.1.2.1 G-proteins
Heterotrimeric guanine nucleotide-binding proteins (G-proteins) relay a 
variety of signals across the plasma membrane by sequential interaction with their 
cognate receptors and effectors, such as adenylyl cyclases and ion channels (Luttrell 
2006). After the receptors are activated, the exchange of GDP for GTP is catalysed on 
the a  subunit of their cognate G-proteins, leading to the conformational changes in the 
G-protein a  subunits (Hepler and Gilman 1992) and the dissociation of a  subunit 
from its high affinity binding complex of py subunits. These dissociated subunits then 
couple to their individual effectors, initiating the distinct signal transduction 
pathways. Afrer specific cell signals have been initiated, GTP hydrolysis returns G a 
to the GDP-bound state, allowing refonnation of the inactive heterotrimer. To date, 16 
distinct a  subunit genes have been identified in human. This gives rise to isoform 
multiplicity, which may explain the multitude of cAMP-induced physiological 
responses activated by the same stimuli in different cells. Based on the amino acid 
sequence and their functions, G-protein a  subunits can be categorised into four 
classes: Ga, Gi, Gq and G12 (Berman and Gilman 1998), among which cAMP 
signalling is largely regulated by activation of adenylyl cyclase through Gs and 
inhibition through Gi.
1.1.2.2 G-protein coupled receptors (GPCRs)
G-protein coupled receptors (GPCRs) are cell-surface receptors. They have 7 
transmembrane helices, bind effectors at the external surface of the plasma membrane 
and interact with G-proteins at the cytosolic surface (Jacoby et al. 2006). They 
respond to a wide range of extra-cellular stimuli, such as light, odour, 
chemoattractants, peptides, neurotransmitters, lipids, and hormones. They constitute 
one of the largest protein families in the human genome, with at least 600 putative 
members (Pierce et al. 2002; Maudsley et al. 2005). These GPCRs serve to translate 
extracellular messages by increasing or decreasing levels of second messengers, such 
as cAMP or cytosolic Ca^ "*". GPCRs are of gi'eat interest for pharmaceutical industries 
and account for nearly 40% of all cuiTcnt therapeutic targets (Brink et al. 2004).
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1.1.2.3 Beta-adrenergic receptors (pARs)
■
(3-adrenergic receptors (|3ARs) are Gs-coupled receptors, activation of which 
leads to the increase in cAMP production in cells (Rockman et al. 2002). Tliree types
of pARs, Pi, p2 , and psAR have been cloned to date, each of which has its own 
molecular characteristics and functions (Jahns et al. 2006; Johnson 2006; Lamba and 
Abraham 2000; Babol and Blasiak 2005).
et al. 2000). Therefore, manipulation of PAR signalling constitutes a route for 
therapeutic strategies in treating heart failure (Petrofski and Koch 2003).
In addition to the well-studied piAR, vasoactive intestinal peptide receptors 
(Luo X. et al. 1999) and prostacyclin receptors (Lawler et al. 2001) also have the 
ability to undergo Gs/Gi switching after agonist stimuli, providing independent
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Best known are PiAR and P2 AR. PiAR shares a 54% amino acid homology 
with P2 AR (Freedman et al. 2005) and undergoes a similar but not identical 
desensitisation, internalisation, down-regulation and re-sensitization process to the 
P2AR (Rapacciuolo et al. 2003; Gardner et al. 2004; Jockers et al. 1999; Freedman et 
al. 1995; Luttrell and Lefkowitz 2002). The piAR and P2 AR represent the primary 
targets for sympathetically derived catecholamines in the heart and are fundamental to 
the overall regulation of cardiovascular homeostasis (Rockman et al. 2002).
Alterations, for example, desensitisation and down-regulation, in pAR function are 
associated with cardiac hypertrophy and the development o f heart failure (Lefkowitz
i
Although the PiAR and P2 AR have differential effects on cardiac myocyte 
apoptosis, with pi-AR appearing to be pro-apoptotic and P2 AR anti-apoptotic, they 
both undergo Gs/Gi switching upon agonist stimuli in a PKA-dependent manner as 
explained below (Martin et al. 2004; Baillie et al. 2003). Thus P2 ARS localise within 
caveolae in the membrane of cardiac myocytes (Xiang et al. 2002). Following 
stimulation of adenylyl cyclase via Gas, cAMP production results in PKA activation. 
Phosphorylation of the PKA consensus sites within the third intracellular loop 
(Ser261, Ser262) and C-terminal tail (Ser345, Ser346) of the P2 AR causes an 
attenuation of receptor-Gs coupling and facilitates the coupling of receptor to Gi 
proteins, leading to the activation of the MAP kinase pathway. Pertusis toxin, which 
ADP-ribosylates the G ia subunit and prevents receptor-Gia coupling, is generally 
used to inhibit P2 AR switching-mediated MAP kinase activation (Daaka et al. 1997).
evidence for the prevalence of the cell-used strategy in mediating multiple signal 
transduction cascades via the same receptor.
A cell model (HEKB2 cells) that over-expresses FLAG and GFP tagged 
P2 ARS, a prototype of GPCRs, is used in many of the experiments described in this 
thesis. HEKB2 cells provide a well-established model system for studying the P2 AR 
signalling pathway in which cAMP-specific phosphodiesterases 4 (PDE4s) have been 
shown to influence P2 AR functioning, in particular the phosphroyaltion of the P2 AR 
by PKA (Perry et al. 2002).
Various investigators have shown that activation of P2 AR can lead to the 
activation of ERK pathway via two pathways, both of which utilize a common 
upstream pathway to activate PKA in the presence of increased levels of cAMP due to 
the stimulation of adenylyl cyclases by activated P2 AR (Lefkowitz et al. 2002). The 
differences emerge from the downstream of PKA activation. In one pathway, cAMF- 
mediated ERK activation is achieved through PKA activation of B-raf and consequent 
activation of MEK and ERK. The details of this activation are unclear at present. 
There have been competing theories, such as EPAC/Rap 1-mediated B-Raf activation 
and the largely discredited PKA phosphorylation of Rapl, which leads to B-Raf 
activation. Undoubtedly mechanisms differ in various cell types and much more work 
is needed to clarify these mechansiams (Housaly and Kolch 2000). In another 
pathway, the coupling of PKA phosphorylated P2 AR switches from Gs to Gi. This 
leads to a Src-dependent Ras/c-Rafl/MEK/ERK cascade activation (Lefkowitz et al. 
2002).
P2 AR signalling is seen in very many cell-types, including peripheral blood T 
lymphocytes, which are involved in mediating immune responses. In this cell type 
GRK2 activation is achieved through Src-mediated phosphorylation, and is followed 
by phosphorylation of P2 AR by GRK2, p-arrestin binding, as well as a switching from 
Gs to Gi. This mechanism by which GRK2 is activated appears to be different from 
that in HEK293 cells where GRK2 is activated by PKA (Cong et al. 2001; Heijink et 
al. 2005).
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1.1.3 Adenylyl Cyclases (ACs)
A single polypeptide that would both recognize hormone and synthesize 
cAMP was first shown to exist by Sutherland and Rail (Sutherland and Rail 1960), 
and is now known as adenylyl cyclases (ACs). ACs is a critically important family 
that is responsible for the conversion of ATP into cAMP, a ubiquitous intracellular 
second messenger (Antoni 2000). This biological process is used in virtually all types 
of organisms from prokaryotes to eukaryotes (Danchin 1993),
1.1.3.1 Structure of AC
AC is an integral membrane protein composed of an N-terminus, two 
tandemly repeated trans-membrane segments (unlike GC which has only one 
transmembrane domain) connected by a cytoplasmic loop, and another C-terminal 
cytoplasmic loop (Antoni 2000). The N-termini of the two cytoplasmic domains are 
highly conservative and dimerize to form the catalytic site.
1.1.3.2 Diversity and Distribution of ACs
Molecular cloning techniques have identified nine mammalian genes that 
encode membrane-bound ACs, and one gene encoding a soluble isoform (Cooper 
2003). These ten AC isofbrms can be categorized into five distinct families according 
to their primary stmcture similarity and functional attributes (Sunahara and Taussig
2002); ACl, AC3, and ACS, are a class of Ca^^-CaM sensitive forms; AC2, AC4 and 
AC7 are a class of Gpy-stimulatory forms; AC5 and AC6 are a class that shows 
sensitivity to inhibition by both Ca^^ and Gai isofbrms (GaO, G a il, Gai2, Gai3, and 
Gaz); while AC9 is distinguished from the other membrane-bound ACs by its 
insensitivity to the small molecule forskolin; and sAC, a soluble enzyme, is incapable 
of responding to stimuli such as GTP, G proteins, and forskolin.
1.1.3.3 Regulation of ACs
ACs are susceptible to many modes of regulation depending on their specific 
cellular compartment and propensity to associate with scaffolding proteins. Such 
regulation can impart their signalling specificity and discrimination.
1.1.3.3.1 Stimulation by Gas
Adrenaline, dopamine, prostaglandin PGE2, adenosine, and glucagon are a 
few examples of many hormones that activate AC to initiate the generation of cAMP. 
This activation occurs primarily through the receptors coupling to GTP-bound Gas- 
Although there are three splice variants of Gas, only Gas-shoit and Gas-long are able to 
mediate this effect upon hormone stimuli (Klemke et al. 2000).
1.1.3.3.2 Inhibition by Gai
Gai has five isofomis, Gaii, Gai2 , Gais, GaO. and Gaz, Among the ACs that have 
been tested for the inhibition by Gai, AC 1, AC5, AC6, and ACS are inhibited by Gai, 
with selectivity for AC5 and AC6; while AC2, AC3 and AC7 are not (Cooper 2003). 
Gai subunits are subjected to long-chain acyl (myristolyl) and thioacyl (palmitoyl) 
post-translational modification, and its myristoylation has been shown prerequisite for 
Gal-mediated inhibition of AC (Sunahara and Taussig 2002).
1.1.3.3.3 Regulation by Gp^
G-protein Py-subunits also regulate ACs, but in an AC subtype-specific 
manner. In the case of AC2, AC4 and AC7, Gp^-subunits stimulate their activities; as 
for ACl and ACS, Gpy-subunits inliibit their activities (Sunahara and Taussig 2002). 
The effect of Gpy on AC2, AC4 and AC7 is only substantial in the presence of Gas 
(Antoni 2000). Since Gsa is relatively less than Gia and Goa in the plasma membrane, 
it is thought of Gpy from Gi or Go as the co-activator of Gas, conferring a positive 
‘cross talk’ by simultaneous activation of Gs- and Gi-coupled receptors. Less is 
understood about the relationship between Gpy and AC5 and AC6. However, 
Baye witch et al. (Baye witch et al. 1998) have suggested that they exert an indirect 
inhibitory action on AC5 and AC6 through Gpy.
1.1.3.3.4 Regulation by
Ca^^ also has isoform-specific effects on ACs. Ca^'^/CaM activates isoforms 
A Cl, ACS and possibly AC3 (Krupinski et al. 1989; Cali et al. 1994; Choi et al. 1992), 
while AC5 and AC6 are inhibited by a concentration of Ca^  ^ within a physiological 
concentration range (Cooper 2003). Strikingly, Ca^^-sensitive AC isoforms are able
discriminate the source of increased intracellular Ca^^ before regulation can occur. 
For example, ACl and ACS are only sensitive to voltage-gated Ca^^ channels or 
capacitative Ca^ "^  entry (CCE, the entry of Ca^^ that is triggered by depletion of Ca^ '*') 
but not IP3 released Ca^^ (Fagan et al. 2000; Gu and Cooper 2000), while AC5 and 
AC6 are only sensitive to CCE (Cooper 2003). Although it is uncertain if AC9 is 
regulated by Ca^ "^  in systems mainly expressing AC9, cAMP synthesis is inhibited by 
Ca^^ through calcineurin (Antoni 2000).
1.13.3.5 Regulation by other small molecules
The diterpene, forskolin is known to potentially activate all known isofonns 
o f membrane-bound ACs, except for AC9 (Sunahara et al. 1996), while pyrophosphate 
and P-site inhibitor negatively regulate AC activities (Sunahara and Taussig 2002).
1.1,3.3.6 Post-translational modification
ACs can undergo phosphorylation and this can alter their activities (Cooper
2003). For example, PKA directly phosphorylates AC5, resulting in its reduced 
activity; PKC has also been shown to regulate ACs in an isofoim-specific manner. 
This is supported by evidence that phorbol ester treatment can stimulate the activities 
of ACl, AC2, AC3 and ACS, but inhibit that of AC4 and AC6 (Sunahara and Taussig 
2002).
1.1.3.4 Expression pattern and their physiological roles
The physiological importance of ACs has been related to learning and 
memory (ACl and ACS) (Kandel and Schwartz 19S2), drug dependency (AC7) and 
sperm capacitation (Sunahara and Taussig 2002). Generally, AC isofonns have broad 
distribution, however, some isoforms are expressed tissue specifically. For example, 
ACl and AC3 are only expressed in brain (Xia et al. 1992); AC5 is at its highest level 
in striatum and cardiac tissue; AC9 is highly abundant in the brain (Antoni 2000), 
whereas sAC is expressed predominantly in the testis (Sunaharah 1996).
1.1.3.5 Compartmentalisation of ACs
The susceptibility of ACs to multiple modes of regulation raises the problem 
of signalling specificity and confidelity. However, compartmentalisation of the
relevant factors in close proximity helps ensure a particular regulatory context 
(Cooper 2003). GPCRs, the a-subunits of G-proteins, and ACs have been found in 
phospholipid rafts (Huang et al. 1997), and Ca^^-sensitive AC co-localise with and 
respond to capacitative Ca^^ entry CCE (Goraya and Cooper 2004). Similarly, the 
endogenous AC5 and AC6 and P2 AR of cardiac myocytes were suggested to co-abide 
in caveolae (Rybin et al. 2000; Ostrom et al. 2000), to allow orchestration of cAMP 
signalling. In neuronal tissue, ACs are rich in post-synaptic densities (PSDs) and thus 
conveniently interact with other PSDs-related scaffolding proteins to relay specific 
signals (Cooper et al. 1998). In addition to the constraints exerted by co-expression in 
lipid microdomains, scaffolding proteins, such as PKA-anchoring proteins (AKAPs) 
can also achieve an organised compartmentalisation (Baillie et al. 2005).
1.1,4 Effectors of cAMP pathways
1.1.4.1 Protein Kinase A (PKA)
Protein kinase A (PKA) is the most well known cAMP effector. This 
serine/threonine specific protein kinase, is composed of two catalytic subunits (C) and 
two regulatory subunits (R). The R-subunits maintain PKA in an inactive state. 
However, cAMP binding to two sites on each R subunit releases active C subunits and 
the activated PKA can now phosphorylate specific substrates with R/K, R/K, X, S/T, 
Xhydrophobic consensus sequence (Tasken and Aandahl 2003).
Based on the differences within the R subunit, PKA isoenzymes are 
categorized into type I and type II holoenzymes. A further heterogeneity is achieved 
as three isoforms of catalytic subunit (Ca, C|3, Cy) and four (RIa, Rip, R lla, RIip) of 
regulatory subunits are found in mammals (Dumaz and Marias 2005). RI and RII 
subunit have different affinities for cAMP and distinct subcellular localizations: RI 
holoenzymes have a higher affinity for cAMP, and are mainly cytoplasmic; whereas 
RII holoenzymes are typically particulate and confined to cell structures and 
organelles by virtue of anchoring to A-kinase anchoring proteins (AKAPs). NMR 
solution structures of the PKA regulatory subunits delineates the molecular 
mechanism of PKA R subunits binding to AKAP by which an AKAP amphipathic
helix interacts with the hydrophobic groove in the dimerization domain of the PKA R 
subunit (Tasken and Aandahl 2003).
1.1.4.2 cAMP-regulated GEFs (GTP-exchange factors)
The exchange protein directly activated by cAMP (Epacs), is another 
category of cAMP effectors (Tasken and Aandahl 2003). So far, two proteins in this 
family, Epacl and Epac2 have been identified. Epacl and Epac2 share a similar 
organisation structure, with the slight difference that Epacl has one cAMP binding 
site, whereas Epac2 contains two binding moieties (De Rooij et al. 2000), The binding 
of cAMP to Epac via its cAMP binding domain leads to the allosteric activation of its 
GEF domain (Rehmann et al. 2003), therefore promoting its ability to activate Rapl, a 
small Ras-like GTPase (Vossler et al. 1997; Dumaz and Marias 2005; Bos et al. 2003).
In order to discriminate PKA and Epac-mediated effects, a novel synthesized 
analogue, 8pCPT-2’OMe-cAMP is widely used to specifically activate Epac (Bos et 
al. 2003).
1.1.4.3 cAMP-gated membrane ion channels (CNG Ion Channels)
The third set of cAMP effectors is cyclic nucleotide-gated (CNG) cation 
channels. These channels open in response to the direct binding of cAMP/cGMP, 
therefore regulating the membrane potential and intracellular Ca^^ levels (Kaupp and 
Seifert 2002). Retinal rod photoreceptor, which is directly activated by cGMP, an ion 
channel in olfactory transduction, which binds both cAMP and cGMP, as well as the 
most recently reported GatSper that is involved in cAMP-mediated spenn motility, 
comprise cun'ently known CNG ion channels (Fesenko et al. 1985; Nakamura and 
Gold 1987; Ren et al. 2001).
1.1.5 Compartmentalization of cAMP
In the 1980s, a study on cardiomyocytes in which different Gs-coupled 
receptors were found to selectively activate type I and type II PKA holoenzymes, 
brought up a new concept — compartmentalization of cAMP (Buxton and Brunton 
1983). Evidence for the existence of cAMP microdomains has since been obtained in 
cardiac myocytes (Brunton 2003; Zaccolo and Pozzan 2002; Vandecasteele et al. 
2006) as well as other cell types (Cooper 2003; Kaipen and Rich 2001). It is now well
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%recognized that cAMP signalling responses are compartmentalized (Houslay and 
Adams 2003; Baillie and Houslay 2005; Cooper 2005; Cooper and Crossthwaite
2006). Recently, the use of fluorescence resonance energy transfer (FRET), based on 
either PKA or Epac, cAMP-gated ion channels, or the selective activation of AKAP 
anchored PKA isoforms (Baillie and Houslay 2005), consolidated this hypothesis by 
visualising spatial and temporal giadients of cAMP in living cells (Zaccolo and 
Pozzan 2002).
Indeed, the molecular mechanisms behind cAMP compartmentalization are 
far more complex than previously recognised. The components o f the cAMP- 
gencrating pathway (GPCRs, adenylyl cyclases) are localized to specific regions of 
the plasma membrane. PKA, which detects cAMP, and PDEs, which degi’ades cAMP, 
are also targeted to specific regions within the cell. This allows cAMP gradients to 
form within the 3-D matrix of the cell whereby the cAMP concentration is highest 
nearest the membrane and least in areas that contain the highest levels of PDEs. Thus, 
the activation of a certain GPCRs can increase the cAMP levels within discrete 
compartments in the cell and cause unique physiological responses (Hayes et al. 1982). I
In addition to PICA isoenzymes, A-kinase anchoring proteins (AKAPs) are also shown 
to able to assemble signalling complexes to include other proteins such as cAMP 
phosphodiesterases, PKC and protein phosphatases that are targeted to specific 
subcelluar compartments. Thus AKAPs provide scaffolds for the four-dimensional 
organization of cAMP signalling in both space and time (Baillie et al. 2005).
1.2 The 3’5’ cyclic nucleotide phosphodiesterase (PDE) superfamily
Cyclic nucleotide phosphodiesterases (PDEs) are a class of enzymes 
responsible for the hydrolysis of the cyclic nucleotides cAMP and cGMP to 5 AM P 
and 5’GMP, respectively (Figure 1.2). The function of PDEs in cells is to control the 
resting level of cyclic nucleotides, to restore the steady state levels after cAMP or 
cGMP-stimulating events and to form and shape intracellular gradients of these cyclic 
nucleotides. This superfamily of enzymes plays a key regulatory role in the 
orchestration of signalling cross-talk, desensitisation and compartmentalisation of 
cAMP (Houslay and Adams 2003). PDEs were first identified by Sutherland and co­
workers (Rail et al. 1958). An increasing number o f studies have suggested PDEs as
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putative therapeutic targets, with this gaining global recognition upon the 
development of Viagra as a selective PDE5 inhibitor used to originally treat penile 
erectile dysfunction and, more recently, infantile pulmonary hypertension (Kulkarni 
and Patil 2004). To date, a number of PDE inhibitors have been in clinical trials, and 
some have already entered the market place. In particular, the PDE3 selective inhibitor 
cilostazol (Pletal) is widely used as a dmg for the reduction of symptoms of 
intermittent claudication and PDE5 inhibitors sildenafil (Viagra), vardenafil (Levitra) 
and tadalafil (Cialis) are used for the treatment of male erectile dysfunction. Selective 
PDE inhibitors appear to have a potentially broad application in treating various 
diseases, such as asthma, chronic obstructive pulmonary disease, heart failure, 
atherosclerotic peripheral arterial disease and neurological disorders (Tasken and 
Aandahl 2003; Jeon et al. 2005).
PDEs are made up of 11 families based on their amino acid sequence 
identities, substrate specificities, allosteric regulatory characteristics, and 
pharmacological properties (Tasken and Aandahl 2003) (Figure 1.3). 8 PDE families 
generate over 30 different iso forms that are able to hydrolyse cAMP (Houslay and 
Adams 2003). This is due to the multiple genes encoded, as well as additional 
alternative mRNA splicing (Baillie and Houslay 2005). The existence of multiple 
PDE isoforms underscores their individual functional importance. Despite the 
heterogeneity across the superfamily, all PDE isoforms share a modular architecture, 
with a suiprising degree of homology within their catalytic domains (in proximity to 
the COOH tenninus), but with distinct regulatory domains and targeting domains 
invariably located at the NH2 terminus (Francis et al. 2001).
The catalytic domains of PDEs are well conserved, with slight structural 
differences in their catalytic domains determining if the PDE is cAMP-specific 
(PDE4, PDE7, PDE8), cGMP-specific (PDE5, PDE6, PDE9) or has dual substrate 
specificity (PDEl, PDE2, PDE3, PDEIO, PD E ll (Goraya and Cooper 2005). This 
highlights the importance of achieving a precise understanding of the catalytic 
domains of PDEs, which can provide a molecular basis for rational drug design of 
competitive inhibitors. So far, several three-dimensional (3D) stmctures of the 
catalytic domains of PDEs in the presence of their inhibitors or substrates have been
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resolved, and this includes PDEl, PDE2, PDE3, PDE4, PDE5 and PDE9 (Jeon et al. 
2005; Scapin et al. 2004).
Compared to the evolutionarily conservative catalytic domains of PDEs, the 
N-teiminal regions of PDEs are highly divergent in both amino acid sequences and 
their family-specific determinants. These family-specific determinants are: (1) 
calmodulin binding sites (PDEl), (2) non-catalytic cGMP binding (GAP) sites (PDE2, 
PDE5, and PDE6), (3) membrane targeting sites, protein-protein interaction sites and 
regulatory (UCR) sites (PDE4), (4) hydrophobic membrane associate sites (PDE3), 
and (5) phosphorylation sites for either the calmodulin-dependent kinase (PDE2), the 
cAMP-dependent kinase (PDEl, PDE3, and PDE4), or the cGMP dependent-kinase 
(PDE5) (Iffland 2005). Therefore, N-temiinal regions of PDEs provide an important 
platfoim where the multiple PDE isofomis are subjected to specific protein 
interactions and response to distinct regulatory signals. PDES isoforms contain an N- 
temiinal REC and a PAS domain that are not found in other PDEs, however, the 
functions of these REC and PAS domains are not known at present (Bender and 
Beavo 2006).
In line with the tight compartmentalization of cAMP/cGMP (Zaccolo et al.
2002), PDE isofonns have their distinct patterns of regulation and intracellular 
localization, which were obseiwed through either fractionation techniques or 
histoimmunofluorescence teclmiques. PDEs, in most cases, are associated with the 
particulate and/or cytosolic fraction (Houslay 2001), but a few reports have shown 
nuclear localisation. Nuclear localisation has, however, been shown for PDE4 
enzymes, which have been observed on the nuclear envelope (Kapiloff et al. 2001) 
and in perinuclear regions (Verde et al. 2001).
PDE regulation also occurs at the level of transcription and translation (Conti 
et al. 2002). Increases in cAMP levels seem to up-regulate PDEs so that the induction 
of PDEs will combat the augmented cAMP effect and adaptation to clrronic activation 
will be realised. This type of regulation has been seen with PDE3, PDE4 and PDE7 
(Seybold et al. 1998; D ’Sa et al. 2002; Lee et al. 2002), and is likely due to the 
cAMP-response elements as well as other elements involved in transcription found in 
the promoters of these genes (D’Sa et al. 2002; Torras-Llort and Azorin 2003).
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Phamiacological data have shown that the compound vinpocetine is able to 
inhibit all PDEl isoforms, but inhibits PDE 1C with less potency (Chen et al. 1996). 
The inhibitors specific to PDEl are suggested to alter sperm motility and capacitation 
in humans. Recently, Giembycz (2005) advocated the development of dual-specific 
inhibitors of PDEIC and PDE4, the application of which could effectively target 
proliferating aiiivay smooth muscle cells by retarding the remodelling process through 
PDEIC inhibition and aiTesting inflammation by way of PDE4 inhibition.
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1,2.1 The PDEl enzyme family
3%5’-cyclic nucleotide phosphodiesterase 1 (PDEl) was the first PDE to be 
discovered, cloned and characterized (Kakiuchi et al. 1970). PDEl consists of a 
family of enzymes that are Ca^^-calmodulin (Ca^‘^ -CaM)-dependent, and this family 
mediates the cross talk between cAMP and Ca^ "^  signalling. PDE Is are encoded by 
three distinct genes (PDEl A, PDE IB, and PDEIC), with further complexity arising 
from alternative mRNA splicing (Giembycz 2005). Two 5’-splice variants have been 
identified for bovine PDEl A, namely PDEl Al and PDE1A2, with different affinities 
for CaM. In humans, six different PDEl A isoforms (PDEl A 1 through PDE1A6) 
arising from the 5’ or 3’ mRNA splicing were isolated and were validated by both 
RT-PCR and tissue expression (Peter et al. 1999). PDE IB generates two splice 
variants (PDEIBI and PDE1B2). The amino teimini of PDEIBI and PDE1A2 show 
close homology, which might explain the similarity in their CaM binding affinity 
(Mark et al. 2001). Despite the similarity in their N-termini, PDEl A and PDEIB have 
tissue-specific distribution (Mark et al. 2001).
PDEIC has been suggested to be involved in smooth muscle proliferation 
(Rybalkin et al. 2002) which is characteristic of COPD and other airway inflammatory 
diseases (Giembycz 2005). Compared to PDEl A and PDEIB, which preferentially 
hydrolyse cGMP, PDEIC degrades both cAMP and cGMP with high affinity 
(Giembycz 2005). To date, five alternatively spliced products of PDEIC gene have 
been identified in mouse (PDEICI, PDE1C2, PDE1C3, PDE1C4, and PDE1C5). 
These related isoforms showed similar high affinities and V^ax for both cAMP and 
cGMP, although responded to Ca^ "^  stimulation differently (Chen 1996).
1.2.1.1 Structure of PDEl
The overall structure of PDEl isoforms is well conseiwed. PDEl isoforms are 
composed of dual CaM binding domains, called CaMl and CaM2, at the N-termini 
together with an inhibitory domain and a catalytic domain at the C termini (Goraya 
and Cooper 2004). Although the mechanism by which the PDEl inhibitory domain 
maintains basal low activity state is still debatable, it has been suggested that in the 
presence Ca2VCaM creates a large hydrophobic cleft on the surface of each of its 
lobes, which can accommodate the amphipathic a  helices of PDEl and relieve auto­
inhibition.
1.2.1.2 Regulation of PDEl
Like Ca^’^ '-sensitive ACs, PDEl is activated almost exclusively through 
extracellular Ca^^ influx in intact cells (Goraya and Cooper DMF 2004), although this 
may not occur exclusively via CCE channels (capacitative Ca^^ entry). PDEl can 
undergo phosphorylation and this reduces the affinity of PDEl for CaM and its 
sensitivity to Ca^^ (Rajendra 1991), In addition, dephosphorylation by Ca^VCaM- 
dependent protein phosphatase essentially reactivates PDEl. Thus, such regulation 
confers a possible scenario in vivo whereby increased cAMP induced by hormonal 
stimulation temporarily inhibits PDEl (through PKA). This would generate a positive 
feedback loop to evoke a physiological response before Ca^  ^ influx-activated 
Ca^^/CaM-dependent protein phosphatase overrides the inhibition of PDEl by PKA. 
The net effect o f this is to return the high cAMP level back to noimal (Goraya and 
Cooper 2004). This hypothesis has been supported by a study in olfactory receptor 
cells where both AC3 and PDEIC were expressed.
1.2.2 The PDE2 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 2 (PDE2) is encoded by a single 
gene. It is sensitive to both cAMP and cGMP and is able to hydrolyse both (Yang et 
al. 1994). PDE2 is highly expressed in the brain and heart, and is also found in lung, 
kidney, and liver (Rosman et al. 1997).
The family-specific N-terminal domain of the full length PDE2A contains a 
phosphorylation site for calmodulin-dependent kinase, as well as two GAP domains.
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one being responsible for the activation of PDE2 enzymes in response to cGMP, 
another promoting dimerization of PDE2A (Martinez et al. 2002). Full length PDE2A 
hydrolyzes both cAMP and cGMP, with a slightly preference to cGMP under basal 
conditions; however, following the binding of cGMP to the allosteric GAP domain, 
the enzyme undergoes a conformational change that leads to its activation and results 
in a 10-fold lower Km for cAMP (Iffland et al. 2005).
To date, two generations of compounds have been used to specifically inhibit 
PDE2; the first generation PDE2-selective inhibitor EHNA (erythro-9-(2-hydroxy-3- 
nonyl) adenine and the more selective second generation PDE2 inhibitor BAY 31 - 
9472 (Netherton and Maurice 2005). The application of EHNA to cardiac myocytes 
has been shown to increase L-type Ca^ "^  currents (Vandcasteele et al. 2001). Recently, 
Iffland et al. determined the crystal structure of the catalytic domain of human 
PDE2A at 1.7Â and identified the active site residues involved in inhibitor and 
substrate selectivity in PDE2A. This study provides a rational explanation for the 
potent inhibition of PDE2A by EHNA, but not by rolipram, and provides insights into 
the dual substrate specificity of PDE2A enzymes (Iffland et al. 2005).
1.2.3 The PDE3 enzyme family
The 3 %5’-cyclic nucleotide phosphodiesterase 3 (PDE3) family comprises 
two subfamilies, PDE3A and PDE3B, both of which can catalyse the hydrolysis of 
cAMP and cGMP. Although PDE3 binds to both cAMP and cGMP with high 
affinities, the apparent lower Vmax for hydrolyzing cGMP than that for cAMP allows 
cGMP to act as a potent competitive inliibitor of cAMP hydrolysis by PDE3 (Aizawa 
et al. 2003), thus cGMP is considered to inhibit PDE3 (Manganiello et al. 1995).
Three isofonns PDE3A1, PDE3A2, and PDE3A3 are generated from PDE3A 
gene due to the alternative splicing, while only one isoform of the PDE3B gene has 
been identified so far (Movsesian et al. 2002; Wechsler et al. 2002).
1.2.3.1 Structure of PDE3
The structural organization of PDE3A and PDE3B proteins is identical and 
follows the typical pattern of all the PDE family members (Degennan et al. 1997).
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The catalytic domain of PDE3 is flanked by a divergent N-tenninal region and a 
hydrophilic C-teiminal region. Although the amino acid sequence of the N-terminal 
portions of PDE3A and PDE3B are different, both are indicated in the potential 
membrane targeting and regulation by PKA (Leroy et al., 1996). Within the catalytic 
domain of PDE3 is a 44 amino acid insert that has no counterpart in the cognate 
domain of other PDEs, this distinguishes PDE3 from other PDEs and may also 
distinguish the two subfamilies of PDE3 (Degerman et al 1997). It has been 
speculated that the unique insertion within the PDE3 catalytic region may contribute 
part, if not all, to the differences in substrate and inhibitor specificities between PDE3 
and other PDEs (Tang et al. 1997), or even between PDE3 subfamilies. Recently, the 
presentation of a three dimensional structure of the catalytic domain of human PDE3B 
by Scapin et al. (Scapin et al. 2004) provides supportive evidence for this. Although 
the functional role of this unique insert is not fully understood, it has been suggested 
that this PDE3 specific insert region is important to maintain the effective stmcture of 
the catalytic domain of PDE3 enzymes (Tang et al. 1997).
1.2.3.2 Biological importance of PDE3 enzymes
The two PDE3 subfamilies, PDE3A and PDE3B, are highly homologous, but 
they show a tissue-specific expression pattern (Beavo 1995). PDE3A is mainly 
expressed in vascular smooth muscle, platelets, and cardiac muscle, whereas PDE3B 
is predominately identified in adipose and liver. This different distribution thus 
confers their individual effects on different organisms and different cAMP pathways.
Ding et al. (2005) have shown that the expression and activity of PDE3A are 
significantly reduced in human failing hearts and suggested that PDE3A plays a 
unique role in the regulation of cardiomyocyte apoptosis through the proapoptotic 
transcriptional repressor inducible cAMP early repressor (ICER). This action is 
unique to PDE3 family, as the inhibition of only PDE3, but not PDE4 which is also 
largely present in cardiomyocytes, promoted cardiomyocyte apoptosis, indicating that 
PDE3 and PDE4 regulate distinct pool of cAMP in cardiomyocytes. This concept is 
consistent with the previous observation that PDE3 and PDE4 inhibitors elicited 
different cAMP dynamics when real-time imaging of cAMP in situ via fluorescence 
resonance energy transfer was applied in live cardiomyocytes (Mongillo et al. 2004).
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Although PDE3A is the major PDE3 isoform in cardiac muscle and PDE3 inhibitors 
show great effects on cardiac contractility, interestingly, mice lacking PDE3A 
(PDE3A’^‘) are viable with no other obvious deficiencies except that female PDE3A'^‘ 
mice are completely sterile due to cAMP/PKA dependent meiotic aiTest of the oocyte 
(Maurice et al. 2003; Masciarelli et al 2004). This may be explained by the fact that 
depletion of PDE3 A alone may not be sufficient to induce cardiac injury in vivo, and 
additional challenge with chronic pressure overload might be required.
It has long been believed that the major PDE3 isoform in cardiomyocytes is 
PDE3A. However, a recent study suggested that PDE3B is also important in the 
regulation of cardiac function (Patmcco et al. 2004) via the interaction with 
phosphoinositide 3-kinase y (PI3Ky), albeit this direct interaction is not sufficient to 
drive PDE3B activation. PDE3B is indicated as a key agent in the stimulatory action 
of cAMP on pancreatic p-cell exocytosis and insulin release (Hamdahl et al. 2002), 
and the increased activity of PDE3B in p-cells dramatically decreases insulin release. 
PDE3B thus is a candidate for therapeutic inteiwention in type 2 diabetes. It has also 
been reported that PDE3B is involved in lipolysis and metabolic turnover, and 
therefore may provide a target for obesity treatment (Scapin et al. 2004).
A number of commercial PDE3 inliibitors exist, such as cilostamide, 
milrinone and amrinone, all o f which have a pyridazinone core that has been shown to 
be important for selectivity over other PDEs (eg. PDE2, PDE4, and PDE7) 
(Edmondson et al. 2003). However, inhibitors that distinguish between PDE3A and 
PDE3B are limited. So far, MERCK 1 is one such compound that selectively inhibits 
PDE3B. Recently, the crystal structure of human PDE3B was resolved by Scapin et al. 
(2004) and this finding can be expected to aid in the design of future improved PDE3 
selective inhibitors.
1.2.4 The PDE4 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 4 (PDE4) is one of the members of 
the superfamily that specifically hydrolyses cyclic adenosine monophosphate (cAMP). 
Another characteristic of this family is their selective inhibition by the compound, 
rolipram (Houslay et al. 1998). Selective inhibitors of PDE4 foim the largest group of
2004).
vascular tissue and platelets (Kulkarni and Patil, 2004). PDE5 comprises a C-tenninal 
catalytic domain of -250 amino acids that are well conserved between mammalian
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inhibitors for any PDE family and have been studied as anti-inflammatory drugs 
targeting asthma and clironic obstiuctive pulmonary disease (COPD) and also as 
therapeutic agents for rheumatoid artlrritis, multiple sclerosis, type II diabetes, septic 
shock, and atopic dennatitis (Giembycz 2000; Souness et al. 2000; Huang et al. 2001; 
Piaz and Giovannoni 2000; Barnette and Underwood 2000; Sturton and Fitzgerald
2002). The prototypical PDE4 selective inhibitor rolipram has shown to exhibit anti­
depressant and memory-enhancing properties (Scott et al. 1991). The development of 
dual-specific compounds that can inhibit PDE4 and either PDEl, 3, 5 or 7 may be 
desirable because of their potential benefit for the treatment of COPD (Giembycz 
2005). The most advanced compound in clinical trials for the treatment of asthma and 
COPD is Altana’s pumafentriene (roflumilast).
Mammalian PDE4 genes are orthologous for the dunce gene in the fruitfly 
Drosophila melanogaster (Conti et al. 2003), and they encode four subfamilies, called 
PDE4A, PDE4B, PDE4C, and PDE4D. Like Drosophila, mammalian PDE4 genes are 
composed of multiple transcriptional units and multiple promoters. So far, a total of at 
least 20 open reading frames for PDE4 genes have been identified, each of which is 
characterised by a unique N-terminal region (Houslay et al. 1997; Houslay and Adams
2003).
1.2.5 The PDE5 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 5 (PDE5) is one of the members of 
superfamily that specifically cleaves cyclic guanosine monophosphate (cGMP), a key 
intracellular second messenger. In smooth muscle, PDE5 is the most expressed 
cGMP-hydrolysing PDE and plays a pivotal role in NO/cGMP signalling, which 
modulates smooth muscle tone (Corbin and Francis, 1999). Recently, PDE5 has also 
been suggested to play a critical role in tubule function and regulate the cGMP
■jr
signalling that is important for epithelial fluid transport in Drosophila (Broderick et al.
PDE5 is composed of 875 amino acids and was first identified in lungs.
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IPDEs and an N-terminal cGMP-binding domain (GAP) which is also present in PDE2 
and PDE6 (Stacey et al. 1998). To date, only one gene, PDE5A is identified for the 
PDE5 family. This gene generates two alternatively spliced variants, PDE5A1 and 
PDE5A2 (Corbin and Francis, 1999). In large pulmonary arteries, synthesis of 
PDE5A2 protein has been suggested to account for the decreased cGMP levels and 
subsequent decrease in acetylcholine-induced vasodilation under chronic hypoxic 
conditions (Muiray et al. 2002), providing a molecular mechanism by which PDE5 
inhibitors exert their beneficial effects.
PDE5 exists as a dimer, and the N-tenninal region of each monomer contains 
one phosphorylation site (Ser92), two allosteric cGMP binding sites of -110 amino 
acids arranged in tandem, and at least a small portion of the dimérisation domain 
(McAllister-Lucas et al. 1995; Corbin and Francis, 1999). Like the other known 
mammalian PDEs, PDE5 contains two sequences (ELY3 llAr„(E/D)) that resemble the 
Zn^ "*" binding sites in the catalytic domain, which are involved in the catalysis function 
of the enzyiue (Francis et al. 1994). In the catalytic domain, a cGMP-binding 
substrate site is also present. The binding of cGMP at the catalytic site precedes the 
binding of cGMP at the allosteric binding sites and this is required for the specific 
phosphorylation of Ser92 by PKG or PKA which results in the subsequent activation 
of PDE5 (Corbin and Francis, 1999; Bums et al. 1992). This implies a negative 
feedback regulation of cGMP levels in the cells. Recently, it has been identified that 
PDE5 can interact with recombinant PDE6y and this interaction serves to prevent the 
activation of PDE5 by PKA (Lochhead et al. 1997). In addition, caspase-3 has also 
been shown to either directly or indirectly interact with PDE5A1, leading to the 
cleavage and inactivation PDE5A1 via caspase-3 activated proteases, (Frame et al.
2003). Interestingly, rod PDEy was found to interact with PDE5A1 and therefore 
promote this cleavage of PDE5A1 by caspase-3 (Frame et al. 2001).
"7:
Sildenafil (Viagra®), a potent and reversible inhibitor of PDE5 (IC5o~4 nM), 
is highly selective for this PDE when compared with other known PDE families 
(Ballard et al. 1998) and is used as a clinical treatment for male erectile dysfunction.
Recently, other PDE5 inhibitors that are functioning in vascular smooth muscle have 
also been reported they have been shown to amplify the pulmonary vasodilator
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response to inlialed prostacyclin (Schermuly et al. 1999). These include tadalafil 
(Cialis™) and vardenafil (Levitra™) (de Tejada et al. 2001; Eardley and Cartledge,
2002). As PDE5 is also involved in a number of maladies, such as angina, 
hypertension, in addition to erectile dysfunction, new and selective inhibitors are now 
being intensely explored (Kulkarni and Patil, 2004).
1.2.6 The PDE6 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 6 (PDE6) is known as the 
photoreceptor cGMP phosphodiesterase. It is cGMP specific and highly concentrated 
in the internal membrane of the rod and cone photoreceptors of the retina (Cote 2004). 
This family of PDEs has been shown to play important role in vertebrate 
phototransduction by mediating the photoresponse from rhodopsin to cGMP-gated ion 
channels. This results in vision through neuronal activities (Arshavsky et al. 2002). 
Compared to other PDE families, PDE6 is unique in its composition, because it is a 
tetrameric protein, composed of two catalytic subunits and two identical inhibitory y 
subunits. For rod PDE6 enzymes, the two catalytic subunits (a  and (3) form a 
heterodimer, while for retinal PDE6, the two catalytic subunits are identical (two as) 
forming a homodimer (Artemyev et al. 1998). Each catalytic subunit of PDE6 
contains three distinct domains, a catalytic domain and two GAF domains 
(responsible for allosteric cGMP binding) (Cote 2004). The inhibitory subunits of rod 
and cone PDE6 are different in their N-terminal regions (Wan et al. 2001). In 
response to light, GTP-bound G-protein (transducin) binds to the PDEY subunits and 
displaces them, thereby activating the PDE6 catalytic subunits. Recently, it has been 
suggested that rod and cone PDEY are also expressed in lung, kidney, testes, liver, 
heart, airway, pulmonary smooth muscle and even HEK293 cells. Intriguingly, it has 
been shown that PDEY serves as a novel, non-receptor phosphorylation substrate for 
GRK2, allowing it to interact with dynamin II so as to regulate p42/p44 MAPK 
signaling in human embryonic kidney 293 cells (Wan et al. 2001). In addition, PDE6 
is also known as an effector for the Wnt/Ca^'^/cGMP-signalling pathway cmcial in 
development (Wang et al. 2004). This represents another non-visual function of PDE6.
PDE6 resembles PDE5 with a degree of homology in amino-acid sequence as 
well as in three-dimensional structure of the catalytic dimer. Both also have the ability
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to bind cGMP at the regulatory GAP domains. This might explain the observation that 
a number of compounds that inhibit PDE5 also inhibit PDE6 (Cote 2004).
1.2.7 The PDE7 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 7 (PDE7) is a cAMP-specific 
enzyme, insensitive to cGMP and refractory to inhibitors of PDE3 and PDE4 
(Michaeli et a l l 993). This family of enzymes was first isolated at the gene level in 
1993 from a human glioblastoma cDNA library and expressed in a cAMP-deficient 
strain of the yeast Saccharomyces cerevisiae. To date, two PDE7 genes, PDE7A and 
PDE7B, have been identified in humans. Transcription of PDE7À gives rise to tlmee 
isoenzymes (PDE7A1, PDE7A2, and PDE7A3) due to alternative mRNA splicing; 
while PDE7B exists as a single isoenzyme with about 70% sequence similarity to 
PDE7A (Smith et al. 2004). Except for PDE7A2 that has not been detected at protein 
level, PDE7A isofonns and PDE7B have distinct expression patterns, indicating their 
non-overlapping, tissue-specific functions (Gardner et al. 2000). PDE7A1 is 
distributed ubiquitously across human proinfiammatory and immune cells, PDE7A3 is 
mainly expressed in human T-lymphocytes, while PDE7B has a broader distribution 
pattern, and is found in brain, liver, heart, thyroid glands, and skeletal muscles 
(Gardner et al. 2000),
Although the physiological role of PDE7 is not well understood, the 
development of PDE7 inhibitors has progi'essed over the past several years because 
the distribution of PDE7A1 across human proinfiammatory and immune cells miiTors 
the expression pattern of PDE4 and that a PDE7A inhibitor increased anti­
proliferative and cAMP elevating activity of rolipram in T cells without itself 
achieving such effects (Smith et al. 2004). There may be a use for developing a novel 
class of therapeutic inhibitors which can inhibit both PDE7 and PDE4. This may also 
reduce the significant side effect of emesis from PDE4 inhibitor treatment in the 
treatment of a wide variety of immune and inflammatory diseases.
1.2.8. The PDES enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 8 (PDE8) is a class of PDEs which 
has high affinity for cAMP and are IBMX-insensitive (Fisher et al. 1998).Unlike
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classical PDEs such as PDE 1-6, PDE8 was identified using a bioinformatics 
approach. Little detailed studies have, however, been done on PDE8 and our 
understanding of this reeently discovered PDEs function is poor. PDE8 is known to 
have characteristic features that include the PAS (Period, Amt, Sim) domain and REC 
domain, N-teiminal to the PDE catalytic domain. However, the functions of these 
domains regarding PDE8 are not known yet.
In humans, the PDE8 family is encoded by two genes, PDE8A and PDE8B 
(Kobayashi et al. 2003), which are 68% identical in sequence. So far, PDE8A cDNAs 
has been isolated from humans and mice, and PDE8B cDNAs have been isolated from 
humans and rats. Human PDE8A1 is expressed at protein levels in testis, spleen, 
colon, small intestine, ovary, placenta and kidney; while human PDE8B is expressed 
in a unique tissue-restricted pattern, which is confined to the thyi'oid gland. Hayashi et 
al. have shown that recombinant PDE8B is not inhibited by various PDE inhibitors 
including vinpocetine, a PDEl inhibitor; milrinone, a PDE3 inhibitor; rolipram, a 
PDE4 inhibitor, but dipyridamole, at a concentration of 40 pM, inhibited PDE8B by 
50% (Hayashi et al. 1998).
1.2.9 The PDE9 enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 9 (PDE9) is a class of cGMP- 
specific PDEs. It is encoded by a single gene PDE9A in humans and mice (Wang et al.
2003). The transcriptional gene product with alternative N-teiminal splicing gives rise 
to five isoforms, PDE9A1, PDE9A2, PDE9A3, PDE9A4, and PDE9A5 (Guipponi 
1998; Wang et al. 2003). These five splice variants have distinct tissue distribution 
and subcellular localisation pattern, implying their differential cGMP-hydrolysing 
ability within specific cellular compartments in appropriate tissues. Recently, Wang et 
al. (2003) reported that PDE9A is highly expressed in immune tissues and cells, 
indicating a pivotal role for PDE9A in the regulation of immune functions.
Interestingly, as a high affinity cGMP-hydrolysing PDE, PDE9A lacks a 
region homologous to the allosteric cGMP binding domain found in other cGMP- 
binding PDEs, such as PDE2, PDE5 and PDE6 (Fisher et al. 1998).
I'gA'
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PDE9A was shown to be insensitive (up to 100 pM) to a variety of 
commonly used PDE inhibitors including rolipram, vinpocetine, SKF-94120, 
dipyridamole, and IBMX, but was inhibited by zaprinast, which inhibits various 
cGMP PDEs (Fisher et al. 1998).
1.2.10 The PDEIO enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 10 (PDEIO), a dual specificity 
PDE, was identified by a bioinformatics approach (Fujishige et al. 1999). PDEIO can 
hydrolyse both cGMP and cAMP, but has been suggested to function as a cAMP- 
inhibited cGMP PDE (Soderling et al. 1999).
PDEIOA contains two conserved GAF domains at its N-terminus, similar to 
their counterparts in PDE2, PDE5, or PDE6 (Soderling et al. 1999). The 
phosphorylation site of cAMP- or cGMP-dependent kinase in the N-tenninal region of 
PDEIOA is absent but in its place a putative protein kinase C (PfCC) phosphorylation 
site was obseiwed, suggesting that PDEIOA may be regulated by PKC (Fujishige et al.
1999). PDEIOA has a tissue specific expression pattern, and was found particularly 
abundant in the putamen and caudate nucleus regions of brain as well as in thyroid 
and testis. To date, not much is known about the physiological role of PDEIO. 
However, selective inhibitors are actively being sought to treat affective disorders.
Sequence analogy study reveals a high degree of homology in the catalytic 
domain of PDEIOA to that of PDE5A (47%) and PDE2A (42%). This might lead to a 
conclusion that inhibitors of PDE5 or PDE2 can inhibit PDEIO isoenzymes. Indeed, 
only cGMP PDE inliibitors (zaprinast, E4021, SCH51866, and dipyridamole), but not 
PDE2 inhibitor (EHNA) or non-selective PDE inhibitor (IBMX), antagonized 
PDEIOA activity efficiently (Fujishige et al. 1999).
1.2.11 The PD E ll enzyme family
3’,5’-cyclic nucleotide phosphodiesterase 11 (PD Ell) is the most recently 
discovered member of the PDE superfamily. So far, only one gene, PD Ell A, has 
been discovered. In common with various other PDE family gene members, PDEl lA 
encodes four isofonns by virtue of alternative splicing, and these isofoms are named
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PD E ll A l, PDE11A2, PD E ll A3, and PD E ll A4. P D E llA l possess an incomplete 
GAF domain, PDEl 1 A3 has a complete GAF domain and an incomplete GAF domain, 
while PDEl 1 A4 contains two complete GAF domains (Yuasa et al 2000; Fawcett et al.
2000). To date, only two of the isoforms, PD E ll A3 and PD E ll A4 were detected at 
the level of protein. PD E ll A3 transcripts are specifically expressed in the testis, 
while PDEl 1 A4 transcripts are found in human prostate, pituitary, heart and liver, but 
not in blood vessels, cardiac myocytes, skeletal muscle, testis or penis. The 
physiological role of PD E ll A has not been determined, but a PDE5A inliibitor, 
Tadalafil (Cialis®), has been shown to partially inhibit PDEl 1.
1.2.12 PDE and diseases
Mutations in subunits of PDE6 in the retina are the basis of some forms of 
hereditary retinitis pigmentosa and stationary night blindness (Dryja et al. 1999; Gal 
et al. 1994). Differential expression of PDE4 isofoims has been described in lung 
macrophages from patients with COPD, with an increased expression of PDE4A4 
transcripts (Barber et al. 2004). Recently, the PDE4D gene has been identified as the 
most likely candidate susceptibility gene for cardiogenic and carotid ischemic stroke 
(Gretarsdottir et al. 2003). Although the precise pathogenic mechanism of the 
disregulation of PDE4D expression for stroke is still not clear, it is known that 
PDE4D is expressed in many cells that are important for the pathogenesis of 
atherosclerosis, an important risk factor in stroke. More recently, a PDE4B gene 
dismpted by a balanced translocation has been identified in a subject diagnosed with 
schizophrenia and a relative with chronic psychiatric illness. This finding therefore 
provides a primary evidence for PDE4B as a genetic susceptibility factor for 
schizophrenia (Millar et al. 2005).
1.3 Molecular biology and biochemistry of the PDE4 enzyme family
1.3.1 PDE4
PDE4 is encoded by four genes, PDE4A, PDE4B, PDE4C, and PDE4D. 
PDE4A, 4B, 4D are expressed in inflammatory cells such as T cells, B cells, 
eosinophils, neutrophils, airway epithelial cells and endothelial cells (Bumouf and 
Pruniaux 2002). The expression of PDE4C is usually weak in these cases. In HEK293
Functional PDE4s can be categorized into three groups, namely long PDE4 
isoenzymes that exhibit both upstream conserved region 1 and 2 (UCRl and UCR2), 
short PDE4 isoenzymes that lack UCRl but have intact UCR2, and super short PDE4 
isoenzymes that not only lack UCRl, but have a NH2-terminally tmncated UCR2 
(Houslay and Adams 2003). UCRl is adjacent to the N-terminal of long isoenzyme,
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cells, PDE4B and PDE4D are predominantly expressed, while PDE4C was hardly 
detected (Lynch et al. 2005). PDE4 isoforms have been suggested (Houslay et al.
2005) to have non-overlapping functions in the cells, and the understanding of this is 
much accelerated with the advent of gene knockout approaches (Hansen et al. 2000; 
Jin and Conti 2002; Ariga et al. 2004), and cmcially, the development of both 
dominant-negative (Baillie et al. 2003; McCahill et al. 2005) and siRNA-mediated 
knockdown strategies (Lynch et al. 2005). These approaches have helped to discern 
the functional role of individual PDE4 isofoims. siRNA-mediated knock down can be 
used to target either entire PDE4 subfamilies or specific isoforms, dependent on the 
probe design (Lynch et al. 2005), whereas dominant negative strategies exploit the 
targeting of specific isofonns by overexpressing a catalytic inactive forms to displace 
the tethered endogenous active species from the functionally relevant site in the cell 
(Baillie et al. 2003; Baillie and Houslay 2005).
1.3.1.1 Structure of PDE4 isoforms
The 16-18 different PDE4 isoenzymes that are expressed in mammalian cells 
have closely related kinetic properties and ion requirement (Conti et al. 2003). 
Products of any single PDE4 gene all have a common unit, consisting of a highly 
conserved catalytic domain together with a PDE4 subfamily-specific C-terminal 
domain. The signature of each isoenzyme is a unique variant-specific N-terminal 
region (Houslay and Adams 2003). In most cases, the N-terminal region is encoded by 
a single 5’ exon, although two such 5’ exons are present in PDE4C1 (Sullivan et al,
1999). The promoters that drive the generation of these isoenzymes are shown to lie 
immediately upstream of the 5’ exon that encodes their N-terminus (Houslay and 
Adams 2003; Rena et al. 2001; Wallace et al. 2005). The four PDE4 subfamilies, 
PDE4A, PDE4B, PDE4C and PDE4D are each encoded by large genes around 50 kb 
consisting of multiple exons.
1
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while UCR2 is adjacent to the N-teraiinal of the catalytic unit. These two modules are 
joined together through linker region 1 (LRl) and LR2, both of which vary in the four 
PDE4 subfamilies (Figure 1.4).
Uniquely, the PDE4A gene encodes an isoform, PDE4A7 that lacks PDE 
activity. Inspection of the gene sequence has suggested that the molecular basis of this 
phenomenon is due to the mRNA splicing at both the 5’ and 3’ end (Horton et al. 
1995; Johnston et al. 2004).
UCRl and UCR2 function as a regulatory domain that controls the catalytic 
unit, and confers regulatory functions on PDE4 by orchestrating the functional 
outcome of phosphorylation by PKA and ERK (Houslay and Adams 2003). This gives 
a key insight into the existence and importance of alternative mRNA splicing variants 
(Beard et al. 2000; Mackenzie et al. 2000; Sette and Conti 1996). Biochemical pull­
down and two-hybrid analyses show that it is the hydrophobic C-terminal portion of 
UCRl that interacts with the hydrophilic N-terminal region of UCR2 (Beard et al.
2000), and the direct contact of UCR2 with the catalytic unit may exert an inhibitory 
effect on the activity of the PDE4 catalytic unit. This was found in both PDE4D (Lim 
et al. 1999; Jin et al. 1992) and PDE4A5 (Beard et al. 2002). In brief, long PDE4 
isofonns are phosphorylated by PKA at a site present in the N-tenninal of UCRl 
leading to an increase in Vmax of the enzyme. The interaction of UCRl and UCR2 is 
thought to be relevant to the mechanism of enzyme activation by PKA 
phosphorylation. Moreover, PKA phosphorylation also enhances the sensitivity of 
PDE4D3 and PDE4A4 to stimulation by Mg^ "^  (Houslay and Adams 2003).
I
All PDE4 subfamilies, except for PDE4A, contain a single ERK consensus 
motif (Pro-Xaa-Ser-Pro) within their third subdomain of the catalytic unit. This serine 
residue is subject to phosphoiylation by ERK both in vitro and in vivo (MacKenzie et 
al. 2000). Flanking this motif are two ERK docking sites, one of which is a common 
docking site (‘KIM’), utilized by both ERK and JNK, another is specific for ERK, 
called ‘FQF’ motif. More complicated than PKA phosphorylation, ERK 
phosphorylation of PDE4s leads to different activity changes due to the nature of 
PDE4 isoforms as well as the cell type, the nature of the prevailing stimuli and 
temporal window over which analyses are made (Houslay and Adams 2003). In PDE4
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long isoforms, a novel feedback regulatory system exists, where the transient 
inhibition of PDE4 by ERK is rapidly overturned by the subsequent activation of PKA 
(Hoffmann et ah 1999). Interestingly, ERK was shown to mediate PKA activation of 
PDE4D isoforms in aortic smooth-muscle cells through a different pathway involving 
COX2 (Baillie et ah 2001; Liu and Maurice 1999).
1.3.1.2. Presence of signalling complexes involving PDE4s
The plethora of PDE4 isofoims are uniquely characterized by their distinct 
N-terminal region, which can confer intracellular targeting, as well as interaction with 
putative binding partners. Thereby they may form spatially constrained signalling 
complexes that underpin the compartmentalization of cAMP and integiate with other 
signalling pathways. These properties can be seen in the binding of Src family tyrosyl 
kinases to PDE4A4/5 (McPhee et ah 1999) and PDE4D4 (Beard et ah 1999), of 
RACKl to PDE4D5 (Yarwood et ah 1999; Bolger et ah 2002); of (3-aiTestin to 
PDE4D5 (Bolger et ah 2003); of myomegalin to PDE4D3 (Verde et ah 2001); of the 
immunophilin XAP2 to PDE4A5 (Bolger et ah 2003) and of DISCI to PDE4B1 
(Millar et ah 2005).
The ability of PDE4D3 to interact with mAKAP through its unique N- 
terminal region has also been shown (Dodge et ah 2001). This offers a signalling 
complex with potential for controlling a unique negative feedback. Thus, as cAMP 
level rise and mAKAP-associated PKA activated, it will phosphorylate and activate 
PDE4D3, which in turn lowers cAMP levels then facilitates the de-activation of 
mAKAP-bound PKA and the subsequent dephosphorylation of PDE4D3. In cardiac 
myocytes under hypertrophic conditions, the spatial redistribution of PDE4D3, due to 
the dynamic interaction with mAKAP, is thought to contribute partly to the altered 
cellular functioning seen subsequent to heart failure. In addition to mAKAP, another 
AKAP, called AKAP450, has also been shown to interact with PDE4D3, but 
differently as their interaction is earned out through the UCR2 module of PDE4D3 
(Tasken et ah 2001).
Interestingly, the super-short fonn PDE4A1 is entirely membrane-associated 
and its bilayer association is attributable to the novel microdomain, called ‘TAPAS-1 ’
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(tryptophan anchoring PA selective domain 1), which confers gated insertion and 
shows a preferential binding for net -2  charge phosphatidic acid (Baillie et al. 2002).
PDE4 isofonns interact with signalling or scaffolding proteins not only via 
their N-terminal or UCR2 regions, as demonstrated above, but also through the 
catalytic domains with which they provide the substrate domain for ERK (MacKenzie 
et al. 2000) and p-arrestin (Perry et al. 2002). As the catalytic domain in each PDE4 
isofonn is well conserved across PDE4 subfamilies, these interactions are not 
reckoned to be isofomi-specific.
1.3.1.2.1 RACKl
RACKl was originally identified as a scaffolding protein for activated C- 
kinase (Ron et al. 1994), but its role has been expanded tlirough identification of a 
number of novel binding partners (McCahill et al. 2002), ranging from protein kinases 
(Yaka et al. 2002; Ron et al. 1999; Kiely et al. 2002; Chang et al. 2002), the 
phosphodiesterase PDE4D5 (Yarwood et al. 1999) to numerous receptors (Yaka et al. 
2002; Kiely et al. 2002; Geijen et al. 1999; Thornton et al. 2004). This variety of 
RACK-binding partners suggest that RACKl is a multi-purpose protein that is 
involved in various biological functions, such as the regulation of heart contraction by 
noradrenaline (Johnson et al. 1996), glucose-stimulated insulin secretion in pancreatic 
p cells (Yedovitzky et al. 1997), NMDA channel function (Thornton 2004), and 
integration of adhesion and insulin-like growth factor I signalling and cell migration 
(Kiely et al. 2005).
RACKl is a 36-kDa protein that contains seven tryptophan/aspartate (WD) 
repeats that are believed to foim a seven-bladed P-sheet propeller stmcture, confening 
the availability of multiple protein interaction surfaces (Sondek et al. 1996). Recent 
biochemical and stmctural studies have shown that at least two of the WT repeats are 
important for RACKl self-regulation. One is the 4‘^’ repeat which is involved in the 
foiTnation of RACKl-homodimer (Kiely et al. 2005), another is the 6^ '^  WD repeat 
where two highly conserved tyi’osines are phosphorylated by Src kinase (Chang et al.
2002). In addition, WD repeats 5, 6, and 7 have recently been shown to provide a 
bifurcated trough that can accommodate PDE4D5 through its RAIDl (RACKl
29
interaction domain) located within its unique N-terminal region (Steele et al. 2001).
>
Although GPy shares a highly identical sequence homology with RACKl, it does not 
interact with PDE4D5 (Yarwood et al. 1999). The interaction sites on both RACKl 
and PDE4D5 has been extensively explored, however, the functional consequences of 
their interaction are still an enigma. Nevertheless, the most possible role of their
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interaction has been proposed that the recruitment of PDE4D5 to RACKl -containing 
complex controls cAMP levels in the close proximity of this complex and therefore 
regulates the PKA-phosphorylation status of RACKl-associated proteins within the i
same complex (Houslay and Adams 2003).
1,3.1.2.2 p-arrestins
Two visual amestins, p-arrestin 1 and p-arrestin2 comprise a family of 
intracellular proteins that play a vital role in the desensitization of many GPCRs
:(Luttrell and Lefkowitz 2002). Visual aiTestin is 60% and 65% identical in amino acid 
composition to p-anestinl and p-arrestin2 respectively and predominantly localized 
in rod photoreceptor cells of the retina. The P-aiTestins are 78% identical in amino 
acid sequence and widely expressed in tissues, but their expression level varies in a 
cell-specific fashion (Attramadal et al. 1992; Steme-Marr et al. 1993).
In the classic paradigm of receptor desensitization, agonist-occupied and
activated PiAR couples to Gs, leading to the activation of membrane-bound ACs and 
generation of cAMP. This process is rapidly desensitized when G-protein-coupled 
receptor kinases (GRKs) phosphorylate the activated P2 AR, which promotes the 
recruitment of cytosolic p-arrestins to the plasma membrane and thus uncouples the 
further interaction between p%AR and Gs (Luttrell and Lefkowitz 2002). Recent 
studies add a new facet of p-aixestin function to this P%AR desensitization process as 
P-anestin has been shown to form a complex with PDE4 enzymes (Peiry et al. 2002). 
This provides a means of delivering a cAMP-degrading enzyme to the site of cAMP 
synthesis and quenching the existing cAMP at the plasma membrane in an agonist- 
dependent manner (Figure 1.7). Indeed, all PDE4 isoenzymes bind p-arrestin, 
independent o f agonist treatment, tlirough a common site located within their 
conseiwed catalytic domain (Bolger et al. 2003; PeiTy et al. 2002). In addition, 
PDE4D5 preferentially interact with p-arrestin through an extra P-arrestin binding
region located within its unique N-terminal region (Bolger et al, 2003). The functional 
significance of this interaction was clearly demonstrated using an overexpressed 
catalytically inactive PDE4 constmct, which resulted in a selective amplification of 
agonist-induced PKA activation towards P2 AR and the subsequent Src-regulated Gi 
switching which allowed activation of ERK pathway (Baillie et al. 2003).
Following desensitization, GPCRs are removed from the cell surface by a 
process of internalization (also termed endocytosis or sequestration). GRK-mediated 
phosphorylation and p-arrestin binding facilitates many GPCRs internalization. This 
includes P2 AR, angiotensin II type la, m2-m5 muscarinic cholinergic endothelin A, 
D2 dopamine, follitropin, monocyte chemoattractant protein-1, CCR5 and CXCRl 
receptors (Ferguson 2001). More than one mechanism is involved in mediating 
internalization of GPCRs, which are clathrin-coated vesicles, caveolae and uncoated 
vesicles (Claing et al. 2002). The extent of p-arrestin involvement is dependent on the 
receptor, agonist and cell type. In general, many GPCRs interact with p-anestins and 
undergo internalization via clathrin-coated pits. Thus, p-aiTestins both desensitizes 
agonist-activated receptors and promotes their internalization through clathrin-coated 
pits by binding to clatlnin (von Zastrow and Kobilka 1994). In addition, p-arrestin 
links directly to the p2 -subunit of the clathrin-AP2 (adaptor protein 2) complex, a 
complex that targets many receptors to the clathrin endocytic machinery and is 
involved in the initiation of clathiin-coated pit formation (Laporte et al. 2000). 
Therefore, by binding to both clathrin and AP2, p-arrestin facilitates the targeting of 
the activated receptors to the endocytic machinery. Based on the pattern o f p-anestin- 
mediated GPCRs trafficking in the cells, GPCRs are classified into two gi’oups 
(Oakley et al. 2000). Class A receptors include P2 AR, aib-adrenergic receptor, p- 
opiod receptor, endothelin ETIA receptor and dopamine Di receptor, the binding of 
which to P-arrestin is transient during internalization. On the other hand, Class B 
receptors, represented by the angiotensin ATia, neurotensin 1, vasopressin 2, 
thyrotropin-releasing honnone and neurokinin NK-1 receptors, form stable complexes 
with p-arrestin and traffic together during endocytosis. Recently, Lefkowitz et al. 
have reasoned that these distinct intracellular trafficking patterns of the two classes of 
receptors may be due to the different kinetics of p-arrestin ubiquitination and de- 
ubiquitination (Lefkowitz and Whalen 2004).
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Research on arresting has rapidly expanded over the past few years. There 
has been very considerable interest in how it links to the activation of ERK. This rose 
from demonstrations that the Src family non-receptor tyrosine kinase was shown to 
bind p-amestin (Luttrellet al. 1999). Recently, the components of MAP kinases 
including ERKs, JNKs, and p38 (Marinissen and Gutkind 2001), the downstream 
elements of highly conserved cascades of MAPKKKs and MAPKKs that lead to the 
activation of the MAP kinases (Reiter and Lefkowitz 2006), have all been found to 
bind to p-aiTestins. Due to the heterogeneity and diversity of kinases of each level of 
the MAPK cascades (for example, there are five ERKs, four p38 and three JNKs), p- 
an'estins have been suggested to function as scaffolding molecules to ensure fidelity 
and efficiency in activating specific MAPK molecules.
Furthermore, p-arresting have also been shown to be involved in cell motility, 
chemotaxis and apoptosis (Lefowitz and Shenoy 2005), which require p-aiTCstin- 
dependent activation of ERK or p38 MAPK (Wei et al. 2003; Azzi et al. 2003; Sun et 
al. 2002).
1.3.1.2.3 AKAPs
AKAPs are a large family of stmcturally umelated proteins that bind to PKA 
(Michel and Scott 2002). This interaction is earned out through the amphipathic helix 
from the AKAP and the hydrophobic pocket formed at the dimerization interface of 
the RII regulatory (cAMP binding) subunit of PKA. Functioning as other scaffolding 
proteins, AKAPs constrain PKA pools at different subcellular localizations, therefore 
conferring the compartmentalized response on PICA substrates that are either within 
the same complex or in their close proximity. Recently, a number o f studies on 
AKAPs have broadened the list of the identification of AKAP-associated proteins. 
This includes other kinases (eg. PKC) (Klauck et al. 1996), phosphodiesterases 
(Houslay and Adams 2003), phosphatases (Smith et al. 2006), GPCRs (Malbon et al.
2004) and G proteins (Diviani et al. 2006).
One of the properties of AKAPs is to target signaling intermediates to a 
specific microenvironment where they can respond to upstream signals. This has been 
demonstrated extensively for PDE4D3 and mAKAP (muscle-selective AKAP).
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mAKAP uses a site distinct from its PKA-R subunit interaction site to bind to the 
unique N-tenuinal region of PDE4D3 and faeilitates the phosphorylation and 
activation of PDE4D3 by localized PKA (Houslay and Adams 2003). This provides a 
unique negative feedback loop. Indeed, when cMAP levels rise and mAKAP-PKA is 
activated, PDE4D3 that is located in the same signaling complex is consequently 
activated by the phosphorylation by PKA. This activation thus amplifies the ability of 
PDE4D3 to degrade cAMP, hence decreasing the activity of mAKAP-bound PKA. As 
such, the system resets itself to the basal condition (McConnachie 2006). The 
PDE4D3-mAKAP-PKA module in a spacially localized self-regulatory system has 
been suggested to have clinical importance in the altered cellular function seen after 
heart failure (Dodge et al. 2001).
AKAP450 has the same complex of PDE4D and PKA RII (Tasken et al.
2001) in Sertoli cells of the testis, located in the centrosome. The interaction site on 
PDE4D for AKAP450 was mapped to its UCR2, indicating that other long PDE4 
isoenzymes may also bind to AKAP450 (Tasken et al. 2001). Additional components 
of this signaling complex, such as PPl and PP2A have also been suggested as 
AKAP450 can bind to these phosphatases (Westphal et al. 1999).
Recently, it has been suggested that PDE4D3 is in complex with the Ca^^ 
channel RyR, PICA, mAKAP and PPl in cardiomyocytes (Marx et al. 2000; Kapiloff 
et al. 2001).
In addition, AKAP79, which constitutively anchors PKA to the P2 AR, and 
gravin that binds the P2 AR in an agonist-dependent manner, are both involved in an 
exquisite orchestration of spatial and temporal downstream signaling (Tao et al. 2003; 
Cong et al. 2001).
In Jurkat T cells, another PDE isofonu PDE7A which is has been identified 
to be associated with AKAP 149 at the nuclear membrane, with AKAP95 in the 
nucleus and with novel Golgi associated AKAPs derived from the myeloid 
translocation gene (MTG) (Asirvatham et al. 2004). This new evidence of functional
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PDE-AKAP complexes present in real cells underpins the importance of such 
complexes in tightly controlling compartmentalized cAMP signaling.
1.3.1.3 Inhibitors
Selective inhibitors of PDE4 form the largest group of inhibitors for any PDE 
family, and have been studied as potential therapeutic reagents for many diseases (see 
review: Lipworth 2005). Rolipram, a highly selective first generation of PDE4 
inhibitor, has been used for many years as a research tool to chemically ablate PDE4 
activity and investigate the role of PDE4. Recently, Sanz et al. (2005) have reviewed 
the anti-inflammatory and anti-immunomodulatory effects of rolipram. It is now 
generally accepted that PDE4 has at least two confoitnations, HARBS and LARBS, 
for which rolipram has high and low binding affinities, respectively (Houslay and 
Adams 2003). While PDE4L is associated with anti-inflammatory activity, HARBS, 
which is generally expressed in the central nervous system, has been linked to the 
high levels of adverse effects, such as nausea and vomiting triggered by rolipram 
treatment (Chung 2006). This limitation by class-associated side effects thus calls for 
a need for a PDE4 inhibitor with a wide therapeutic ratio.
New second generation PDE4 inhibitors have now been developed with the 
hope of providing a wider therapeutic ratio, particularly with respect of overcoming 
nausea and vomiting (Burnouf and Pruniaux 2002). These inhibitors include 
cilomilast, roflumilast, arofylline, C-3885 etc. However, cun^ently, among these 
inhibitors, only two of them, cilomilast and roflumilast, have reached phase III 
clinical trial stage (Chung 2006; Lipworth 2005).
In addition, PDE4 inhibitors have been investigated in the mediation of 
memory (Zhang et al. 2005) and infection-induced preterm labour (Oger et al. 2004).
Selective inhibitors of PDE4 sub-families may represent a favourable 
pharmacological strategy for the treatment of TNF-a mediated diseases such as 
rheumatoid arthritis, Crohn’s disease and septic shock. PDE4D-specific inhibitors are 
used in the treatment of airway diseases associated with smooth muscle contraction, 
such as asthma and chronic obstmctive pulmonary disease (Mehats et al. 2003); while
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targeting of PDE4B gene revealed an essential role of this isoform in the innate 
immune response mediated by TNF-a.
Recently, it has been suggested that nausea and emesis, the most common 
side effect of PDE4 inhibitors, may be caused by the inhibition of PDE4D in the brain 
(Robichaud et al. 2002). However, this has yet to be proven. In addition, an increasing 
amount of evidence has indicated the non-redundant functions between PDE4 
isoforms. Thus design of inhibitors selective for specific PDE4 subtypes is strongly 
desired. Undoubtedly, the understanding of these PDE4 subtypes at the atomic level, 
would greatly facilitate the design of PDE4 isoenzyme-specific inhibitors with 
reduced side effects and improved therapeutic use in a varieties of diseases. To date, 
several papers have elucidated the isoenzyme stmcture of PDE4 family members, 
including PDE4B (Xu et al. 2000) and PDE4D (Huai et al. 2003; Lee et al. 2002). 
These structures reveal that the selective binding of rolipram to PDE4s, shows a 
conserved variation of inhibitor binding residues across the PDE families, suggesting 
that the inhibitor specificity is determined by the chemical nature of amino acids and 
the conformational variation of the binding pockets (Houslay and Adams 2003; Card 
et al. 2004; Huai et al. 2003). Zhang et al. (2004) have described the mechanism of 
nucleotide selectivity based on the co-crystal structure of PDE4B and PDE4D with 
AMP, PDE5A with GMP, and the apostmcture of PDEIB. In their study, an invariant 
glutamine has been suggested as the key specificity determinant for recognizing the 
purine moiety in cAMP or cGMP, and the surrounding residues contribute to 
anchoring the glutamine in different orientations for cAMP and for cGMP. In addition, 
the crystal stmcture of the human PDB4D2 catalytic domain in complex with AMP 
was obtained independently by another group, and it has been suggested that a 
hydroxide ion or water bridging two metal ions may serve as the nucleophile for the 
hydrolysis of the cAMP phosphodiester bond (Huai et al. 2003). This stmctural 
information on PDE4 in complex with AMP/GMP sheds liglit on the hydrolysis action 
of PDE4, provides insight into how more specific PDE4 inhibitors can be rationally 
designed (Zhang et al. 2004).
1.3.1.4 Compartmentalization of cAMP and FDE4 enzymes
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The pioneering work of Bmnton and colleagues (Brunton et al. 1998) has led 
to recognition of the paradigm for cAMP signalling compartmentalization. They 
showed that in cardiac myocytes, various Gs-coupled receptors caused different 
physiological outputs via the compartmentalized changes in cAMP and the 
subsequent selective activation of ‘pools’ of PKA. In some instances, PKA and PDE 
have been shown to be part of the same scaffold signalling complex where a negative 
feedback loop can be rapidly activated (Tasken et al. 2001; Dodge et al. 2001). The 
recruitment of PDE4 to activated receptors, as seen in cardiac myocytes and T cells 
(Bolger et al. 2003; Arp et al 2003), contributes to the degiudation of cAMP near the 
site of synthesis. This delimits the spatial-temporal wave of cAMP propagation in 
combination with intracellular moleeular and physical barriers to diffusion.
The advances in development of visualisation techniques using FRET 
probes, based on either PKA or EPAC, cAMP gated ion channels, or the selective 
activation of AKAP-anchored PKA isoforms, have helped overcome the difficulties in 
visualizing compartmentalized cAMP (Zaccolo and Pozzan 2002; Zhang et al. 2001; 
Bos 2003; Nikolaev 2004).
Adenylyl cyclases and PDEs are pivotal in shaping and controlling 
intracellular cAMP giadients in cells (Baillie and Houslay 2005; Houslay and Adams
2003). ACs are located at the plasma membrane, and activation of AC sub­
populations found in distinct plasma membrane sub-domains by specific Gs-coupled 
receptors is suggested to generate spatially segregated ‘clouds’ of cAMP fi'om 
different plasma membrane locales. However, the plethora of PDE4 isoforais, 
together with their individual defined intracellular micro-enviromnents and particular 
regulatory properties, make them predominant players in compartmentalizing cAMP 
and regulating inputs from other signalling pathways (Baillie et al. 2005) (Figure 1.6). 
Indeed, selective chemical knockout of PDE4 activity, coupled with the use of 
dominant negative PDE4 constructs, has identified this family of isoenzymes as a key 
contribute in modulation of isoprenaline-stimulated gradients of cAMP in cardiac 
myocytes and cultured cells (Rochais et al. 2004; Mongillo et al. 2004; Lynch et al.
2005). That PDE4s can associate with other proteins, allowing them to be strategically 
anchored throughout the cells (Houslay and Adams 2003) further confii*ms their role 
in shaping the cAMP gradients. Furthermore, as the importance of PDE4 in
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engineering compartmentalised cAMP gradients is recognised in a number of papers, 
the use of selective PDE4 inhibitors as drugs to combat a number of human diseases 
looks likely (Baillie et al. 2003; Lynch et al. 2005; McCahill et al. 2005; Abrahamsen 
et al. 2004).
More recently, Karpen and coworkers have shown that a pool of cAMP 
below the plasma membrane does not equilibrate rapidly within the bulk of the 
cytoplasm, and more importantly, that PDE4 activity is crucial for this 
‘ micro domain ’ - concentrated cAMP regulation. Thus, PDE4 regulation is likely to be 
involved in controlling cAMP access to its effectors close to the plasma membrane 
(Rieh et al. 2001). A similar cAMP microdomain modulated by PDE4 has also been 
demonstrated in cardiac myocytes where cAMP accumulation in response to p- 
adrenergic agonists occurs preferentially in a region covering the Z band and the T- 
tubules (Zaccolo and Pozzan 2002). This is consistent with the observation that 
myomegalin serves to anchor long isoforms of PDE4 close to the Z band in proximity 
to the L-type channels, RyR and PKA (Marx et al. 2000;Verde et al. 2001).
1.3.1.5 Short-term regulation of PDE4s
Post-translational modification often governs short-term regulation of 
proteins. Responses to many extracellular and intracellular stimuli often elicit post- 
translational modification on a variety of cellular proteins, which in turn further 
propagates the signal downstream. This can be achieved via the activation of several 
signalling pathways, alterations in subcellular localization, and the formation of 
physical protein-protein interactions (Jesen 2004). So far, almost every cellular 
pathway discovered uses post-translational protein modifications to generate and 
transmit signals in respond to gi'owth signals, stresses and chemical stimuli (Johnson
2004). Until recently, only large molecule moieties that covalently attach to cellular 
proteins had been studied extensively. Such modifications, triggered by cellular 
responses involved phosphates, various lipids, acetate or sugars (Muller et al. 2001). 
Among those modifications, protein phosphorylation is best understood (Hunter 1995). 
All PDE4 isofonns from four subfamilies (apart from PDE4A) can be phosphorylated 
by ERK and all long isoforms are shown to be suseeptible to PKA phosphorylation 
(Baillie et al. 2000; Houslay and Adams 2003). The outcome of a specific
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phosphorylation event varies dependent on the category of the PDE4 isoform, as well 
as the identity of the protein kinase. Much is known about the functional 
consequences of activity regulation of PDE4s resulting from phosphorylation post- 
translational modifications.
In the past two decades, ubiquitination and sumoylation have been identified 
as novel and important post-translational modifications that contribute to the altered 
functioning of the modified proteins. Sequence analysis of PDE4 genes during my 
PhD studies has revealed that some specific PDE4 gene products may have the 
potential to undergo ubiquitination and sumoylation. These two post-translational 
modifications and their characteristics are further discussed with respect to PDE4 in 
Chapters 4 and 5.
1.3.1.5.1 Phosphorylation
Recently, PDE4 has been identified as a key modulator of integrin-induced 
actin assembly at the cell periphery, which, in turn, controls cell migration and this 
effect is PKA dependent (Fleming et al, 2004).
The activity of the PDE4 isoenzymes can be regulated by phosphorylation at 
certain key sites and the mode of this regulation has been shown to be rapid and 
transient. The best example comes fiom the studies on the PDE4D3 isoform. PDE4D3 
is a long PDE4 isoform, which contains a conserved single serine residue Ser54 at the 
N-teiminal of UCRl within the PKA consensus motif, RRESF. In mammals, such 
phosphorylation increases PDE4D3 activity (Sette and Conti 1996), This was 
confirmed by the observation that replacement of Ser54 with an aspartate residue, 
which mimicked the phosphorylation at this site, led to a 3~fold increase in enzymatic 
activity (Hoffinann et al. 1998). It has been suggested that this phosphorylation results 
in a conformational change in the catalytic domain, therefore increasing the PDE4D3 
affinity towards rolipram. Recently, the frmction of another PDE4D3 serine (Seri 3) 
phosphorylation was revealed. This phosphorylation modification promoted the 
binding of PDE4D3 to mAKAP (Carlisle Michel et al. 2004), which can provide part 
of the cellular desensitization mechanism of cAMP signalling.
:
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In addition to being phosphorylated by PKA in its N-terminal and UCRl 
region, PDE4D3 is able to undergo phosphorylation by ERK2 at its COOH-terminal
Adams 2003).
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end of the catalytic domain (Figure 1.5) (Hoffinann et al, 1999). Activation of ERK 
pathway by epidennal growth factor (EOF) in COS-1 or HEK293 cells resulted in a 
rapid (within 5 min) drop in the activity of recombinant PDE4D3, and this inhibition
i-ii.was indicated as the result of being phosphorylated by ERK2 at its Ser579. However, 
over 20 minutes this inhibitory effect on PDE4D3 was reversed due to the feedback 
action of PKA that activated PDE4D3 by phosphorylating its Ser54. Therefore,
PDE4D3 provides a perfect point of crosstalk between the ERK pathway and cAMP 
pathway.
As the UCRl single serine Ser54 in PDE4D3 is found in all long PDE4 
iso forms, it confers the ability of these enzymes to be phosphorylated by PKA 
(Houslay and Adams 2003). Indeed, long PDE4 isofonns from all four sub-families 
(PDE4A8, PDE4B1, PDE4C and PDE4D3/5) have been shown to be phosphorylated 
at a single serine residue in UCRl by PKA in COS! cells (MacKenzie et al. 2002) and 
this seiwes to increase their activity, modulate Rolipram affinity, Mg^ "^  sensitivity and 
the re-progi'amming of the functional output of ERK phosphorylation (Houslay and
7-
Interestingly, the ERK2 phosphoiylation site (Pro-Xaa-Ser-Pro) at the third 
subdomain of the catalytic unit is present in all PDE4D, PDE4B and PDE4C isoforms, 
to confer these isofonns the ability to be phosphorylated by ERK2. The exception to 
this is PDE4A that contains a slightly different sequence (RXSP), and fails to provide 
a substrate for ERK2 (Hoffinann et al. 1999). Indeed, PDE4A5 can in fact be 
phosphorylated after gmwth hormone treatment through a process that lies 
downstream of both PI-3 kinase and p70S6 kinase (MacKenzie et al. 1998). 
Interestingly, ERK2 phosphorylation has profoundly different functioning outcomes 
for the three different categories of PDE4 isoenzymes. For example, phosphorylation 
of long PDE4 isofonns that contain both UCRl and UCR2 by ERK2 leads to the 
catalytic inhibition, and such inliibition causes a localized increase in cAMP levels. In 
contrast, short PDE4 isofonns such as PDE4D1 that lacks UCRl but contains an 
intact UCR2 are stimulated by ERK2 phosphorylation. Furthermore, super short 
PDE4 isofonns, represented by PDE4D2 that lack all the UCRl and the first 32 amino
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acids of UCR2, are inhibited by ERIC2 phosphorylation, but to a lesser extent than 
that seen with PDE4 long isoforms (MacKenzie et al. 2000; Houslay and Adams
2003). All these suggest an intrinsic inhibitory role of UCR2 in regulatingPDE4 
activity (Figure 1.5).
1,3.1.5.2 Ubiquitination
Ubiquitin (Ub) is a 76-amino acid protein which is highly conserved in all 
eukaryotes and present in most organisms studied (Hatakeyama and Nakayama 2003). 
It is a very stable protein and recalcitrant to high temperature and acid or alkaline 
exposure. Ubiquitin is synthesised as a precursor protein, the C-terminal of which 
needs to be processed by specific proteases to expose a double glycine end. The 
covalent attachment of Ub molecule to a substrate protein is called ubiquitination. 
Ubiquitination is a chemieally complex process that forms an isopeptide bond 
between the COOH-terminal glycine of Ub and 8-amino gioup of a lysine residue in 
the substrate (Di Fiore et al. 2003). Ub, as its name suggests, is ubiquitously 
expressed and regulates a number o f fundamental cellular processes, including 
metabolic homeostasis, protein quality control, transcription, translation, signal 
transduction, response to hypoxia, cell cycle progression, DNA repair, protein 
trafficking, chromatin remodelling, viral budding and immune responses (Van 
Demark and Hill 2002; Passmore and Barford 2004).
Protein ubiquitination involves a sequential action of three enzyme families, 
El activating enzyme, E2 conjugating enzyme, and E3 ubiquitin ligase (Di Fiore et al. 
2003; Hershko and Ciechanover 1998). This enzymatic reaction starts from the 
activation of ubiquitin by El in an ATP-dependent manner: the El adenylates the C- 
terminal glycine of Ub and then forms a thioester bond between the ubiquitin C- 
terminus and a catalytic El cysteine residue. The thioester-linked ubiquitin is then 
transferred from El to a similar cysteine residue in the active site of an E2, where it 
again forms a thioester bond. With the direct or indirect help of an E3, the transfer of 
ubiquitin is promoted from a thioester linkage within the E2 to an amide linkage 
within a substrate. Substrate specificity in the ubiquitination pathway is mostly 
contributed by E3s as E3s are able to recognize and bind to specific substrate 
sequences directly (Hershko and Ciechanover 1998; Pickart 2001; Cilckman and
i
Ciechanover 2002). A combination of E2 and E3 deteimines the synthesis of a 
specific topology of the ubiquitin chain (Passmore and Barford 2004).
Based on the primary structure and enzymatic mechanism, E3s are 
categorised into two gi'oups: HECT (homology to E6-AP carboxyl tenninus) domain 
E3s and RING (really interesting new gene) domain E3s. HECT E3 uses their HECT 
domain to bind Ub-conjugated E2, and accept this ubiquitin moiety from Ub-E2 
complex to foim a covalent E3-Ub thioester intermediate before Ub is transferred to 
the substrate (Scheffner et al. 1995). Many HECT E3s, but not E6-AP, share the 
feature of having the WW domain and an amino-terminal C2 domain that frmction as 
protein protein interaction motif (Wang et al. 1999; Kanelis et al. 2001). Distinct from 
HECT E3s, RING E3s do not function as a catalyst, but rather work as a molecular 
scaffold to bring ubiquitin-conjugated E2 and substrate in close proximity (Passmore 
and Barford 2004), without foiming a Ub-E3 thioester inteimediate (Joazeiro and 
Weissman 2000).
The large number of RING E3s are further divided into single subunit E3s 
where the RING domain and the substrate recognition elements are on the same 
polypeptide and multisubunit E3s where the RING finger domain is organized to foiin 
a complex with other subunits on a member of cullin family based scaffold 
(VanDemark and Hill 2002; Weissman 2001). The single subunit E3s include the 
oncoprotein Mdm2 (Fang et al. 2000; Shenoy et al. 2001; Lin et al. 2002), 
protooncoprotein c-Cbl (Watemian et al. 1999), the inhibitors of apoptosis (lAPs) 
(Yang et al. 2000) and Parkin (Tanaka et al. 2004). RING finger E3 complex is found 
in SCF E3s, APC/cyclosome and VCB-CUL2 E3s (Weissman 2001). In SCF E3s, the 
F box protein executes the substrate protein recognition by recognizing those 
substrates that have a phosphorylated serine or threonine on their sidechains.
More recently, U box domain E4 has been identified and suggested to 
mediate substrate polyubiquitin chain elongation (Namekata et al. 2002).
Strictly regulated like phosphorylation, ubiquitination is a reversible process, 
in which deubiquitinating enzymes (DUBs) serve to catalytically remove the ubiquitin 
or ubiquitin chains from the modified substrates (Wilkinson 2000). DUBs fall into
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two groups: ubiquitin carboxyl-terminal hydrolases (UCHs) and ubiquitin-specific 
processing enzymes (UBPs), both of which are thiol proteases. UCHs preferentially 
work on small fusion proteins to remove the carboxyl-terminal from ubiquitin (a 
subset of ubiquitin that is translated as a fusion protein), while UBPs are generally 
responsible for removing ubiquitin from residual peptides or multiubiquitin chains 
(Papa and Hochstrasser 1993; Lam et al. 1997).
Numerous cellular proteins are post-translationally modified by ubiquitin, but 
the functions conferred by this vary. It is now clear that different types of ubiquitin 
conjugation decide the fate of the substrates. Mono-ubiquitination, where a single 
ubiquitin is added to a substrate (Schlessinger 2000), is often implicated in non- 
proteolytic functions, such as endocytic trafficking, virus budding, vacuolar sorting, 
DNA repair, hi stone activity and transcriptional regulation (Hicke 2001). In contrast, 
poly-ubiquitin chains formed by Lysine 48 of two adjacent ubiquitin targets modified 
substrates for proteasomal degradation (Weissman 2001). In addition, other modes of 
lysine conjugation (eg. Lysine 63) used by poly-ubiquitin chains have been shown to 
function differently (Koegl et al. 1999; Spence et al. 1995; Spence et al. 2000).
To date, six conserved ubiquitin binding modules exist (Schnell and Hicke
2003), the structures of five of which have been determined. These include the UIM 
(ubiquitin interacting motif) (Hoffuami and Falquet 2001), UBA (ubiquitin-associated 
domain) (Mueller et al. 2004), UEV (ubiquitin E2 variant domain) (Pornillos et al,
2002), NZF (npl4 zinc finger domain) (Meyer et al. 2002), and CUE (coupling of 
ubiquitin conjugation to ER degradation domain) (Pouting 2000). These motifs have 
been shown to be able to bind ubiquitin in vitro, and adopt interactions with Ub via 
the same hydrophobic patch on the surface of the five stranded |3-sheet of Ub (Mueller 
et al. 2004). The centre of the binding site on Ub is mapped to Ile44.
1.3.1.5.3 Sumoylation
Small ubiquitin-related modifier (SUMO) is a protein of 97 amino acids. Due 
to multiple independent discoveries, it has been called by other names, like Smt3p, 
Pmt2p, PIC-1, GMP-1, Ubll and sentrin (Melchior 2000). SUMO was first found in 
mammalian cells where it was found to be covalently conjugated to the GTPase
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activating protein RanGAPl (Matuni et al. 1996), and since then, more than 60 target 
proteins have been sequentially identified to be able to conjugate to SUMO under 
different conditions (Seeler and Dejean 2003). Although only one gene encodes 
SUMO in yeast species and invertebrate, eight and four genes in plants and mammals, 
respectively, have been identified to date. The four genes encoded in mammalian cells 
are termed SUMO-1, SUMO-2, SUMO-3 and SUMO-4. SUMO-4 is most recently 
identified and shown to express in a tissue-specific manner (Bohren et al. 2004). 
SUMO-2 and SUMO-3 are very similar in sequence (95% sequence identity for the 
human proteins), whereas SUMO-1 only shares 47% identical to SUM02/3 (Melchior 
2000; Muller et al. 2004). In addition to the sequence homology, SUMO-1 and 
SUMO-2/3 are also differ in their substrate specificities (Johnson 2004), as well as the 
ability to form SUMO chains in vitro (Seeler and Dejean 2003; Bohren et al. 2004; 
Tatham et al. 2001), indicating their different functions (Gill 2004).
As its name indicates, SUMO is related to Ub to some extent (Figure 1.8). It 
shares a similar protein fold that is characterized by [JpapfJap, a similar three- 
dimensional structure (Bayer et al. 1998), and a similar conjugation pathway (Hilgarth 
et al. 2004). The route of SUMO conjugation to target proteins, termed sumoylation, 
involves four discrete steps: maturation, activation, conjugation and ligation (Hilgarth 
et al. 2004). Like Ub, all SUMO isofonns are initially synthesized as inactive 
precursors, which need to be C-teiminal proteolytic cleaved by SUMO-specific 
carboxyl-terminal hydrolase to produce a C-terminal diglycine motif. This motif is 
required for the formation of an isopeptide bond between the carboxyl terminus of 
SUMO with an e-amino group of a lysine residue within a target protein. After 
maturation, the conjugation to proteins involves the ATP-dependent dimeric SUMO 
activating El enzyme (SAE1/SAE2 in humans) and the E2 conjugating enzyme Ubc9. 
Sumoylation is also highly dynamic and reversible (Dohmen 2004). SUMO-specific 
proteases are involved in both SUMO maturation and SUMO detachment from its 
substrate proteins (Melchior et al. 2003).
Many differences exist between ubiquitin and SUMO functionality (Dohmen
2004). This is apparent in the enzymes they use to become conjugated 
to/deconjugated from, target proteins and the fates of the proteins that they modify
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I(Dohmen 2004; Johnson 2004; Li and Hochstrasser 1999). Instead of targeting the 
substrates for degradation, SUMO conjugation exerts effects relating to changes in 
transcription (Nakagawa and Yokosawa 2002; Yang and Sharrocks 2004), subcellular 
localization (Lin et al. 2003; Muller et al. 2001), antagonism of ubiquitination 
(Desterro et al. 1998), cell cycle, maintenance of genome integrity and viral 
replication (Hay 2005). Compared to Ub, SUMO has a short flexible N-teiminal 
extension that is absent in Ub. This extension, which varies among different SUMO 
proteins, is rich in charged amino acids like glycine and proline, providing excellent 
candidates for specific protein-protein interactions (Wilson and Rangasamy 2001). In 
contrast to the numbers of Ub El and E2 enzymes, single SUMO-El and SUMO-E2 
exist in most organisms and are required for the conjugation of all SUMO isoforms.
Most strikingly, SUMO E2 Ubc9 can directly interact with substrate proteins via their 
sumoylation consensus sequence \|/KXE (\|/ is a large hydrophobic residue and 
preferably L, I, or V; E is an acidic amino acid, such as D or E; K is the site of SUMO 
conjugation) in most cases (Sampson et al. 2001) and imparts partiality on substrate
selection.
;
Although not required for sumoylation in vitro (Bernier-Villamor et al. 2002),
SUMO E3 ligases are important in regulating substrate selection in vivo, especially 
for the substrates that lack SUMO attachment consensus sequence. To date, three 
unrelated SUMO E3 ligases have been identified: the PIAS proteins, RanBP2, and the 
polycomb group protein Pc2. PIAS family is composed of four members, PIASl,
PIAS3, PIASx and PIASy (Hay 2005). Although there is still in controversy in the 
identification of substrate specificities between different PIAS proteins, it is known 
that p53, jun (Schmidt and Muller 2002), Lef-1 (Sachdev et al. 2001), nuclear 
androgen receptor (Kotaja et al. 2002), Mdm2, Sp3, and Tcf-4 (Dohmen 2004) 
undergo sumoylation via this family of E3 proteins. In addition, RanBP2 has been 
shown to exert SUMO E3 ligase activity for the promyelocytic leukaemia (PML) 
nuclear body (NB) protein, splOO (Pichler et al. 2002), the hi stone deacetyl ase 
HDAC4 (Kirsh et al. 2002), and Mdm2 (Miyauchi et al. 2002), while Pc2 is the 
SUMO E3 ligase for transcriptional corepressors CtBPl and CtBP2 (Kagey et al.
2003). The different substrate specificities of these SUMO E3 ligases are consistent 
with their distinct subcellular localization (Jolinson 2004; Hay 2005).
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1.3,1.6 cAMP gated long-term PDE4 expression
In addition to the short-term regulation of PDE4 due to post-translational 
modifications, PDE4 expression is also regulated at the transcriptional level. Both 
PDE4B and PDE4D genes contain promoters that include several potential cAMP 
regulatory elements. In vitro and in vivo data have shown that increased intracellular 
cAMP largely induces mRNA levels for both PDE4B and PDE4D, as well as their 
corresponding short iso form proteins (Swinnen et al. 1989; Swinnen et al. 1991; Le 
Jeune et al. 2002). The function of this feedback regulation of PDE4D from sustained 
cAMP signalling has been linked to the growth and maturation of the follicle in the 
ovary because ablation of PDE4D gene causes a 75% decrease in the rate of ovulation 
and consequent reduced fertility (Jin et al. 1999). In addition, the Toll-receptor-related 
signalling pathway activated by LPS in macrophages or monocyte cells can cause a 
large increase in PDE4B2 mRNA and its protein (Jin and Conti 2002). This has 
helped identify a function for PDE4B2 as in PDE4B gene knockout mice, the 
induction of PDE4B2 by LPS is a positive feedback regulation required to remove a 
negative cAMP constraint (Jin and Conti 2002).
1.3.2 PDE4A
The human PDE4A gene is mapped to chi'omosome 19p-31.1 in man 
(Sullivan et al. 1998). To date, five isofoims of human PDE4A gene have been 
cloned. This includes a short form, PDE4A1 (Sullivan et al. 1998), the long form 
PDE4A4B (Bolger et al. 1993), PDE4A5 (McPhee et al. 1995), and PDE4A10 (Rena 
et al. 2001) and a catalytically inactive N- and C-terminally truncated PDE4A7 
(Johnston et al. 2004). Specific PDE4A isoforms have been suggested to have distinct 
roles in the brain, thus providing valid targets for therapeutic interventions (McPhee et 
al. 2001).
The changes in the expression of PDE4A isoforms seem to correlate with the 
status of the cells. PDE4A4B long isoform is found upregulated in macrophages fi'om 
smokers with chronic obstmctive pulmonary disease (Barber et al, 2004), and 
PDE4A10 seems to be up-regulated upon differentiation of monocytes to 
macrophages (Shepherd et al. 2004).
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To date, PDE4A7 is the only PDE4 isoform that is generated from both 5’ 
and 3’ domain swaps, providing both a unique N-terminal and C-terminal region 
(Sullivan et al. 1998), and it is this unique C-terminal region that leads to the lack of 
crucial phenylalanine, thus lack of the catalytic activity in PDE4A7 (Johnston et al.
2004).
1.3.3 PDE4B
PDE4B is a key enzyme in mediating TNF-a production. It has been shown 
that PDE4B is involved in LPS-induced TNF-a production in macrophage (Jin et al.
2005), as well as in Abeta peptide-induced TNF-a production in Alzheimer’s disease 
(AD) patients (Sebastian! et al. 2005). As this regulation of TNF-a production was 
specific for PDE4B, consistent with the study in PDE4B null mice (Jin and Conti
2002), it suggests the non-overlapping functions between PDE4 isofonns. In addition, 
a combination o f pharmacological and genetic strategies provides evidence that 
PDE4B and PDE4D genes are non-redundant and complementary in neutrophil 
recruitment to the lung, even though PDE4B has gieater impact than PDE4D (Ariga et 
al. 2004). This further indicates that PDE4B and PDE4D control two different pools 
of cAMP in neutrophils.
In addition to pro-inflammatory outcomes, PDE4B is also involved in other 
biological process. PDE4B3 has been reported to change its translational and 
transcriptional regulation during hippocampal long-teim potentiation (LTP), 
suggesting a possible molecular model where it plays an important role in learning 
and memory fonuation (Ahmed et al. 2004). Targeting of PDE4B2 to the 
immunological synapse tlirough its N-terminus interaction with lipid rafts has been 
shown to regulate TCR-mediated interleukin-2 production. Thus, dynamic re­
distribution of PDE4B2 seems to regulate the T-cell activation during immunological 
synapse fomiation (Arp 2003).
Recently, Millar et al. reported a primary evidence for PDE4B as a genetic 
susceptibility factor for Schizophrenia. They found that the dismpted in schizophrenia 
1 (DISCI) interacts with the UCR2 domain of PDE4B in a compartmentalized 
manner, and that only when the cellular cAMP is elevated will sequestered PDE4B
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dissociate from DISCI and retain its activity. Any functional vaiiation in DISCI 
and/or PDE4 is therefore speculated to have a concomitant physiological and 
psychiatric outcome (Millar et al. 2005),
It is well accepted that inhibitors with increased selectivity towai’d one PDE4 
isoform may have advantages over non-selective PDE4 inliibitors due to the decreased 
side effect. Recently Robichaud et al. (Robichaud et al. 2002) indicated that the main 
contribution to the emetic side effects may involve PDE4D, but not PDE4B. 
Therefore, a compound that preferentially inactivates PDE4B is much favourable, 
because PDE4B inactivation should retain some of the beneficial properties of 
PDE4D inactivation, such as blockade of neutrophil adhesion and chemotaxis and can 
be used in a higher dose (Robichaud et al. 2002).
The expression level of PDE4B is regulated under different conditions with 
different mechanisms. Nitric oxide has been shown to increase PDE4B expression in 
rat pulmonary artery smooth muscle cells via a mechanism that requires cGMP 
synthesis (Busch et al. 2005). In diffuse large B-cell lymphoma (DLBCL), PDE4B is 
up-regulated through phosphotidylinositol 3-kinase (PI3K)/AKT pathway mediated 
apoptosis that is induced by cAMP, highlighting the useful development of PDE4 and 
PI3K/AKT inhibitor in treating the B-lymphoid malignancies (Smith et al. 2005).
1.3.4 PDE4C
PDE4C is one of the four mammalian genes that encode multiple PDE4 
isofonns which are inhibited by rolipram. Unlike other PDE4 species, PDE4C is 
restrictly expressed in certain tissues, indicating their distinct function roles (Sullivan 
et al. 1999).
The human PDE4C gene was reported to localize on clnomosome 19p, where 
PDE4A gene is also present. However, the relative location and any possible linkage 
between PDB4A and PDE4C are still poorly understood (Sullivan et al. 1999).
To date, four cDNAs of PDE4C have been isolated, which represent three 
different PDE4C long isoforms, PDE4C1, PDE4C2, and PDE4C3 (Engels et al. 1995;
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Obemolte et al. 1997; Owens et al. 1997). Compared to the short foims of PDE4A, 
PDE4B and PDE4D characterized at cDNA and protein levels, no PDE4C short forms 
have been reported so far. The absence of PDE4C short forms can be explained by the 
analysis of the sequence where introns separating PDE4C exon 5, 6 and 7 equivalents 
are unlikely contain either additional exons or alternative promoters (Sullivan et al. 
1999), which is in reminiscent of the Drosophila dunce gene that does not produce 
short isoforms (Qiu 1991).
1.3.5 PDE4D
PDE4D is the predominant PDE4 forni in tracheal extracts and airway 
epithelia and plays a cmcial role in balancing relaxant and contractant cues in airway 
smooth muscle (Mehats et al. 2003; Barnes et al. 2005). It has been suggested that a 
PDE4D suhtype inhibitor has important therapeutic implications for resolution of 
asthmatic bronchoconstriction (Giembycz 2000). Indeed, it has been shown that mice 
deficient in PDE4D exhibited absence of muscarinic cholinergic airway responses 
(the tone of which has been associated with clinical asthma) and this is thought to be 
due to the impaired muscarinic cholinergic receptors M2 and M3 signalling pathway 
(Hansen et al. 2000). In the same mice deficient in PDE4D, delayed growth as well as 
reduced viability and female fertility were also observed (Jin et al. 1999), suggesting 
that the activity of this isoenzyme is also required for the regulation o f growth and 
fertility.
PDE4D is known to play an important role in regulating vascular smooth 
muscle and endothelial cells that are involved in atherosclerosis (Gretarsdottir et al.
2003). Recently, a number of independent groups have reported the association 
between PDE4D variants and ischemic stroke (Gretarsdottir et al. 2003; Meschia et al.
2005), which appear to converge on PDE4D as an ischemic stroke risk factor gene. 
However, no identified ‘at-risk’ single nucleotide polymorphisms or haplotypes has 
been reported to date. Indeed, it is not clear that any specific PDE4D variant will be 
found associated with stroke in replication studies. In addition, a recent new study 
records the possibility of the association of PDE4D gene with cardioembolic stroke 
and despite the failure of showing that PDE4D is a major risk factor for ischemic 
stroke, the authors could not exclude a connection (Bevan et al. 2005).
48
Although until now there have been no reports implicating any member of 
the PDE4 gene family in human osteoporosis, an association between a variation in 
PDE4D gene and bone mineral density has been indicated (Reneland et al. 2005). In 
addition, PDE4D has been suggested to be involved in impaired memory in a water 
maze task (Giorgi et al. 2004).
To date, nine PDE4D isoforms have identified, PDE4D1 through to PDE4D9, 
which are further categorized into short isoforms (PDE4D1), long isoforms (PDE4D3, 
4, 5, 7, 8 and 9), and supershort isoforms (PDE4D2 and 6) (Richter et al. 2005; Wang 
et al. 2003). Compared to the high restricted tissue distribution of PDE4D4, PDE4D6 
(in brain), PDE4D7 (in cortex, testis and kidney) and PDE4D8 (in lung, heart and 
liver), PDE4D1, PDE4D2, PDE4D3, PDE4D5 and PDE4D9 are all widely distributed 
and present to some extent in most tissues in rat (Richter et al. 2005). PDE4D1 and 
PDE4D2 have been shown to be up-regulated in activated vascular smooth muscle 
cells (VSMC) (Tilley and Maurice 2005). As the induction of these specific PDE4 
isofonns seems to serve to desensitise the susceptibility of activated VSMC to the 
inhibitory action of cAMP, inhibitors of these two specific isofoims are desirable for 
the treatment of adjunetive phannacotherapy after percutaneous coronary 
interventions (Tilley and Maurice 2005). PDE4D7 is a long isofoim and it has been 
suggested its putative promoter is associated with Icelandic stroke (Gretarsdottir et al. 
2003; Houslay 2005).
PDE4D enzymes are the major PDE4 isofonns found in a variety of cells, 
with the PDE4D3 and PDE4D5 long isoforms predominating (Conti et al. 2003; 
Houslay 2001). Conti and co-workers, together with Houslay’s lab, have shown that 
PDE4D3 is phosphorylated at Ser54, PDE4D5 at Seri 26, both sites located at the 
beginning of UCRl and this activates these isofoims (Hoffinann et al. 1998; Sette et 
al. 1994; MacKenzie et al. 2002). PDE4D3 and PDE4D5 are also phosphorylated by 
ERK2, at Ser579 and S651, respectively, and this inhibits enzyme activity (Hoffmami 
et al. 1999; MacKenzie et al. 2000; Baillie et al. 2001). As the various PDE4D 
isoforms provide a panel of enzymes that can be differentially regulated to different 
extents by ERK2 phosphorylation, together with their distinct subcellular distribution 
properties, they offer the potential to tailor cAMP signalling in specific cell types, as 
well as in discrete intracellular domains. This may explain why cells might choose to
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express particular PDE4 isoforms and adds the PDE4 enzymes to the growing list of 
machinery responsible for cAMP signalling compartmentalization (MacKenzie et al. 
2000).
It has been reported recently that during P2 AR desensitisation, the 
cytoplasmic adaptor p-arrestin recmits the PDE4D isoforms to the plasma membrane 
(Perry et al. 2002) where they may regulate the receptor coupling to G proteins 
(Baillie et al. 2003). PDE4D5 has been shown to preferentially bind to two sites in p- 
arrestin2 through its unique N-terminal region, as well as the common PDE4 catalytic 
domain. And it has been suggested that it is this unique N-terminal region of PDE4D5 
that allows it for the binding specificity over PDE4D3, which accounts for the 
observation that more PDE4D5 compared to PDE4D3 is recruited with p-arrestin to 
the membrane fraction upon p-agonist stimulation in HEKB2 cells. Wliereas in 
HEKB2 cells the total protein level of PDE4D3 is greater than that of PDE4D5, 
challenge of these cells with isoprenaline leads to more PDE4D5 than PDE4D3 
translocation to membrane fraction (Bolger et al. 2003).
Xiang et al. have identified the selective role of PDE4D in impacting p%AR 
subtype-specific signalling in neonatal cardiomyocytes, therefore favouring the view 
that PDE4D controls a functionally and perhaps physically discrete pool of cAMP 
(Xiang et al. 2005). Indeed, this might be partially due to the fact that P2 AR has more 
binding affinity than piAR towards arrestin which recruits PDE4D to the plasma 
membrane (Shiina et al. 2000; Xiang et al. 2005).
Recently, Robichaud and colleagues have provided evidence that PDE4D 
mediates the known emetic effects of PDE4 inhibitors through a sympathetic pathway 
by mimicking the phanuacological actions of yohimbine, a az-adrenoceptor 
antagonist (Robichaud et al. 2002). Although this is an unfortunate finding because 
the most clinically advanced PDE4 inliibitors are selective for PDE4D, the data may 
readily account for the poor tolerability of these compounds in clinical trials.
50
Ligand
CNG
Figure 1.1 General schematic of cAMP signalling pathway initiated by G-protein 
coupled receptors (GPCRs).
An appropriate ligand binds to and activates GPCRs, which results in the dissociation 
of the Gas subunit. Gas subunit can stimulate adenylyl cyclases (ACs), therefore 
generating cyclic AMP (cAMP). The cAMP signalling can be mediated by PKA, 
EPAC or cyclic nucleotide gated ion channels. The sole means to inactivate cAMP is 
through cyclic nucleotide phosphodiesterases (PDEs) that hydrolyse cAMP into 5’- 
AMP. PKA, Protein Kinase A; Epac, exchange protein activated by cAMP; CNG, 
cyclic nucleotide-gated channels.
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Figure 1.2 Cyclic nucleotide hydrolysis by cyclic nucleotide phosphodiesterases.
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PDE family Regulatory domains Substrate
speicificity
Property Specific
inhibitors
PDEl Ca'^VCaM binding cAMP/cGMP Ca^VCaM-
activated
Nimodipine
PDE2 cGMP binding GAP 
domain
cAMP/cGMP cGMP-activated EHNA
PDE3 Transmembrane
domain
cAMP specific cGMP-inhibited Cilostamide,
milrinone
PDE4 UCRl and UCR2 cAMP specific PKA/ERK-
phosphorylated
Rolipram, Ro 20- 
1724, roflu­
milast
PDE5 cGMP binding GAP 
domain
cGMP specific PKA/PKG-
phosphorylated
Zaprinast, 
DMPPO, E4021, 
Sildena-fil
PDE6 cGMP binding GAP 
domain
cGMP specific Transducin-
activated
Zaprinast, 
DMPPO, E4021, 
Sildena-fil
PDE7 cAMP specific Rolipram-
insensitive
BRL 50481, 
1C 1242
PDE8 PAS domain cAMP specific Rolipram-
insensitive
IBMX-insensitive
Unknown
PDE9 Unknown cGMP specific IBMX-insensitive Unknown
PDEIO cGMP binding GAP 
domain
cAMP/cGMP Unknown Unknown
PD Ell cGMP binding GAP 
domain
cAMP/cGMP Unknown Unknown
Figure 1.3 Table of phosphodiesterases superfamily (adapted from Lugnier 
review, 2006).
All human PDE gene families identified to date are listed.
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laoform specific 
N terminal 
region
UCRl UCR2 Catalytic unit
Long
Lack UCRl Short
Lack UCRl; 
Truncated UCR2 Super - short
Figure 1.4 Schematic of the PDE4 isoenzymes.
Functional PDE4 isoforms are divided into three categories: long, short, and super­
short isoforms dependent on the combined presence of upstream conserved regions 
(UCRs). Long isoforms possess both UCRl and UCR2, short isoforms lack UCRl, 
whereas super-short isoforms lack UCRl and only have a truncated UCR2.
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KIM FQF
Catrtjftic unit
UCR2 N terminal
RRES
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FQFKIM
N terminalRRE§
PKA
Activated
Figure 1.5 The effects of PKA and ERK2-mediated phosphorylation on PDE4 
long isoforms.
PDE4 long isoforms processes both UCRl and UCR2. ERK2-mediated 
phosphorylation of PDE4 long isoforms leads to their enzymatic inhibition, whereas 
PKA-mediated phosphorylation increases their enzymatic activity.
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MyoroegaHn AKAP450 RACK1
Figure 1.6 Compartmentalization of PDE4s.
The known sequestration of PDE4 in signalling complexes and their subcellular 
localization are depicted in a hypothetical cell. The yellow barrels represent the 
scaffolding proteins. (Taken from Conti et al. 2003).
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Figure 1.7 Schematic of Pz-adrenergic receptor (P2AR) desensitization.
Agonist occupancy of the pzAR initiates PKA and GRK mediated phosphorylation of 
the receptor. PKA phosphorylation of PzAR leads to the switching of PzAR signalling 
from Gs to Gi, and hence the activation of ERK. This switching is mediated by p- 
arrestin delivered PDE4D isoforms. GRK mediated phosphorylation of PzAR results 
in the membrane recruitment of p-arrestin/PDE4 complexes, p-arrestin serves to 
sterically blocks coupling of the pzAR to Gs, whereas delivered PDE4 isoforms 
actively degrade cAMP in the prime site of cAMP generation.
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Ubiquitin SUMO
Size 9kD a 11 kDa (-20 amino acids longer in 
an N-terminal extension)
Surface charge Positive Negative
Family
members
One ubiquitin isoform Four members: SUMO-1, SUMO- 
2,
SUMO-3 and SUMO-4
Polymeric
chains
Both in vivo and in vitro, with 
different topology
SUM02, 3 and 4 are found to 
form chains in vitro so fai*
El enzymes Single UBAl SAE1 (AO S1 )-S AE2 (UBA2) 
heterodimer
E2 enzymes Multiple, including UBC4 and 
UBC7, which have negative or 
neutral potentials
Single UBC9 , the surface of 
which is mainly postively charged, 
functions in substrate recognition
E3 ligases Classified into: HECT domain 
E3s and RING domain E3s.
Three types: RanBP2, the PI AS 
proteins, and the Pc2.
Substrate
specificity
No concensus site \|/KXE consensus sequence
Cleaving
enzymes
Cystein proteases Distantly related to viral cystein 
proteases and shows no similarity 
to ub-cleaving enzymes
I
j
I.
Figure 1.8 Table of the differences between Ubiquitin and SUMO families.
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Chapter 2
Materials and Methods
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Throughout the following methods the names of the companies used for the 
purchase of specific reagents or materials are given in parentheses. Where no 
company is mentioned, the reagent was purchased from Sigma-Alrich. All reagents 
were of analytical grade.
Plasmids used in this study:
Plasmids encoding N-tenmnally 6his-tagged human SUMOl (6His-SUM0- 
1), N-tei-minally 6his-tagged SUM02 (6His-SUMO-2) and C-terniinally SV5 tagged 
Ubc9 (Ubc9-SV5) in pcDNA3.1 vectors, those encoding N-tenmnally haemagluttinin 
tagged mouse PIASy (HA-PIASy) in pKW2T, and those encoding GST fusion protein 
of Ubc9 were kindly gifted by Dr. R. Hay (University of Dundee, UK). The plasmid 
encoding C-terminally VSV-tagged human PDE4D3 (PDE4D3-VSV) in pCIneo was 
created by Dr. R. Hofhnann (Sandoz, Switzerland). Plasmids encoding C-tenninally 
VSV-tagged human wild type PDE4D5 and C-terminally VSV-tagged R34A PDE4D5 
mutant in pcDNAS.l, those encoding GST fusion protein of p-arrestin2 in pGEX-5X- 
3 were created and gifted by Dr. G. Bolger (University of Alabama, USA). The 
plasmid encoding N-terminally HA-tagged human ubiquitin (HA-Ub) in BSSK" was a 
gift from Dr. D. Bohnamm. The plasmid encoding a GST fusion protein of p-araestinl 
in pGEX4T was created by Dr. R.J. Lefkowitz (Duke University, USA). The plasmid 
encoding GST fusion protein of ERK2 (p42) was subcloned into pGEX-2T by Dr. W. 
Kolch (Beatson Institute, Glasgow). Plasmids encoding C-terminally VSV-tagged 
PDE4A5, PDE4B1, PDE4B3, PDE4B4 and PDE4C1 in pcDNA3 were generated 
previously by others working in the Houslay Laboratory. Plasmids encoding N- 
terminally HA-tagged UbK48R, UbK63R and UbK29, 48, 63R in pcDNA3 were 
generated by Dr. Martin Lynch in the Houslay Laboratory.
2.1 Mammalian Cell Culture
2.1.1 Maintenance of cell lines
2.1.1.1 HEK293 cell line
HEK293 cell line (ATCC CRL 1573) is a human embryonic cell with an 
epithelial cell morphology. Cells were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 2mM Glutamine, 10% foetal bovine serum 
(FBS) and 1% penicillinystreptomycin (100 units/ml) in an atmosphere of 5% CO2  and
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37°C. When cells were passaged at 80-90% confluency, they were split 1:5. To 
passage the cells they were rinsed with pre-warmed sterile PBS and l-2mls of pre­
warmed 0.25% tripsin/0.03% EDTA solution were added. Flasks were incubated at 
37°C until cells detatched. Cells were collected by adding lOmls of culture media and 
centrifugation at 72.8 x g for 3 min. The cells were then resuspended in fresh culture 
media and transferred into new culture flasks at approximately lO^cells/ml final 
volume.
2.1.1 2 COS-1 cell line
The COS-1 cell line (ATCC CRL 1650) is an African green monkey derived 
cell line, with a fibroblast morphology transformed with the SV40 virus. This cell line 
was maintained and passaged as with the HEK293 cell line.
2.1.1.3 HEKB2 cell line
The HEKB2 cell line was derived from HEK293 cell line, with stably over­
expressing FLAG and GFP- tagged Pz adrenergic receptors and is resistant to the 
G418 antibiotic. Cells were maintained in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with 2mM glutamine, 10% newborn calf serum (NCS), 1% 
penicillin/streptomycin (lOOunits/ml) and 1 mg/ml G418 antibiotic in an atmosphere 
of 5% COz and 37°C. G418 here was used to select the cell generations with GFP 
tagged p2  adrenergic receptors expressed. Cells were passaged at 90-100% confluency 
with a split ratio of 1:4. To passage the cells, they were rinsed with pre-warmed sterile 
PBS and then 2ml of pre-warmed 0.25% trypsin/0.03% EDTA solution was added to 
the 75mm flasks. Flasks were incubated at 37°C until cells detached. Cells were then 
collected by addition of 8ml of culture media and subsequent centrifugation at 72.8 x 
g for 3 minutes. The cells were resuspended in fresh medium and transfeiTed into new 
culture flasks at approximately 10  ^cells/ml final volume.
2.1.2 Transfection
2.1.2.1 PolyFect transfection of HEK293 cells (and HEKB2 cells)
Transfection of HEK293 cells was carried out using PolyFect reagent 
(Qiagen). 1.2 x 10  ^ cells per 100 mm dish were seeded in 7 ml of DMEM 
supplemented with 2mM glutamine, 10% newborn calf semm (NCS) and 1%
61
?l
penicillin/streptomycin (100 units/ml) in an atmosphere of 5% CO2  and 37°C. Once 
the cells reached 40-80% confluency the transfection was carried out. For each 
transfection, 8pg of DNA was dissolved in TE buffer (lOmM Tris-HCl pH7.5, ImM 
ethylenediaminotetra-acidic acid (EDTA)) with DMEM containing no serum protein 
or antibiotics to a total volume of 300pl. The solution was mixed well for a few 
seconds to remove drops from the top of the tube containing this DNA. 80pl of 
PolyFect Transfection Reagent was then added to the DNA solution, which was 
followed by mixing by pipetting up and down 5 times. The DNA complex was formed 
when it was incubated for lOmin at room temperature (20-25°C). While complex 
foimation took place, the growth medium from the 100mm dish was gently aspirated 
and replaced with 7 ml of fresh cell growth medium (containing semm and 
antibiotics). After being mixed by pipetting up and down twice, the formed DNA 
transfection complexes were transfeined from the reaction tube to the cells in the 
100mm dish. Then the dish was gently swirled to ensure unifonn distribution of the 
complexes before put into the incubator at 37°C and 5% CO2  to allow for gene 
expression. The cells were harvested 48-72 hr after transfection.
2.1.2.2 DEAE-Dextran transfection of COSl cell line
The cells were split the day prior to transfection and allowed to grow to 50- 
70% confluency. lOpg of the plasmid DNA was diluted in TE buffer (ImM 
ethylenediaminotetra-acidic acid (EDTA), lOmM TrisCl, pH 7.5) to a total volume of 
250pl in a sterile 15ml centrifuge tube. To this tube, 200pl of sterile DEAE Dextran 
(lOmg/ml in PBS) was added, mixed and incubated at room temperature for 15 
minutes. Meanwhile, the culture media in the 100mm dish seeded with COSl cells 
was replaced with medium and lOOpM chloroquine (filter sterilized) was added. Once 
the DNA complexes foimed, the DNA-DEAE dextran mixture was dropped onto the 
cells and mixed by swirling. The cells were then incubated at an atmosphere of 5% 
CO2  and 37°C for 3-4 hours. Following this incubation, the media were removed and 
replaced with 5ml sterile PBS supplemented with 10% DMSO. Cells were incubated 
in this 10% DMSO for 2 minutes and washed with 5ml fresh sterile PBS twice. Then 
7ml of fresh culture media was added to the cells that were then incubated for 48hours 
at 37°C in an atmosphere of 5% CO2 . The cells were then harvested. Mock
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transfections were performed by treating the cells exactly as described above except 
adding the DNA into the mixture.
2.2 Biochemical techniques
2.2.1 Protein analysis
2.2.1.1 Whole Cell lysate
Cell culture dishes were maintained on ice and all buffers used were ice-cold 
to minimize protein degradation and denaturing of enzymes. The cell growth media 
was aspirated and the cells washed with PBS. The PBS was drained and approx 
lOOpl/100 mm dish 3T3 lysis buffer (20mM N-2-hydroxyethylpiperazine-N’-2- 
ethanesulfonic acid (HEPES), pH7.4, 50 mM NaCl, 50mM NaF, 10% glycerol, 1% 
Triton X-100, lOmM ethyleneglycol-bis(P-aminoethylether)-N,N,N’ ,N’-tetra-acetic 
acid (EGTA), 30mM sodium pyrophosphate and Roche proteases inhibitor cocktail) 
was added. The cells were scraped, transferoed to a 1.5 ml eppendorf tube and snap- 
frozen. The cell samples were then thawed at 4°C and subjected to mechanical 
disruption using a micropestle (Eppendorf). The cell debris was removed by 
centrifugation at 18,000 x g for 3 min. The cell lysates were stored at -20°C until 
required for use.
2.2,1.2. Protein quantification (Bradford assay)
All protein assays were earned on 96 well titre plates, with triplet samples 
loaded as indicated below. Different amount of lOOpg/pl BSA was diluted in distilled 
water to a total volume of 50jul, which was used for making the standard 
concentration curve. lOpl of each cell extract was diluted in 490pl distilled water, 
mixed well, and 50pl of the mixture was loaded into the Elisa 96-well plate in 
triplicate. Once all the standards and samples were loaded, 200pi of 20% Bio-Rad 
protein assay reagent (5ml in 20ml distilled water) was added to each well. The 96- 
well plate was then analysed using the Revelation Program and an MRX micro titre 
plate reader (absorbance read at 590 mn). Protein concentiations were obtained by 
plotting the standard carve and using least regression analysis to obtain the line of best 
fit. The equation of the line of calculated best fit was used to deteimine the protein 
concentration of samples in pg/pl.
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2.2.2 Gel electrophoresis and Western blotting
2.2.2.1 Sample preparation
2.2.2.1.1 Cell lysis samples
Cell lysates were obtained by using lysis buffer or needle/syringe passaging, 
followed by centrifugation at 18,000 x g for 3 min. The supernatants were assayed for 
protein concentration as described above. Then equal amounts of protein were taken 
and diluted 1/5 with 5x Laemmli sample buffer (260mM TrisCl, pH 6.7, 55.5% 
glycerol, 8.8% SDS, 0.007% bromophenol blue, 11.1% 2-mercaptoethanol), which 
was boiled for 3-5 minutes to cause proteins to denature.
2.2.2.1.2 Membrane Recruitment samples
Once the cells were treated as indicated in experimental text, medium was 
taken off and the plates to which the cells adhered were put on ice. The cells were 
washed with ice cold KHEM (50mM Hepes KOH, pH7.4, 50mM KCl, lOmM EGTA, 
1.92mM MgCIz) twice and the excess wash fluid was removed by tapping. To a 
lOOmm dish, 300pl of complete KHEM (50mM Hepes KOH, pH7.4, 50mM KCl, 
lOmM EGTA, 1.92mM MgClz, ImM DTT, Roche protease inhibitor) was added. 
Cells were scraped with complete KHEM into new Eppendorf microcentrifuge tubes 
and kept on ice. Then cells were broken by passaging 10 times using 26G gauge 
needles. The resulting lysate was centrifuged at 366 x g for 3 minutes to isolate the PI
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boiled samples, according to the capacity of the gel type, was loaded into each 
following well. The gels we:
(Bio-Rad) for around 1 hour.
2.2.2.3 Protein Transfer
The SDS gel was disassembled from the gel cassette and placed onto a piece 
of Whatmann 3MM paper pre-soaked in Ix NuPage Transfer Buffer (Invitrogen). A 
piece of nitrocellulose paper (Schleicher& Schuell), pre-soaked with the Ix NuPage 
Transfer Buffer, was overlaid on the SDS gel, while ensuring the absence of bubbles 
between the layers. The nitrocellulose was, in turn, covered by another pre-soaked 
Whatmami 3MM paper to result in a sandwich that was later placed in Xcell II™ Blot 
Module between two pieces of foam soaked in Ix Transfer Buffer. The module was 
placed with the nitrocellulose to the positive electrode in the Hcell SureLod^'^ tank,
I
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fraction (enriched in nuclear and cytoskeletal components). The supernatants were 
then removed to ultracentrifuge tubes and further eentrifuged at 245,000 x g for 30 
minutes to make the P2 fraction (enriched in plasma membrane, vesicles foimed from 
the Golgi apparatus and the endoplasmic reticulum, lysosomes and endosomes). The 
supernatants were kept as S fraction (enriched in cytosolic proteins), and the pellets 
were carefully washed in 750pl complete KHEM, followed by further centrifugation 
at 245,000 x g for 30 minutes. The pellets were resuspended in 200pi complete 
KHEM as P2 fractions. Protein concentrations were then determined by above 
description, and equal amount of proteins were loaded with sample buffer to the Nu- 
PAGE gel.
2.2.2.2 Nu“Page™ gel system
Pre-cast 4-12%, 10-well, 12-well or 15-well Bis-Tris 1.0mm gels (Invitrogen) 
were used for all the western blotting. The gels were assembled in Xce// SureLod^^ 
tanks (Invitrogen) according to the manufacturer’s instmetion. Depending on the 
molecular weight of protein interest, either NuPage™ MOPS SDS running buffer or 
NuPage™ MES SDS running buffer (Invitrogen) was used to fill the tank. 2pi of Bio- 
Rad prestained broad range precision protein marker was loaded in the front lane as a 
standard to determine protein migi’ation weight, and an appropriate volume of pre­
re run at 160V constant (operated by POWER-PAC 300
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filled with Ix NuPage Transfer Buffer. The proteins were transferred with an applied 
voltage of 25V for 1 hour or 1OV overnight.
2.2.2.4 Imniunoblotting
Once transfeiTed onto the nitrocellulose, Ponceau S stain (0.1% Ponceau S, 
3% Trichloroacetic Acid) was used to visualise the proteins. The Ponceau S was 
added to the nitrocellulose for a few minutes until the proteins became stained, then 
the nitrocellulose membrane was washed with distilled water. 5% skimmed milk 
powder was dissolved in TBS-tween20 (137mM NaCl, 20mM TrisCl, pH 7.6, 0.1% 
Tween20), and the unoccupied protein binding sites on the nitrocellulose membrane 
were blocked in 5% skimmed milk powder for 1 hour at room temperature with 
agitation. After 1 hour blocking, the appropriate primary antibody was added to the 
membrane with a dilution 1:1000 (for polyclonal antibody) or 1:5000 (for monoclonal 
antibody) in 1% skimmed milk powder in TBS-Tween20, This incubation was carried 
out for 2 hours with vigorous shaking. Then the nitrocellulose membrane was washed 
thi'ee times in TBS~Tween20, each time for 10 minutes. A secondary antibody was 
diluted 1:5000 in TBS-Tween20, added to the membrane and incubated with the 
membrane for 1 hour with vigorous shaking. The secondary antibody was an anti­
immunoglobulin (IgG) antibody conjugated to horse-radish peroxidase (HRP) and 
directed against the primary antibody. After 1 -hour secondary antibody incubation, 
the nitrocellulose membrane was washed in TBS-tween20 three times, each time 10 
minutes. Then the membrane was incubated with ECL reagents (Amersham) for 1 
minute, according to the manufacturers instmetion, followed by subjection to a piece 
of x-ray film (Kodak) in a dark room, which was then developed using a Kodak X- 
moat machine.
2.2.3 Immunoprécipitation
Depending on which source is the antibody generated, either Protein G 
Sepharose (Amersham Biosciences) or Protein A Agarose (Invitrogen) was used to 
immunoprecipitate the target protein. Among all the animal sources, Protein A 
Agarose can only be used when the antibody against the target protein is generated 
from mouse, human, rabbit, guinea pig; while Protein G sepharose can be used for any 
type of animal-generated antibody. For optimal precipitation, protein G sepharose was
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prefeiTed to immunoprecipitate a monoclonal antibody or a polyclonal antibody raised 
in a sheep, while Protein A Agarose was chosen to immunoprecipitate any other 
polyclonal antibodies.
2.2.3.1 Sepharose pre-wash
50|ul of the appropriate beads were washed in TOOpl of a decent buffer that 
was used for haiwesting the cells, and recovered by centrifugation at 18,000 x g for 1 
minute at 4°C (Heraeus refrigerated bench-top centrifuge). This was carried out three 
times. After the final wash, the supernatant was thrown away, and the same volume of 
the decent buffer as the spun beads was added to resuspend the beads.
2.2.3.2 Pre-clearing
For 400pi of cell extracts (approx 400 pg), 25 pi of 50% (v/v) pre-washed 
beads was added and this mixture was incubated with end-over-end rotation at 4°C for 
30 minutes. The sample was then centrifuged at 18,000 x g for 1 minute at 4°C to 
recover the beads.
2.2.3.3 Pre-immune
If a pre-immune antibody was available, it was incubated with the cell lysate 
with end-over-end rotation at 4°C for 30 minutes. 25 pi of pre-washed beads were then 
added to the lysate and again incubated with end-over-end rotation at 4°C for 30 
minutes. The beads were recovered by centrifugation.
2.2.3.4 Binding of antibody and target protein complex to beads
After pre-clearing/incubation with pre-immune antibody, the beads were 
collected by centrifugation at 18,000 x g at 4°C for 1 minute, and the supernatant was 
removed to a fresh 1.5ml-Eppendorf tube as the pre-cleared cell extract. To this fresh 
tube, 1-5pi of the antibody (depending on the quality of the antibody provided, but 
usually -  2pg) against the target protein that was in the cleared cell extract was added, 
and this tube was rotated end-over-end at 4°C for 1 hour, to enable the binding of the 
protein to the antibody. Then, 25 pi of pre-washed protein beads were added to the 
sample and rotated end-over-end for at least 2 hours at 4“C. The beads were isolated 
from solution by centrifugation at 18,000 x g at 4°C for 1 minute and washed with
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750pl of cell harvesting buffer. The resuspended beads in the wash buffer were 
recovered by the same speed centrifugation, and the supernatant was thrown away. 
This wash was perfonned twice to minimise any non-specifically bound protein to the 
beads. The third time wash of the beads was earned out in 20mM TrisCl, pH 7.4, if 
the protein was to be used for a PDE assay. For later western blotting, the beads were 
diluted 1/5 with 5x Laemmli Sample Buffer. The sample was boiled for 3 minutes to 
release the target protein from the beads. For optimal release, the Eppendorf tube 
containing the sample was inverted several times during the boiling. The beads were 
then recovered again by a 18,000 x g speed centrifugation at room temperature, and 
an appropriate amount of supernatant was subjected to the Nu-Page™ gel for 
immunoblotting. The following procedures were performed as above described for 
western blotting.
2.2.4 Kinase Assays
2.2.4.1 PKA assay
2.2.4.1.1 Cell lysate extraction for PKA assay
Mammalian cells were grown and treated as required, after which time the 
cell media was removed, the cells were washed with PBS once, followed by another 
wash by extraction buffer (5mM EDTA, 50mM Tris, pH7.5). The extraction buffer 
was poured off, and the cells were drained by pipetting out the left-over extraction 
buffer in the plates where the cells were growing. This gives a high concentration of 
cells in which the PKA is also concentrated. The monolayer of cells were snap-frozen 
and thawed in the ice, which was followed by homogenisation achieved by drawing 
the cell suspension through a 26 gauge needle around 10 times. The cell debris was 
then removed by centrifugation for 2 mins at 18,000 x g at 4°C (Heraeus refrigerated 
bench-top centrifuge) and the supernatant was transferred into new 1.5ml Eppendorf 
tubes to be used for a PKA assay.
2.2.4.1.2 PKA assay tube pre-incubation
For each cell lysate, the following was set up on ice in 1.5ml Eppendorf 
tubes. The cell extracts were added last, and then mixed well by vortexing. The cells 
were incubated on ice for 20 mins to allow the inhibitor to bind PKA. N.B. due to the
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time restrictions, during the assay, a maximum of 9 different lysates can be analysed 
at any one time:
Tube Cell Extract Diluent 4x PICA 
inhibitor
4x PKA 
Activator
A lOpl 20pl Opl Opl
B lOpl lOpl lOpl Opl
C lOpl lOpl Opl lOpl
D lOpl Opl lOpl lOpl
4x PKA Inhibitor-4|LiM PKI(6-22) amide, 50mM Tris, pH 7.5. 
4x PKA Activator-4pM cAMP, 50mM Tris, pH 7.5.
2.2.4.1.3 PKA assay reaction
To 1 ml of the 4x PKA substrate (200pM Kemptide, 400pM ATP, 40mM 
MgCh, 1 mg/ml BSA, 50mM Tris, pH 7.5) 6000pCi/mmol of [y-^^P]ATP (Amersham 
Biosciences) was added whilst maintained on ice. To the first assay tube (1 A), lOpl of 
radioactive 4x PICA substrate solution was added; the contents were mixed gently 
before being placed in a rack within a water bath at 30°C for lOmins. 15 seconds after 
substrate addition to the first tube, lOpl of the radioactive substrate was added to the 
next tube (IB), which was then mixed and incubated. This method of addition of 
substrate to tubes every 15 seconds continued until all the tubes with substrate were 
incubated at 30°C. After the lOmin incubation of the first tube, 15pi of the reaction 
mix was removed from the water bath and spotted onto a pre-marked piece of ion 
exchange phosphocellulose paper P81 (Wliatman). This was carried out for each tube 
after they had each undergone the 10 min incubation with the substrate. The 
phosphocellulose pieces were then placed into a larger beaker containing 1% (v/v) 
phosphoric acid (H3PO4) and washed for 3 min with slight agitation. The waste acid 
was removed and the acid wash repeated. The phosphocellulose was then washed 
twice in dHzO before being placed in 1.5ml Eppendorf tubes, to which 1ml 
scintillation fluid was added. The ^^ P incorporated into the peptide bound to the 
phosphocellulose was counted on the Wallac 1409 liquid scintillation counter. To two
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separate vials 10pi of the radioactive 4x PKA substrate was added to scintillation 
fluid, to enable the determination of the total counts from the substrate solution.
2.2.4.2 Phosphodiesterase activity assay
A cAMP hydrolysis assay was used to measure phosphodiesterase activity, 
which was modified based on the two step procedure of Thompson and Appleman 
(Thompson and Appleman 1971) and Rutten et al, as described previously by 
Marchmont and Houslay (Marchmont and Houslay, 1980). The prineiples of this two- 
step assay are illustrated in Figure 2.2. In the first step, the samples to be assayed were 
incubated with 1 pM 8-[^H]-labelled cAMP substrate. In the second step, the [^H]- 
labelled product of cAMP hydrolysis, 5’AMP, was dephosphorylated to adenosine by 
incubation with 0.2 mg/ml snake venom that has 5’-nucleotidase activity. The 
conditions were such that complete conversion took place within the snake venom 
incubation time. The negatively charged unhydrolysed cAMP was then separated 
from the uncharged adenosine by incubation with Dowex ion exchange resin. The 
amount of unbound [^H]-adenosine in the supernatant was determined by scintillation 
counting in order to calculate the rate of cAMP hydrolysis.
2.2.4.2.1 Activation of Dowex
To activate, 400g of the Dowex 1 X8-400 resin was suspended in 4 litre of 
NaOH and incubated at room temperature for 15 minutes with gentle mixing. The 
resin was allowed to settle by gravity, after which the IM NaOH was removed. The 
resin was then extensively washed with 4 litre of distilled water (30 washes). After the 
last wash, the resin was resuspended in 4 litre of IM HCl and incubated at room 
temperature for 15 minutes with gentle mixing before being allowed to settle by 
gravity. The IM HCl was removed and the activated resin was resuspended 1:1 in 
distilled water and stored at 4°C until required.
2.2.4.2.2 Assay preparation
Samples of cell lysate (0.1-50 pg depending on activity) were placed into 1.5 
ml Eppendorf tubes and made up to a volume of 25 pi with 20 mM Tris-HCl, pH 7.4. 
Each sample was assayed in triplicate. All tubes were set up on ice, and remained on 
ice until all components for the assay had been added. To every tube, 50 pi of 2 pM
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cAMP containing 3 |aCi [^H]-cAMP in 20 mM Tris/HCl/lOmM MgCk pH 7.4 was
added, the tubes were vortexed and incubated at 30 °C for 10 min. After this time, the 
tubes were boiled for 2 min to tenninate the reaction and cooled on ice. 25 pg snake 
venom (either Ophiophagus Hannah or Crotalus atrox venom) in 25 pi 20 mM 
Tris/HCl, pH 7.4 was added to each tube, mixed by vortexing and incubated at 30 °C 
for 10 min. The tubes were cooled on ice and 400 pi Dowex/ethanol/distilled water, in 
a 1:1:1 ratio was added and mixed. The tubes were then further incubated on ice for at 
least 20 min. The tubes were vortexed and the Dewex separated from supernatant by 
centrifugation at 18,000 x g for 2 min (Heraeus bench top centrifuge). Finally, 150 pi 
of the clear supernatant was added to 1 ml Opti-seint scinllation fluid (Fisons 
Chemicals Ltd) and the [^H]-adenosine in these samples was counted for 1 min in a 
Wallac 1409 liquid scintillation counter. The cpms for each sample were conected for 
a background using a blank reaction (containing no PDE). The corrected counts were 
used to determine the initial rate of reaction (pmol cAMP hydrolysed/min). 
Determination of the protein content of the samples allowed the results to be 
expressed in units of pmol cAMP/min/mg protein.
2.2.4.2.3 Determination of PDE4 activity
The PDE4 family is specifically inliibited by the compound rolipram. 
Rolipram was dissolved in DMSO as 10 mM stock and this inhibitor was diluted in 
PDE assay dilution buffer (20 mM Tris/HCl/10 mM MgClz pH 7.4) for use in assay. 
DMSO itself does not affect PDE activity at the concentration used. Measurement of 
PDE4 activity with and without rolipram (10 pM) present gave the contribution of 
PDE4 in total PDEs.
2.2.5. Expression and Purification of GST Fusion Proteins
2.2.5.1 Induction and Purification of GST Fusion Proteins
A sample of the plasmid DNA of interest from glycerol stock was put into a 
50ml falcon tube that contained 30ml of L-Broth (170mM NaCl, 0.5% (w/v) Bacto 
Yeast Extract, 1% (w/v) Bacto-Tryptone pH 7.5) and lOOpg/ml ampicillin and 
cultured at 37°C overnight. The next day the overnight culture was inoculated into 
450ml of L-broth containing lOOpg/ml ampicillin and left for growing to OD^oo 
between 0.6 and 1.0 at 37°C. The protein that the interest plasmid DNA encodes were
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then induced by the addition of IPTG to a final concentration of 0.2mM, shaken in the 
incubator for a further 2-5 hours at 25°C-30°C at 200 i*pm. 1ml of the samples at 2.5hr 
intervals were taken to pellet at 18,000 x g and analysed by SDS-PAGE to monitor 
the induction. The cells after 5hr IPTG addition were pelleted at 2,400 x g at 4°C for 
lOmin and fi'ozen at -80°C overnight (In this step, the cells can be kept in -80°C for at 
least one month). The next day the frozen cells were thawed on ice, resuspended with 
10ml of ice cold resuspension buffer (50mM TrisCl pH8.0, lOmM sodium chloride, 
ImM EDTA, lOmM P-mercaptoethanol, Ix Roche protease inhibitor tablet) and 
transferred to ‘oak ridge’ centrifuge tubes. 1/10 volume of lOmg/ml Lysozyme was 
then added to the resuspended cells, and the mixture was incubated on ice for 15min. 
The cells were sonicated at power level 4 on ice (4x 30secs with 30sec rest). 1/500 
volume of 10% Triton X-100 was added to each oak ridge tube, mixed and 
centrifuged at 12,000 x g at 4°C for 15 minutes. The supernatant was transfeiTed to 
10/15ml centrifuge tube and 1 ml of glutathione beads pre-equilibrated in wash buffer 
(50mM TrisCl pH8.0, lOmM sodium chloride, ImM EDTA, lOmM (3- 
mercaptoethanol, Ix protease inhibitor tablet, 0.05% NP-40). The mixture was 
incubated at 4°C, end over end, for 1 hour, followed by centrifugation at 366 x g at 
4°C for 2 min. The supernatant was carefully removed and the beads were washed in 
5 ml wash buffer. The beads were centrifuged at 366 x g at 4°C for 2 min, and the 
supernatant was removed. 1 ml wash buffer was then used to transfer the beads to a 2- 
ml Eppendorf, and the beads were given a further 3x wash in 1 ml wash buffer. It is 
very important to keep the sample on ice as much as possible. The GST tagged fusion 
proteins were eluted from Glutathione Sepharose 4B (Amersham Biosciences) with 
lOmM glutathione in 50mM TrisCl pH 8.0. The beads were resuspended in 600pi of 
elution buffer (lOmM glutathione, 50mM TrisCl, pH 8.0), incubated at 4°C end over 
end for 20 min, and centrifuged at 18,000 x g in micro-centrifuge tubes for 10 
seconds. The supernatant was carefully removed to a fresh eppdorf tube. This elution 
step was kept repeating another 2-3 more times, and the elutes were pooled into a new 
2-ml Eppendorf tube. Again, during this procedure, the samples were kept icecold. In 
order to get rid of the free glutathione in the elutes, the pooled elutes in Slide-A- 
Lyzer® Dialysis Cassette (0.5-3.0ml capacity) (PIERCE) were dialysed in 650ml of 
chilled dialysis buffer (50mM TrisCl pH8.0, lOOmM NaCl, 5% glycerol), with three
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buffer changes. The dialysed fusion protein was collected and subject to protein 
concentration assay.
2.2.5.2 SDS PAGE
Samples of each stage from induction to purification were diluted 1/5 with 5x 
Laemmli sample buffer (260mM TrisCl, pH 6.7, 55.5% Glyeerol, 8.8% SDS, 0.007% 
Bromophenol Blue, 11.1% 2-mercaptopethanol), and boiled for 3 minutes to denature. 
3Opl of each sample was loaded into each well of the 4-12% Bis-Tris NuPage gel. The 
gel was run at a constant voltage until the dye front reached the bottom of the gel.
2.2.5.3 Staining of SDS Polyacrylamide Gels with Coomassie Brilliant Blue
Following separation by gel electrophoresis, the gel was ineubated in at least 
5 volumes of Coomassie Blue (1.25mg/ml Blue R250, 44.4% methanol, 5.6% acetic 
acid, 50% distilled water) with gentle shaking at room temperature for at least 4 
hours. The limit of detection for protein on Coomassie stained gel is 0.3-1 .Opg.
2.2.5.4 Visualisation of Proteins
Protein bands were visualised by incubation of the stained gel with Destain 
Buffer (44.4% methanol, 5.6% acetic acid, 50% distilled water) overnight at room 
temperature with gentle shaking. After destaining, the gel was rehydrated by 
incubating in 1% glycerol for 30 minutes at room temperature with gentle shaking.
2.2.5.5 Drying SDS Polyacrylamide Gels
Gels were dried on a Bio-Rad gel drier. The gel was placed on a wetted piece 
of filter paper, on top of which covered a cling film. The filter paper was facing the 
drying surface of the drier, and the cover sheet of the drier was then laid over the cling 
film. A vacuum was applied so the cover sheet made a tight seal over the gel. The lid 
of the drier was then closed and the gel was dried at 63°C for 2 hours.
2.2.6 Peptide Array Analysis
Peptide libraries were produced by automatic SPOT synthesis (Kramer and 
Schneider-Mergener 1998). Peptide libraries were synthesized on continuous cellulose 
membrane supports on Whatman 50 cellulose membranes according to standard
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protocols by using Fmoc-chemistry with the AutoSpot-Robot ASS 222 (Intavis 
Bioanalytical Instruments AG, Koln, Gennany).
Fresh peptide array membranes were immersed in pure ethanol for activation 
and then washed with Ix TEST (137mM NaCl, 20mM TrisCl, pH 7.6, 0.1% tween20) 
for 5 min, 3 times to get rid of the ethanol. The non-specific protein binding sites on 
the membrane were blocked with 5% skimmed milk powder in Ix TBST for 2 hrs at 
room temperature with agitation. The interaction of spotted peptides with either GST 
or the indicated GST fusion proteins was tested by overlaying the cellulose membrane 
with 10 pg/ml of recombinant protein overnight at 4 °C with vigorous shaking. The 
next day, the membrane was washed with Ix TBST for 5 min, 3 times, followed by 
incubation with rabbit antisera for the indicated protein species at room temperature 
for 2 hrs with vigorous shaking. Then the membrane was again washed with Ix TBST 
for 5 min, 3 times and subject to secondary anti-rabbit horseradish peroxidase coupled 
antibody incubation at room temperature for 1 hr with vigorous shaking, after which 
the membrane was washed three times in TBST. The membrane was then incubated 
with ECL reagents (Amersham Biosciences), according to the manufacturers’ 
instructions. The membrane was exposed to X-ray film (Kodak) in a darkroom and 
then developed using a Kodak X-omat.
2.2.7 In vitro Ubiquitination Assay
A Ubiquitination Kit (Biomol) was used in this procedure.
2.2.7.1 Ubiquitination Assay Pre-incubation
Assay components were added to a 15ml falcon tube in order shown below. 
All enzymes were kept on ice throughout the assay.
Components Volume / pi
dHzO 700
1 Ox Ubiquitination Buffer 250
IPP (lOOU/ml) 500
DTT (50mM) 50
Mg-ATP (O.IM) 125
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20x El (2pm) 125
lOx Ubc5Hb (0.5mg/ml) 250
20x GST-Mdm2 (2pM) 125
20x Bt-Ub (50pM) 125
2 2 ,1.2 In vitro Ubiquitination reaction
The contents in the falcon tube was mixed gently and then incubated with a 
PDE4D5 peptide array membrane at 37°C for 60 minutes. Reaction was stopped by 
washing the membrane with Ix TBST. Detection of the ubiquitin moieties on the 
peptide array was carried out as described above in Peptide AiTay Analysis, with the 
antibody that is specifically against the Ub.
2.3 Molecular Biology Techniques
All molecular biology techniques were earned out with sterilised equipment 
and buffers, to prevent contamination.
2.3.1 Large-scale production of plasmid DNA
Wizard Plus® Maxipreps (Promega) were used in this procedure.
2.3.1.1 Production of a cleared lysate
A pinch of plasmid DNA from glycerol stock was sub-cultured in 5 ml L- 
broth (170mM NaCl, 0.5% (w/v) Bacto Yeast Extract, 1% (w/v) Bacto-Tryptone 
pH7.5) containing lOOpg/ml ampicillin, shaken at 200 rpm 37°C for 4 hours. Then the 
subeulture was inoculated into 500ml L-broth containing the same concentration of 
antibiotics for overnight culture. The next day, the cells were harvested by 
centrifuging at 3754 x g using the JA-14 rotor in the Beckman refrigerated centrifuge 
for 10 minutes at room temperature. The supernatant was thrown away and the pellet 
was finely resuspended in 15ml Cell Resuspension Solution. 15ml Cell Lysis Solution 
was added to the cells that were then mixed by gently and thoroughly inverting. Once 
the solution became clear and viscous, 15ml Neutralization Solution was added to the 
cells and the centrifuge bottle which contained the mixed solution was immediately 
and gently mixed by gently inverting several times. The undesired cell debris was 
isolated by centrifugation at 5,000 x g for 10 minutes in room temperature. 30ml of
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Icleared supernatant was transferred by filtering through a Muslin cloth into a clean 
50ml centrifuge tube. 18ml of room temperature isopropanol was added into this tube, 
and mixed by inversion. The mixture was then subject to centrifugation at 14,000 x g 
for at least 2 hours in room temperature. The supernatant was discarded and the DNA 
pellet was resuspended in 2 ml of distilled water.
2.3.1.2 Plasmid DNA purification
10ml of Wizard® Maxipreps DNA purification Resin that was incubated in a 
37°C water bath beforehand was added to the resuspended DNA solution and swirled 
to mix. The resin/DNA mix was then transfeired into the Maxicolumn that was 
connected with a vacuum manifold port. A vacuum of at least 15 inches of Hg was 
applied to pull the resin/DNA mix into the Maxicolumn. 25ml of Column Wash 
Solution was added to the Maxicolumn and a vacuum was applied to draw the 
solution through the Maxieolumn. To rinse the resin, 5ml of 80% ethanol was added 
to the Maxicolumn and a vacuum was applied to draw the ethanol through the 
Maxicolumn. To allow all the ethanol removed, additional 1 minute was taken to 
vacuum the column. The undesired fraction was centrifuged at 1,300 x g with a 
swinging bucket rotor (Themro Life Sciences) for 5 minutes and discarded. The resin 
was then dried by applying to a vacuum for 5 minutes. The Maxicolumn was placed 
in a clean 50ml centrifuge tube and added 1.5ml of preheated (65-70°C) nuclease-free 
water. To elute the DNA, the Maxi column/5 0ml centrifuge tube were let stand for 1 
minute, followed by centrifugation at 1,300 x g for 5 minutes in a centrifuge with a 
swinging bucket rotor. The eluted DNA was then subject to DNA concentration 
determination and kept frozen in at least -20 °C.
2.3.2 Small-scale production of plasmid DNA
QIAprep Spin Miniprep Kit was used in this performance. A pinch of 
plasmid DNA from glycerol stock was cultured in 5 ml of L-broth medium containing 
desired antibioties with shaking at 200 rpm 37°C overnight. The next day, the cells 
were pelleted by a microcentrifuge at full speed for 10 minutes (18,000 x g). The 
pelleted bacterial cells were then resuspended in 250pl Buffer PI and transferred to a 
1.5ml microcentrifuge tube. 25Opl Buffer P2 was added into this tube, and the tube 
was gently inverted 4-6 times to mix. Then 350pl Buffer N3 was added, followed by
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another immediate gentle inversion 4-6 times, A compact white pellet formed after the 
tube was centrifuged at 18,000 x g for 10 minutes in a tabletop microcentrifuge. The 
supernatant was applied to the QIAprep Spin Column that was then subject to 
centrifuge at full speed for 1 minute. The flow-through was discarded. In order to 
remove trace nuclease activity, 500pl Buffer PB was added to the QIAprep Spin 
Column and centrifuged at full speed for 1 minute. Again, the flow-through was 
discarded. Then the QIAprep Spin Column was washed by addition of 750pl Buffer 
PE and centrifuged at full speed for 1 minute. After the flow-through was discarded, 
additional 1 minute was taken for spinning down the residual wash buffer at full 
speed. The QIAprep column was then placed in a clean 1.5ml microcentrifuge tube. 
To elute DNA from the column, 5Opl Buffer EB (lOmM TrisCl, pH 8.5) was added to 
the center of each QIAprep Spin Column, let stand for 1 minute, and centrifuged for 1 
minute at full speed (18,000 x g) to get the purified DNA that was collected in the 
microcentrifLige tube.
2.3.3 Quantification of purified DNA
The DNA concentrations were measured using a WPA light wave 
spectrophotometer blanked with distilled water. 5pi of DNA was diluted in 1 ml f  
distilled water and the absorbance measurements were taken at 260nm and 280nm.
The concentration of the DNA was then calculated using the following 
approximations:
An absorbance of 1 at 260nm correspond to 50pg/ml double stranded DNA
37pg/ml single stranded DNA
Easily, the concentrations of the plasmid DNA stored hum the lab would be 
equal to 10 times the number of the absorbance at 260nm.
The ratio between the absorbance measurements at 260nm and 280nm 
provided an indication of the purity of the DNA. In solution, DNA should have an 
A2 6 q:A2 8 o ratio around 1.8. If the absorbance ratio is significantly less than 1.8, it 
indicates that the DNA may be impure.
2.3.4 Site-Directed Mutagenesis
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2.3.4.1 Primer designs
For optimal 5’-primer design, the desired nucleotide bases that encode the 
new amino acid were chosen as identical to those that encode the parent amino acid as 
possible. The length of the flanking nucleotide sequence was varied dependent on the 
estimated melting temperature. Generally, between 45 and 50 nucleotides in length 
containing the desired mutation and flanked by unmodified nucleotide sequence with 
the estimated melting temperature around 75 °C was considered good, G or C was 
always chosen for the first and the last nucleotide in the primer.
The following fonnula is commonly used for estimating the melting 
temperature of the primers:
Tm (°C) « 2 (N a+Nt) + 4 (Nq+Nc)
Where N equals the number of primer adenine (A), thymidine (T), guanidine (G), or 
cytosine (C) bases.
The 5’- and 3 ’-primers designed for FDE4D5 UIM mutant (PDE4D5 723E) and that 
for PDE4D5 SUMO K mutant (PDE4D5K323R) were shown as follows:
5’-primer 3’-primer
723 E CTTGATGAACAGGTTGCAGCG TTCTTCCCCTACTGCCGCCGCTGC
GCGGCAGTAGGGGAAGAA AACCTGTTCATCAAG
K323R CCCAAGGTTTGGAGTTCGAACT
GAACAAGAAGATGTCC
GGACATCTTCTTGTTCAGTTCGAAC
TCCAAACCTTGGG
The mutated nucleotides were underlined.
2.3.4.2 Mutant Strand Synthesis Reaction (Thermal Cycling)
Site directed mutagenesis was performed using the QuickChange Site- 
Directed Mutagenesis Kit from Stratagene. For each mutant, two complimentary 
oligonuleotides containing the desired mutation and flanked by umnodified nucleotide 
sequence were synthesized and purified by high-pressure liquid chromatogiaphy
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(HPLC). The sample reactions were then prepared in Theimo-tubes (Abgene) as 
indicated below:
5 pi of lOx reaction buffer (supplied with the kit);
X pi (5-50 ng)of dsDNA template;
X pi (125 ng) of oliconucleotide primer #1 (sense primer);
X pi (125 ng) of oligonucleotide primer #2 (antisense primer);
1 pi of dNTP mix (supplied with the kit);
Sterile, deionised HzO to a final volume of 50pl;
NB: a series of sample reactions were set up with various concentrations of dsDNA 
template ranging from 5 to 50 ng (eg., 5, 10, 20, and 50 ng of dsDNA template) while 
the primer concentration was kept constant.
Then Ipl of PfuTurbo DNA polymerase (2.5U/pl) was added into each tube, 
followed by a good mix by gently vortexing. The reactions were cycled in a Techgene 
thermocycler PCR machine by using the cycling parameters outlined in Table II.
TABLE II.
Cycling Parameters for the QuickChange Site-Directed Mutagenesis Method
Segment Cycles Temperature Time
1 1 95°C 30 seconds
2 12 95°C 30 seconds
55°C 1 minute
68°C 2 minutes/kb of 
plasmid length
Following temperature cycling, the reactions were placed on ice for 2 
minutes to cool the reaction under 31°C.
2.3,4.3 Dpn I Digestion of the Amplification Products
1 pi of the Dpn I restriction enzyme (U/pl) (Stratagene) directly was added to 
each amplification reaction using a small pointed pipette tip. Each reaction mixture 
was gently and thoroughly mixed by pipetting the solution up and down several times.
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The reaction mixtures were then centrifuged at 18,000 x g in a microcentrifuge for 1 
minute and immediately incubated at 37°C for 1 hour to digest the parental 
supercoiled dsDNA.
2.3.4.4 Transformation of XLl-Bulue Supercompetent cells
The XL 1-Blue supercompetent cells (Stratagene) were gently thawed on ice. 
For sample reaction to be transformed, 50pl of the supercompetent cells were 
aliquoted to a pre-chilled Falcon® 2059 polypropylene tube. Ipl o f the Dpn I-treated 
DNA was then carefully transferred from each sample reaction to separate aliquots of 
the supercompetant cells, and the transfonnation reactions were swirled gently to mix 
and incubated on ice for 30 minutes. Heat pulse was performed to the transfoimation 
reactions by incubating those reaction samples in the water bath with temperate 42°C 
for 45 seconds, and then the reactions were placed on ice for 2 minutes, 0.5ml of the 
preheated to 42°C NZY+ broth (lOg casein hydrolysate, 5g yeast extract, 5g sodium 
chloride, in 1 litre, pH 7.5, autoclaved and supplemented with the filter-sterilized 
12.5ml Magnesium chloride, 12.5ml magnesium sulphate and 10ml 2M glucose) was 
added and the transformation reactions were incubated at 37°C for 1 hour with 
shaking at 200 rpm. For each sample mutagenesis, 250pl of each transformation 
reaction was placed on an agar plates containing lOOpg/ml ampicillin and incubated at 
37° for around 16 hours. The single colony was picked for further DNA extraction by 
using QIAprep Spin Miniprep Kit. The mutated DNA was sent to sequence before it 
was used in the later experiment.
2.3.4.5 Sequence Analysis
Routine DNA and deduced amino acid sequence analysis were performed on 
the Gene Jockey II programme. The identity of the sequences within 500 kilo-base 
pairs length of either side of the mutated site to the DNA templates was thought to be 
good.
2.3.4.6 Glycerol Stocks
A single colony was picked from an agar plate and was inoculated with 5ml 
of L-broth supplemented with a selection antibiotic (usually lOOpg/ml ampicillin). 
The culture was gi'own overnight at 37°C. After 16 hours, 1 ml of the overnight
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culture was transferred into a sterile eppendorf tube where was SOOjul of sterile 
glycerol (Riedel-deHaën) on the bottom. The glycerol stock was immediately frozen 
by dry ice and then stored at -80°C.
2.3.5 Agarose Gel Analysis of DNA
DNA was visualised using agarose gel electrophoresis. 1% agarose was 
dissolved in Ix TBE (9M Tris base, 20mM EDTA, 0.9M Boric acid) by heating in the 
microwave, during which the bottle that contained the mixture was gently swirled to 
reduce the bubbles in the solution. To this solution, 0.01% ethidium bromide was 
added, which enables visualisation of the DNA under a UV light source. A comb and 
end stoppers were then set up in the gel apparatus, according to the manufacturer’s 
instruction. Once the ethidium bromide was well mixed in the agarose solution, it was 
poured into the set up gel apparatus and allowed to set completely. The comb and end 
stoppers were then carefully removed, and the gel tank was filled with Ix TBE until 
the TBE buffer covered the solid gel. 5pi of standard 1Kb DNA ladder marker 
(Roche) was added to the first lane to enable the prediction of the size of DNA 
fragments, and all the diluted DNA samples 6:1 with 6 x Blue/Orange loading dye 
(Promega) were added sequentially from the second lane onto the gel. The gel was run 
at 50v until the dye front migrated along the gel and the fragments of DNA were 
separated. Then the gel was carefully removed from the tank and subject to UV light.
2,4 Laser Scanning Confocal Microscopy (LSCM)
2.4.1 Preparation of slides
HEK-B2 cells were plated onto poly(L-lysine)-treated coverslips (18mm x 
18mm) at approx. 40% confluence in 6  well tissue culture plates. After treatment with 
the indicated ligands, cells were fixed for 10 min in 4% (w/v) parafoiinaldehyde 
(dissolved in Tris buffered saline (TBS) (150 mM NaCl, 20 mM Tris, pH 7.6) and the 
coverslips were washed three times, for 5 min each time, in TBS. Cells were then 
permeabilized in 0.2% Triton-contained TBS for 15 min, and blocked in a blocking 
solution (10% goat serum, 4% BSA dissolved in TBS) at room temperature for llir. 
The primary antibody used specifically to detect phosphorylation of the piAR on 
Ser355/356 by GRK2 or on Ser345/346 by PKA was diluted to the required 
concentration in diluting buffer (blocking buffer dilute 1:1 with TBS) and 200 pi of
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the primary antibody solution was added to each slide. This incubation time was 
around 2 hrs at room temperature. The cells were washed three times with 5 min 
incubations in blocking solution and incubated with 200 pi of 1:400 diluted Alexa 
Fluor 594 fluorophore-conjugated IgG (Molecualr Probes) for 1 hr. Cells were then 
washed extensively with TBS (~5 times), and mounted on microscope slides with 
Immunomount (Sandon).
2.4.2 Visualization of cells
The cells were visualized using a Plan-Apo 40 x 1.4 NA oil immersion 
objective and the Zeiss Pascal laser-scanning confocal microscope (Zeiss, 
Oberkochken, Germany). The Alexa 594-conjugated antibody was excited at 543 mu 
and detected at 590 ran. The GPP tagged on the P2 AR was excited at 495 ran and 
detected at 518 ran.
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Companies Antibodies
Abeam Anti-Proteasome 19S S5A; 
Anti-Proteasome 19S SI; 
Anti-Proteasome 19S S2; 
Anti-Proteasome 19S S6 ; 
Anti-Proteasome 19S S12
Affinity BioReagents Anti-arrestin (Pan)
Amersham Biosciences Anti-mouse IgG peroxidase conjugate
BD Pharmingen Anti-Mdm2
BD Transduction Laboratoties Anti-RACKl;
Anti-Ubc9
Cell Signalling Technology Phospho-p44/42 MAP Kinase 
(Thr202/Tyr204); 
p44/42 MAP Kinase antibody; 
Phospho-(Ser/Thr) PKA substrate antibody
CALBIOCHEM Anti-GFP
GENESIS Anti-GST
ICOS Anti-PDE4D
Santa Cruz Biotechnology p-p2 -AR (Ser345/Ser346) antibody; 
P-P2 -AR (Ser355/Ser356) antibody; 
p2 -AR (H-20) antibody;
Anti-GRKl (C-20); Anti-GRK2 (C-15); 
Anti-GRK3 (C-14); Anti-GRK4 (H-70); 
Anti-GRK5 (C-20); Anti-GRK6  (C-20) 
Anti-Ub (P4D1)
SAPU Anti-PDE4B
UPSTATE Anti-AKAP79; Anti-gravin
Zymed Laboratories Lnc. Anti-GMP-1 (SUMO-1); 
anti-Sentrin 2 (SUMO-3)
Companies Inhibitors
Calbiochem U0126 (forMEK);
H89 (for PKA);
MG-132
Rolipram
Cilostomide
Figure 2.1 Table of antibodies and inhibitors produced by companies other than 
SIGMA.
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Chapter 3
;
The Role of PDE4 in Pi-adrenergic Receptor Desensitization
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3.1 Introduction
Extracellular signals provided by molecules such as hormones and 
neurotransmitters are relayed into cells tlirough a large family of membrane receptors 
known as GPCRs (G protein-coupled receptors) (Lefkowitz and Whalen 2004). These 
agonist-occupied GPCRs are activated, adopting new conformations to confer 
coupling to membrane-localized G proteins, and thus promoting the dissociation of 
membrane bound heterotrimeric G proteins into G a and G(3y subunits. The activated 
G protein subunits then amplify and transduce signals within cells to modulate the 
activity of effector molecules, such as adenylyl cyclases, phospholipases and ion 
channels (Shenoy and Lefkowitz 2003). In order to prevent the potential harmful 
effects resulting from persistent receptor stimulation, an adaptive response used by 
cells to constrain G protein signaling, a process known as ‘desensitization’ is initiated, 
and the intensity of the functional response to hormone wanes over time. For most of 
GPCRs that have been studied, desensitization follows a universal mechanism that 
involves two families of proteins, the GRKs (G protein coupled receptor kinases) and 
the arresting (Lefkowitz and Whalen 2004),
In the case of the prototypic p2 -adrenergic receptor (P2 AR), agonist 
stimulation leads to its binding to and activating the G protein, Gs (Pierce et al. 2002). 
While the freed G a subunit activates membrane-localized adenylyl cylases and 
generates compartmentalized cAMP near plasma membrane, the resultant GPy 
subunits recmit GRK2 to the membrane, allowing it to phosphorylate the P2 AR at 
residues on its carboxyl tenninus (Lodowski et al. 2003). This phosphorylation 
promotes the high affinity binding of cytosolic p-arrestins and triggers the recruitment 
of these aiTestins to the membrane-bound, GRK2-phosphorylated P2 AR. Such binding 
of P-arrestin to the P2 AR prevents further coupling to its cognate Gs proteins, and 
mediates the clathrin-dependent internalization of P2AR (Lefkowitz and Shenoy 
2005). Additionally, phosphorylation of P2 AR appears to play another important 
mechanism for its desensitization, which involves a feedback loop in which the 
increased cAMP generated by the agonist stimulated P2 AR, activates PKA that 
switches the pzAR coupling to the G protein, Gi, and ultimately attenuates production
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of the cAMP (Daaka et al. 1997). This PKA mediated phosphorylation of P2 AR and 
subsequent switching also leads to the activation of ERKl/2 (extracellular signal- 
regulated kinases 1 /2 ) pathway.
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PDEs (phosphodiesterases) provide the sole means to degrade cAMP in cells 
(Houslay and Adams 2003). Currently, there is much interest in members of the 
cAMP-specific PDE4 family, because PDE4 selective inhibitors have potential 
therapeutic benefits for treating asthma and chronic obstructive pulmonary disease, 
and they can also act as cognitive enhancers and anti-depressants (Houslay et al. 2005; 
O’Donnell and Zhang 2004).
The PDE4 family is encoded by four genes, called PDE4A, PDE4B, PDE4C, 
and PDE4D (Houslay and Adams 2003). Each gene generates a number of isoforms 
due to the different transcriptional starting site as well as alternative mRNA splicing. 
These isoforms are expressed on a tissue and cell type-specific basis (Houslay and 
Adams 2003; Conti et al. 2003). A feature o f PDE4 isofomis is their ability to target 
to distinct intracellular sites. This feature can be due to their foiming signaling 
complexes with a variety of scaffolding or signaling proteins and thus integrating with 
other signaling pathways. So far, there are a number of proteins that are identified to 
interact with specific PDE4 isoforms, such as Src family tyi'osine kinases (McPhee et 
al. 1999), RACKl (receptor for activated C-kinase 1) (Yaiivood et al. 1999), 
myomegalin (Verde et al. 2001) and AKAPs (McCahill et al. 2005; Tasken et al. 2001; 
Dodge et al. 2001). Recently, Peny et al. demonstrated that the p-arrestins bind 
PDE4D family, and in particular, PDE4D5 (Perry et al. 2002). These complexes exist 
in the cytosol and are recruited to the plasma membrane in an agonist-dependent 
manner by viitue of P-arrestin translocation. The functional importance of this P- 
aiTestin-delivered PDE4D is to hydrolyse localised cAMP around the activated 
receptor at an enhanced rate, thus slow the rate of PKA activation and subsequent 
P2 AR Gi switching with consequential ERK activation. In doing so, p-arrestin plays a 
dual role in desensitizing P2 AR as it not only slows the rate of P2 AR/Gs-stimulated 
cAMP generation, but in a coordinated fashion increases the rate of cAMP 
degradation in proximity to receptor-adenylyl cyclase signalling unit.
Several recent studies have shown that receptor phosphorylation by GRK2 is 
modulated by other kinases, such PKA, PKC, Src and ERKl/2 (Figure 3.1) (Kohout 
and Lefkowitz 2003). The effects of a particular phosphoiylation event are dependent 
on what sites are being phosphorylated. Phosphorylation effects include the changes 
in GRK2 catalytic activity, protein binding affinity and its turnover rate. Among these 
phosphoiylating kinases, PKA has been shown to phosphorylate GRK2 at Ser685 and 
increase its binding affinity towards free GPy, rather than directly enhance its activity, 
thereby accelerate the recmitment of active GRK2 to the plasma membrane. This 
facet of GRK2 regulation provides a fundamental step in the P2 AR desensitization. In 
the case of PKA, its activity is mediated by the intracellular levels of cAMP that is 
shaped by PDEs in HEKB2 cells. Thus, PDE4 may be acting as a guardian that 
coordinates this event that is crucial to the initial stages of P2 AR desensitization.
The experiments outlined in this chapter, investigate whether PDE4 activity 
can regulate GRK2 phosphorylation by PKA, and whether PDE4 activity can 
influence the rate of P2 AR desensitization thi'ough its direct action on GRK2 
distribution.
3.2 Results
3.2.1 The isoprenaline-stimulated PKA phosphorylation of GRK2 is amplified by 
inhibition of PDE4
3.2.1.1 GRK2 is the major species among 7 GRKs in HEKB2 cells
So far, 7 members of GRK family have been identified. As GRKl and GRK7 
are almost exclusively expressed in retina, so detection of the expression of the other 
five GRK species was attempted in HEKB2. Endogenous GRK2-GRK6 were 
analysed in resting HEKB2 cells by Western blotting using antisera specific against 
GRK2, GRK3, GRK4, GRK5 and GRK6 , respectively. In contrast with that of GRK2, 
antisera against GRK3, GRK4, GRK5 and GRK6  failed to detect these species in 
HEKB2 cells (Figure 3.2), suggesting that GRK2 is the major species in these cells. 
Thus, in this chapter, I will only focus on the effect of PDE4 on GRK2.
3.2.1.2 Isoprenaline stimulates PKA phosphorylation of GRK2 in HEKB2 cells
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Cong et al. have shown that GRK2 can be phosphorylated at Ser685 by PKA 
in vitro, so I set out to investigate whether this phosphorylation can occur in HEKB2 
cells when the p-agonist isoprenaline was added.
HEKB2 cells were subjected to an isoprenaline time course (O-lOmin), and 
haiwested in 3T3 lysis buffer. As no phospho-antibody to the PKA phosphorylation 
site on GRK2 was available, GRK2 was immunopurified and then blotted with an 
antibody that specifically detects PKA phosphorylated substrates. Once the lysates 
were obtained, GRK2 was inimunoprecipitated from HEKB2 cells using a GRK2- 
specific antibody. The resultant immunoprecipitate was probed with anti-GRK2 
(Figure 3.3 a, lower panel), and anti-PKA substrate antibody (Figure3.3 a, upper 
panel), respectively. GRK2 migi'ated as a single immunoreactive species at 79 kDa. In 
the presence of isoprenaline, the anti-PKA substrate antibody revealed a time- 
dependent appearance o f PKA-phosphorylated GRK2 (Figure 3.3 a,b). Similarly, 
when the anti-PKA substrate was used to immunoprecipitate PKA-phosphorylated 
proteins from HEKB2 cells, followed by probing the immunopurified samples with 
anti-GRK antibody, a single 79 kDa species was detected following 5 min of 
isoprenaline treatment (Figure 3.3 c,d). Both these experiments confirm that 
isoprenaline causes a time-dependent PKA phosphorylation of GRK2 in HEKB2 cells.
3.2.1,3 PDE4 inhibition enhances isoprenaline-induced PKA phosphorylation of 
GRK2 in HEKB2 cells
PDEs provide the sole means of hydrolyzing cAMP in cells (Houslay and 
Adams, 2003). In HEKB2 cells, approximately 60% of the cAMP PDE activity is 
contributed by PDE4 (Peny et al. 2002; Lynch et al. 2005). The functional importance 
of PDE4 family can be assessed by chemical ablation of PDE4 activity using the 
PDE4-selective inhibitor rolipram (Houslay and Adams, 2003). In order to determine 
whether PDE4 is involved in the PKA phosphorylation of GRK2, the PDE4-selective 
inhibitor rolipram was used to chemically ablate PDE4 activity in HEKB2 cells. Cells 
were pre-incubated with lOpM rolipram for 10 min, and then challenged with 
isoprenaline for a 1-10 min time course. Then these treated cells were haiwested in 
3T3 lysis buffer at the indicated time, followed by centrifugation to pellet cell debris 
at 18,000 X g. Supernatants were then analysed. In all experiments the protein
concentration of the lysates for each time point was normalized. In similar 
experiments to those described above but this time using a rolipram pre-incubation, I 
observed that the presence of the PDE4-selective inhibitor rolipram accelerated the 
ability of isoprenaline to cause PKA phosphorylation of GRK2 (Figure 3.3 a, c).
In order to confirm that the enhanced PKA phosphorylation of GRK2 
mediated by PDE4 inhibition was actually PKA-dependent, a specific PKA inhibitor 
H89 (IpM ) was pre-incubated together with rolipram for 10 min before the 
isoprenaline challenge. Doing this, no PKA phosphorylation of GRK2 was detected 
(Figure 3.3 a, c).
3.2,1.4 PDE4 inhibition alone is able to cause time-dependent PKA 
phosphorylation of GRK2
In the studies above, HEKB2 cells were challenged with isoprenaline after a 
10 min pre-incubation with rolipram. However, PKA phosphorylation of GRK2 was 
clearly evident in rolipram-pretreated cells before the addition of isoprenaline (zero 
time; Figure 3.3 a, c). Thus, I set out to examine if the addition of rolipram alone can 
elicit PKA phosphorylation of GRK2 and if this phosphorylation is time-dependent. 
HEKB2 cells were subjected to rolipram treatment alone (0-10 min time course) and 
GRK2 phosphorylation by PKA was observed as before. The results here showed that 
addition of rolipram alone can cause the time-dependent PKA phosphorylation of 
GRK2 (Figure 3.4 upper panel), and that PKA inhibitor H89 ablated this effect 
(Figure 3.4 lower panel).
Interestingly, despite the fact that 40% of total cAMP PDE activity in 
HEKB2 cells is contributed by PDE3 (Lynch et al. 2005), the PDE3-selective 
inhibitor, cilostamide, failed to trigger such a PKA phosphorylation of GRK2 (Figure
3.4 lower panel). This suggests that PDE3 exerts different compartmentalized actions 
from PDE4 in HEKB2 cells. Indeed, in many cell types, it has been shown that 
selective inhibition of PDE3 and PDE4 result in very different functional outcomes 
(Maurice et al. 2003; Huang et al. 2001).
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3.2.2 The effect of PDE4 inhibition on PKA phosphorylation of GRK2 is not 
PDE4 subfamily-specific
Recently, Lynch et al. developed siRNA reagents and transfection conditions 
that allow for the selective ablation (>95%) of expression and activity of PDE4B, 
(PDE4B2), which contributes 30% of the total PDE4 activity in HEKB2 cells, and 
PDE4D, (PDE4D3 and PDE4D5), which provide 60% of the total PDE4 activity in 
HEKB2 cells. Although the use of rolipram can assess the functional importance of 
PDE4 action, it cannot discriminate between the actions of PDE4 subfamilies. Thus, 
in order to evaluate the individual contribution of PDE4B and PDE4D to the PKA 
phosphorylation of GRK2, I used HEKB2 cells that were treated with siRNA against 
PDE4B, PDE4D, or both PDE4B and PDE4D.
Ablation of either PDE4B or PDE4D subfamilies resulted in an enhanced 
agonist triggered PKA phosphorylation of GRK2 (Figure 3.5 upper panel). Such 
results support the data obtained from chemical ablation of PDE4 activity (Figure 3.3 
a, c). However, in contrast to the detection of increased PKA phosphorylation of 
GRK2 in resting HEKB2 cells (Figure 3.4 upper panel), siRNA-mediated knockdown 
of either PDE4B or PDE4D alone failed to achieve this effect (Figure 3.5 upper 
panel). Interestingly, knockdown of both PDE4B and PDE4D together did achieve 
such an increase (Figure 3.5 lower panel). Indeed, such a combined knockdown 
resembles that of rolipram, which inhibits both of these PDE4 families. Thus, it 
appears that the effect of PDE4 on PKA phosphorylation of GRK2 is not subfamily- 
specific.
3.2.3 PDE4 inhibition enhances isoprenaline-stimulated membrane translocation 
ofGRK2
PKA phosphorylation of GRK2 has been previously suggested (Cong et al. 
2001 ) to increase the binding affinity of GRK2 towards free Gpy subunits near the 
plasma membrane. This event occurs after activation of the agonist-occupied receptor, 
promoting membrane recruitment of GRK2 and subsequent GRK2 phosphorylation of 
the receptor. As inhibition of PDE4 enhances isoprenaline-sitmulated PKA 
phosphorylation of GRK2, I investigated the functional consequences of this and
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examined whether enhanced PKA phospolirylation of GRK2 resulted in changes in 
GRK2 membrane translocation.
HEKB2 cells were treated with 1 OpM isoprenaline in the absence/presence of 
lOpM rolipram, and harvested at indicated times. Membrane fractions were obtained 
as described in Materials and Methods, and analysed by Western blotting with a 
specific anti“GRK2 antibody. The amount of GRK2 which had translocated to the 
membrane under different treatments was quantified by densitometry. Here, I show 
that challenge of HEKB2 cells with isoprenaline elicited a time-dependent membrane 
translocation of cytosolic GRK2 (Figure 3.6 a, left panel). However, if  the cells were 
pre-treated with rolipram, this recruitment was not only accelerated, but also was 
clearly transient in nature (Figure 3.6 a, left panel).
This surprising change in the kinetics of GRK2 membrane recruitment led 
me to examine further the factors that might directly mediate this process. 
Considering the other kinases that can regulate GRK2 by direct phosphorylation, ERK 
was chosen to study as it has been shown (Penn 2000) that ERK phosphorylation of 
GRK2 decreases its binding affinity to Gpy subunit and thus potentially promotes its 
release from the plasma membrane back to the cytosol. By additionally treating cells 
with the MEK (mitogen-activated protein kinase/ERK kinase) inhibitor, U0126, I 
observed that such transient translocation of GRK2 to membrane, after rolipram pre­
incubation, was abolished and GRK2 was maintained in the plasma membrane 
throughout the time course (Figure 3.6 a, right panel).
Again, it was evident that rolipram pre-treatment alone sufficed to stimulate 
GRK2 translocation (Figure 3.6 a, left panel; zero time). In order to investigate the 
kinetics of the rolipram induced translocation, a 0 - 1 0  min time course was earned out 
using 10 pM rolipram (Figure 3.6 b, upper panel). As a control, IpM  H89 was added 
10 min before rolipram challenge, and this ablated GRK2 recruitment to the 
membrane fraction (Figure 3.6 b, lower panel). Thus, treatment o f HEKB2 cells with 
rolipram alone can cause both the PKA phosphorylation of GRK2 (Figure 3.4) and its 
time-dependent membrane translocation (Figure 3.6 b).
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In order to further assess the PKA phosphorylation status of GRK2 at the 
plasma membrane, I combined both membrane fractionation and subsequent 
immunoprécipitation (as described in Materials and Methods) after treating the 
HEKB2 cells (3 min isoprenaline challenge; 10 min Roli+H89 pre-treatment, 
followed by 3 min isoprenaline challenge; or 10 min rolipram pre-treatment plus 3 
min isoprenaline challenge). Similar to the results obtained from experiments using 
cell lysates, the PKA phosphorylated form of GRK2 was shown to be membrane 
recruited following isoprenaline treatment, and accumulate more in the presence of 
rolipram. Recruitment was abolished by pre-treatment with H89 (Figure 3.7) 
reinforcing the absolute requirement of activated PKA for this process to occur.
3.2.4 PDE4 inhibition accelerates phosphorylation of the P2AR by GRK2
One of the functions of membrane-localized GRK2 is to phosphorylate P2 AR 
and mediate the subsequent desensitisation process. Since PDE4 inhibition has been 
shown to result in enhanced and more transient membrane translocation of GRK2, I 
set out here to study the GRK2 phosphorylated status of piAR.
HEKB2 cells were challenged with isoprenaline during a 0-10 min time 
course, and haiwested in 3T3 lysis buffer. Clear lysates were obtained after 18,000 x g 
centrifugation and nonnalised to equal protein levels. These nonnalised lysates were 
then subjected to Western blotting and probed with a specific phospho-antiserum 
against the GRK2 phospho site on the P2 AR, Ser 355/356. It was clear that 
isoprenaline challenge of HEKB2 cells led to the time-dependent phosphorylation of 
P2 AR by GRK2 (Figure 3.8 a). This action was ablated upon siRNA-mediated 
knockdown of GRK2 (Figure 3.8 b), confirming the requirement o f GRK2.
In order to assess the effect of PDE4 inhibition on GRK2-phosphorylation of 
the P2 AR, HEKB2 cells were pretreated with rolipram before isoprenaline challenge 
at indicated times. This treatment appeared to accelerate the ability of isoprenaline to 
trigger the phosphorylation of the P2 AR by GRK2 (Figure 3,8 a), indicating that 
PDE4 gates the action of GRK2 on P2 AR after agonist binding.
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Indeed, challenge with rolipram alone can also cause the time-dependent 
GRK2 phosphorylation of the piAR (Figure 3.9 a). This corresponded well with the 
obseiwed recruitment of GRK2 after rolipram treatment (Figure 3.6 b, upper panel). 
The ability of rolipram to promote the GRK2 phosphorylation of P2 AR was ablated 
upon GRK2 knockdown (Figure 3,9 b).
Results shown earlier in this chapter suggested that the combined effects of 
PDE4B and PDE4D contributed to the change in PKA phosphorylation of GRK2, 
which mimicked rolipram action. Using siRNA I investigated whether the combined 
action of PDE4B and PDE4D also resulted in increased phosphorylation of p%AR by 
GRK2.
Control cells and cells pre-treated with specific siRNA to PDE4B and 
PDE4D were challenged with 10 pM isoprenaline during a 0~5 min time course. The 
lysates were subjected to Western blotting by specific antibodies against PDE4B and 
PDE4D, respectively. And it was observed that 95% of PDE4B and PDE4D were 
knocked down. Following siRNA-mediated knockdown of both PDE4B and PDE4D, 
the lysates were probed with antiserum specific against the P2 AR phospho 
Ser355/356. As was the case with GRK2 recruitment to the membrane (Figure 3.6 a), 
GRK2-mediated phosphorylation of P2 AR increased when both PDE4B and PDE4D 
were genetically ablated (Figure 3.10).
Consistent with previous data from rolipram experiments, siRNA-mediated 
ablation of PDE4B and PDE4D also increased the GRK phosphorylation of the P2 AR 
in resting (unstimulated) cells (Figure 3.10, zero time).
3.2.5 PDE4 inhibition accelerates membrane recruitment of p-arrestin and 
PDE4D
Perry et al. have shown that isoprenaline stimulates the time-dependent, 
transient and concomitant membrane recruitment of both p-arrestin and PDE4D in 
HEKB2 cells (Perry et al. 2002). I confirmed this in the present study by probing the 
membrane fiaction from each time point with antiserum against p-anestin and 
PDE4D respectively. Additionally, I showed that in isoprenaline-challenged cells that
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%had been pre-treated with lOpM rolipram for 10 min, the transient membrane 
recruitment of p-arrestin and PDE4D, occuned more rapidly (Figure 3.11).
Indeed, I noticed that challenge of HEKB2 cells with rolipram alone sufficed 
to cause membrane recruitment of both p-arrestin and PDE4D3/D5 (Figure 3.12, left 
panel). Comparing these time courses to experiments when GRK2 translocation was 
examined under the same conditions, it was apparent that the concomitant membrane 
recruitment of p-arrestin and PDE4D3/D5 occurred later than the recruitment of 
GRK2 (Figure 3.6 b) and GRK phosphorylation of the P2AR (Figure 3.9 a). These 
kinetics make sense as others have shown that the recruitment of arrestin is dependent 
on the phosphorylation of the receptor by GRK2 (Lefkowitz and Shenoy 2005). All 
such rolipram-induced translocations were ablated by H89 (Figure 3.12, right panel).
3.2.6 Analysis of PDE4 inhibition effect on ERK-phosphorylated GRK2
HEKB2 cells were challenged with isoprenaline in the absence/presence of 
rolipram over a 0-10 min time course and haiwested in KHEM buffer. Membrane 
fractions were obtained and subjected to Western blotting with the specific antiserum 
against phospho-GRK2 Ser670 (which is the site of ERK phosphorylation on GRK2). 
It was shown that challenge of HEKB2 cells with isoprenaline caused a time- 
dependent increase in the level of ERK-phosphorylated GRK2 at the membrane 
(Figure 3.13, upper panel), and that in the presence of rolipram, such an increase was 
not only accelerated, but was also shown to be profoundly transient in nature (Figure 
3.13, lower panel). In fact, the transience o f this effect bears similarities with the time- 
dependent membrane recruitment of GRK2 (Figure 3.6 a). However, in contrast with 
this observation (Figure 3.6 b), I did not detect any signal for ERK phosphorylated 
GRK2 fi'om the 10 min rolipram alone-treated HEKB2 cells (Figure 3.13), as 
indicated by the zero time point in the isoprenaline challenge time course with 1 0  min 
rolipram pre-incubation.
The two distinct observations on the effect of sole PDE4 inhibition in 
regulating GRK2 membrane recruitment and ERK phosphorylation status of GRK2 
can be further explained by the different actions of PKA and ERK.
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In the absence of isoprenaline, rolipram alone is sufficient to stimulate PKA 
and subsequently, induces PKA phosphorylated GRK2 (Figure 3.4, upper panel), 
triggering GRK2 membrane translocation (Figure 3.6 b). However, inhibition of 
PDE4 by rolipram was not able to cause ERK activation (Figure 3.14, zero time point; 
negative time course of 0-10 min, 10 pM rolipram), which is due to the lack of pzAR 
switching from Gs to Gi. Indeed, challenge of HEKB2 cells with isoprenaline is 
known to be required to activate ERK (Figure 3.15) (Baillie et al. 2003; Lynch et al. 
2005). Rolipram pre-treatment of isoprenaline-challenged cells markedly enhanced 
the magnitude and kinetics of this process (Figure 3.15). This may explain the more 
rapid ERK phosphorylation of membrane associated GRK2 that ensues in rolipram 
pre-treated cells challenged with isoprenaline (Figure 3.13).
3.2.7 Analysis of PDE4 inhibition on the trafficking and GRK phosphorylation 
status of the P%AR in HEKB2 cells
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To evaluate the contribution of PDE4 to the development of p%AR 
phosphorylation by GRK and to visualize internalization by confocal 
immunohistochemistry, I examined the ability of the PDE4-selective inhibitor to 
affect these processes in an agonist dependent maimer. GRK-phosphorylated P2 AR 
(Ser355/356) can be detected using a specific antibody which has been extensively 
characterized by others (Tran et al. 2004). Thus, I used this reagent to define the 
temporal and spatial dynamics o f the GRK2-phosphorylated foim of the P2 AR in 
HEKB2 cells (Figure 3.22). In these studies, the green fluorescent chamiel detects the 
GFP-tagged P2 AR, and the red channel detects the GRK2 -pho sphoryl ated P2 AR.
Therefore, the merged images of the two channels will identify the GRK2- 
phosphorylated form of P2 AR as a yellow signal (Figure 3.22). Here, I observed that 
challenge of HEKB2 cells with isoprenaline leads to a steady increase in pzAR 
phosphorylation by GRK over the time course (Figure 3.22, upper panel). Also 
evident is that internalisation of the pzAR began after 8 min of isoprenaline 
stimulation and a major fraction of the pzAR population is internalised some 16 min 
after isoprenaline challenge (Figure 3.22, upper panel). In the presence of rolipram, 
the increases in both pzAR phosphorylation and internalisation are seen earlier 
throughout the time course. Additionally, basal GRK phosphoiylation of the pzAR
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and internalisation in HEKB2 cells pre-treated with rolipram (without agonist) are 
evident, indicating that rolipram alone can affect the kinetics of GRK-phosphorylation 
of this receptor (Figure 3.22, lower panel), which is consistent with the biochemical 
data presented previously (Figure 3.3 a, c).
3.2.8 Rolipram triggers PKA phosphorylation of GRK2 in cardiac myocytes
It is known that impaired PzAR signalling, especially impaired 
desensitisation resulting from persistent GRK2 activation, leads to the pathogenesis of 
heart failure (Pemi et al. 2000; Tachibana et al. 2005). It is also known that PDE4D 
gene inactivation in mice can lead to accelerated heart failure after myocardial 
infarction (Kehnart et al. 2005). Consequently, work in this chapter sought to 
investigate whether the underlying trend that PDE4 activity could gate PKA 
phosphorylation of GRIC2 and influence subsequent downstream signalling events 
could also be envisaged in cultured neonatal cardiac myocytes. To this end I 
perfomied similar biochemical techniques in these cells to those employed for 
HEKB2 cells. The results showed that challenge of cardiac myocytes with 
isoprenaline caused the time-dependent PKA phosphorylation of GRK2 (Figure 3.16), 
and also caused membrane recmitment of GRK2 (Figure 3.17). These responses were 
amplified by pre-incubation with rolipram (Figure 3.16, Figure 3.17). Consistent with 
the previous data obtained in HEKB2 cells, treatment of cardiac myocytes with 10 
pM rolipram alone sufficed to trigger both PKA phosphorylation of GRK2 (Figure 
3.16) and membrane recmitment of GRK2 (Figure 3.17). As a negative control, 1 pM 
H89 was added before challenge with rolipram, which ablated the actions of rolipram 
(Figure 3.16 and Figure 3.17, right panel), confirming the role of rolipram in gating 
PKA actions on GRK2 in cardiac myoctyes. This provides further evidence of the 
cmcial role of PDE4 in preventing inappropriate activation of GRK2 in cardiac 
myocytes. These observations may have potential for the development of novel 
therapies to treat heart failure.
3.2.9 PDE4 inhibition enhances isoprenaline-stimulated PKA phosphorylation of 
PzAR
The P-agoni S t ,  isoprenaline, elicits the phosphorylation of the PzAR both by 
GRK and by PKA (Pierce et al. 2002; Pronin et al. 2002; Perry and Lefkowitz 2002;
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Lefkowitz et al. 2002). Both kinases contribute to pzAR desensitization, via different 
molecular mechanisms. As I have already studied the role of PDE4 in GRK2- 
mediated pzAR desensitization, here, I will focus on its effect in the PKA-mediated 
pathway.
HEKB2 cells were challenged with 10 pM isoprenaline in the 
absence/presence of 10 pM rolipram during a 0-10 min time course. Cells were 
harvested and protein levels were nonnalised. The PKA phosphorylation of pzAR was 
analyzed using a specific phospho-antiserum against the phospho-PzAR at Ser345-346. 
As previously noted (Baillie et al. 2003), isoprenaline challenge of these cells causes 
the transient phosphorylation of the p2AR (Figure 3.18 a). However, the added 
presence of rolipram, profoundly potentiates both the speed and magnitude of this 
response (Figure 3.18 a, b). This amplification was ablated upon treatment of PKA 
inhibitor H89 (Figure 3.18 c). A specific antiserum against total PzAR was used as a 
loading control (Figure 3.18 a).
To study this effect further, I employed confocal immunohistochemistry to 
analyse these effects visually. The PKA-phosphorylated PzAR (Ser345/346) can be 
detected using a specific antibody. Thus, I used this reagent to define the temporal and 
spatial accumulation of the PKA-phosphorylated fonri of the pzAR in HEKB2 cells 
(Figure 3.23). In these studies, the green fluorescent channel detects the GFP-tagged 
P2AR, and the red channel detects the antibody against the PKA-phosphorylated 
pzAR. Therefore, the merged images for both channels will identify the PKA- 
phosphorylated fonn of PzAR as a yellow signal (Figure 3.23). Here, I show that 
without rolipram pre-treatment, no detectable PKA-phosphorylated pzAR is seen 
under basal conditions. However, addition of isoprenaline caused the pzAR to become 
quickly phosphorylated and, subsequently, internalised. Furthermore, rolipram 
treatment alone could induce PKA phosphorylation of the receptor and agonist 
induced effects were both faster and more profound (Figure 3.23, lower panel), when 
rolipram was present (Figure 3.23, upper panel). Taken together, the biochemical and 
immunohistochemical data support each other and suggest that PDE4 has a role in 
controlling the PICA phosphorylation of the PzAR.
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3.2.10 Isoprenaline-stimulated phosphorylation of PzAR by PKA is dependent 
upon AKAP79 but not gravin
Gradients of cAMP in cells are sampled by anchored forms of PKA that bind 
to members of a family protein known as AKAPs (Tasken and Aandahl 2004; Michel 
and Scott 2002). Although AKAPs are stmcturally unrelated, they all interact with 
PKA in the same manner through the dimmerization interface of the regulatory 
subunits (Newlon et al. 1999).
It has been shown previously that the PzAR can be co-immunoprecipitated 
from rat brain with AKAP150, the rodent homologue of human AKAP79 (Fraser et al.
2000), indicative of a constitutive interaction between these two species. Here, I show 
that in HEKB2 cells, the pzAR can be co-immunoprecipitated with endogenous 
AKAP79 (Figure 3.19 a, left panel). Indeed, AKAP79 appears to be constitutively 
associated with the PzAR in HEKB2 cells, and the level of its association with the 
PzAR is seemingly unaffected by challenge of cells with isoprenaline or isoprenaline 
plus rolipram over a period (5min) (Figure 3.19 a, right panel). Such conditions 
suffice, however, to allow for the activation of PKA, PKA phosphorylation of the 
PzAR (Figure 3.19 b, upper panel), and the recruitment of p-arrestin-PDE4D complex 
to the PzAR/membrane fraction (Perry et al. 2002; Bolger et al. 2003). Similarly, over 
this time of challenge there was no charge in the amount of AKAP79 associated with 
the P2 membrane fraction. The siRNA-mediated knockdown of AKAP79, in HEKB2 
cells, ablated either isoprenaline or isoprenaline plus rolipram initiated PKA 
phosphorylation of the pzAR (Figure 3.19 b).
In A431 human epidermoid carcinoma cells, it has been shown that 
isoprenaline challenge elicits the PKA phosphorylation of gravin (AKAP250) (Lin et 
al. 2000; Tao et al. 2003). This allows for the membrane recmitment of gravin where 
it can interact with the pzAR. Data presented here, demonstrates that, in contrast to 
AKAP79, gravin was not constitutively associated with either the PzAR or the plasma 
membrane fi'action in HEKB2 cells (Figure 3.20 a; zero time). However, challenge of 
HEKB2 cells with isoprenaline alone or isoprenaline plus rolipram confers the 
translocation of gi'avin to the P2 membrane fraction, which was maximal after 3 min 
(Figure 3.20 a, right panel). Although challenge with isoprenaline or isoprenaline plus
98
rolipram also allowed gravin to translocate to the pzAR (Figure 3.20 a, left panel), the 
maximal recmitment was delayed till 5 min after agonist challenge (Figure 3.20 a, left 
panel). Again, unlike the effect of knockdown of AKAP79, the siRNA-mediated 
knockdown of gi'avin did not alter the ability of isoprenaline alone or isoprenaline 
plus rolipram to cause the PKA phosphorylation of the pzAR (Figure 3,20 b, upper 
panel). This suggests that isoprenaline-stimulated PKA phosphorylation is via the 
scaffolding of AKAP79 near the receptor.
3.2.11 Interaction with p-arrestin is required for PDE4D to regulate 
isoprenaline-stimulated phosphorylation of ERK
It has been previously suggested that ectopic p~arrestin2 confers 
isoprenaline-stimulated PDE4 membrane translocation, which attenuates switching of 
pzAR coupling from Gs to Gi and subsequent ERK pathway activation (Baillie et al. 
2003). In order to investigate further the role of PDE4 in the regulation of this 
switching, I used catalytically inactive mutants in a dominant negative strategy. Single 
point mutations of PDE4D5 (in the catalytic domain) were generated producing 
catalytically inactive forms which were still able to bind p-arrestins. A dominant 
negative role was assumed by displacement of active endogenous PDE4D from p- 
arrestins, as seen by its ability to enhance isoprenaline-stimulated phosphor-ERK 
formation (Baillie et al. 2003).
HEKB2 cells were transfected with an empty vector or catalytically inactive 
PDE4D5, and then stimulated with 10 pM isoprenaline at the indicated times. Cell 
lysates were hamested in 3T3 lysis buffer and subjected to Western blotting with 
specific antisemm against phospho-ERK. The same blot was stripped and probed with 
anti-ERK antibody as a loading control. Anti-VSV antibodies were used to for 
expression of PDE4D5 D/N. Expression of catalytically inactive PDE4D5 (DN- 
PDE4D5), in HEKB2 cells, markedly increased the ability of isoprenaline to activate 
ERKl/2 (Figure 3.21). However, when the catalytically inactive PDE4D5 was further 
mutated in its isoform-speciftc N terminal region where p-arrestins preferentially 
interacts (Arg34—>Ala) (Bolger et al. 2003), their unique interaction was efficiently 
ablated. The potentiating effect of dominant negative PDE4D5 on isoprenaline- 
stimulated ERK phosphorylation was abolished when an Arg34—>Ala foim of
99
— .....
PDE4D5 was transfected into the HEKB2 cells (Figure 3,21). This shows that the 
potentiating effect of dominant negative PDE4D5 on this response is dependent upon 
its ability to interact with P-aiTestins.
3.3 Discussion
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Previous studies have shown that the functioning of GRK2 in the PzAR 
desensitization process can be regulated by the activity of other kinases, which 
directly phosphorylate GRK2 (Kohout and Lefkowitz 2003). The effects of these 
phosphorylations vary, depending on the identity of the specific kinase. PKA (Cong et 
al. 2001), as well as PKC (Krasel et al. 2001), has been shown to phosphorylate 
GRK2, thereby increasing the ability of GRK2 to interact with Gpy subunits 
(Lodowski et al. 2003; Kozasa 2004). This enhances GRK2 membrane recruitment 
and the ability of GRK2 to phosphorylate GPCRs (Kohout and Lefkowitz 2003). In 
contrast, phosphorylation of GRK2 by ERK dramatically reduces its activity as well 
as its membrane association (Pitcher et al. 1999). In the present study, I identified a 
novel role for PDE4s, showing that they play a significant part in the regulation of 
GRIC2 in the receptor desensitisation process.
Data presented here indicates that inactivation of PDE4 by the PDE4 
selective inhibitor rolipram enhances the isoprenaline-induced PKA phosphorylation 
of GRK2 (Figure 3.3 a, c) and the subsequent membrane recruitment of GRK2 
(Figure 3.6 a, left panel). It is also shown that, in response to isoprenaline, the added 
presence of rolipram facilitates p-arrestin translocation from the cytosol to the plasma 
membrane, leading to an increased rate of receptor internalization (Figure 3.11 a). 
Interestingly, whilst PDE4D provides around 60% of the total PDE4 activity in 
HEKB2 cells, and PDE4B around 30% (Pen-y et al. 2002; Lynch et al. 2005), the 
effect of PDE4 on the enhancement of the isoprenaline-induced PKA phosphorylation 
of GRK2 and subsequent GRK2-mediated phosphorylation of pzAR seems not 
subfamily-specific, as siRNA-mediated knockdown of either PDE4B or PDE4D 
subfamilies is sufficient to facilitate the ability of isoprenaline to cause PKA 
phosphorylation of GRK2 (Figure 3.5). The lack of any selective effects in this 
instance is likely to be because cytosolic GRK2 is being phosphorylated by cytosolic
PKA and thus subject to global rather than compartmentalized cAMP actions, which 
both PDE4B and PDE4D are able to influence.
Following rolipram inhibition of PDE4, it is clear that isoprenaline-induced
GRK2 recmitment to the plasma membrane is more transient in nature (Figure 3.6 a).
GRK2 is a phosphoprotein and constitutively phosphorylated by ERKl/2 at its Ser670
under basal conditions (Pitcher et al. 1999). Before agonist stimulation, GRK2 is
maintained in its inactive state. Only when the agonist stimuli reaches GPCRs, will
GRK2 quickly be dephosphorylated by an un-identified phosphatase and translocate
to the plasma membrane where it phosphorylates GPCRs. The phosphorylation of
GPCRs by GRK2 is highly regulated as when it is in complex with the activated
receptor and GPy subunits, GRK2 quickly associates with ERKl/2 (Elorza et al. 2000)
and becomes phosphorylated again (Pitcher et al. 1999). This phosphorylation then
dramatically decreases its activity, as well as the affinity of binding to Gj3y subunits,
promoting its release fi’om the plasma membrane back to the cytosol. By controlling
the phosphorylation of GRK2 by PKA, and thereby its affinity binding towards Gpy
subunit, ablation of PDE4 activity will promote the ability of isoprenaline to initiate
membrane recmitment of GRK2. However, PDE4 inhibition will also lead to
increased PKA phosphorylation of the PzAR (Figure 3.18) and the switching of its
signaling to the activation of ERK (Figure 3.15) (Baillie et al. 2003). In the present
study, when HEKB2 cells were challenged with isoprenaline and rolipram together,
such increases in activated ERK in the cytosol appear to result in greater but more
transient ERK activation in the membrane fraction (Figure 3.14). This can be
expected to subsequently, transiently phosphorylate GRK2 (Figure 3.13). Such
_actions are likely to control the transience of GRK2 membrane association. Consistent 
with ERK underpinning the release of GRK2 (Kohout and Lefkowitz 2003), under 
conditions of isoprenaline challenge and PDE4 inhibition, I observed that, if  ERK is 
inhibited with U0126, a MEK inliibitor, then GRK2 remains membrane associated 
(Figure 3.6 a).
I also show here that PKA phosphorylation of GRK2 (Figure 3.4), GRK2 
membrane recmitment (Figure 3.6 b) and GRK phosphorylation of pzAR (Figure 3.9) 
can all occur in the absence of agonist in HEKB2 cells, following inactivation of
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PDE4. This would suggest that PDE4 could prevent inappropriate membrane 
recmitment of GRK2 in unstimulated cells. Unsurprisingly, effects caused by 
rolipram alone in these cells were not as pronounced as those seen in the added 
presence of isoprenaline. Rolipram induced PKA phosphorylation of GRK2 and 
consequent membrane recmitment was not confined to HEKB2 cells, but was also 
observed in cardiac myocytes (Figure 3.16 and Figure 3.17).
Current dogma dictates that GRK2 recmitment to the membrane is agonist- 
dependent. However, no one so far has reported the effects of PDE4 inhibition on 
GRK2 distribution. Observations described in this chapter are reminiscent of studies 
into the PKC phosphorylation of GRK2 induced by phorbol esters (Krasel et al.
2001). It is now well established that GPCRs, such as the pzAR, exist in an 
equilibrium between active and inactive states and that agonist binding drives this 
equilibrium towards the activate state (Milligan 2003). Thus, under basal conditions, 
such equilibrium allows for the generation of a small pool of activated Gas, which is 
responsible for basal adenylyl cyclase activity, together with free GPy subunits (Dupre 
et al. 2004). In the cells used here, it would appear that basal adenylyl cyclase activity, 
in the presence of PDE4 inhibition, is sufficient to allow global cAMP levels to reach 
a magnitude whereby PKA can phosphorylate GRK2, increasing its affinity for Gpy 
subunits and facilitating recmitment of GRK2 to the membrane.
That ERK activation is not stimulated by rolipram treatment alone in HEKB2 
cells (Figure 3.15, zero time; negative result from rolipram alone time course) 
indicates that agonist stimulation is essential to allow coupling of the PKA 
phosphorylated PzAR to Gi and consequential ERK. This is consistent with previous 
data obtained via siRNA mediated knockdown of PDE4D, which has been shown to 
be the functionally relevant PDE in mediating the switching of pzAR to the activation 
of ERK (Lynch et al. 2005). Thus, in HEKB2 cells challenged with rolipram alone, 
which do not lead to ERK activation, the recruitment of GRK2 to the membrane is 
sustained (Figure 3.6 b).
As shown in the present study for the first time, PDE4 activity, in regulating 
PKA phosphorylation of GRK2, may, at least in certain cells, provide a means of
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influencing the membrane recruitment of GRK2. There are tluee distinct facets to this. 
First, PDE4 activity is set to regulate the degree of feedback in the regulating PKA 
phosphorylation of GRK2 in stimulated cells, thereby influencing the rate of agonist- 
triggered desensitization. Secondly, PDE4 activity may modulate the degree of 
isoprenaline-stimulated ERK activation, which influences the release of GRK2 from 
membranes and the reversal of desensitization. Finally, PDE4 activity ensures that, 
under normal conditions, GRK2 is prevented from phosphorylation by fluctuations in 
basal PKA owing to intracellular cAMP levels, and only when agonist challenge 
breaches the threshold for PKA phosphorylation of GRK2 set by PDE4, will GRK2 
translocation occur. As this system is also applicable in cardiac myocytes, it would 
appear that the potential importance of PDE4 in preventing inappropriate activation of 
GRK2 in cardiac myocytes may have functional relevance to heart failure, as both 
GRK2 and PDE4D are suggested being involved in heart failure (Tachibana et al. 
2005; Harding et al. 2001; Lehnart et al. 2005).
Apart from GRK, PKA phosphorylation of pzAR is another important route 
by which PzAR desensitisation is regulated. Phosphorylated and activated pzAR 
switches its coupling from Gs-mediated activation of adenylyl cyclase to Gi-mediated 
inactivation of adenylyl cyclase, therefore decreasing the rate of production of cellular 
cAMP (Daaka et al. 1997). Key to gating this phosphorylation process is the 
activation of anchored PDEs, such as enzymes of PDE4 family (Baillie et al. 2003) 
(Figure 3.18). More recently, it has been shown that p-anestin-recruited PDE4D 
controls the cAMP-mediated activation of PKA involved in a defined, 
compartmentalized process focused on pzAR (Perry et al. 2002). This underpins the 
possible existence of PKA tethering to some specific AKAPs as disruption of AKAP- 
PKA complexes resulted in the attenuation of isoprenaline-induced ERK activation in 
HEKB2 cells (Lynch et al. 2005). Interestingly, the PzAR itself has been shown to be 
capable of interacting with specific AKAPs, such as AKAP79 (Fraser et al. 2000). 
AKAP79 is constitutively associated with PzAR in transfected cells whereas gravin 
exhibits dynamic interaction with PzAR following PKA phosphorylation of gravin 
(Lin et al. 2000; Tao et al. 2003). I show here that p2AR can interact with 
endogenously expressed forms of both AKAP79 (Figure 3.19 a, left panel) and gravin 
(Figure 3,20 a, left panel) in HEKB2 cells. Consistent with previous data obtained in
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different systems, I show that the interaction of pzAR with AKAP79 is indeed 
constitutive (Figure 3.19 a, right panel), whereas that with gi'avin is only obsei'ved 
upon isoprenaline challenge (Figure 3,20 a, right panel). Using for the first time 
siRNA against these AKAPs, I show here that the ability o f isoprenaline to cause the 
PKA-mediated phosphorylation of the pzAR, is abolished upon knockdown of 
AKAP79 but not upon knockdown of gravin (Figure 3,19 b and Figure 3.20 b). This 
indicates that the activity of a discrete pool of AKAP79-tethered PKA is responsible 
for agonist-triggered phosphorylation of the associated pzAR. Although it is uncertain 
o f the role of recmited gravin, the selective siRNA-mediated knockdown of AKAP79 
and gravin highlights the functional differences between the membrane bound forms 
of these AKAPs in HEKB2 cells.
In contrast to the PDE4 effect on GRK phosphorylation of pzAR, which is 
not subfamily specific, as indicated by non-subfamily specific PKA phosphorylation 
of GRK2, PDE4 control of PKA phosphorylation of the PzAR and consequential 
switching of its signalling firom activation of adenylyl cyclase to activation of ERK 
(Baillie et al. 2003) is PDE4D5-specific (Lynch et al. 2005). In order to support 
siRNA data, I used a dominant negative strategy to show that overexpression of 
catalytically inactive PDE4D5 enhances isoprenaline-stimulated ERK 
phosphorylation (Figure 3.21), consistent with previous data (Baillie et al. 2003). 
Unsurprisingly, however, such an action is clearly ablated when a PDE4D5-specific 
site for interaction with P-arrestin is dismpted (Figure 3.21). This indicates that the 
unique desensitisation process provided by p-arrestin-mediated delivery of PDE4D5 
can be negated by disruption of this active complex. In this context, it is important to 
note that the presence of AKAP79 and p-arrestin-associated PDE4 has a profound 
effect on the ability of the pzAR to become phosphoi'ylated by PKA. This affects 
switching to Gi, and alters downstrteam signalling and this might be linked to heart 
disease (Xiang et al. 2004).
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Figure 3.1 A schematic of GRK2 (pARKl).
GRK2 is a multi-domain protein able to interact with a variety of cellular proteins. 
Such interactions allow for its different cellular functions and also contribute to 
modulate its activity and subcellular targeting. The figure depicts the regions where 
the regulatory phosphorylation takes place and the interactions sites with other 
proteins are mapped. RGS, regulators of G protein signalling; CaM, calcium- 
calmodulin; PL, phospholipids; PH, pleckstrin homology.
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Figure 3.2 Existence of GRKs in HEKB2 cells.
HEKB2 cells were harvested when confluent in 3T3 lysis buffer. Clear lysates were 
divided into five equal volumes. The five volumes were subjected to western blotting 
probed for GRK2, GRK3, GRK4, GRK5 and GRK6, respectively.
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Figure 3.3 GRK2 is phosphoryiated by PKA in HEKB2 ceils.
(a) HEKB2 cells were treated with either isoprenaline (lOpM) alone or isoprenaline 
following a 10 min pre-incubation with rolipram (lOpM) in the presence and absence 
of the PKA inhibitor H89 (IpM). Cells were harvested in 3T3 lysis buffer and lysates 
were subjected to immunoprécipitation with an anti-GRK2 antibody, followed by 
probing with an anti-(phosphor-PKA substrate) antibody. Upper panel shows the 
GRK2 that has been phosphoryiated by PKA in the immunoprecipitates; lower panel 
shows the equal GRK2 loading in the immunoprecipitates. (b) Quantification of three 
such independent experiments (means± S.D.) from the western blots. Data was 
normalized for loading and represented as fold change basal.
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Figure 3.3 GRK2 phosphorylation by PKA in HEKB2 cells.
(c) HEKB2 cells were treated with either isoprenaline (lOpM) alone or isoprenaline 
following a 10 min pre-incubation with rolipram (lOpM) in the presence and absence 
of the PKA inhibitor H89 (IpM). Cells were harvested in 3T3 lysis buffer and lysates 
were subjected to immunoprécipitation with an anti-(phosphor-PKA substrate) 
antibody, followed by probing with an anti-GRK2 antibody, (d) Quantification of 
three such independent experiments (means± S.D.) from the western blots as shown in 
(c). Data was normalized for loading and represented as fold change basal.
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Figure 3.4 Differential PKA phosphorylation of GRK2 following PDE4 or PDE3 
inhibition in HEKB2 cells.
HEKB2 cells were treated with either rolipram (10 pM) alone, rolipram and H89 (1 
pM) or cilostamide (1 pM) alone for the indicated time. Cells were harvested in 3T3 
lysis buffer and subjected to immunoprécipitation with an anti-(phosphor-PKA 
substrate) antibody, followed by western blotting probed with anti-GRX2 antibody. 
Upper panel shows the PKA phosphoryiated GRK2 under single rolipram treatment; 
lower left panel shows the PKA phosphoryiated GRK2 under rolipram treatment 
following a 10 min pre-incubation of H89; lower right panel shows the PKA 
phosphoryiated GRK2 under single cilostamide treatment.
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Figure 3.5 PKA phosphorylation of GRK2 in PDE4 isoform-knockdown HEKB2 
cells.
HEKB2 cells were transfected with either scrambled siRNA, siRNA specific for 
PDE4B, siRNA specific for PDE4D, or siRNA specific for both PDE4B and PDE4D. 
After efficient transfections, cells were challenged either with isoprenaline (10 pM) 
for 5 min or with isoprenaline ( 10 pM) for 5 min following 10 min pretreatment with 
H89 (1 pM), and then harvested in 3T3 lysis buffer. Clear cell lysates were subjected 
to immunoprécipitation with an anti-GRK2 antibody, and then western blotting 
probed with an anti-(phosphor PKA substrate) antibody. The cell proteins in upper 
panel were normalized, so were those in lower panel, but separately. C, resting 
conditions; I, isoprenaline; IH, isoprenaline plus H89; si4B, siRNA specific for 
PDE4B; siD, siRNA specific for PDE4D; si4B+si4D, siRNA specific for both PDE4B 
and PDE4D. Blots here are typical of separate experiments performed three times.
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Figure 3.6 Membrane translocation of GRK2 in HEKB2 cells.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) at the indicated time in 
either the presence or absence of ERK upstream kinase MEK inhibitor U0126 (10 
pM), and either with or without rolipram (10 pM) pre-incubation for 10 min. Cells 
were harvested in KHEM buffer and subjected to membrane fractionation. Membrane 
(P2 fraction) proteins were normalized and blotted for GRK2 in each case, (b) 
HEKB2 cells were treated with rolipram (10 pM) for the indicated times in the 
absence and presence of H89 (1 pM) and normalized membrane fractions were 
subjected to western blotting probed with an anti-GRK2 antibody. Iso, isoprenaline; 
U0126, a MEK inhibitor; Roil, rolipram; H89, a PKA inhibito
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Figure 3.7 Phosphorylation status of GRK2 in HEKB2 membrane fractions.
HEKB2 cell were challenged with either isoprenaline (10 pM) alone or isoprenaline 
after pre-incubation of rolipram (10 pM) for 10 min or isoprenaline after pre­
incubation of both rolipram (10 pM) and H89 (1 pM) together for 10 min. Cells were 
then subjected to membrane fractionation, followed by protein normalization. The 
membrane fractions were solubilized in 3T3 lysis buffer, and PKA-phosphorylated 
proteins existing in the plasma membrane were immunopurified using an anti- 
(phosphor-PKA substrate) antibody, followed by SDS-PAGE and immunoblotted for 
GRK2. Iso, isoprenaline; Roli, rolipram.
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Figure 3.8 Phosphorylation of the pzAR in HEKB2 cells by GRK2.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times 
either with or without rolipram (10 pM) pre-treatment (10 min). Cells were harvested 
in 3T3 lysis buffer and normalized to have the equal protein levels in each time point. 
Clear lysates were subjected to SDS-PAGE and probed for either phoshorylation of 
the P2 AR by GRK2 on its Ser355/356 or for total P2 AR. (b) HEKB2 cells were 
transfected with scrambled siRNA or siRNA specific for GRK2 and then challenged 
with isoprenaline (10 pM) at the indicated time. Cells were harvested in 3T3 lysis 
buffer and the clear lysates were probed for GRK2 and phosphorylation of P2 AR by 
GRK2 at Ser355/356 individually. Upper panel shows the effect of siRNA mediated 
GRK2 knockdown on P2 AR phosphorylation by GRK2; lower panel shows the 
efficiency of siRNA mediated knockdown. Iso, isoprenaline; pp2 AR, phosphoryiated 
P2AR.
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Figure 3.9 Rolipram induced GRK2 phosphorylation of piAR in HEKB2 cells.
(a) HEKB2 cells were treated with rolipram (10 pM) at the indicated time and 
harvested in 3T3 lysis buffer. Protein levels were normalized and clear lysates were 
subjected to western blotting probed with a specific anti-phospho P2 AR (Ser355/356). 
The same blot was then stripped by stripping buffer and probed for total P2 AR. (b) 
HEKB2 cells were transfected with scrambled siRNA as a control and with siRNA 
specific for GRK2 as a test. Cells were treated with rolipram (10 pM) for the 
indicated times and harvested in 3T3 lysis buffer. Normalized lysates were probed for 
phosphorylation of P2 AR by GRK2 and total P2 AR individually. PP2 AR, 
phosphoryiated P2 AR; scr, scrambled siRNA; siGRK2, siRNA specific for GRK2.
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Figure 3.10 Phosphorylation of P2AR by GRK2 in siRNA mediated PDE4B and 
PDE4D knockdown HEKB2 cells.
Control cells pretreated with scrambled siRNA and cells pretreated with specific 
siRNA to PDE4B and PDE4D, were challenged with isoprenaline (10 pM) at the 
indicated time. Cells were harvested and normalized to equal protein levels. Clear cell 
lysates were probed for PDE4D (upper panel), PDE4B (second upper panel), P2 AR 
(second lower panel) and phosphorylation of P2 AR by GRK (lower panel) 
individually, iso, isoprenaline; siB, siRNA to PDE4B; siD, siRNA to PDE4D; pp2 AR, 
phosphoryiated P2 AR.
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Figure 3.11 Membrane translocation of p-arrestins and PDE4D.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times 
either with or without 10 min rolipram pre-treatment. Cells were harvested in KHEM 
buffer and subjected to membrane fractionation. Membrane (P2) fractions were 
normalized and probed for p-arrestins. (b) Cells were treated as in (a) and subjected to 
western blotting probed with anti-PDE4D. Iso, isoprenaline; Roli, rolipram.
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Figure 3.12 Rolipram alone induced membrane recruitment of p-arrestins and 
PDE4D.
HEKB2 cells were treated with rolipram (10 pM) in a 0-10 min time course, in the 
presence or absence of 10 min H89 (1 pM) pretreatment as indicated. Cells were then 
harvested in KHEM buffer and subjected to membrane fractionation. Membrane (P2) 
fractions were normalized and blotted for p-arrestin and PDE4D individually. Roli, 
rolipram.
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Figure 3.13 Membrane ERK-phosphorylated GRK2 in HEKB2 cells.
HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times either 
with or without, as indicated, 10 min rolipram (10 pM) pre-treatment. Cells were 
harvested in KHEM buffer and subjected to membrane fractionation. Equal amount of 
membrane proteins were obtained and subjected to western blotting probed for ERK 
phosphor-GRK2 Ser670. Iso, isoprenaline; Roli, rolipram.
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Figure 3.14 Activation of ERKl/2 in membrane fraction of HEKB2 cells.
HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times either 
with or without, as indicated, 10 min rolipram (10 pM) pre-treatment. Cells were 
harvested in KHEM buffer and subjected to membrane fractionation. Equal amount of 
membrane proteins were obtained and subjected to western blotting probed for 
phosphor-ERKl/2. The same blot was then stripped and probed with an anti-ERK 1/2 
antibody. Iso, isoprenaline; Roli, rolipram.
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Figure 3.15 ERK activation in HEKB2 cells.
HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times either 
with or without, as indicated, 10 min rolipram (10 pM) pre-treatment. Cells were 
harvested in 3T3 lysis buffer and subjected to western blotting probed for phosphor- 
ERKl/2. The same blot was then stripped and probed for total ERK 1/2. Upper panel 
shows the ERK activation in each instance; lower panel shows the equal loading by 
checking the level of ERK 1/2.
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Figure 3.16 PKA phosphorylation of GRK2 in cardiac myocytes.
Cardiomyocytes were challenged with isoprenaline (10 pM) for the indicated times 
either with or without, as indicated, 10 min rolipram (10 pM) pre-treatment, in the 
presence or absence of H89 (1 pM, 10 min). Cells were harvested in 3T3 lysis buffer. 
Clear, normalized cell lysates were then subjected to immunoprécipitation using an 
anti-GRK2 antibody, followed by western blotting probed for phosphor-PKA 
substrate. The same blot was stripped and probed for GRK2 to check the loading.
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Figure 3.17 Membrane recruitment of GRK2 in cardiac myocytes.
Cardiomyocytes were challenged with the indicated combination of isoprenaline (10 
pM) and/or Roilpram (10 pM) and H89 (1 pM) for the indicated times. When 
rolipram or/and H89 was added together with isoprenaline, cells were then pre­
incubated with rolipram or/and H89 for 10 min before the addition of isoprenaline for 
the indicated times. Cells were harvested in KHEM buffer and subjected to membrane 
fractionation. Equal amount of membrane (P2) fraction proteins were obtained and 
subjected to western blotting probed for GRK2. Ctrl, control; Iso, isoprenaline; Roli, 
rolipram.
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Figure 3.18 PKA phosphorylation of P2AR in HEKB2 cells.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) for the indicated times 
either with or without rolipram (10 pM) pre-treatment (10 min). Cells were harvested 
in 3T3 lysis buffer and normalized to have the equal protein levels in each time point. 
Clear lysates were subjected to SDS-PAGE and probed for PKA phosphorylation of 
the P2 AR at Ser345/346. The same blot was then stripped and probed with an anti- 
P2 AR antibody, (b) Quantification of three experiments as in (a) (means ± S.D.) with 
100% s the maximal effect seen with isoprenaline and rolipram. Iso, isoprenaline; 
Roli, rolipram, (c) HEKB2 cells were pretreated with rolipram (10 pM), with/without 
H89 (1 pM) for 10 min, and then challenged with isoprenaline (10 pM) for 10 min. 
Cell clear lysates were probed for PKA phosphorylation of the P2 AR at Ser345/346. 
The same blot was then stripped and probed with an anti-p2 AR antibody.
123
(a)
(b)
Lys IP Lys IP Lys IP
I I I+R I+R I I I+R I+R
-AKAP79-
5 Timc(min) 0 3 5 Time(min)
I r 1 1
5 0
"V^sa.
J
pp2AR(byPKA)
-AKAP79
5 0  ^ Time (min)
timP79
Figure 3.19 AKAP79-mediated isoprenaline activation of phosphorylation of 
P2AR in HEKB2 cells.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) at the indicated time. In 
the left-hand panel, normalized cells lysates in 3T3 lysis buffer were subjected to 
immunopricipitation with a specific anti-Flag antibody, followed by western blotting 
probed for AKAP79. In the right-hand panel, cells were harvested in KHEM buffer 
and subjected to membrane fractionation. Normalized membrane (P2) fractions were 
then probed for AKAP79. (b) HEKB2 cells were transfected with scrambled siRNA 
for control or siRNA to AKAP79. Following challenged with isoprenaline (10 pM) 
alone or isoprenaline (10 pM) plus Roilpram (10 pM, 10 min pretreatment) as 
indicated, cells were harvested in 3T3 lysis buffer. Normalized clear cell lysates were 
then probed for phosphorylation of P2 AR by PKA. The same blot was stripped and 
blotted with an anti-AKAP79 antibody. Lys, lysate; IP, immunoprecipitaion; scr, 
scrambled siRNA; siAKAP79, siRNA to AKAP79; I, isoprenaline; R, rolipram.
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Figure 3.20 G ravin-mediated isoprenaline activation of phosphorylation of p2AR 
in HEKB2 cells.
(a) HEKB2 cells were challenged with isoprenaline (10 pM) at the indicated time. In 
the left-hand panel, normalized cells lysates in 3T3 lysis buffer were subjected to 
immunopricipitation with a specific anti-Flag antibody, followed by western blotting 
probed for gravin (AKAP250). In the right-hand panel, cells were harvested in KHEM 
buffer and subjected to membrane fractionation. Normalized membrane (P2) fractions 
were then probed for gravin. (b) HEKB2 cells were transfected with scrambled siRNA 
for control or siRNA to gravin. Following challenged with isoprenaline (10 pM) alone 
or isoprenaline (10 pM) plus Roilpram (10 pM, 10 min pretreatment) as indicated, 
cells were harvested in 3T3 lysis buffer. Normalized clear cell lysates were then 
probed for phosphorylation of P2 AR by PKA. The same blot was stripped and blotted 
with an anti-gravin antibody. Lys, lysate; IP, immunoprecipitaion; scr, scrambled 
siRNA; si-gravin, siRNA to gravin; I, isoprenaline; R, rolipram.
125
pERKl pERK2
^ = K K 2
VSV-4D5
0 1 3 5 l O' O 1 3  5 fO 0 1 3 5 Î0  Time(min)
\___________ J \___________ ) \___________ !
& DN-4D5 (R34A)_DN-4D5
Figure 3.21 p-arrestin-scaffolded PDE4D5 is fundamental to regulate p%AR 
switching.
HEK293 cells were transfected, as indicated, with an empty vector (ctr.) and with vsv- 
epitope-tagged forms of either a dominant negative PDE4D5 (DN-4D5) or an Arg-34 
-♦Ala mutant form of dominant negative PDE4D5 (R34A_DN-4D5). Then cells were 
challenged with isoprenaline for a 0-10 min time course. Normalized cell lysates 
were immunoblotted for pERKl/2, total ERK 1/2, and the vsv-epitope tag.
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3.22 GRK2 phosphoryiated PzAR trafficking in HEKB2 cells.
Cells were treated with isoprenaline alone (10 mM) or isoprenaline added together 
with rolipram (10 mM) or with rolipram alone in each case for the indicated times. 
Shown are merged fluorescent confocal images of fixed HEKB2 cells stably 
expressing GFP-tagged P2 AR (green) and stained to detect the GRK phosphoryiated 
form (Ser^^^/Ser^^^) o f the P2 AR (red) as well as nuclei [blue; DAPl (4,6-diamidino-2- 
phenylindole)]. Iso, isoprenaline; -Rol, without rolipram; +R0 I, with rolipram pre­
treatment.
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Figure 3.23 PKA phosphoryiated P2AR trafficking in HEKB2 cells.
Cells were treated with isoprenaline alone (10 mM) or isoprenaline added together 
with rolipram (10 mM) or with rolipram alone in each case for the indicated times. 
Shown are merged fluorescent confocal images of fixed HEKB2 cells stably 
expressing GFP-tagged P2 AR (green) and stained to detect the PKA phosphoryiated 
form (Ser '^^VSer '^^ )^ of the P2 AR (red) as well as nuclei [blue; DAPI (4,6-diamidino-2- 
phenylindole)]. Iso, isoprenaline; -Rol, without rolipram; +R0 I, with rolipram pre­
treatment.
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Chapter 4
Analysis of Ubiquitination of PDE4D5 and its functions in 
HEKB2 cells
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formed by several attacliments of single Ub to multiple lysine residues on the 
substrate.
An increasing body of evidence also suggests that the fate of a substrate that 
undergoes ubiquitination may depend on the type of lysine linkage (K29, K48 or K63) 
involved in forming poly-ubiquitin chains (Spence et al. 2000; Weissman 2001; Koegl
130
4.1 Introduction
Ubiquitin (Ub) is a small polypeptide of 76 amino acids that can be 
covalently attached to other proteins (Hatakeyama and Nakayama 2003), forming an 
isopeptide bond between the activated C-terminal glycine of Ub and the e-amino 
group of a lysine residue in the substrate molecule. This occurs through a three-step 
process involving Ub-activating (El), Ub-conjugating (E2) and Ub ligase (E3) 
enzymes (Pickart 2001) (Figure 4.1).
The intrinsic B3 ligase activity serves as the rate-limiting step of Ub 
modification of substrate proteins and plays a central role in deteimining the 
specificity of Ubiquitination. E3s are classified into two gi'oups: the HECT (homology 
to E6-AP C-terminus) domain-containing E3s and the RING finger-containing E3s. 
The HECT domain proteins, such as E6-AP, are characterized by their ability to form 
a thioester intenuediate with the activated Ub before transfer of Ub to substrates 
(Pickart 2001). In contrast, the RING finger-containing E3s, such as Mdm2, do not 
foim a covalent bond with the activated Ub and instead catalyze ubiquitination by 
association with substrates (Pickart 2001).
Three types of Ub modification can exist on the substrate lysines: mono- 
ubiquitination, multi-ubiquitination and poly-ubiquitination (Figure 4.2). Mono- 
ubiquitination, which is defined by the addition of a single Ub to a substrate lysine, 
can seiwe as a novel endocytic signal (Hieke 2001; Haglund et al. 2003), whereas 
poly-ubiquitin chains, formed through one of the internal lysines within the Ub 
molecule in an iterative process, invariably acts to target substrate proteins for 
degradation by the proteasome (Pickart 2001). However, it also may serve to 
modulate diverse biological processes, such as cell cycle progression, apoptosis, 
antigen presentation and stress response (Weissman 2001). Multi-ubiquitination is
et al. 1999). For example, addition of ubiquitin chains using lysine 63 linkage on Ub 
generally leads to non-proteolytic events (eg DNA repair, endocytosis), whereas 
addition of Ub using position 48 signals for proteasome-mediated degradation.
Some short protein motifs and domains have been shown to bind Ub or 
substrate-bound Ub moieties and therefore have the potential to establish a network of 
protein-protein interactions (Pickart 2000). To date, it is clear that at least six 
conserved Ub binding modules exist (Schnell and Hicke 2003), the structures of five 
of which have been deteiinined, including the UIM (Ub interacting motif) (Hofmann 
and Falquet 2001), UBA (Ub-associated domain) (Mueller et al. 2004), UEV (Ub E2 
variant domain) (Pomillos et al. 2002), NZF (npl4 zinc finger domain) (Meyer et al.
2002), and CUE (coupling of Ub conjugation to ER degi'adation domain) (Ponting
2000). Each of these motifs can allow the binding of Ub in vitro, and the motifs are 
invariably used in a modular fashion to add Ub binding functionality to a large variety 
of multifunctional proteins in vivo.
The initial identification of the UIM originated from studies of the S5a 
subunit of the 19S regulator in the human 26S proteasome (Deveraux et al. 1994) and 
a more general UIM has been defined as a 20 residue sequence corresponding to the 
consensus: X-Ac-Ac-Ac-Ac-O-X-X-Ala-N-X-X-Ser-X-X-Ac-X-X-X-X, where O 
represents a large hydrophobic residue (typically Leu), Ac represents an acidic residue 
(Glu, Asp), and X represents residues that are less well conserved (Hofmann 2001). 
UIM occurs in a wide range of proteins, many of which are endocytic proteins that 
function in the pathway of endocytosis and vacuolar protein sorting (Hofinann 2001). 
Recently, a number of studies have suggested that UIMs can direct protein 
ubiquitination in substrates such as Eps 15, Vps27p and Hrs (Miller et al. 2004; Polo et 
al. 2002; Klapisz et al. 2002; Oldham et al. 2002).
The prevalence of the UIM and its importance in a number of biological 
processes (Hofinann and Falquet 2001) has initiated the studies described here and in 
particular my observation by sequence anaylysis of the presence of a putative UIM 
motif in PDE4D.
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The aims of this chapter are to identify a UIM motif in the C-terminal 
domain of the PDE4D5 isoform and show if  it can act as an important modulator for 
the ubiquitination of this isoform. I show here that this motif acts as a ubiquitination 
signal for combined mono-ubiquitination and poly-ubiquitination. Although it is 
difficult to dissect the functional outcomes of these two ubiquitination types, I have 
shown here that the ubiquitinaion of PDE4D5 is important in modulating its binding 
to the signalling scaffold protein, p~aiTestin.
Recent studies have revealed that p-arrestin serves as an adaptor to bring 
unknown E3-ligases to proximity of p2 ARs, leading to receptors ubiquitination 
(Shenoy et al. 2001). This finding, complete with the strong link between PDE4D5 
and p-arrestin (Bolger et al. 2003) have prompted me to investigate the extent of the 
P-aiTcstin involvement in the ubiquitination of PDE4D5. Following the previous 
observations, I also show that p-arrestin is cmcial for ubiquitination of PDE4D5 by 
acting as an adaptor for the Mdm2 E3 ligase.
4.2 Results
4.2.1 Isoprenaline-stimulated ubiquitination of PDE4D5 in HEKB2 cells
Sequence analysis of PDE4D5 reveals a short motif with high homology to a 
UIM (slight difference in the UIM position 9) at its C-terminal region (Figure 4.3). 
Indeed, this motif is conserved in all PDE4D subfamily members, but not in other 
PDE4 subfamilies. As UIM domains have been reported to be required for mono- 
ubiquitination of some proteins (Miller et al. 2004; Polo et al. 2002; Klapisz et al. 
2002; Oldham et al. 2002), I set out to determine whether the putative UIM motif 
present in PDE4D5 modulates its own ubiquitination. To evaluate the possible Ub 
modification of PDE4D5, I first investigated whether VSV epitope-tagged PDE4D5 
could undergo isoprenaline-induced ubiquitination in HEKB2 cells. Human VSV- 
tagged PDE4D5 was transiently transfected into HEKB2 cells. After 48hi’, HEKB2 
cells were stimulated with the p-adrenergic agonist isoprenaline for the indicated 
times and VSV-PDE4D5 was isolated by immunoprécipitation with VSV-agarose 
(Figure 4.4). The ubiquitinated VSV-PDE4D5 was detected by western blotting the IP 
samples using a specific Ub antibody, while VSV-PDE4D5 was detected with an anti- 
VSV antibody. As shown in Figure 4.4 a, a distinctive smear band, which is typical of
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ubiquitinated proteins (Christianson and Green 2004; Mimnaugh and Neckers 2005), 
was observed in the anti-Ub immunoblot at 10 min agonist challenge. Such 
ubiquitination of PDE4D5 appeared to be due to either different-length ubiquitin 
chains attached to a single lysine site of PDE4D5, several different length 
polyubiquitin chains conjugated to multiple lysine residues within the protein, or the 
combination of both types of ubiquitin modification.
These data show that human VSV-PDE4D5 undergoes at least poly- 
ubiquitination in HEKB2 cells upon isoprenaline stimulation for 10 min. In order to 
exclude the artifacts that might result from the overexpression of VSV-PDE4D5, I 
also examined the endogenous PDE4D5 ubiquitination status upon p agonist 
challenge in HEKB2 cells. Here I showed that endogenous PDE4D5 in HEKB2 cells 
displayed an ubiquitination pattern similar to VSV-PDE4D5 as shown by the presence 
of smear band detected on the anti-ubiquitin immunoblot (Figure 4.4 c). This result 
suggests that the ubiquitination of VSV-PDE4D5 was not influenced by the presence 
o f the VSV tag.
4.2.2 UIM of PDE4D5 is critical for ubiquitination
The PDE4 family is composed of 4 different genes, PDE4A, PDE4B, PDE4C, 
and PDE4D, which generate different isofonns due to the distinct translation starting 
sites and spliced variants (Houslay and Adams 2003). Each isoform is characterized a 
unique N-terminal region and the C-terminal region of each isoform is conserved 
within the same subfamily gene (Houslay and Adams 2003). Sequence analysis of 
PDE4D gene shows the presence of the UIM domain in their C-terminus (Figure 4.3), 
indicating that the various isoforms produced by of this gene might undergo
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ubiquitination. In contrast, no putative UIM was observed in the cognate region o f the 
PDE4A, PDE4B and PDE4C genes (Fig 4.3). Thus, in order to assess whether PDE4A, 
PDE4B and PDE4C display a ubiquitination pattern, I studied the ubiquitination of 
transiently transfected VSV-tagged human PDE4A, VSV-tagged human PDE4B and 
VSV-tagged human PDE4C isofonns in HEKB2 cells. Here I showed that stimulation 
of HEKB2 cells with isoprenaline did not trigger ubiquitination of either PDE4A5, 
PDE4B1, PDE4B3, PDE4B4 or PDE4C1 (Figure 4.5). Interestingly, isoprenaline 
stimulation of HEKB2 cells also failed to induce ubiquitination of VSV-PDE4D3
'
(Figure 4.6 b). Looking into the PDE4D3 sequence, it contains the same UIM 
sequence as PDE4D5 (Figure 4.6 a). Therefore, molecular determinants other than 
UIM itself must contribute to decide upon ubiquitination, to allow for this isofonn 
specificity within the PDE4D sub-family.
Fisher et al. (2003) have suggested that the conserved N-proximal acid patch 
within UIM seems to be most important in contributing Ub binding (Fisher et al.
2003). To detemiine if the acid patch 723EEE is involved in PDE4D5 ubiquitination, I 
created a triple point mutation at amino acids 723, 724 and 725 (723E) in the VSV- 
tagged PDE4D5 construct (Figure 4.7 a) and studied its ubiquitination using the in 
vivo ubiquitination assay. Here I showed that the mutation of this region in the UIM 
(723EEE->AAA) abrogated the ability of PDE4D5 to be ubiquitinated in HEKB2 
cells upon challenge with isoprenaline (Figure 4.7 b). This indicates that PDE4D5 has 
a flmctional UIM and that the three glutamates at the N-tenninal end of this UIM are 
critical for its functioning.
4.2.3 Vasopressin-stimulated ubiquitination of PDE4D5 in HEKV2 cells
GPCRs are categorized into Class A and Class B, based on their binding 
kinetics with P-arrestins (Oakley et al. 2000). The PzAR and VzR, respectively, act as 
prototypes for these two gioups of GPCRs. To evaluate the different effects of two 
GPCR types on the PDE4D5 ubiquitination, I used HEKV2 cells stably 
overexpressing vasopressin Vz receptor to perform the in vivo ubiquitination assay. I 
transiently transfected HEKV2 cells with VSV-tagged PDE4D5 and stimulated them 
with vasopressin for different times. The VSV-PDE4D5 was isolated on the VSV- 
agarose and immunoblotted with a specific ubiquitin antibody as before. Strikingly, 
unlike the highly transient ubiquitination of 4D5 in HEKB2 cells, VSV-PDE4D5 
underwent ubiquitination over a much longer time course in the HEK Vz cells (Figure 
4.8, left upper panel). This phenomenon is reminiscent of the ubiquitination of Class 
B receptors e.g. VzR (Martin et al. 2003) and p-aiTestin in HEKV2 cells (Shenoy et al. 
2001).
The same membrane was stripped and immunoblotted with VSV to confirm 
the equal pull-downed VSV-PDE4D5 (Figure 4.8, left lower panel). As was the case
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in HEKB2 cells after isoprenaline treatment, the VSV-PDE4D5 723E mutant ablated 
PDE4D5S ability to be ubiquitinated upon vasopressin challenge in HEKV2 cells 
(Figure 4.8, middle panel). Control experiments were done in non-transfected V2 cells 
and no ubiquitination signal was detected in the VSV-immunoprecipitated samples 
(Figure 4.8, right panel).
4.2.4 Requirement of p-arrestin binding for PDE4D5 ubiquitination
Previous studies have shown that p-an-estin2 is necessary for pzAR 
ubiquitination (Shenoy et al. 2001). In HEKB2 cells, it is also known that parrestin 
preferentially binds to PDE4D under basal conditions and recruits PDE4D to the 
plasma membrane upon isoprenaline challenge (Perry et al. 2002). To test whether the 
association between PDE4D5 and p-arrestin is required for PDE4D5 ubiquitination, I 
compared the ubiquitination of wild type VSV-PDE4D5 with that of p-arrestin 
binding defective VSV-PDE4D5, in which a critical p-arrestin site was mutated to 
alanine (VSV-PDE4D5 E27A). In HEKB2 cells, isoprenaline treatment led to 
ubiquitination of wild type VSV-PDE4D5 but not the mutant VSV-PDE4D5 E27A 
(Figure 4.9 a, b).
:v'-''
As PDE4D5 is known to exist in a complex with the multi-function scaffold 
protein p-arrestin and it is know that parrestin itself is modified by ubiquitin after p- 
adrenergic stimulation challenge (Shenoy et al. 2001), it is important to exclude the 
possibility that the detected ubiquitination in immunopurified PDE4D5 samples is in 
fact that of associated p-an estin and not PDE4D5 per se. To this end, I perfonned the 
in vivo ubiquitination assay for p-arrestin. HEKB2 cells transfected with wild type 
VSY-PDE4D5 were stimulated with isoprenaline for different times. The endogenous 
p-aiTestin was isolated on Protein G beads using a specific p-aiTestin antibody and the 
IPs subjected to Western blotting with an antibody specifically against Ub. The 
ubiquitinated p-anestin was detected as a smeared band on the Western blot at 15 min 
after isoprenaline challenge, consistent with the previous finding (Shenoy et al. 2001).
Interestingly, p-arrestin ubiquitination occurred 5 min later than did the ubiquitination 
of VSV-PDE4D5 (Figure 4.9 c). Thus supports the notion that the ubiquitination of 
PDE4D5 and p-arrestin are indeed two separate processes.
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4.2.5 Interaction of the E3 Ub ligase Mdm2 with PDE4D5
The finding that p-arrestin binding is required for PDE4D5 ubiquitination 
suggests that p-arrestin might serve as an adaptor protein that bridges PDE4D5 to the 
ubiquitination machineiy. It has been shown that p-aiTestin links RING finger B3 
ligase Mdm2 to the PzAR and initiates its ubiquitination. It is likely, therefore, that 
PDE4D5 is ubiquitinated in a similar manner. Work in this chapter has already shown 
that ablation of the ability of PDE4D5 to bind p-aiTestin leads to its loss of 
ubiquitination (Figure 4.9 b). Here, I set out to examine if  this observation came from 
a diminished/abolished association between PDE4D5 and Mdm2.
To assess the PDE4D5-Mdm2 association in HEKB2 cells, I transiently 
transfected HEKB2 cells with VSV-tagged wild type PDE4D5, a mutant PDE4D5 that 
does not bind to p-arrestin (PDE4D5 E27A), a mutant PDE4D5 that does not bind to 
RACKl (PDE4D5 L29/30A) and a UIM mutant (PDE4D5 723E). I then evaluated 
their interactions with Mdm2 by immunoprécipitation and immunoblotting. Mdm2 
associated more with VSV-PDE4D5 L29/30A and wild type VSV-PDE4D5, but less 
with VSV-PDE4D5 723E and least with VSV-PDE4D5 E27A (Figure 4.10 a). 
Recently, it was discovered that p-an'estin and RACKl mutually interact with 
PDE4D5 (Bolger et al. 2006). This finding may explain the fact that Mdm2 associates 
more with PDE4D5 L29/30A as it has been shown to bind a larger pool of parrestin 
than wild type PDE4D5. I also perfoiined a reverse IP whereby the four different 
types of VSV-tagged PDE4D5 were isolated on the VSV-agarose and their association 
with Mdm2 was analyzed by immunoblotting the IP samples with a specific Mdm2 
antibody. These results again showed that ablation of the interaction between PDE4D5 
with p-arrestin (PDE4D5 E27A) severely attenuated the association between PDE4D5 
and Mdm2 (Figure 4.10 b), confirming that PDE4D5-bound paiTestin is responsible 
for placing Ub E3 ligase Mdm2 in close proximity to PDE4D5, therefore mediating 
its ubiquitination (Figure 4.9).
4.2.6 The ubiquitination signals of VSV-PDE4D5 are composed of mono- 
ubiquitination and poly-ubiquitination
In vivo, three types of poly-ubiquitin chains can be formed by different types 
of linkages within Ub: namely K29, K48, and K63. These are found on a number of
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ubiquitin-modifïed substrate proteins (Pickart 2001), Since each chain type may 
assume a different conformation (Varadan et al. 2002), it has been suggested that 
different types of ubiquitin conjugates have the potential to decide substrate proteins’ 
fate. To test the type of poly-ubiquitin chain attached to VSV-PDE4D5 (Figure 4.4), 
and therefore better understand the functional outcome of PDE4D5 ubiquitin 
modification, three HA-tagged Ub mutants, K48R (lacking any K48-polyubiquitin 
chain), K63R (lacking any K63-polyubiquitin chain) or the triple mutant K29, K48, 
K63R (absence of the major polyubiquitin chains) were used. Mutants and HA-tagged 
wild type Ub were transiently co-transfected with VSV-PDE4D5 into HEKB2 cells 
and assayed for isoprenaline-stimulated ubiquitination. As shown in Figure 4.11, both 
wild type HA-Ub and HA-UbK63R displayed ubiquitination. However, the ability of 
PDE4D5 to be poly-ubiquitinated was severely attenuated when K48 was mutated to 
R, whereas little polyubiquitination signal on PDE4D5 immunoprecipitates was 
detected (Figure 4.11). In addition, when K29, K48 and K63 of HA-Ub were all 
mutated to arginine (R), the polyubiquitin chains on VSV-PDE4D5 were completely 
inhibited (Figure 4.11). Collectively, these findings indicated that the polyubiquitin 
chains on PDE4D5 upon isoprenaline stimulation were composed of K29-linked 
polyubiquitin chains, K48-linked polyubiquitin chains and K63-linked polyubiquitin 
chains, and that K48-linked polyubiquitin chains predominated. Notably, a distinct 
HA band separate from the high molecular weight smear was detected as the same 
molecular weight as VSV-PDE4D5, indicative of mono-ubiquitinated form of 
PDE4D5. Thus, prevention of the ubiquitin chain fonnation does not influence the 
single ubiquitin modification on PDE4D5 (Figure 4.11).
4.2.7 Isoprenaline stimulates the association of VSV-PDE4D5 with proteasome 
19S regulatory subunits 19S1,19S2 and 19S5a in a time-dependent manner
I have suggested above that PDE4D5 undergoes K4 8-linked 
polyubiquitination upon isoprenaline stimulation in HEKJB2 cells. As it is well-known 
that proteins which possess K48-Ub chains target proteins to the proteasome (Pickart
2001), and some 19S regulatory subunits of 26 proteasome seiwe to recognize the 
multi-ubiquitin chains (Glickman 2000), I set out to examine whether ubiquitinated 
PDE4D5 associates with 19S subunits. To determine whether PDE4D5 can interact 
with 19S subunits, I expressed VSV-tagged wild type PDE4D5 in HEKB2 cells and 
stimulated the cells with isoprenaline for different times. Both cell lysates and the
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isolated VSV-PDE4D5 on VSV-agai*ose from these lysates were separated by SDS- 
PAGE and Western blotted with a specific antibody raised against one of a variety of 
19S subunits. Time-dependent increases in the association of PDE4D5 with 19S2 and 
19S5a were observed, however, no interactions were detected between PDE4D5 and 
19S1, 19S6 or 19S12 (Figure 4.12). To further confirm that this association is 
ubiquitin dependant, I sought to determine whether PDE4D5 ubiquitination mutant 
(PDE4D5 723E) would lose its ability to interact with 19S subunits. To this end the 
experiment was repeated after transient transfection of VSV-PDE4D5 723E into 
HEKB2 cells. As shown in Figure, stimulation of HEKB2 cells with isoprenaline did 
not have any effect on PDE4D5 723E association with Î9S subunits (Figure 4.13). 
These results clearly indicate that polyubiquitin chains on PDE4D5 orchestrated by its 
UIM indeed serve to target PDE4D5 to the 19S regulatory subunits.
4.2.8 Isoprenaline promotes PDE4D5 interaction with p-arrestin in HEKB2 cells 
via a ubiquitination-dependent process
To explore the biological function of PDE4D5 ubiquitination, I examined the 
effect of ubiquitin addition on the interaction of PDE4D5 with p-arrestin. It is well 
known that their association and subsequent translocation to the plasma membrane are 
crucial in the regulation of pzAR desensitization (Peixy et al. 2003; Lynch et al. 2005). 
Work described earlier in this chapter shows that the ubiquitination of PDE4D5 
reached a peak at 10 min post isoprenaline challenge. Therefore, a broader time 
window would be beneficial to examine the effect of ubiquitination on PDE4D5 
interaction with p-aivestin. Wild type VSV-PDE4D5 or mutant VSV-PDE4D5 723E 
was singly transfected into FIEKB2 cells, and after 48hr, isoprenaline was 
administrated for different times. Endogenous P-arrestin was isolated by 
immunoprécipitation and the p-anestin-bound VSV-PDE4D5 or VSV-PDE4D5 723E 
was detected by Western blotting using an anti-VSV antibody. Clearly, under basal 
conditions, p-anestin binds more to wild type PDE4D5 than to mutant PDE4D5 723E 
and the association between wild type PDE4D5 and p-an'estin (but not 4D5 723E) 
was noticeably enhanced up to 10 min isoprenaline treatment after which it started to 
decrease (Figure 4.14 a, b). Interestingly, the kinetics of this interaction between 
PDE4D5 and P-arrestin bore a striking resemblance to the kinetics of PDE4D5 
ubiquitination (Figure 4.14 c, d, e). This suggests that the direct effect of Ub
13 8
modification of PDE4D5 is to strongly increase its binding to p-arrestin and therefore 
increase the amount of PDE4D5 which translocates to activated receptors with p- 
arrestin. This may have important consequences for the kinetics of receptor 
desensitization.
4.2.9 In vitro ubiquitination assay on peptide array of PDE4D5 identifies two 
regions where the ubiquitin acceptors reside
To date, it has proved impossible to accurately predict the sites of Ub on 
proteins as no clear consensus has been reported. Indeed, in many cases, a variety of 
lysines within locations having different sequences of substrate proteins are capable of 
functioning as Ub acceptor sites (King et al. 1996; Hou et al. 1994; Crook et al. 1996). 
Therefore, mutation of single lysine or a combination of several lysines to determine 
the actual lysine site that is ubiquitinated in PDE4D5 requires much effort. In the hope 
of circumvent this practical difficulty, I used a novel methodology by performing in 
vitro ubiquitination assays on peptide arrays that covered the entire PDE4D5 sequence. 
The peptide arrays consist of overlapping peptides (25 mers), sequentially shifted by 5 
amino acids to include the complete PDE4D5 sequence, which were then spotted on 
nitrocellulose. The prevalent application of this peptide array analysis will be 
extensively explored in Chapter 6. In vitro ubiquitination of the full-length PDE4D5 
array was achieved using a commercial kit and purified GST-Mdm2 was a kind gift 
from Professor Ron Hay at Dundee University. The membrane was then probed with 
an antibody against Ub. Positive Ub signals were noted as dark spots and negative Ub 
signals were obseiwed as clear areas. Figure 4.15 shows that two separate regions of 
PDE4D5 provide the lysines as Ub acceptors: one area spans the amino acid sequence 
of peptide 10, 11, 12 and 13 (amino acids 46-85), another is spanning the sequence of 
peptide 28, 29 and 30 (amino acids 136-170) (Figure 4.15).
Scanning alanine mutagenesis in two-hybrid and pull-down assay is a 
commonly used analytical method to aid identification of motifs that define sites of 
interaction between proteins, Scanning alanine mutagenesis is combined with peptide 
aiTay technology to further identify lysines involved in Region 1. Instead of the full- 
length sequence of PDE4D5, a family of peptides derived from a 25-mer parent 
peptide 10 whose sequence reflected amino acids 46-70 of PDE4D5 were used. These
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peptides each had a single substitution of successive amino acids to alanine in the 
sequence to fonn the scanning peptide amay. The in vitro ubiquitination assay on 
peptide 10 alanine scan array did not show any reduction of the ubiquitin signal 
(Figure 4.16), suggesting that single mutation of a lysine in this sequence of peptide 
10 was not enough to ablate the modification. Other lysines within the same sequence 
may compensate for a single alanine substitution. In the case of peptide 10, two 
lysines are present (Figure 4.15 b). Control studies were performed with peptide 3 and 
5 alanine scan arrays (Figure 4.16) and no ubiquitination was obseiwed.
4,3 Discussion
In this chapter, it has been demonstrated that the ubiquitin-interacting motif 
(UIM) present on PDE4D5 confers its ability to undergo ubiquitination, by K48- 
linked and K63-linked polyubiquitin chains. Post-translational modification often 
serves to modulate the functions of substrate proteins (Jenson 2004). Here I show that 
ubiquitinated PDE4D5 displays an enhanced association with certain proteasome 19 
regulatory subunits (Figure 4.12), as well as increased binding to p-arrestin (Figure 
4,14). Changes in the proportion of p-aii'estin-bound PDE4D5 can lead to a higher 
percentage of cAMP-degrading PDE4D5 recruited to the plasma membrane upon 
isoprenaline challenge in HEKB2 cells (Perry et al. 2002). The data presented here 
suggests that ubiquitination of this cAMP phosphodiesterase isofonn may be required 
for efficient receptor desensitization as the modification would not only promote 
localized cAMP hydrolysis (down regulating further the PKA phosphorylation o f the 
PzAR) but also initiate the degradation of PDE4D5 after it has perfonned its essential 
function. Both of these actions would serve to reset the receptor for another round of 
agonist challenge.
The four PDE4 genes generate over 20 different isoforms, each of which is 
unique in their N-tenninal region. In addition, the C-tenninal regions from each of the 
four subfamilies are distinct, the role of which is still ill-understood (Houslay 2005). I, 
for the first time, show that one of the functions of these distinct extreme C-terminal 
of PDE4 isofoiTns is to direct their own ubiquitination via the UIM. PDE4A5, 
PDE4B1, PDE4B3 and PDE4B4 do not contain a UIM in their extreme C-terminus 
unlike PDE4D5, which might explain the differences observed in agonist mediated
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ubiquitination of these species (Figure 4.5). Interestingly, although the UIM is present 
in FDE4D3, another long isoform of PDE4D gene subfamily, it does not confer the 
ability of PDE4D3 to be ubiquitinated in HEKB2 cells upon pzAR activation (Figure
4.6 b). This observation can be explained as such: there are molecular determinants, 
other than UIM, that are required for the ubiquitination of PDE4D3. One may argue 
that the lack of ubiquitination on the isofonn PDE4A5, PDE4B1, PDE4B4 and 
PDE4D3 are due to the ‘wrong’ stimuli. Although I did not screen for other conditions 
of stimuli to test the possibilities of their ubiquitination, I preclude the possible 
artificial functional importance of UIM in PDE4D5 ubiquitination by mutating highly 
conserved acidic acids (glutamates) (723E), which completely abolished the 
ubiquitination of PDE4D5 (Figure 4.7 b).
It has been suggested that, in vivo, most UIMs tested biochemically display a 
preference binding to polyubiquitin chains, with respect to monoubiquitin (Polo et al.
2002). However, to date, in the case of UIM-dependent substrate protein self- 
ubiquitination, it exclusively appears to be monoubiquitin modification (Polo et al. 
2002; Hofmann and Falquet 2001). My finding that PDE4D5 undergoes a UIM- 
dependent polyubiquitination therefore suggests a UIM-directed versatile Ub 
modification exists. This is consistent with Miller et al.’s finding (Miller et al. 2004) 
that the presence of an UIM does not exclusively promote monoubiquitination, but 
rather a mixture of mono-, multi- and polyubiquitination.
Two classes of GPCRs have been identified with respect to their distinct 
kinetics of parrestin binding. The PzAR belongs to Class A  receptors, which bind p- 
arrestin transiently during endocytosis and have a slightly higher affinity for the P~ 
arrestin2 isofonn (Oakley et al. 2000). However, the VzR, which is classified as Class 
B receptor, is able to bind paiTestin more stably and shows equal affinity for p- 
arrestinl and p-an’estin2. I have examined the ubiquitination status of PDE4D5 in 
these two receptor systems and found strikingly different kinetics of deubiquitination 
of PDE4D5 with respect to the two classes of receptors. Stimulation of the pzAR leads 
to transient PDE4D5 ubiquitination (Figure 4.4), whereas when VzR is stimulated, 
PDE4D5 remains stably ubiquitinated (Figure 4.8). Interestingly, previous studies 
have shown that p-arrestin also exhibits similar kinetics of deubiquitination in these
141
two model receptor systems (Shenoy and Lefkowitz 2003). As PDE4D5 is known to 
preferentially bind to P-arrestin compared to other PDE4 isoforms (Bolger et al. 2003), 
this coincidence of the same pattern of ubiquitination in PDE4D5 and p-arrestin in the 
two receptor systems reflects the presence of an important factor that bridges these 
two proteins’ namely ubiquitin modification.
I have shown that p-arrestin binding to PDE4D5 is required for PDE4D5 
ubiquitination (Figure 4.9). This suggests that p-arrestin may serve as an adaptor that 
links PDE4D5 to the ubiquitination machinery. It has been known that the oncoprotein 
Mdm2, a negative regulator of p53, interacts with p-arrestin at endogenous level of 
the two proteins (Shenoy et al. 2001). Mdm2 contains a RING (really interesting new 
gene) domain at its C-terminus and catalyses the ubiquitination of p-arrestin. PDE4D5 
ubiquitination, which in itself requires p-anestin, is mediated by Mdm2 that is 
brought by the adaptor protein p-arrestin in close proximity to PDE4D5.The similar 
crucial role of P-aiTestin in acting as adaptor for the Mdm2 E3 ligase has been 
underlined in the case of ubiquitination of Insuline-like Growth Factor-1 Receptor 
(IGF-IR) (Gimita et al. 2005). In addition, although the E3-ligase for ubiquitination 
of PzAR is still unknown, p-arrestin is known to be required as an adaptor to bring 
E3-ligases to close proximity (Shenoy et al. 2001).
My findings indicate that Mdm2 only foims a complex with p-arrestin-bound 
PDE4D5 (Figure 4.10), and this may explain the loss of detection of PDE4D5 
ubiquitination on PDE4D5 mutants that cannot bind to P-arrestin (Figure 4.9 b). More 
convincingly, 4D5 ubiquitination was attenuated when endogenous Mdm2 was 
knocked down using siRNA (data not shown). Interestingly, mutation of PDE4D5 
UIM resulted in both a decreased association between PDE4D5 723E and Mdm2 
(Figure 4.10) and an ablation of ubiquitinated PDE4D5 (Figure 4.7 b). This might 
suggest that in the case of PDE4D5, Mdm2 exerts its substrate specificity on the 
recognition code -  UIM domain. In other words, Mdm2 might recognize the UIM on 
PDE4D5 and recruit the E2-conjugated Ub to the substrate protein, PDE4D5, 
therefore mediating its ubiquitination. If this is true, overexpression of another UIM- 
containing protein may lead to a decrease in PDE4D5 ubiquitination.
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Ub has 7 lysine residues and at least five of them (K6, K ll, K29, K48, and 
K63) can function as a linkage for polyubiquitin chains (Passmore and Barford 2004). 
It is now well accepted that different types of ubiquitin linkages have the potential to 
decide the modified proteins’ fate (Weissman 2001). PDE4D5 has been shown to be 
conjugated with Ub-chains (Figure 4.7 b), therefore it is of importance to dissect 
which type of linkage mediates this modification as this may provide evidence as to 
the function of such an event. Although Ub contains seven lysine residues, they are 
not used with the same frequency in polyubiquitin chain assembly. The predominant 
linkages observed are Lys48-Gly76 (Chau et al. 1989), Lys29-Gly76 (Mastrandrea et 
al. 1999), and Lys63-Gly76 (Seibenhener et al. 2004), of which K48-linked chains 
appear to be the most frequently used signal. Mutation of K48 (so that K48-linked Ub 
chain can not occur) nearly abolished the detection of PDE4D5 ubiquitination to a 
similar degree as the triple K mutant (K29, 48, 63R), suggesting that K48-linked 
chain is predominantly present on PDE4D5 when PDE4D5 is ubiquitinated. Further 
study of K63-linked chain shows that blocking the fonnation of K63-linked ubiquitins 
also contributes to the ubiquitination signals of PDE4D5, as mutation of K63 to 
arginine also somewhat reduces PDE4D5 polyubiquitination (Figure 4.11). As the 
other lysine mutant ubiquitins were unavailable I did not study the possibility of their 
presence on PDE4D5. However, at least in the case of PDE4D5, K29, K48 and K63 
are most important in fonning the polyubiquitin chains as mutating of all these lysines 
totally ablated the detection of PDE4D5 polyubiquitination (Figure 4.11).
The canonical Ub signal, a K48-linked polyubiquitin chain, is known to 
target substrate proteins to the 26S proteasome degradation pathway (Layfield et al.
2003). The 26S proteasome comprises two main particles: the 20S core proteasome 
and 19S regulatory complex (Figure 4.17). The 19S regulatory particle confers 
substrate specificities (Glickman 2000) via the UIM-containing subunit 19S5a (also 
known as RpnlO) and recently, another subunit RptS is suggested to have a role in 
recognizing polyubiquitinated proteins (Lam et al. 2002). The 18 subunits of each 19S 
cap can be grouped into the Lid and the Base (Figure 4.17), which are tethered by the 
two largest subunit Sl/Rpn2 and S2/Rpnl (Voges et al. 1999).
Due to the limited availability of commercial antibodies against 19S subunits, 
I picked one subunit from the Base (19S6), two from the Lid (19S12 and 19S5a) and
the two joint subunits (19S1 and 19S2) to study the interactions with PDE4D5 under 
conditions where PDE4D5 is ubiquitinated. Compared to the PDE4D5 Ub mutant 
723E, wild type PDE4D5 associates with 19S1, 19S2 and 19S5a in a time-dependent 
manner (Figure 4,12 a, b, e). This suggests that ubiquitinated PDE4D5 are targeted to 
the 26S proteasome for degradation by these specific 19S subunits. It is well known 
that 19Sa recognizes polyubiquitin chains through its prototype UIM domains UIMl 
(LALAL) and UIM2 (lAYAM) (Pickart 2000). Interestingly, the two proteins of the 
19S regulatory complex, 19S1 and 19S2, have also been shown to contain a number 
of repeated sequences that resemble the LALAL or lAYAM found within the UIMl 
and UIM2 regions of 19S5a (Young et al. 1998). Recently Rpnl is indicated to 
recognize Ub-like proteins (Elsasser et al. 2002). The findings presented here, provide 
an independent experimental support that in addition to 19S5a, 19S2 can also 
recognize the ubiquitinated proteins in vivo and potentially target these proteins for 
26S proteasome degradation.
Ub modifications have also been suggested to signal nonproteoytic, 
reversible events, such as changes in protein activity, subcellular localization or 
protein-protein interactions (Schnell. and Hicke 2003). It is clear from the data 
outlined above, that ubiquitination o f PDB4D5 changes its ability to bind to P-arrestin 
(Figure 4.14). Recently, it has been shown that p-arrestin forms a complex with PDE4 
enzymes, thereby providing a means of delivering a cAMP-degrading enzyme to the 
plasma membrane in an agonist-dependent fashion (PeiTy et al 2002). My findings 
suggest that ubiquitination of the PDE may be essential to promote efficient complex 
formation and translocation (Figure 4.14 a). It is apparent that in response to 
isoprenaline in HEKB2 cells, the ability of wild type PDE4D5 to bind p-aiTestin 
increases within 10 min, followed by a sliglit decrease afterwards. The kinetics of the 
PDE4D5 binding to p-anestin coincidently match that of the Ub modification of 
PDE4D5 (Figure 4.14 c).Indeed, the ubiquitination and deubiquitination of PDE4D5 
may synchronize the kinetics of binding and release between PDE4D5 and p-arrestin. 
In addition, ablation of the ability of PDE4D5 ubiquitination by mutating the UIM 
region of PDE4D5 strongly diminished the time-dependent association of PDE4D5 
with p-arrestin (Figure 4.14 e).
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Compared to the relatively conserved phosphate acceptor site within 
substrates of kinases which direct binding and phosphorylation, no such consensus 
motif exists for ubiquitination. In many cases, any lysine within the substrate protein 
is capable to accept Ub (King et al. 1996; Hou et al. 1994; Crook et al. 1996). 
Recently, however, many groups have uncovered a higher chance of a number of 
specific positioned lysines that are ubiquitinated in the substrate proteins. These 
include: (1) lysines located within or adjacent to PEST sequence (Roth and Davis 
2000; Marchai et al. 2000); (2) two adjacent lysine residues positioned 10 and 9 
residues upstream of E3 substrates of the DSG(XX)2+nS destruction motif
(Kumar et al. 2004); (3) one or more of the lysines present in the region between two 
UIMs in the same substrate protein; (4) the lysines located at least 22 residues N- 
terminal to the UIM in an orientation-dependent manner (Miller et al. 2004). In order 
to make identification of acceptor lysine residues in PDE4D5 simple, I took advantage 
of the newly developed peptide array technology, (discussed in more detail in Chapter 
6), to perform in vitro ubiquitination assays. Each spot on the peptide aiTay of 
PDE4D5 represents a specific sequence of PDE4D5, presumably having some 
measure of secondary structure, therefore, given the full ubiquitination machinery and 
appropriate incubation temperature, Ub may be conjugated to the right lysine residues 
as it does in vivo. Immunoblotting the post-m vitro ubiquitinated peptide array with a 
specific Ub antibody identified two separate regions where the Ub-modified lysine 
residues were located. Suprisingly, Region 1 (peptidelO-13) is part of the Pan'estin 
binding site o f PDE4D5 (but not RACKl) (Figure 4.15 a; Figure 6.5). This suggests 
that the ubiquitination of PDE4D5 and the association between PDE4D5 and p~ 
arrestin are intrinsically related. In order to ascertain the exact lysine residues that are 
ubiquitinated, I used peptide 10-derived alanine scanning array that was subjected to in 
vitro ubiquitination. Since two lysine residues are present in the same peptide 
(peptide 10), substitution of either of them did not abolish the ubiquitination signals, 
indicating that both of the lysines are indeed ubiquitinated (Figure 4.16 b). Further 
experiments need to be done on peptide 13-derived alanine scanning array to 
deteitnine if the lysine within this sequence can also be ubiquitinated.
The second region of the positive ubiquitination sites on PDE4D5 extends 
Irom D136 through to R 170 (Figure 4.16), where only one lysine resides. Therefore I
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would propose investigating the peptide28-derived alanine scanning array under the in 
vitro ubiquitination conditions. Unexpectedly, this lysine (K140) is 14 residues C- 
terminal to the PDE4D5 PKA phosphorylation site, giving rise to a speculation that 
PKA phosphorylation of PDE4D5 on S I26 might feed into the signal of its 
ubiquitination (Mackenzie et al. 2002). To evaluate this hypothesis, fuilher 
experiments need to be done on PDE4D5 using mutants that either abolish or mimics 
phosphorylation of PDE4D5 by PKA and compare their ability to be ubiquitinated. 
Unfortunately, alanine scans of peptides D136 were unavailable during my time of 
study.
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Figure 4.1 The ubiquitination pathway.
Free ubiquitin (Ub) is activated in an ATP-dependent manner with the formation of a 
thiol-ester linkage between Ub activating enzyme El and the carboxyl terminus Gly76 
of Ub. Ubiquitin is transferred to one of a number of different Ub conjugating 
enzymes (E2s). Ub ligases (E3s) catalyze the formation of an isopeptide bond 
between the s-amino group of a lysine residue in substrate proteins and the carboxyl 
terminus Gly76 of Ub. Two families of E3s are known. For HECT domain E3s, Ub is 
transferred to the active-site cysteine of the HECT domain followed by transfer to 
substrates. For RING E3s, Ub is transferred directly from the E2 to the substrate. 
(This schematic is adapted from Di Piore et al. 2001 Nature)
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4.2 Different forms of ubiquitin modification.
Monoubiquitination (MonoUb) is obtained by the attachment of a single Ub molecule 
(red circle) to a lysine residue (K), whereas multiubiquitination (MultiUb) is the result 
of addition of several single Ubs to different lysine residues in a protein. These 
modifications are implicated in cellular processes, including endocytosis and 
membrane trafficking. Polyubiquitination (PolyUb), however, is obtained by the 
formation of a polymeric chain of Ub molecules by the subsequent additions o f Ub 
molecules to the preceding Ub. The functions of Lys48-linked ubiquitin chains target 
proteins for degradation by the 26S proteasome, whereas chain elongation via Lys63 
is involved in several non-proteolytic functions, including signaling DNA repair, the 
stress response, endocytosis and signal transduction. The biological function of 
ubiquitin chains coupled via Lysll and Lys29 remains to be determined, but it has 
been suggested by some group that the linkage through Lysll or Lys29 may target 
proteins to the poteasome.
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4.3 Characterization of the UIM.
(a) Alignment of C-terminal extreme sequence of PDE4D with the UIM-containing 
sequences of several endocytic proteins. Consensus UIM is indicated and delineated 
in red line. N-proximal acidic patch was shown in blue, hydrophobic residue is shown 
in pink, nearly invariable alanine is shown in green, conserved serine at position 13 is 
indicated in red and conserved glutamate at position 16 is indicated in violet, (b) 
Extreme C-terminal of PDE4A11, PDE4B1, PDE4C, and PDE4D5 were aligned by 
GENEDOC Software. Conserved amino acids within these four gene families are 
indicated by the letters at the bottom line. The red line delineates where the UIM is 
located.
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4.4 Isoprenaline-stimulated ubiquitination of PDE4D5.
(a) HEKB2 cells were transiently transfected with PDE4D5-VSV and the endogenous 
PzARs were stimulated for the indicated times. PDE4D5 was immunoprecipitated 
with VSV affinity beads, the bound protein sample was separated by SDS-PAGE and 
the presence of ubiquitinated forms in the immunoprecipitates (IP) was detected with 
a ubiquitin-specific antibody, (b) Shows the equal amount of PDE4D5 in the IP 
samples, (c) HEKB2 cells were stimulated with isoprenaline for the indicated times 
and endogenous PDE4D5 was immunoprecipitated with Protein-G beads by a specific 
PDE4D antibody. The presence of ubiquitinated forms in the IP samples was detected 
with a ubiquitin-specific antibody.
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Figure 4.5 Isoprenaline-stimulation of HEKB2 cells failed to lead to 
ubiquitination of PDE4A5, PDE4B1, PDE4B3, PDE4B4 and PDE4C1.
HEKB2 cells were transiently transfected with one of the VSV-tagged PDE4 isoforms 
(PDE4A5, PDE4B1, PDE4B3, PDE4B4 and PDE4C1) and the endogenous pzARs 
were stimulated for the indicated times. PDE4 isoforms were immunoprecipitated 
with VSV affinity beads, and the presence of ubiquitinated forms in the 
immunoprecipitates (IP) was detected with a ubiquitin-specific antibody.
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4.6 Absence of ubiquitination of PDE4D3 in response to isoprenaline in HEKB2 
cells.
(a) Sequence alignment of the extreme C-terminal residues of PDE4B1, PDE4D3 and 
PDE4D5, respectively. UIM domains are shown in red. (b) HEKB2 cells were 
transiently transfected with VSV-PDE4D3 and stimulated with isoprenaline at 
indicated times. Immunoprécipitation (IP) was performed with VSV affinity beads, 
and ubiquitination was assessed using a specific Ub antibody on the IP samples. 
Positions of the molecular mass markers (kDa) are indicated.
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Figure 4.7 The extreme C-terminal of PDE4D5 contains a UIM domain essential 
for ubiquitination.
(a) Schematic representation of VSV-PDE4D5 ubiquitination mutant. Catalytic 
domain connects N-terminal region of PDE4D5 with its extreme C-terminal doamain. 
The VSV tag is located at the C-terminus o f the molecule (black box). Triple point 
mutations in the context of the full-length VSV-PDE4D5 are indicated (*). (b) 
HEKB2 cells were transiently transfected with PDE4D5 723E-VSV and stimulated 
with isoprenaline at indicated times. Ubiquitination of the isolated PDE4D5 723-VSV 
on VSV affinity beads was assessed by Western blotting using a specific Ub antibody. 
Positive control was performed using VSV-tagged PDE4D5 wild type (PDE4D5 wt) 
transfected HEKB2 cells. Positions of the molecular mass markers (kDa) are indicated.
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Figure 4.8 Vasopressin-stimulated ubiquitination of PDE4D5-VSV in HEKV2 
cells.
Left Panel: HEKV2 cells were transiently transfected with PDE4D5-VSV and the 
endogenous VzRs were stimulated with vasopressin for the indicated times. PDE4D5 
was immunoprecipitated with VSV affinity beads, and the presence o f ubiquitinated 
forms in the immunoprecipitates (IP) was detected with a Ub-specific antibody. The 
same blot was stripped and probed with an anti-VSV antibody to confirm the equal 
amount of PDE4D5 pull-downed in the IP samples. Middel Panel: Under the same 
conditions as Left Panel but with transfected VSV-PDE4D5 723E mutant, the 
ubiquitination status of VSV-PDE4D5 723E was assessed by probing the isolated 
PDE4D5 723E on the VSV agarose with a specific Ub antibody. Right Panel: control 
experiment was done in the non-transfected HEKV2 cells. Positions of the molecular 
mass markers (kDa) are indicated.
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Figure 4.9 p-arrestin-mediated PDE4D5 ubiquitination in HEKB2 cells.
(a) HEKB2 cells were transiently transfected with VSV-tagged wild type PDE4D5 
and stimulated with isoprenaline at indicated times. Immunoprécipitation (IP) was 
performed with VSV-agarose, and ubiquitination of PDE4D5-VSV was assessed by 
Western blotting using a specific Ub antibody, (b) HEKB2 cells were transiently 
transfected with VSV-tagged PDE4D5 mutant that does not bind to P-arrestin 
(PDE4D5-VSV E27A) and stimulated with isoprenaline at indicated times. 
Immunoprécipitation was performed with VSV-agarose, and ubiquitination of 
PDE4D5-VSV E27A was assessed using a specific Ub antibody by Western blotting,
(c) Endogenous PzARs were stimulated with isoprenaline for the indicated times. 
Endogenous p-arrestin was isolated on Protein-G beads with a specific anti-p-arrestin 
antibody and ubiquitinated forms of p-arrestin in the IP samples were assessed by 
Western blotting using a specific Ub antibody. The positions of molecular mass 
marker (kDa) are indicated.
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4.10 PDE4D5 interacts with Mdm2 via a p-arrestin-dependent manner.
HEKB2 cells were transiently transfected with VSV-tagged PDE4D5, PDE4D5 29/30 
mutant (that blocks its binding to RACKl), PDE4D5 723E mutant (that blocks its 
ubiquitination) and PDE4D5 E27A mutant (that does not bind to p-arrestin), 
respectively, (a) Endogenous Mdm2 in HEKB2 cells were immunoprecipiated on 
Protein-G beads with an antibody specific to Mdm2 and the association of Mdm2 with 
those overexpressed proteins was determined by Western blotting analysis with VSV 
antibody. Equal amount of immunoprecipiated Mdm2 was verified by blotting the IP 
samples with Mdm2 antibody, (b) Different forms of VSV-tagged PDE4D5 in HEKB2 
cells were isolated on VSV-agarose and the association of these different forms of 
VSV-tagged PDE4D5 was assessed by Western blotting analysis with a specific 
Mdm2 antibody. Equal amount of immunoprecipitated VSV-tagged different forms of 
PDE4D5 was verified by blotting each IP sample with VSV antibody.
156
W tH A 48K-R HA-Ub
IPVSV 
IB HA
3R HA-Ub 63K-R HA-Ub
IB VSV
Lysate 
IB HA
0 10 0 10 mins Iso
4.11 A mixture of K29-Iinked, K48-linked and K63-linked polyubiquitin chains 
on PDE4D5 in response to isoprenaline in HEKB2 cells.
HEKB2 cells were transiently transfected with VSV-tagged wild type PDE4D5 and 
one of the following HA-tagged Ub forms: wild type Ub (WT HA-Ub), or K29, 48, 
63R mutant of Ub (3R HA-Ub), or K63R mutant of Ub (K63R HA-Ub) or K48R 
mutant of Ub (K48R HA-Ub). HEKB2 cells were then stimulated with isoprenaline 
for different times and harvested in 3T3 lysis buffer. An equal protein concentration of 
cell lysate was subject to immunoprécipitation (IP) with VSV-agarose and the 
ubiquitination forms of VSV-tagged PDE4D5 in the IP samples were determined by 
Western blotting analysis using a HA antibody. The expression of PDE4D5 constructs 
and Ub constructs were verified by blotting an aliquot of the transfected cell lysate 
(30 pg) with VSV antibody and HA antibody, respectively.
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4.12 Isoprenaline-stimulated wild type PDE4D5 interaction with proteasome 
19S1,19S2 and 19S5a in a time-dependent manner in HEKB2 cells.
HEKB2 cells transiently transfected with VSV-tagged wild type PDE4D5 were 
stimulated with isoprenaline for different times. PDE4D5 was isolated on VSV- 
agarose and its association with proteasome 19 regulatory complex subunits was 
assessed by Western Blotting analysis using specific antibodies against (a) 19S1, (b) 
19S2, (c) 19S6, (d) 19S12 and (e) 19S5a, respectively. The expression of 19S subunits 
were verified by blotting an aliquot of the transfected cell lysate (30 pg) with their 
corresponding antibody. Equal amount of immunoprecipiated PDE4D5 in each IP 
sample was determined by Western Blotting using a specific VSV antibody.
(a ) (b)
IB:19S1
IB:VSV
0 3 5 (min)
( c )
IB:19S6
IB: VSV
(d)
IB:19S2 
IBiVSV 
3 0 (min)
IB:19S12 
IB: VSV
( e )
0 (min)
B:19S5a
IB: VSV
5 3 0 (min)
Figure 4.13 Loss of ability of VSV-tagged PDE4D5 UIM mutant 723E to interact 
with proteasome 19S regulatory complex in HEKB2 cells in response to 
isoprenaline.
HEKB2 cells were transiently transfected with VSV-tagged PDE4D5 UIM mutant 
723E, followed by stimulation with isoprenaline at indicated times. VSV-tagged 
PDE4D5 723E was isolated on VSV-agarose and the interaction between PDE4D5 
723E and 19S regulatory complex subunits were assessed by Western blotting 
analysis using antibodies against (a) 19S1, (b) 19S2, (c) 19S6, (d) 19S12, and (e) 
19S5a as indicated. A VSV antibody was used to confirm the equal amount of 
PDE4D5 723 in each set of IP samples.
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Figure 4.14 Ubiquitination of PDE4D5 enhances its binding to p-arrestin.
(a) HEKB2 cells transiently transfected with either VSV-tagged wild type PDE4D5 or 
its UIM mutant 723E were stimulated with isoprenaline for different times. 
Immunoprécipitation (IP) was performed with anti-P-arrestin antibody to isolate 
endogenous p-arrestin in those transfected HEKB2 cells. The association of P-arrestin 
with either wild type PDE4D5 or UIM mutant 723E was assessed by Western blotting 
analysis on IP samples using a specific VSV antibody, (b) Quantification of three 
experiments as in (a) (means ± S.D.) with 100% as the maximal effect seen with 
isoprenaline.
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Figure 4.14 Ubiquitination of PDE4D5 enhances its binding to p-arrestin.
(c) HEKB2 cells were transiently transfected with wild type VSV-tagged PDE4D5 
and stimulated with isoprenaline at indicated time. VSV-PDE4D5 was isolated on 
VSV-agarose and the ubiquitination of VSV-PDE4D5 on the VSV affinity beads was 
detected by Western blotting analysis using a specific Ub antibody. The levels of 
immunoprecipitated VSV-PDE4D5 were examined by immunoblotting with anti- 
VSV antibody, (d) Quantification of three experiments as in (c) (means ± S.D.) with 
100% as the maximal effect seen with isoprenaline. (e) Plot for comparison between 
the kinetics of isoprenaline-stimulated p-arrestin binding and that of isoprenaline- 
induced ubiquitination of PDE4D5, which is concluded from Figure 4.14 (b) and (d).
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Peptide 10-13
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Peptide 28-30
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Peptide PKA site location (blue)
nPMTSPGSGTJFOANFVHSORRESFLYRSDSDYDLSPKSMSRNSSIASDIH
GDDLIVTPFAQV
Figure 4.15 I n  v i t r o  ubiquitination assay determines PDE4D5 putative 
ubiquitination sites.
(a) The PDE4D5 peptide array that underwent in vitro ubiquitination assay using a 
commercial Ubiquitination Kit was incubated with a specific Ub antibody and subject 
to ECL. Positive signals are scored as dark spots and negative signals are scored as 
blank spot, (b) Two regions that encompass the Ub acceptor sites amino acid 
sequences in sequential peptides on PDE4D5 peptide array are delineated. Ub 
acceptor sites are indicated in red. The amino acid sequence that contains both PKA 
phosphorylation consensus (marked in blue) and the second regions of ubiquitination 
sites (underlined) are also delineated.
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Figure 4.16 The in  v i t r o  ubiquitination of sequential alanine substitution version 
of a peptide 10-derived peptide.
Here shows an array of peptides based on a 25mer parent peptide (Ctr, peptide 10 in 
Figure 4.15 a) of sequence Ala46-Arg68 in PDE4D5. Further spots reflect a scanning 
peptide array o f this parent peptide where indicated amino acids were sequentially and 
individually substituted with alanine. Cellulose membrane was blocked before 
immunoblotting with a specific anti-ERK2 antibody. Ctr, control.
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Figure 4.17 Organization and structure of the 26S proteasome and 19S 
regulatory particles.
(a) Organization of the 26S proteasome, which is composed of 19S regulatory particle 
(RP) and 20 core protease (CP), (b) Proposed organization of 19S regulatory particle 
with its Lid and Base subparticles. N, RP non-ATPase subunits; T, RP AAA-ATPase 
subunits.
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Chapter 5
Initial Exploration of Sumoylation of PDE4D5 in HEK293 
cells
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5,1 Introduction
Reversible post-translational modifications are widely used to dynamically 
regulate protein functions (Hochstrasser 2000). This has been further supported in the 
study of my last chapter, where ubiquitination of PDE4D5 was shown to affect its 
binding affinity towards p-arrestin. In addition to Ub, several other ubiquitin-like 
proteins (Ubls) have recently been identified and suggested to be able to alter the 
function of their conjugated proteins (Hochstrasser 2000; Johnson 2004; Pickart and 
Eddins 2004). One Ubl in particular, the small ubiquitin-related modifier (SUMO), is 
perhaps the best-studied example of a post-translational modification after 
modification by Ub (see reviews: Seeler and Dejean 2003; Gill 2004; Verger et al. 
2003; Muller et al. 2004; Hilgarth et al. 2004).
Small ubiquitin-related modifiers (SUMOs) are a group of proteins that 
conjugate to a wide range of proteins in the cell (Hay 2005). They are highly 
conserved fiom yeast to mammals. So far, only one SUMO gene has been identified
in yeast species and invertebrate, whereas eight isoforms have been found in plants 
(Dohmen 2004). In human cells, four types of SUMO, termed SUMO-1, SUMO-2, 
SUMO-3 and SUMO-4 have been identified (Dohmen 2004). Human SUMO 
isoforms have a similar protein folding that is characterized by ppappap , but they 
differ in their sequence identity. SUMO-2 and SUMO-3 are very similar in sequence 
(95% sequence identity for the human proteins), but SUMO-1 is only about 47% 
identical to SUMO-2 and SUMO-3 (Melchior 2000; Muller et al. 2004). Another 
difference between SUMO isoforms is their cellular status; for example, the majority 
of SUMO-1 exists in the conjugated form, whereas the SUMO-2 and SUMO-3 
isofonns exist primarily as free proteins that are strongly subject to rapid conjugation 
that is distinct from SUMO-1 (Saitoh et al. 2000).
SUMO molecules conjugate to their target proteins through an isopeptide 
bond fonned between the C-terminal glycine residue of SUMO and a lysine residue in 
the substrate. In most cases, the lysine residues are embedded in a consensus sequence 
composed o f  a characterized yKXE motif, where \j/ represents a hydrophobic amino 
acid residue, including Leu, He, Val or Phe (Johnson 2004), and K is the site of 
SUMO conjugation. As is generally known, in a SUMO conjugation reaction SUMO
167
hydrolase first removes the four C-terminal amino acids of SUMO. This exposes a 
diglycine motif to facilitate SUMO conjugation. The SUMO molecule is then 
adenylated and covalently linked to a SUMO-activating El enzyme. Subsequently, 
SUMO is transfen'ed to the SUMO-conjugating E2 enzyme Ubc9, which catalyzes the 
transfer of SUMO to its target proteins (Figure 5.1). To note, Ubc9 does not 
discriminate between SUMO isofonns and carries out all SUMO paralogues-mediated 
modification (Melchior 2000). Distinct from its counterpart in the ubiquitination 
pathway, the SUMO E2, Ubc9 can, in many cases, directly bind to substrate proteins 
via their sumoylation consensus sequence yKXE (Sampson et al. 2001). The B3 
ligase, which stimulates SUMO conjugation to target proteins, including PIAS, 
RaiiBP2, and Pc2, has only been recently identified. Although not required for 
sumoylation in vitro (Bernier-Villamor et al. 2002), SUMO E3 ligases seem to 
modulate the efficiency of sumoylation of target proteins in vivo. This is especially of 
importance for substrates that lack SUMO attachment consensus sequences.
There are several models describing the functional consequences of SUMO 
modification: it may compete with ubiquitination and affect protein stabilities 
(Desterro et al. 1998), alter substrate protein subcellular localization (Wilson and 
Rangasamy 2001), affect transcriptional activities (Seeler and Dejean 2003), or 
mediate protein protein interactions (Reverter and Lima 2005). Compared to the 
classic function of ubiquitination, which leads to the 26 proteasome-dependent 
degradation, the biological consequences of SUMO modification vary in a substrate- 
specific manner.
My alignment of the PDE4D5 amino acid sequence (Figure 5,2) reveals one 
conserved sumo modification consensus motif in its catalytic domain. This motif is 
considered to provide the potential site for recognition by the SUMO-conjugating E2,
Ubc9 and therefore directs target protein sumoylation. In exploring here whether 
PDE4D5 is a substrate for sumo modification I found that PDE4D5 was indeed 
susceptible to SUMO modification if  appropriate conditions were provided to aid in 
the detection of this modification. Mutations affecting sumoylation of PDE4D5 have 
significant functional consequences on its association with other binding partners, 
such as p-an'estins, RACK-1, and ERK2. These findings identify sumoylation as a
s
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post-translational modification that affects the interaction of PDE4D5 with proteins 
that sequester it. This occurs in such a manner that is dependent on the presence of a 
lysine residue within the SUMO modification consensus sequence present in the 
PDE4D5 catalytic domain.
5.2 Results
5.2.1 Mutation of the potential target lysine residne located within SUMO 
modification consensus sequence in PDE4D5 ablates its sumoylation in vitro.
Wild type PDE4D5 contains a short motif, VKTE, in the N-teiTninal of its 
catalytic domain, which suggests that this PDE4 isoform may become SUMOylated. 
This motif fits the minimal SUMO modification consensus sequence \(/KXE (Figure 
5.2). If this hypothesis is coiTcct, the lysine residue (K323) within VKTE motif would 
be a strong candidate to provide a SUMO modification site. In another words, if 
VKTE provides the lysine to be modified by SUMO, mutation of this lysine residue to 
arginine would ablate any such modification. To test whether human PDE4D5 is 
modified by SUMO, I first performed site-directed mutagenesis on lysine 323 of 
PDE4D5, which is contained within the putative SUMO consensus sequence. This 
mutation (K323R) thus can be used as a negative control for detection of PDE4D5 
sumoylation if  lysine 323 is susceptible to SUMO modification.
An in vitro translational sumoylation study, performed by the Hay laboratory, 
using 35S-methionine wild type PDE4D5 DNA, SUMO-activating El enzyme 
(SAE1/SAE2), SUMO-conjugating E2 enzyme (Ubc9), SUMO isoforms, SUMO-1 or 
SUMO-2, both of which lack the four C-terminal amino acid residues, and an ATP 
regenerating system, was performed to determine whether PDE4D5 is modified by 
SUMO-1 or SUMO-2. After incubation for 4 hour at 37°C, Fractionate reaction 
products was analysed by 4-12% SDS-PAGE, subsequent staining and fixing, and 
subject to phosphoimager after the gels were dried. In the reaction that contained 
SUMO-activating El enzyme, SUMO-conjugating E2 enzyme Ubc9 and SUMO-1, 
proteins with a molecular mass larger than that of PDE4D5 were detected, suggesting 
that PDE4D5 is conjugated by SUMO-1 (Figure 5.3, lane 5). In the reaction that 
contained SUMO-2, instead of SUMO-1, together with SUMO E l, E2 enzymes, 
proteins with a mass larger than that of PDE4D5 were also detected, indicating that
îPDE4D5 is attached to SUMO-2 (Figure 5.3, lane 6). However, these bands were not 
detected if ATP was not added to the reaction mixture (UN, Figure 5.3, lane 4), 
indicating that SUMO-activating El enzyme, Ubc9, and SUMO isofonns are 
necessary for PDE4D5 sumoylation in vitro, A similar finding was observed for the in 
vitro study of a positive control, sumoylation of SplOO, a transcription factor that has 
been shown to be able to undergo sumoylation under decent conditions (Figure 5.3,
lane 2 and 3). On the other hand, when purified recombinant El enzymes (Aoasl and 
Uba2 subunits), Ubc9 and SUMO-1 or SUMO-2 were mixed with the in vitro 
translated substrate proteins PDE4D5K323RK or PDE4D5K323RJ in the presence of 
ATP, SDS-PAGE and autoradiography did not reveal the slower migi'ating, 
sumoylated form of PDE4D5 (Figure 5.3, lane 7-12) as that of wild type PDE4D5. 
This suggests that mutation of lysine residue within VKTE motif of PDE4D5 ablates 
its ability to become sumoylated in vitro, and that lysine 323 in PDE4D5 indeed 
provides a site where SUMO can be attached to and modify.
5.2.2 Modification of PDE4D5 by SUMO-1 in cells
5.2.2.1 Conditions that I have tried to detect sumoylation of PDE4D5 in cells.
Although SUMO modification only occurs to a small fraction of substrate, its 
biological consequences seem to affect long-term fate of modified proteins (Hay 
2005). Therefore, it appears that a history of SUMO modification makes a difference 
between the proteins modified and non-modified. In vitro data has suggested that 
PDE4D5 is a SUMO target. However, it cannot be simply presumed that PDE4D5 can 
also be modified by SUMO-1 or SUMO-2 in vivo in intact cells. Thus, I set out here 
to assess whether SUMO can modify PDE4D5, and if the sumoylation site is within 
VKTE motif.
In order to amplify the detection of SUMO modification of PDE4D5, I first 
overexpressed a small epitope VSV-tagged wild type PDE4D5 in HEKB2 cells, and 
used overexpressed VSV-K323R as a control. Cells were haiwested in 3T3 lysis buffer. 
Immunoblotting of the immunoprecipitates obtained using anti-VSV agarose beads 
with SUMO-1 or SUMO-2 antibody failed to reveal the SUMO associated with the 
immunoprecipitants. Then I tried to co-overexpress VSV-PDE4D5 (wild type) and 
His6-tagged SUMO-1 (or SUMO-2), but the immunoprecipitate of VSV-PDE4D5 
again did not reveal the interaction with either SUMO-1 or SUMO-2. As SUMO E2
*
170
Ubc9 has been shown to mediate SUMO transfer to its target, I wish to study if co­
expression of VSV-PDE4D5 (wild type) and Ubc9 could help detect the sumoylation 
of PDB4D5 in HEKB2 cells. Unfortunately, signals for SUMO were not apparent in 
the VSV-pulled down immunoprecipitates.
HEKB2 cells have been stably transfected with p 2 -adrenergic receptors. Thus, 
in order to preclude any potential artefacts resulting from the use of this cell line, I 
then also used COS-1 cells and HEK293 cells to study the interaction between VSV- 
PDE4D5 and SUMO under the same conditions. Again, I failed to detect any 
modification of PDE4D5 with SUMO.
As the SUMO modification of its target has been suggested to be mediated 
by some other post-translational modifications on the same substrate protein, and it 
has been shown that PDE4D long isofonns are susceptible to PKA mediated 
phosphorylation via increased cAMP levels, therefore, I set out here to assess if 
elevating the intracellular levels of cAMP would help detect the SUMO modification 
of PDE4D5 in vivo. HEKB2 cells or HEK293 cells were transfected with VSV- 
PDE4D5 or the SUMO mutant form of this isoform where the putative target lysine 
was mutated to arginine. The transiently transfected cells were challenged for 5 min 
with 10 pM p-agonist isoprenaline or 100 pM IBMX (a non-selective PDE inhibitors) 
/ lOOpM forskolin (that activates adenylyl cyclase directly so as to increase 
intracellular cAMP), respectively. The lysates in 3T3 lysis buffer were subject to 
immunoprécipitation with anti-VSV agarose. The following western blot using an 
anti-SUMO-1 antibody failed to detect endogenous SUMO-1 in the VSV-PDE4D5- 
containing precipitates.
In order to preclude the possibility that 3T3 lysis buffer obscured the 
detection of sumoylation of PDE4D5, I also used a non-detergent-containing buffer 
KHEM buffer to haiwest cell under the test conditions mentioned above. Similar to the 
results obtained above, I could not detect any association between wild type PDE4D5 
tagged with VSV and endogenous/transfected SUMO-1 or SUMO-2.
1 7 1
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As SUMO-1 and SUMO-2 confer different patterns of conjugation onto 
substrate proteins, where SUMO-1 exists predominantly in its conjugating fonn, but 
SUMO-2/3 are dramatically subject to rapid conjugation upon heat shock and 
oxidative or ethanol stress (Saitoh et al; Manza et al. 2004). Therefore, I tried to 
assess if treatment of HEK293/HEKB2 cells with H2 O2  for 30 min would trigger the 
SUMO-2 modification of VSV-PDE4D5. The null interaction between VSV-PDE4D5 
and endogenous SUMO-2 indicates that wild type PDE4D5 did not undergo 
sumoylation under oxidative stress conditions.
So far, all the possible conditions under which PDE4D5 might be modified 
by SUMO have been tried, except the consideration of the importance of SUMO E3 
ligase. Only recently has it been appreciated that SUMO E3 ligases are important in 
regulating substrate selection, promoting the efficiency of target protein sumoylation 
in vivo (Hay 2005). As the failure of detection of SUMO mofidification of PDE4D5 in 
vivo might result fi*om the weak activity of SUMO E3 ligase in those studied cells, 
especially when isopeptidase activity is high, 1 set out to examine if the 
overexpression of one of the SUMO E3 ligases, PlASy, would enhance the degi ee of 
PDE4D5 being modified by SUMO, to which its conjugation can be detected in vivo. 
In this set of experiments, HEK293 cells were cotransfected with VSV- tagged 
PDE4D5 (C-terminal epitope tag) and HA-tagged PlASy (N-tenninal epitope tag), 
and haiwested in the modified RIPA buffer that contains 25 pM NEM (a de- 
ubiquitinating enzyme) and 10 pM MG 132 (proteasome inhibitor). The VSV- 
PDE4D5 was immunoprecipitated with anti-VSV agarose beads and immunoblotted 
with SUMO-1 (Figure 5.4). A sumoylated species was observed at about 125 kDa on 
the SDS gel. Overlaid VSV antibody on the same blot revealed two bands, one 
reflecting the size of unmodified wild type PDE4D5 (-105 kDa), another 25 kDa 
larger and corresponding to the previous SUMO-1 signal in the VSV-precipitates 
(Figure 5.4). This suggests that wild type PDE4D5 exists in a dual fonn, one being 
SUMO modified, another not. A form of PDE4D5, where lysine 323 has been 
mutated to arginine, was co-expressed with HA-PlASy in HEK293 cells. Failure to 
detect SUMO modification of VSV-K323R under the same experiment conditions as 
that of VSV-PDE4D5 (wild type) provides an independent support that lysine 323,
located within VKTE in PDE4D5, is the site of SUMO modification of PDE4D5 in 
intact cells (Figure 5.4).
5.2.3 Effects of SUMO-1 modification on PDE4D5 interaction with its binding 
partners.
Sumoylation has previously been shown to affect protein-protein interactions 
(Matunis et al. 1998). As PDE4D5 has a number of binding partners, such as p- 
arrestins (Bolger et al. 2003), RACK-1 (Yarwood et al. 1999), BRK2 (MacKenzie et 
al. 2000) and AKAP186 (unpublished data), 1 set out to test whether sumoylation of 
PDE4D5 can affect its association with these various binding partners. Here, 1 
performed two strategies to address this question. One was sequential 
immunoprécipitation, where VSV-PDE4D5 was transfected in HEK293 cells and 
PDE4D5 endogenous binding partners were sequentially immunoprecipitated from 
the lysates. Then both the lysates and immunoprecipitates were probed with anti-VSV
antibody. Here, 1 show that wild type PDE4D5, either in the pre-IP lysates, or post-lP 
lysates, or in the individual IP samples, as indicated in Figure, appears in two forms: 
one is migi'ating faster and has the native size of 105 kDa; another is migrating slower 
and located about 25 kDa above the other (Figure 5.5 a). As it has been suggested that 
SUMO-1 migrates as an approximately 25 kDa species on SDS-PAGE, this larger 
mass of PDE4D5 is likely to be due to the addition of SUMO-1 onto VSV-PDE4D5. 
In order to confiim this, 1 stripped the blot and probed it with anti-SUMO-1 antibody. 
As shown here, only one band was evident in each sample lane and each band 
corresponded to the upper band of the VSV blot used to identify epitope-tagged 
PDE4D5 (Figure 5.5 b). This confirms the SUMO conjugated status of PDE4D5 in 
the sequential IP experiment. Interestingly, in all cases the amount o f the sumoylated 
foim of PDE4D5 detected in each immunoprecipitated species was greater than that 
of non-sumoylated form of PDE4D5 (Figure 5.5 a), suggesting that those PDE4D5 
binding partners preferentially bind to the SUMO-conjugated fonn of PDE4D5. In 
another word, SUMO modification enhances the association of PDE4D5 with the
■:s
known binding partners, namely (3-an'estins, RACK-1, ERK2 and AKAP18Ô under 
the conditions that 1 per fonned these experiments.
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Another strategy I performed to address the effect of sumoylation on 
PDE4D5 interaction is the comparison of the signals obtained from VSV-PDE4D5 or 
VSV-K323R associated binding partners. These experiments utilized VSV tagged 
wild type PDE4D5 and VSV tagged lysine 323 mutated form of PDE4D5. Under the 
experimental conditions utilised with PDE4D5 /K323R and PIASy (Figure 5.6 a), 
wild type PDE4D5 binds much more to p-arrestins, RACK-1, ERK2 and AKAP185 
than its SUMO mutant (K323R), providing an independent support for the previous 
data obtained from the first strategy performance (Figure 5.6 b,c,d,e). These data 
suggest that SUMO modification of PDE4D5 enhances its interaction with certain of 
its binding partners.
5,3 Discussion
This investigation demonstrates that PDE4D5, a unique PDE4 isofoim, exists 
in a dual form, one of which is SUMO-1 modified, another is not so modified (Figure 
5.4, 5.5 a). I have presented evidence that this modification occurs both in vitro and in 
vivo in a HEK293 cell line engineered to express VSV-tagged PDE4D5. However, co­
transfection with HA-tagged PIASy is required to identify SUMO-1 modification of 
PDE4D5. I have mapped the SUMO modification site on PDE4D5 to one consensus 
lysine (K323) in the N-teiminal portion of catalytic domain of PDE4D5 (Figure 5.4). 
Sumoylation of PDE4D5 seems to affect its interaction with some other proteins 
(Figure 5.5 a). Alignment of four different PDE4 genes reveals that PDE4A and 
PDE4D both possess sumoylation consensus motif. Although, to date, I have not been 
able to show that PDE4A can be modified by SUMO-1, this at least suggests that 
SUMO modification might be not restricted to PDE4D gene family members, but also 
members of the PDE4A family. The effects of sumoylation of PDE4D5 isoform may 
be also important for regulation of all o f the PDE4A/D family members, which 
contain the SUMO modification consensus motif.
Sumoylation is now known highly dynamic and reversible (Dolimen 2004), 
equilibrating between sumoylation and desumoylation. The major difficulties in 
identifying SUMO targets are: (I) these proteins are rapidly deconjugated by SUMO- 
specific proteases upon cell lysis in nondenaturing buffer (Melchior F. 2000); (2) only 
a small fi'action of the substrate, frequently below 1 % is sumoylated at any give time
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(Johnson 2004). This might explain why I could not detect any sumoylated foim 
PDE4D5 in the initial screen unless a lysis buffer containing SDS and NEM (modified 
RIPA buffer) was used in the analysis, which correlates with the characteristics of 
many SUMO-conjugated proteins (Chang et al. 2004; et al. 2002; Hofinann et al. 
2000).
Although in vitro sumoylation of PDE4D5 has been shown to occur in the 
presence of SUMO-E, E2, Ubc9 and SUMO-1 (or SUMO-2) in the absence of a 
SUMO-E3 (Figure 5.3), the extent of detecting sumoylation of PDE4D5 in intact 
HEK293 cells was shown to increase in the presence of the PIASy, which serves as a 
SUM0-E3 ligase (Figure 5.4). This investigation demonstrates that PIASy is cmcial 
for PDE4D5 sumoylation to be detected in vivo in the model system used here. PIASy, 
one of the isoform of PIAS proteins, has a SP-RING domain, which resembles RING 
finger motif found in many Ub E3s (Hochstrasser 2001) and is responsible for the 
direct binding to SUMO E2 conjugating enzyme Ubc9. Common to other PIAS 
proteins, PIASy contains a SIM (SUMO interacting motif) domain, which is 
implicated in binding to SUMO non-covalently (Minty et al. 2000). Therefore, it 
appears that introducing exogenous HA-PIASy into HEK293 cells increases the E3 
ligase-dependent activity by efficiently bringing both E2 Ubc9 and SUMO isoforms 
in close proximity to PDE4D5, therefore making the sumoylation of PDE4D5 in vivo 
possible and detectable. Owing to the low amount of PDE4D5 expressed 
endogenously in HEK293, exogenously expressing VSV-PDE4D5, together with HA- 
PIASy, increases the amount of PDE4D5 being sumoylated.
Although the conditions under which sumoylation of PDE4D5 has been 
identified in several experiments were optimized and kept through all my in vivo 
experiments, the frequency of detecting sumoylated fonn of PDE4D5 is still relatively 
low, in another word, the chance of being able to detect PDE4D5 in vivo is variable. 
Thus a large number of evaluations were carried out in order to obtain definitive 
results. Therefore, the following functional analyses of sumoylation of PDE4D5 were 
perfonned in samples that were first tested and proven to produce positive 
sumoylation results.
PDE4D5 contains 745 amino acids and has an estimated molecular mass of
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84.4 kDa. However, PDE4D5 normally migrates to positions significantly higher than
84.4 kDa in an SDS-PAGE gel at about 105 kDa. Moreover, although SUMO-1 has an 
estimated molecular mass of -12  kDa, several previous studies have demonstrated 
that may SUMO-conjugated proteins usually have a size increase of -20  kDa after 
conjugation by one SUMO-1 molecule (Johnson 2004). Under the optimized 
conditions, protein bands of 105 and 130 kDa were clearly detectable by immunoblot 
analysis with an anti-VSV antibody (Figure 5.5, lane 1). The size difference between 
these two bands implies that VSV-PDE4D5 is conjugated by one SUMO-1 molecule. 
As SUMO-1 does not have \|/KXE motif, or the possible acceptor lysines that are 
homologous to lysine 29, 48, 63 of Ub, this finding is consistent with previous 
observations that SUMO-1 does not form poly-SUMO chains (Seeler and Dejean
2003). The evidence demonstrating that VSV-PDE4D5 is conjugated by SUMO-1 also 
comes fiom immunoprécipitation experiments. In the lysate prepared from HEK293 
cells transfected with VSV-PDE4D5 and HA-PIASy, VSV-tagged PDE4D5 was 
immunoprecipitated and detected by an anti-SUMO-1 antibody (Figure 5.5 b) or VSV 
antibody (Figure 5.5 a). As is generally known, proteins are often sumoylated on the 
lysine residue of a \j/KXE sequence. In the N-teiminal of catalytic domain of PDE4D5 
resides such a consensus motif VKTE (Figure 5.2). Mutating the lysine residue of this 
site influenced PDE4D5 sumoylation, indicating this lysine residue is the actual site 
for SUMO modification (Figure 5.4 b). This result also eliminates the possibility that 
the proteins detected are non-specifically immunoprecipiated by anti-VSV agarose 
beads. Interestingly, when I tried to do the reverse IP, in which anti-SUMO-1 antibody 
was used to immunoprecipitate sumoylated form of PDE4D5, VSV-PDE4D5 did not 
come down together with the SUMO-1 antibody. This might be attributed to the fact 
that the SUMO-1 antibody used in this study can not be used for immunoprécipitation. 
Notably, the quantity of VSV-PDE4D5 that is sumoylated appears to be a small 
percentage of the total VSV-PDE4D5 (Figure 5.3; 5.4 a). However, in one rare case, I 
obtained high quantity of sumoylated form of PDE4D5 (Figure 5.5 a).
Sumoylation often affects the function of protein-protein interactions 
(Matunis et al. 1998; Johnson 2004). The sequential IP results demonstrate that the 
sumoylated form of VSV-PDE4D5 is more abundant than the non-sumoylated VSV- 
PDE4D5 (-105 kDa) in each IP sample, as the band at 130 kDa is observed more
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eintense than that at 105 kDa in immunoblot (Figure 5.5, lane 1). This phenomenon is 
possibly owing to the fact that sumoylated PDE4D5 preferentially interacted with 
various numbers of scaffolding/signalling proteins, such as p-arrestins, RACK-1, 
ERK2 andAKAP185.
Additionally, the availability of lysine323 in PDE4D5 largely affects the 
extent to which PDE4D5 interacts with a number of its binding partners, as 
sumoylated form of PDE4D5 accounts for a large proportion of the total PDE4D5 that 
is associated with the scaffolding or signalling proteins (Figure 5.5). In another word, 
wild type PDE4D5, composed of both sumoylated and non-sumoylated fonn, binds to 
its binding partners studied here more than that in only non-sumoylated fonn (K323R). 
As the signalling complexes containing PDE4D5 and its individual binding partners 
are sequestered in distinct focal points and serve as shaping cAMP gradients, the 
changes in the binding affinities of PDE4D5 towards its binding partners due to its 
sumoylation status thus provides a possible mechanism for fine-tuning the 
compartmentalization and desensitization of cAMP in the cells. The magnitude of the 
differences in binding affinity towards those binding partners between wild type 
PDE4D5 and the non-sumoylated fonn of DPE4D5 are considerably large and 
therefore potentially capable of representing a biologically important homeostatic 
mechanism.
To elucidate the meaning of the sumoylation of PDE4D5, it is important to 
know what kinds of signal can induce or suppress the sumoylation of PDE4D5. 
Although I have shown that SUMO E3 ligase PIASy is important, there still leaves a 
number of questions to be answered. (1) What is the SUMO isopeptidase involved? It 
is well known that the level of the sumoylation is a balance between the activities of 
sumoylation enzyme (E l, Ubc9, or SUMO E3 ligase PIASy) and SUMO-specific 
proteases. So far, there are three genes, SENPl, SENP2 (also known as Axam, Supr-1, 
SSP3, and SMT31P2), and SENP3 (SMT31P1), that have been shown to function as 
SUMO-specific proteases in mammals (Hay 2005; Melchior et al. 2003). Possibly the 
knockdown of one of the SUMO-specific protease in HEK293 cells using siRNA 
technique would reveal the answer, which application into the cells will surely make 
the detection of the SUMO modification of PDE4D5 easier and more reliable. (2) Is
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sumoylation of PDE4D5 a constitutive process or a regulated one? If regulated, what 
signals trigger or inhibit the pathway? A number of post-translational modifications, 
such as those that can target the same acceptor lysine as SUMO (for example, 
ubiquitination and acétylation) or those that modify other residues, such as 
phosphorylation, have been suggested to regulate sumoylation either positively 
(Desten'o et al. 1998; Everett et al. 1999; Muller et al. 2000; Yang et al. 2003) or 
negatively (Hietakangas et al. 2003; Sobko et al. 2002). Thus, it will be intriguing to 
see if phosphorylated or ubiquitinated forms of PDE4D5 transfected in cells will 
make a difference in its sumoylation status. (3) Are there any other macromolecules 
able to bind to PDE4D5 and regulate its SUMO modification? This is inspired by the 
fact that sumoylation of Mdm2 and p53 in vivo has been shown to be enhanced by 
association with the tumor suppressor ARP (Chen and Chen 2003), and that 
sumoylation of the transcriptional factor Sp3 was reduced when bound to DNA 
(Sapetschnig et al. 2002). I have already shown that sumoylation of PDE4D5 
increases its binding to p-arrestins, RACK-1, ERK2 and AKAP185, but it will be 
interesting to see if blocking the interactions between PDE4D5 and these binding 
partners using the mutants of PDE4D5 will affect the SUMO modification status of 
PDE4D5.
To further discuss the function of sumoylation of PDE4D5, it will be 
necessary to check its activity, its sub-cellular localization. Given the instability of 
SUMO modifications in vivo, the SUMO-1 fusion protein, which SUMO proteases 
cannot cleave, might provide an alternative means to elucidate the nature of 
sumoylation of PDE4D5.
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Figure 5.1 Enzymatic conjugation mechanism of sumoylation.
The SUMO precursor is cleaved by SUMO-specific proteases (SENPs) with C- 
terminal hydrolase activity to expose a C-terminal diglycine. In an ATP-dependent 
reaction, mature SUMO forms a thioester conjugate with the heterodimer SUMO El 
activating enzyme (in yeast is SAEI/SAE2, in mammals is AosI/Uba2). SUMO is 
then transferred to the SUMO E2 conjugating enzyme Ubc9 and formed a thioester 
intermediate again. From Ubc9, SUMO is conjugated to a substrate protein via an 
isopeptide bond with a lysine residue (K). Recently several unrelated SUMO E3 
ligases have been shown to crucial for substrate protein sumoylation in step 3. SUMO 
modification is reversible and SUMO is removed from substrates by SUMO specific 
proteases (SENPs) with isopeptidase activity. Schematic is taken from Wojcikiewicz
2004).
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Figure 5.2 PDE4D5 amino acid sequence alignment.
The entire sequence of human PDE4D5 is illustrated here. Letters in red indicate p- 
arrestin binding sites on PDE4D5; letters in orange are the SUMO modification 
consensus motif (n/KXE); letters in green indicate the potential ubiquitin interaction 
motif (UIM).
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VSV-4D5K323RK VSV-4D5K323RJ VSV-4D5WT SPlOO
Figure 5.3 PDE4D5 is a substrate for SUMO-1 and SUMO-2 conjugation in vitro.
In vitro expression of 35S labelled PDE4D5 and following in vitro SUMO 
modification of PDE4D5 were performed by the Hay laboratory in Dundee University. 
Fractionate reaction products were subject to SDS-PAGE gel and subsequent staining, 
fixing and drying. Results were analysed by phosphoimager. As a positive control, the 
PDE4D5 unrelated protein SPlOO, which has been shown to be modified by SUMO, 
was used (lane 1-3). For negative controls for all samples (UN), ATP regenerating 
system was omitted in the reactions.
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Figure 5.4 Exogenously expressed VSV-tagged PDE4D5 is modified by SUMO-1 
in  v iv o .
HEK293 cells were transfected with VSV-PDE4D5 and HA-PIASy, and harvested in 
modified RIPA buffer containing 0.1% SDS and 25 pM NEM. Clear cell lysates were 
immunoprecipitated with anti-VSV agarose beads, (a) Immunoprecipitates were 
analyzed by Western blotting with an anti-VSV monoclonal antibody, (b) The same 
membrane was then stripped and reprobed with an anti-SUMO-1 monoclonal 
antibody. The positions of free and putative SUMO-1 conjugated PDE4D5 are 
indicated. Molecular weight markers are shown on the right.
182
(a)
P r e lP  IP  IP IP IP P o s t  IP  
L ysa te  p-arrestin R A C K l EKK, A K A P 1 8  L y sa te
- 1 5 0
sumoylated 4D5 — * V # #
Non-modif.ed4D5 ^  W #  ^  - I » »
(b)
■ i
<-
P r e lP  f f  IP IP IP P o s t  IP  
L ysa te  p -atrestin  R A C K l E R K  A K A P IS  L ysate kDa
= v % T -  ---------— ^  —
—100
I
Figure 5.5 Illustration of sumoylated form of FDE4D5 preferentially binding to 
P-arrestin, RACK-1, ERK2, and AKAP18.
HEK293 cells were transfected with VSV-PDE4D5 and HA-PIASy. Cells were 
harvested in modified RIPA buffer containing SDS and NEM. p-arrestin, RACKl,
ERKl/2, and AKAP186 were individually and sequentially immunoprecipitated with 
their corresponding antiserum, (a) The sequential IP samples run together with the 
pre-immunoprecipitate and post-immunoprecipitate samples were analyzed by 
Western blotting with an anti-VSV antibody, (b) The same blot was stripped and 
reprobed with SUMO-1. Running position of molecular weight markers and of 
SUMO-1 conjugated PDE4D5 are indicated.
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Figure 5.6 SUMO-1 conjugation enhances PDE4D5 interaction with P-arrestins, 
RACK-1, ERK and AKAP18Ô.
(a) Immunoprécipitation of VSV-tagged PDE4D5 was performed in HEK293 cells 
transfected with VSV-PDE4D5 and HA-PIASy. Sumoylation status of VSV-PDE4D5 
was analyzed by Western blotting of the immunoprecipitates with anti-VSV antibody. 
VSV tagged 4D5K323R was used as a control. The position of conjugated and non­
conjugated PDE4D5, as well as the protein molecular weight marker is indicated.
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Figure 5.6 SUMO-1 conjugation enhances PDE4D5 interaction with p-arrestins, 
RACK-1, ERK and AKAP18Ô.
HEK293 cells were transfected with VSV-PDE4D5 and HA-PIASy and harvested in 
modified RIPA buffer containing SDS, NEM, Confirmation of the sumoylation of 
PDE4D5 was required prior the further explore of the interactions between PDE4D5 
and p-arrestins, RACK-1, ERK 1/2 or AKAPlSô (see Figure 5.6 a), (b) Shows the 
difference between wild type PDE4D5 and SUMO mutant of PDE4D5 (K323R) in 
interacting with p-arrestins. This association was analyzed by Western blotting with 
anti-P-arrestin antibody, (c) Shows the interaction of wild type PDE4D5 or SUMO 
mutant of PDE4D5 with RACK-1. (d) Shows the association between PDE4D5 or 
SUMO mutant of PDE4D5 and ERK 1/2. (e) Shows the interaction of wild type 
PDE4D5 or its SUMO mutant with AKAP18Ô. Running position of protein molecular 
weight marker and the studied proteins that are associated with PDE4D5 are indicated.
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Chapter 6
Analysis of Binding Sites on PDE4D5 to (3-arrestin, ERK2 
and Ubc9
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6.1 Introduction
Individual signaling pathways consist of a number of discrete components. In 
many instances individual members of a signaling pathway have been shown to 
interact with the components of other signaling pathways, therefore the two or more 
signaling systems are integrated and form highly intensive networks to achieve the 
integrated function of cells in one organism (Houslay and Milligan 1997). The 
complex foimations, which involve protein-protein interactions, take place either 
between potential scaffolding/adaptor proteins and signaling proteins or between two 
different signaling proteins (Pawson and Scott 1997). The rapidity at which the 
reversible interactions can be altered depends on the concentration o f constituents and 
their affinities for each other.
Our group (see for review: Houslay and Adams 2003) and, more recently, 
others have demonstrated that specific PDE4 isofoims can interact with a number of 
distinct proteins, including signal scaffolding proteins, like p-arrestins (Bolger et al. 
2003), RACK (Yamood et al. 1999), protein kinases like c-Src (McPhee et al. 1999), 
DISCI (Miller et al. 2005), XAP2 (Bolger et al. 2003), myomegalin (Varadan et al. 
2002), mAKAP (Dodge et al. 2001), AKAP450 (McCahill et al. 2005; Tasken et al. 
2001) and ERK (MacKenzie et al. 2000). Such interactions are thought to provide the 
molecular machinery that is responsible for underpinning the fonnation of 
compartmentalized cAMP signaling (Houslay and Baillie 2003).
The signalling scaffold proteins, p-arrestinl and p-aiTestin2 can bind to a site 
within the highly conserved catalytic unit of PDE4 isoforms from all four subfamilies 
(Bolger et al. 2003). This interaction confers a new feature o f the GPCR/p-arrestin 
desensitization system, whereby p-aiTestin-delivered PDE4 appears to regulate the 
activity of PKA at the plasma membrane and thereby regulate the PKA 
phosphorylation status of the pzAR itself (Lynch et al. 2005). A functional 
consequence of this is switching o f signalling of the P2 AR from activation of adenylyl 
cyclase through Gs to activation o f ERK tlirough Gi (Baillie et al. 2003). Although all 
PDE4 isofonns have the potential to interact with p-airestin and regulate P2 AR 
phosphorylation by PKA, it has been shown that invaiiably it is the PDE4D5 isofoim 
that perfoims such a role (Bolger et al. 2003; Lynch et al. 2005). This is because the
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unique 88-amino acid N-tei*minal region of this isoform contains an additional 
interaction site for interaction with p-arrestins, thereby conferring preferential 
recruitment o f PDE4D5 to complexes with p-arrestin when this isoform is expressed 
in cells.
PDE4 isoforms of the B/C/D families provide a point of cross-talk that links 
ERK2 activation to the regulation of cAMP signaling (Houslay and Adams, 2003; 
Houslay and Kolch 2000). Thus activation of ERK tlirough EGF challenge causes the 
rapid inhibition of long PDE4 isofonns that can trigger an increase in cAMP levels. A 
functional consequence of this is to allow for activation of PKA, which can 
subsequently elicit the phosphorylation and re-activation of long PDE4 isofonns 
(Hofhnann et al. 1999). That PDE4 isofonns are authentic substrates for ERK 
phosphorylation was the discovery that the PDE4 catalytic unit contains a consensus 
KIM docking site for MAP Kinases as well as a FQF motif that confers specificity for 
phosphorylation by ERK rather than INK (MacKenzie et al. 2000). These sites are 
both located in the C-tenninal of the catalytic unit of PDE4 and straddle the target 
serine residue for ERK2 phosphorylation, which are essential for in vivo binding and 
phosphorylation of PDE4 by ERK2.
In last chapter, I proposed that PDE4D5 contains a SUMO modification 
consensus sequence (\|/KXE) in the N-terminal portion of the PDE4 catalytic domain 
and that this sequence might be responsible for conferring sumoylation upon PDE4D5 
(Figure 5.4). Ubc9, a single E2-type-conjugating enzyme (Melchior 2000), plays an 
important role in SUMO substrate recognition as it has been shown physically 
interacting with almost all known SUMO substrate in yeast two-hybrid assays 
(Sampson et al. 2001), Although some studies (Sampson et al. 2001) have 
demonstrated that Ubc9 directly recognizes substrate proteins, through their yKXE 
consensus sequence, it has not been generalized in all \)/KXE-containing proteins. 
This prompted me to assess the possible binding between PDE4D5 and Ubc9 and any 
involvement o f the putative Ubc9 binding motif on PDE4D5.
Studies on protein-protein interaction have mainly been analyzed through 
immunoprécipitation, pull-down and yeast two-hybrid techniques as readouts. These
are then coupled to mutation and truncation to gain insight into the binding sequence. 
The generation of panels of mutants and truncates requires extensive amounts of work. 
Recently, however, peptide anay analysis has been developed in order to provide a 
novel, powerflil and rapid technology to identify potential sites o f interaction between 
proteins (Kramer and Schneider-Mergener 1998). Here I employed this technique, 
together with traditional immunoprécipitation methodologies, to evaluate further the 
mode of interaction of (3-an*estins, EKR2 and Ubc9 with PDE4D5.
6.2 Results
6.2.1 Analyses of PDE4D5 binding to p-arrestins
PDE4D5 preferentially binds p-arrestins compared to other PDE4 isofoims 
(Bolger et al. 2003). Consequently, it is preferentially recmited to the GRK- 
phosphorylated piAR where it serves to degrade the cAMP in the local environment 
of the piAR (Bolger et al. 2003; Lynch et al. 2005). Such preferential binding of 
PDE4D5 is because it, uniquely, has two sites for interaction with p-arrestin2, one in 
its unique N-terminal region and another within the conserved PDE4 catalytic region 
(Bolger et al. 2003).
Although p-an'estinl and P-arrestiii2 are -80%  sequence identical (Miller et 
al. 2001, Figure 6.2), this does not guarantee that they both interact with PDE4D5 in 
the same manner. Therefore, I set out here to assess individual p-arrestinl and p- 
arrestin2 binding sites on PDE4D5 by using the peptide aiTay analyses.
6.2.1.1 Purification of GST-p-arrestinl and GST-p-arrestin2 fusion proteins
In order to caiTy out the peptide an'ay analyses I first expressed the full- 
length p-an'estinl and p-an*estin2 fused with GST in E. Coli and purified them as 
described in the Materials and Methods. After each step, equal amount of samples 
were collected and all were run in the same SDS-PAGE gel to help trace the progi'ess 
of this purification. This gel was then subject to Coomassie Blue to visualize the 
proteins, followed by extensive washes in de-staining buffer to get rid of the 
background. Here, I show that both p-arrestinl and P-anestin2 recombinant proteins 
are reasonably homogenous, with the size of 73 kDa and 75 kDa, respectively on the 
gel (Figure 6.3).
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6.2.1.2 Peptide arrays identify sites in PDE4D5 that interacts with parrestin2
As a novel and powerful technology, peptide array analysis is used here to 
identify potential sites of interaction between PDE4D5 and p-an’estin2. In this, 
overlapping peptides (25 mers), shifted along by 5 amino acids in the sequence and 
representing the entire sequence of PDE4D5 were ‘spot-synthesized’ and immobilized 
on cellular membranes (Kramer and Schneider-Mergener 1998; Frank 2002). The 
membrane was then overlaid with recombinant p-aiTestin2-GST protein and probed 
with antiserum to p-aiTestin. A control study was performed with GST alone, which 
did not bind to PDE4D5 peptide aiTay. Positive interactions were indicated by 
darkspots and negative interactions were indicated by clear areas (Figure 6.4). Here 
the peptide array analysis identified two potential binding regions for p-arrestin2 on 
PDE4D5, one located in the N-terminal region of PDE4D5 and the other in the 
common catalytic region (Figure 6.5). Previous progiussive N-terminal truncation 
analysis inferred that amino acids 70 through 88 in PDE4D5 were important for p- 
arrestin2 binding (Bolger et al. 2003). The evident interaction of P-arrestin2 with 
peptide 13, which encompasses amino acid 61-85 of PDE4D5, is entirely consistent 
with this (Figure 6.5). However, I show here that p-arrestin2 may actually bind a 
much wider part of the unique N-terminal region of PDE4D5, extending from amino 
acid 11 through to 85, as indicated by the positive signal from peptide spots 3 through 
to 13 (Figure 6.5). Thus, my peptide anay analysis suggests that p-arrestin2 may bind 
to an extended surface across the unique N-teiminal region of PDE4D5.
Previous analyses also indicated that p-aiTCstin2 was able to bind to the C- 
terminal portion of PDE4D5 catalytic region, namely the EKFQFELTLEE sequence, 
which extends from amino acid 668 through to 678 (Bolger et al. 2003). This 
sequence is cognate to that found in other PDE4 isofoims, and therefore considered as 
the common binding site for p-arrestin2 (Bolger et al. 2003). Here, my peptide array 
analysis provides an independent support for this finding (Figure 6.5), because P- 
arrestin2 is clearly shown to interact with four sequentially located peptides (132-135) 
in the PDE4D5 array library whose sequence share the common motif 
EKFQFELTLEE. Consistent with the importance of the components of such a motif, 
peptide 131, which lacks the LEEDG sequence found in peptide 132, and peptide 136, 
which lacks the FQFEL sequence, show no binding to PDE4D5, and peptide 135 that
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lacks the GQTEK sequence appears to show a considerable diminution in the signal 
for interaction of P-arrestin2 compared to peptide 134.
6.2.1.3 Peptide arrays identify sites in PDE4D5 that interacts with p-arrestinl
The peptide array data obtained from the detection of PDE4D5 binding to P- 
arrestin2 supports and extends previous studies, therefore validating the application of 
this approach to assess PDE4D5 binding to proteins.
between PDE4D5 and p-arrestin2.
During the time when I was studying the interaction between PDE4D5 and P-
To date there is no evidence detailing the p-arrestinl binding sites on 
PDE4D5. I wished to see if P-an'estinl interacts with PDE4D5 in the same manner as 
p-arrestin2. Here I show that p-anestinl binds to PDE4D5 on the same sites as p- 
arrestin2 and exhibits exactly the same interaction pattern (Figure 6.5). This might be 
explained by the high sequence homology between P-arrestinl and p-aiTestin2 (-80%) 
(Miller et al. 2001, Figure 6.2).
6.2.1.4 Scanning substitution identifies individual amino acids on PDE4D5 that 
require for it to interact with p-arrestin2
Scanning alanine mutagenesis in yeast two-hybrid and pull-down assays is a 
commonly used analytical method to identify the sites of interaction between proteins. 
Recently, a new, but cognate, procedure where the peptide an'ay analysis is applied 
has been developed in our laboratory. This involves the sequential single substitution 
of successive amino acids in the sequence of the 25 progeny of parent peptide of 
interest to alanine to form the scanning peptide a iT ay (Figure 6.4). Identical 
procedures are earned out, as described above, for detection of interaction. This 
approach aids in the identification of particular amino acids where substitution for 
alanine can negate interaction of the 25-mer peptide with overlaid GST-fusion 
proteins.
Since p-arrestinl and P-arrestin2 show the same binding sites on PDE4D5
(Figure 6.5), I chose p-arrestin2 as a representative to further evaluate the interactions
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6.2.2 Analysis of PDE4D5 association with ERK2
6.2.2.1 Expression and purification of GST-ERK2 fusion proteins
Full length ERK2 fused with GST was expressed in E. Coli and subject to 
purification as described in the Materials and Methods. A small sample from each step 
was mixed with 2x sample buffer and loaded in 4-12% SDS-PAGE gel. The 
progression of this purification and the purity of the GST-ERK2 fusion proteins was
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arrestins, the interaction between RACKl and PDE4D5 was analyzed by my 
colleague (George Baillie) using the same peptide anay technique. The peptide spot 
indicating the binding PDE4D5 with RACKl-GST came out positive in the N- 
tenninal region of PDE4D5. This is consistent with previous tmncation and mutation 
data identifying an interaction site for RACKl in the unique N-tenninal region of 
PDE4D5 (Steele et al. 2001). However, interestingly, this peptide spot (spot 5) falls 
into the N-terminal PDE4D5 binding region for p-aiTestin2 that I identified in my 
studies (Figure 6.5). I set out then to perfonn further analysis of peptide spot 5 to 
identify important amino acids used by PDE4D5 to interact with either p-aiTestin2 or 
RA CK l. Thus, I used alanine scanning substitution of the 25-mer peptide representing 
amino acids 22-45 (spot 5) of PDE4D5 to define the p-arrestin2-PDE4D5 interaction. 
This alanine scan demonstrated that the interaction was either ablated (L33, R34) or 
severely attenuated (N26, E27, D28, L29, V30) when the indicated amino acids were 
changed to alanine (Figure 6,6 a). These data might help explain why p-aiTestin2 and 
RACKl bind in a mutually exclusive fashion to PDE4D5.
In order to gain further insight into the interaction of p-arrestin2 with 
PDE4D5 catalytic domain, again I used scanning alanine substitution, this time of a 
peptide representing amino acids E660-E685 (spot 133 on parent peptide aiTay) within 
the catalytic unit o f PDE4D5 (Figure 6.6 b). The alanine scanning array of parent spot 
133 was overlaid with p-arrestin2-GST, followed by the detection of p-aiTestin2 using 
antiserum specific to p-an'estin on the array. Here I show that substitution, with 
alanine, of any one of F670, F672, E673, L674 and L676 led to either ablation or 
severe attenuation of the interaction with P-arrestin2 (Figure 6.6 b). This shows 
considerably agreement with the prediction of the importance of this region for the 
binding to p-arrestin 2 as deduced from bioinformatic analysis (Bolger et al. 2003).
visualized with 2 hour-Coomassie Blue staining, followed by extensive wash in de- 
staining buffer. I show here that GST-ERK2 recombinant protein was purified to 
homogeneity, with a size of some 67 kDa on the gel (Figure 6.7).
6.2.2.2 Selective immunoprécipitation identifies the association between PDE4D5 
and ERK2
PDE4D3 has been shown to have FQF and KIM docking sites for 
extracellular signal-related kinase 2 (ERK2) (p42‘^ *^'*^ ) (MacKenzie et al. 2000), 
which confers PDE4 binding to ERK2 and is essential for ERK2 to phosphorylate 
PDE4 in intact cells. PDE4D5 is a long PDE4D isoform that differs from PDE4D3 
solely by virtue of its unique N-terminal region arising through alternative niRNA 
splicing (Bolger et al. 1997). It thus shares with PDE4D3 a consensus site for 
phosphorylation by ERK2, in this case S651 in the motif PQSP, as well as the two 
EKR docking motifs (Hofhnann et al. 1999). Although S651 on PDE4D5 has been 
proven to provide a substrate for C-terminal catalytic domain phosphorylation by 
ERK2 (Hoffmann et al. 1999), the potential binding region of PDE4D5 with ERK2 
has not been validated through direct experimentation. Therefore, I set out here to 
examine the domains and specifically, the amino acids that are important for ERK2 
interaction with PDE4D5.
In order to evaluate potential ERK2 binding to PDE4D5, I examined 
immunopurified complexes from HEKB2 cells. Transfected PDE4D5-VSV was 
immunoprecipitated with VSV affinity beads, followed by western blotting to probe 
for ERK2. Control experiments were done with the equal amount of proteins from 
lysates of cells that were not transfected to express PDE4D5-VSV. Here, I identified 
endogenous ERK2 co-immunoprecipitating with PDE4D5 (Figure 6.8). This shows 
that PDE4D5 can directly bind to ERIC2. A specific VSV antibody was also used to 
probe the immunoprecipitates to confmn the pull-down of recombinant PDE4D5-VSV.
6.2.2.3 Peptide array analysis identifies the interaction sites for ERK2 on 
PDE4D5
To explore further the ERK2 binding sites on PDE4D5, I again perfonned 
peptide array analyses. Full length PDE4D5 peptide library was overlaid with 10 
pg/ml of purified recombinant ERK2-GST protein. Bound GST-ERK2 was then
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detected with an anti-ERK2 antibody, the procedure of which is identical to that 
employed using western blotting. A control study was also performed with GST alone, 
which did not bind to the PDE4D5 peptide array. That MAP Kinase docking element 
facilitates the substrate phosphorylation by MAPK was firstly fonnulated by Michael 
Karin (Karin 1995) and this idea is now well accepted and proven. The KIM domain 
potentially allows interaction of either INK or ERK, however, the presence of the 
FQF domain confers specificity for ERK docking. Such an FQF domain is generally 
located some 5-30 residues carboxyl-tenninal to the ERK2 phosphorylation site (see 
Review: Sharrocks et al. 2000). In PDE4D5, the putative ERK2 specificity motif, 
namely the FQF motif, is located some 19 amino acids COOH-terminal to S651, the 
target for ERK2 phosphorylation (Mackenzie et al. 2000; Houslay and Adams 2003). 
Here, my peptide array analysis provides additional experimental support for such a 
contention (Figure 6.9). Thus, the ERK2 probe clearly interacts with four, sequentially 
located peptides (131-134) in the PDE4D5 array whose sequence contains the FQF 
motif. Consistent with the importance of such a motif, I show here that there was no 
interaction of ERK2 with peptide 130, which lacks the QF, the second and the third 
amino acid in the FQF sequence (Figure 6.9). This indicates that the last two amino 
acids in FQF are crucial to allow for PDE4D5 interaction with ERK2. Additionally, 
there appears an evident ablation in the signal for interaction of ERK2 with peptide 
135, which lacks the first two amino acids FQ, indicating the importance of these two 
amino acids for ERK2 to bind PDE4D5 (Figure 6.9). Combined together, the peptide 
array analysis suggests that the sequence of PDE4D5, extending from amino acid 650 
tlirough to 690 contributes its ERK2 binding, in which FQF integrity seems crucial, 
consistent with previous hypothesis (MacKenzie et al. 2000).
However, a KIM domain is clearly present in the catalytic domain of 
PDE4D5, located some 122 amino acids C-terminal to the ERK phosphorylation site 
S651, and has been shown to be functional by mutation analysis (MacKenzie et al. 
2000). Despite this, no peptides that represent partial or entire KIM domain of 
PDE4D5 were observed to interact with GST-ERK2 when probing PDE4D5 with 
ERK2-GST in the peptide an'ay analysis (Figure 6.9). This suggests that the peptides 
in the anay do not fold appropriately to form a functional KIM binding site and that 
other interaction are necessay in the folded protein so as to present an effective KIM 
site. Indeed, the KIM site is clearly Icolated on an exposed beta-hairpin loop in the
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The alanine scan anay of PDE4D5 peptide 133 was exposed to equal molar 
amount of P~arrestin2 and ERK2-GST fusion proteins and the binding of these
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folded intact catalytic unit (Houslay and Adams 2003). It may be that attributes from a 
folded catalytic unit are required for the KIM motif to be presented appropriately in 
the form of a beta-hairpin loop. This does signify that peptide anays can have 
limitations in identifying binding sites that require complex folded structures.
6,2.2.4 Scanning substitution identifies individual amino acids in the PDE4D5 
required for it to interact with ERK2
My peptide an'ay analyses have demonstrated that the sequence in peptide
133, as well as binding p-arrestin2, is also involved in the binding of ERK2 (Figure
:
6.9). In order to define this interaction further for ERK, I again used alanine scan 
substitution. This time of the 25-mer peptide, representing amino acids E660 to E685 
in PDE4D5. GST-ERK2 fusion proteins were incubated with this alanine scan an'ay of 
original peptide 133, followed by detection with an anti-ERK2 specific antibody. This 
demonstrated that the interaction was either ablated (G662, R663, F670, F672, E673,
L674, T675, L676, E677) or severely attenuated (E661, Q664, G665, E678, D679) 
when the indicated amino acids were changed to alanine (Figure 6.10). These cover a 
broad span of PDE4D5 C-tenninal catalytic domain that also binds p-arrestin2 and 
includes the amino acids that seem to be essential for p-anestin2 binding to PDE4D5, 
such as F670, F672, E673, L674, and L676 (Figure 6.6 b). These data suggest that 
ERK2 and p-anestin2 might compete for interaction within the catalytic unit of 
PDE4D5.
I
Odyssey analysis provides another novel and sensitive technology to assess 
the interactions between proteins. Odyssey system uses two infra red detection 
channels that can be used to detect the signal of two different antisera with different 
wavelength tags to analyze simultaneously signals. This can be used to analyse 
interactions involving the array peptides with two proteins of interest. This extension 
fr om its traditional application of probing SDS-PAGE gels, allows me to show here 
that Odyssey analysis is ideal to evaluate binding of p-arrestin2 and ERK2 to 
PDE4D5 peptide arrays.
i
proteins to the PDE4D5 peptide alanine scan aiTay was achieved using both an anti-P- 
arrestin2 rabbit antibody and an anti-ERK2 mouse antibody, each linked to distinct 
secondary antisemm labeled with different wavelength probes. I here identified p- 
arrestin2 (gieen) and ERK2 (red) associating with specific peptide spots representing 
the alanine scanning substitution an'ay in single channel analyses using the Odyssey 
system (Figure 6.11 a). I then combined signals from both channels as an overlay.
Analysis using merged channels identified peptide spots with predominant or solely 
p-anestin2-FDE4D5 complexes (indicated in green), those with predominant or solely 
BRK2-PDE4D5 complex (indicated in red) and those with mixed populations of p- 
arrestin2-PDE4D5 and ERK2-PDE4D5 (indicated in yellow). Those not interacting 
with either p-arrestin2 or ERK2 gave a null result (black) (Figure 6.11 b).
Interestingly, it shows there that only with F670, F672, L674 and L676 was the 
binding of these two fusion proteins simultaneously ablated (Figure 6.11 b; black).
This indicates that these amino acids provide a common docking site on the PDE4 
catalytic unit for both p-arrestin2 and ERK2.
6.2.3 Analyses of PDE4D5 binding to Ubc9
'7
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6.2.3.1 Selective immunoprécipitation analyses indicate PDE4D5 binds to Ubc9
Analysis o f the PDE4D5 sequence led me note that its catalytic domain 
contains an eligible SUMO modification consensus site, namely \}/KXE, which is of 
VKTE (Johnson 2004). Many of the SUMO target proteins that contain this minimal 
sequence have been shown to directly interact with SUMO-conjugating enzyme Ubc9 
(Sampson et al. 2001) through this motif. Thus, I set out to examine if this was the 
case for PDE4D5 by employing immunoprécipitation experiments to address this 
possibility.
Endogenous PDE4D3 and PDE4D5 were selectively immunopurified from 
HEKB2 cells with an antiserum specific to PDE4D. Control experiments were 
perfonned using HEKB2 cells subject to PDE4D knockout using siRNA. Doing this I 
found endogenous Ubc9 was detected in the immunopurified complex from HEKB2 
cells, but not in control cells where the expression of PDE4D was ablated by siRNA- 
mediated knockdown (Figure 6.12). No such association between PDE4D5 and Ubc9
was detected when pre-immune serum was used together with Protein G beads as a 
control (Figure 6.12). These data suggest that PDE4D, represented by PDE4D3 and 
PDE4D5 in HEKB2 cells, can interact with Ubc9. However, these data do not prove 
that this occurs in a direct manner, as other linker proteins may be present in 
immunoprecipitates fonn whole cell lysates. Further pull-down studies using Ubc9- 
GST and PDE4D5-MBP are therefore required to show if  the direct interaction exists.
6.2.3.2 Purification of GST-Ubc9 fusion proteins
Recombinant Ubc9 protein fused with GST was expressed in E. Coli and 
subject to purification as described in the Materials and Methods. Equal small amount 
of samples from each step was taken and mixed with 2x Sample Buffer, followed by 
electrophoresis performed on 4-12% gel. The progression of the purification, as well 
as the purity of GST-Ubc9 proteins in each step were visualized by 21ir Coomassie 
Blue staining and the following extensive wash in de-staining buffer. I show here that 
GST-Ubc9 recombinant protein is purified as homogenous protein, with the size of 
some 40 kDa on the gel (Figure 6.13).
6.2.3.3 Peptide arrays identify sites in the PDE4D5 that interacts with Ubc9
Although the immunoprécipitation data obtained above demonstrates, for the 
first time, association between PDE4D5 and Ubc9, it does not provide evidence of 
direct interaction and does not indicate the nature of any putative binding site for 
Ubc9 on PDE4D5 if  binding was direct. Therefore, I again used peptide an ay analysis 
to provide evidence for a possible direct interaction and to provide details as to what 
region of PDE4D5 might interact with Ubc9. Here, I show that the Ubc9 probe clearly 
interacts with two distinct regions in PDE4D5, both of which are located C-terminal 
to the PDE4D5 potential sumoylation site at K323.
Region 1 is composed of spot 75, 76 and 77, whose amino acids extend from 
371 through to 405. Region 2 is composed of spot 132, 133, 134 and 135, whose 
amino acids extend fi'om 655 through to 695. The second binding region is 
reminiscent of that for both p-aiTestin2 and ERK2 binding, whose sequence contains 
the EKFQFELTLEE motif and extends from amino acids 656 to 695. The integrity of 
the EKFQFLTLEE motif seems important for the Ubc9 binding on PDE4D5 as I show
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here that there was no reaction of Ubc9 with PDE4D5 peptide 131, which lacks the 
LEEDG sequence found in peptide 132 (Figure 6.14). This indicates that at least 
certain of these amino acids are crucial to allow for PDE4D5 interaction with Ubc9. 
Additionally, there seems a considerable diminution in the signal for interaction of 
Ubc9 with peptide 135 compared to peptide 134 (Figure 6.14), implying the 
importance of amino acids within the QTEK sequence. Interestingly, Ubc9 shows no 
interaction with peptide 136 whose sequence does not contain the FQF domain. These 
data indicate that FQF domain is required for PDE4D5 to interact with Ubc9.
f
Ô.2.3.4 Alanine scanning substitution identifies individual amino acids in the 
PDE4D5 catalytic region that may contribute to a binding site for Ubc9
In order to gain further insight into the interaction of Ubc9 with the PDE4D5 
catalytic unit, I used scanning alanine substitution of a peptide representing amino 
acids P376 to N400 of PDE4D5 (from parent peptide 76, which shows strongest 
interaction) and a peptide representing amino acids E660 to E685 (from parent 
peptide 133, which has been shown to interact with p-arrestiii2 and ERK2) of 
PDE4D5 (Figure 6.15). These two alanine scanning arrays were incubated with GST- 
Ubc9 and then probed with a specific anti-Ubc9 antibody. Here, I show that in the 
spot 76 alanine scamring array, interaction with GST-Ubc9 was either ablated (Y383,
Y391) or severely attenuated (L387, E388, D394, Y397, N400) when the indicated 
amino acids were changed to alanine (Figure 6.15 upper panel). This suggests that 
these amino acids may be important for Ubc9 binding to PDE4D5. In the spot 133 
alanine scan anuy, I show that substitution, with alanine, of any one of F670, F672,
E673, L674, L676 and E677 led either to ablation or severe attenuation of the 
interaction of GST-Ubc9 with PDE4D5 (Figure 6.15 lower panel). This result has 
strong similarity to the mode through which both p-arrestin2 and ERK2 interact with 
PDE4D5 at this site. Specifically, my data suggests that a core, common binding 
surface for p-arrestin2, EKR2 and Ubc9 is provided by F670, F672, L674 and L676.
Thus it is likely that p-arrestin2, EKR2 and Ubc9 bind in a mutually exclusive fashion 
to PDE4D5, providing the molecular basis for sequestered distinct ‘pools’ of PDE4D5.
6.2,4 Analyses of p-arrestiu2 binding to Ubc9
Analysis of the sequence of full-length p-arrestin2 led me to note a potential
sumolylation site at K295 residue located with a SUMO consensus sequence (\j/KXE) 
which takes the form of LKHE in p-an'estin2. This minimal consensus sequence, 
reminiscent of that in PDE4D5 (VKTE; see above), might also be able to interact with 
Ubc9 and thus promote P~arrestin2 sumoylation of P-aiTestin2. Therefore, I set out 
here to evaluate any potential interaction between p-arrestin2 and Ubc9. '!
6.2.4.1 Peptide array and scanning substitution array identify sites in the p- 
arrestin2 that may allow interaction with Ubc9
1 probed p-arrestin2 peptide arrays with Ubc9-GST and discerned clear 
interactions between Ubc9 and two separate regions on p-arrestin2. Region 1 is 
composed of the amino acids from spot 36 to 39, whose sequence extends from amino 
acid 176 thimigh to 215. Region 2 is indicated by interactions with spot 74 and spot 
75, whose sequence spans amino acid 366 through to amino acid 395 in p-an'cstin2.
Region 1 extends from the C-tenninal part of the p-arrestin2 N-domain through to the 
N-terminal portion of its C-domain, whilst Region 2 is located in the C-domain.
In contrast to the two putative regions of PDE4D5 that bind Ubc9, the two 
putative interaction sites on p-arrestin2 for Ubc9 straddle the potential target 
sumoylation K295 residue within the consensus \|/KXE motif (LKHE, Figure 6.16). 
Such potential binding sites may then promote sumoylation at the K295 site. It would 
be interesting to assess if this is the case as it has been previously shown that ERK2 
uses this strategy to dock on PDE4D3, which facilitates the phosphorylation of 
PDE4D3 on the straddled serine residue (S579) (MacKenzie et al. 2000). Compared 
to spots 74 and 75, the adjacent spots 73 and 76 did not show any interaction with 
Ubc9. This indicates that the sequence IVFED found in spot 74, but not in spot 73, 
and the sequence TNLIE found in spot 75 but not 76, may also contribute to the 
binding of Ubc9 to p-arrestin2.
In order to gain further insight into specific amino acids that might be 
directly implicated in the interaction of p-arrestin2 with Ubc9 I, again, employed 
alanine scanning substitution analysis. In this instance I analysed the region bounded 
by amino acid 186 through amino acid 210 and the region extending from amino acid 
371 thi'ough to 395. In the first binding region, I showed that substitution of any of
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F191, S197, L204, E207, L208, Y209 and Y210 ablated interaction with Ubc9, while 
substitution of single L I92, S I94, D195, R196, L198, L200 or D205 severely 
compromised Ubc9 binding. In the second binding region, I demonstrated that F376, 
Y380, F388, D390, F391, L394 and R395 were important for Ubc9 binding, as their 
single substitution to alanine either ablated or severely attenuated the binding to Ubc9 
(Figure 6.17). Due to the time left for me to finish my PhD, I did not perform any 
mutagenesis of these potential sties to confmn their binding importance, but it is 
essential that this is done.
6.3 Discussion
A key feature of PDE4 family members is their ability to interact with a 
variety o f signaling or signaling scaffolding proteins (Houslay and Adams 2003). 
Members of all four PDE4 sub-families have been shown to bind to (3-arrestin in pull 
down assays (Peiry et al. 2002) and the binding regions were subsequently mapped to 
their conserved catalytic domains in two-hybrid assays (Bolger et al. 2003). However, 
PDE4D5, a long PDE4 isofomi, has been shown to bind preferentially to p-amestin 
because it has an additional site within its unique N-terminal region that can bind to p- 
arrestin. Thus p-arrestin-tethered PDE4D5 is preferentially delivered to agonist- 
stimulated, GRK-phosphorylated PzARs where it serves to degrade local cAMP 
(Lynch et al. 2005). In the studies described here, I have used a novel methodology to 
show that PDE4D5 is able to bind to p-arrestin thi'ough a broad surface on its unique 
N-terminal region, as well as through a domain in its catalytic unit. I also show that 
the region in the catalytic region of PDE4D5 that p-amestin binds to is likely to form a 
multi-functional docking site as both EKR2 and Ubc9 also bind to this region. My 
studies suggest that the binding of p-amestin, ERK2 and Ubc9 to PDE4D5 will be 
mutually exclusive and thus these interacting proteins may act to sequester distinct 
pools of PDE4D5 that each has particular functional roles.
PDE4D5 has a unique 88 amino acid N-terminal domain that is able to 
interact with the signaling scaffolding protein p-arrestin (Bolger et al. 2003). Previous 
studies, using progressive N-tenninal truncation analyses, inferred that amino acids 70 
through to 88 in PDE4D5 were involved in its unique binding to p-arrestin compared 
to other PDE4 isofonns (Bolger et al. 2003). However, using a novel peptide array
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approach, I show here that p-arrestin can actually interact over an extended surface of 
the unique N-tenninal region of PDE4D5. This surface appears to extend from amino 
acids 11 through to 85 in PDE4D5 (Figure 6.5). Interestingly, it has been previously 
shown that RACKl, an exclusive binding partner of PDE4D5, interacts with PDE4D5 
N-terminal region via RAIDl, whose sequence spans amino acids 23 through to 44 
(Bolger et al. 2002). Therefore, it appears that p-arrestin and RACKl might compete 
to bind to PDE4D5 in this region and interact with PDE4D5 in an exclusive manner. 
Although I did not perform further the experiments to prove this hypothesis, work 
done at the same time in the Houslay laboratory has provided evidence to prove that 
this is indeed the case (Bolger et al. 2006),
Previously, analysis of N-terminal truncation (Bolger et al. 2003) indicated 
that only when the last 18 amino acids of the 88 amino acid N-terminal region of 
PDE4D5 were deleted was the increased interaction with p-arrestin delimited. The 
peptide array analysis reported here is not only consistent with this portion of 
PDE4D5 being involved, but also implies that part of the previously N-terminal 
truncated portion also might provide an interacting surface. Thus, it might be expected 
to see that progressive N-terminal truncation within this newly-identified p-arrestin- 
interacting region of PDE4D5 will likely yield constructs with gradually diminishing 
affinities for p-arrestin2.
During my investigation, others in the Houslay Laboratory assessed
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1competition between RACKl and p-arrestin for binding to PDE4D5 (Bolger et ah, 
2006). In my studies I focused on the amino acids 21-45 (peptide 5; Figure 6.5), 
which includes RAIDl and to which p-arrestin also binds. Scanning array analysis of 
peptide 5 indicated a number of amino acids within a motif of ^^NEDLVxxLR^'^, as 
being important for PDE4D5-p-arrestin interaction (Figure 6.6 a). Interestingly, 
previous N-teiminal truncation of this sub-region had not been shown to overtly 
compromise PDE4D5-p-arrestin interaction in either two-hybrid or 
immunoprécipitation studies (Bolger et ah 2003), whilst certain point mutations 
within this region could (Bolger et al 2006). This seeming discrepancy can be 
explained if mutation of certain amino acids in this sub-region acted to trigger 
extensive changes in the confonnation of the N-tenninal portion o f PDE4D5 as a
whole such that p-arrestin binding site there was ablated/compromised. Thus, whilst 
mutations in this sub-region can cause loss of p-ainestin binding, its deletion does not 
ablate binding. It may, of course, affect affinities for interaction. However, such 
binding analyses would require a great deal o f resource to undertake.
Previous truncation analyses indicated that P-arrestin binding region within 
the PDE4 catalytic unit was located between amino acid 662 and 683 of PDE4D5 
(Bolger et al. 2003). Here, my peptide amay analysis shows that p-an’estin2 interacts 
with the catalytic domain of PDE4D5 in a sequence that spans Ala655-Glu694 (Figure 
6.5), which contains the EKFQFELTLEE motif conseiwed in all PDE4 sub-families.
The alanine scanning peptide array analysis clearly provides a rapid and 
effective way of identifying the potential amino acids that are important for protein- 
protein interaction, which has been shown to provide a powerful approach in the 
present studies. Scanning alanine substitution arrays identified F670, F672, E673, 
L674 and L676 in PDE4D5 as being involved in this interaction (Figure 6.6 b). Indeed, 
this region was previously implicated as being located in sub-domain 3 of the PDE4 
catalytic unit as deduced from the bioinfomiatic analysis (Bolger et al. 2003). 
Interestingly, the presence of an FQF motif has been demonstrated in all authentic 
ERK substrates and suggested to be recognized specifically by ERK but not INK 
(ShaiTocks et al. 2000). Such an FQF motif is found in helix-17 of the PDE4 catalytic 
unit and shown to provide a docking site for ERK interaction and essential for its in 
vivo phosphorylation (Mackenzie et al. 2000). My peptide aiTay analysis provides an 
independent experimental support for such a contention (Figure 6.9). Here I show that 
PDE4D5 binds to ERK2 through a sequence that encompasses amino acids 650-690 
of FDE4D5, which contains the EKFQFELTLEE motif that was also found in (3- 
arrestin binding (Figure 6.5). In addition to this FQF motif, another putative ERK 
docking site, namely the KIM motif, the consensus sequence of which is proposed as 
(V/L)X2 (R/K)(R/K)A3 .6 L and is found in various ERK transcription factor substrates, 
has also been suggested to mediate the interaction of PDE4D with ERK2 (MacKenzie 
et al. 2000). In the case of PDE4D3, mutation of the core residues of KIM 
(K455/K456) stops its association with ERK2 (MacKenzie et al. 2000). In PDE4D5, 
the KIM motif is located 122 residues N-terminal to the ERK target Ser651 residue.
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which can be recognized by all MAP kinases. However, this region, the entire 
sequence of which is found in peptides 104 and 105 did not seem to interact with 
ERK2-GST in the peptide aiTay analysis. This is in contrast with the observation of 
PDE4D3 interaction with ERK2, where both KIM and FQF are cmcial for their 
binding and mutation of either of them would lead to the loss o f interaction 
(MacKenzie et al. 2000). As the peptide array technique bears limitations whereby the 
peptides sometimes are not able to fold properly on the cellulose membranes, 
therefore negating the potential protein interactions, it is likely that the KIM- 
containing peptide of PDE4D5 did not fold properly to form a binding surface as in 
the crystal structure this motif is on a defined beta-hairpin loop and so such a structure 
may be needed to present the residues appropriately. Therefore, it is necessary to see if 
the truncation or mutagenesis studies in co-immunoprecipitation and two-hybrid 
assays produce the same results.
As the focus of the present study was on the possible competition between (3- 
arrestiii2 and ERK2 for binding to PDE4D5, I focused on amino acids 660-685 
(peptide 133; Figure 6.9), which includes FQF and to which |3-arrestin2 also binds 
(Figure 6.5). Interestingly, alanine scanning of this region indicates a series of amino 
acids that appear to be important for the FDE4D5-ERK2 interaction (Figure 6.10). 
Unexpectedly, the amino acids that are cmcial for PDE4D5-(3-an'estin binding are 
subset of those important for PDE4D5-ERK2 binding (Figure 6.6 b and 6.10). This 
suggests a potential for competition. In order to explore this, I performed peptide 
competitive binding experiment on PDE4D5 alanine substitution array (660-685) by 
using Odyssey system. This analysis shows that under conditions when (3-arrestin2 
and ERK2 are present at identical molar concentration in the assay, F670, F672, L674 
and L676 are all cmcial for the binding of PDE4D5 to both (3-anestin2 and ERK2, 
additionally supporting the hypothesis that P-arrestin2 and ERK2 compete to bind 
PDE4D5 (Figure 6.11).
■4
Both peptide aiTay analysis (Figure 6.14) and co-immunoprecipitation assays 
(Figure 6.12) demonstrate that PDE4D5 can bind to the SUMO-conjugating enzyme, 
Ubc9 (Hay 2005). Peptide array analysis identifies two regions on PDE4D5 that are 
involved in its ability to bind to Ubc9, both of which are located downstream to the
putative SUMO modification consensus motif yKXE, with the form of VKTE in 
PDED4D5 (Figure 6,14). Intriguingly, the second interaction domain falls into the 
region of sequence that spans amino acids 655-695, to which both p-an*estin2 and 
ERK2 bind (Figure 6.5 and 6.9). This implies that by interacting with this sub-domain 
on PDE4D5, p-anustin2, ERK2 and Ubc9 might compete for the same docking site. 
Alanine scanning substitution arrays of this sequence, which extends amino acid 660- 
685, supported such a hypothesis as substitution of any amino acid within the cluster 
F670, F672, L674 and L676 led to the evident ablation of the interaction between 
PDE4D5 and Ubc9. This concurred with observations assessing binding of both P- 
aiTestin and ERK2 to this scanning array set (Figure 6.15).
As shown here, the region representing amino acids E660 to E685 in 
PDE4D5 shows remarkable importance for the binding of p-aiTestin, ERK2 and Ubc9. 
Further insight into the mode of the folding of this region might be gained by 3-D 
analysis of the crystal stmcture. At present, there is little structural literature available 
for the region cognate to the portion from Phe670 to Leu676 of PDE4D5. However, 
two crystal structures for a truncated PDE4B2 enzyme, namely (IFOJ) (Xu et al. 2000) 
and 1XM6 (Card et al. 2004), extend as far as residues 672 and 677 cognate in 
PDE4D5, respectively. The PDE4D C-terminal stretch, involving amino acids 324- 
677 in PDE4D5, shows 85% sequence identity to the cognate region in PDE4B. This 
allowed our collaborators to build a stractural homology model o f this portion of 
PDE4D using the PDE4B structures as templates (Figure 6.18). Both templates taken 
together indicate that the sequence coiTesponding to “^^ ^EEGRQGQTEKFQFELTLE^^^ 
in PDE4D5 fonned an a-helix-containing stmcture (helix-17) that is separated fr om 
helix-16 by a flexible linker. However, the alignment o f helix-17 within the catalytic 
domains in both templates is different. In the IFOJ stmcture, which is for a tmncated 
PDE4B the helical region equivalent to PDE4D5 316-672, does not make any packing 
contacts with the core catalytic domain of its parent protein molecule, although it 
juxtaposes a symmetry-related molecule in the crystal stmcture (Xu et al. 2000). This 
might suggest that helix-17 is connected to the compact core of the catalytic unit by a 
flexible linker region rather than packing tightly onto the core catalytic domain. 
Interestingly, in the 1XM6 stmcture, which is for a truncated PDE4B enzyme 
equivalent to PDE4D5 295-692, helix-17 is folded across the mouth of the catalytic
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pocket, trapping the PDE4 inhibitor, mesoprain inside (Card et al. 2004). This would 
likely be a catalytically inactive form and exemplifying an extreme case. However, it 
is consistent with helix-17 being able to be mobile rather than fixed, which would be 
important for a multi-functional docking region. Consequently, two models for 
PDE4D5 containing this region were constructed. In the model based upon IFOJ 
(Figure 18), helix-17 is conformationally mobile and does not interact with the 
catalytic domain. The residues involved in p-arrestin2, ERK2, and Ubc9 binding, 
namely Phe670, Phe672, Leu674 and Leu676 fonn a semi-circular patch on an 
exposed surface located upon one side of the C-tenninal part o f helix-17. It is 
therefore likely that this part o f the surface of helix-17 physically interacts with, as 
appropriate, either p-anestin or ERK2 or Ubc9. On the other hand, the PDE4D model 
based on the 1XM6 structure presents the ability of helix-17 to fold across the 
opening of the catalytic site. In this anangement, a key residue needed for the binding 
of each of p-arrestin, ERK2 and Ubc9, namely Leu674 is entirely packed against the 
catalytic domain (Figure 6.18). This partially occludes the surface implicated in 
binding of p-arrestin, ERK2 and Ubc9. Therefore, it seems likely that if helix-17 does 
nonnally abut the catalytic site, then some modification needs to trigger its movement 
away from this surface so as to expose helix-17 for interaction of these proteins and to 
allow access of cAMP substrate and inhibitors to the active site. Thus a model based 
on IFOJ, which provides an open docking site for p-arrestin2, ERK2 and Ubc9 to 
compete for binding and appears to be most likely to reflect the nonnal state of 
PDE4D5. The flexibility of helix-17 linker may be needed so that it can adopt 
different confonnations when docking of these other molecules occur that have a 
second interaction site elsewhere on the PDE4D5 surface. It may also allow for 
regulation of binding and also for selectivity in binding, especially if  regulated in 
some way, such as by phosphorylation.
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Figure 6.1 Schematic of long isoform PDE4D5.
Long isoform PDE4D5 is unique in its N-terminal region which is responsible for its 
interaction with other proteins and subcellular localization. The figure depicts the 
regions where PDE4D5 uses to bind to a variety of proteins. RAIDl, RACKl 
Interacting Domain 1; UCRl, Upstream Conserved Region 1; UCR2, Upstream of 
Conserved Region 2; ^KXE, SUMO modification consensus sequence.
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Figure 6.2 Sequence alignments of the residues of full-length p-arrestinl and P- 
arrestinZ.
The full-length sequence of human P-arrestinl and full-length P-arrestin2 are aligned 
by ClustalW software. Conserved amino acids are indicated in black and the varied 
amino acids are indicated in grey. B-arrestin, P-arrestinl; B-arr2, p-arrestin2.
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6.3 Over-expression and purification of recombinant proteins of GST-p-arrestinl 
and GST-P-arrestin2.
GST-p-arrestinl and GST-p-arrestin2 were over-expressed at 37°C in E. Coli DH5a 
cells by induction with ImM IPTG Samples from different stages of the Glutathione 
Sepharose column purification process (see section 2.2.5) were separated on a 4-12% 
SDS-PAGE gel stained with Coomassie brilliant blue. Expression of GST-p-arrestinl 
and GST-p-arrestin2 are indicated as arrows. Free GST present in the final elute is 
also indicated as arrows. Molecular weight markers are shown with sizes indicated in 
kDa. The listing numbers are indicated as follows: 1, before induction; 2, 5 hr after 
induction; 3, before elution with glutathione buffer; 4, glutathione sepharose beads 
alone; 5, after elution with glutathione buffer. The observed molecular weight of full- 
length (a) GST-p-arrestinl on SDS-PAGE is ~75 kDa; full-length (b) GST-p-arrestin2 
on SDS-PAGE is -73 kDa.
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Figure 6.4 Detection of protein-protein interaction by using Peptide Array 
Analysis and subsequent Alanine Substitution Analysis.
Upper panel shows how peptide array analysis works. GST fusion protein was 
overlaid onto the cellulose membrane that contains the overlapping peptides (25 mers), 
each shifted along by 5 amino acids in the whole sequence of the protein of interest. 
This interaction was detected with the antiserum against the protein that was fused 
with GST. Spots were blank, indicative of null interaction. Spots were dark, indicating 
the positive interaction. The numbers ahead of each peptide indicate their order in the 
array. Lower panel shows how alanine substitution analysis works. The amino acids 
from the parent peptide shown positive in upper panel were singly and successively 
substituted to alanine, except the amino acid alanine which needed changing to be 
aspartic acid. Similar to the procedure of peptide array analysis, GST-fused protein 
was overlaid and detected by its specific antiserum. The wild type parent peptide was 
used as a control (1).
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Figure 6.5 Probing PDE4D5 peptide array for P-arrestin2 interaction sites.
PDE4D5 is shown schematically with its unique N-terminal region, UCRl, UCR2, 
catalytic region and C-terminal domain. Cellulose membrane containing overlapping 
peptides and representing the entire sequence of PDE4D5 was blocked in 5% milk 
before being overlaid with recombinant p-arrestin2-GST or p-arrestinl-GST. The 
detection was performed using immunoblotting with a specific anti-P-arrestin 
antibody. Shown here are the only sections in the array that generate dark spots 
(positive interactions).
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Figure 6.6 The binding of p-arrestin2 to sequential alanine substituted version of 
a RAIDl-containing peptide.
(a) Here shows an array of peptides based on a 25mer parent peptide (Ctr, peptide 5 in 
Figure 6.5) of sequence Asn22-Thr45 in PDE4D5. Further spots reflect a scanning 
peptide array of this parent peptide where indicated amino acids were sequentially and 
individually substituted with alanine. Cellulose membrane was blocked before 
overlaid with GST-P-arrestin, followed by immunoblotting with a specific anti- 
arrestin2 antibody, (b) Cellulose membrane containing the control (peptide 133, 
representing the sequence Glu660-Glu685 in PDE4D5 in Figure 6.5) and the alanine- 
sequentially and singly substituted (derived) peptides were overlaid with p-arrestin2- 
GST after being blocked with milk. This array was then subject to immunoblotting 
using anti-p-arrestin antibody. Wild type peptide (Ctr) plus progeny with the indicated 
residue substituted for alanine were marked under the spots. Ctr, control.
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Figure 6.7 Purification of recombinant protein of GST-ERK2.
GST-ERK2 was over-expressed at 37°C in E. Coli DH5a cells by induction with 
ImM IPTG Samples from different stages of the Glutathione Sepharose column 
purification process (see section 2.2.5) were separated on a 4-12% SDS-PAGE gel 
stained with Coomassie brilliant blue. Expression of GST-ERK2 is indicated as 
arrows. Free GST present in the final elute is also indicated as arrows. Molecular 
weight markers are shown with sizes indicated in kDa. The listing numbers are 
indicated as follows: 1, before induction; 2, 5 hr after induction; 3, before elution with 
glutathione buffer; 4, glutathione sepharose beads alone; 5, after elution with 
glutathione buffer. The observed molecular weight of full-length GST-ERK2 on SDS- 
PAGE is ~60 kDa, which corresponds closely with its calculated molecular weight of 
67 kDa.
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Figure 6.8 Association of PDE4D5 with ERK2 in HEKB2 cells.
Intact HEKB2 cells (control cells, lane B) and those transfected with VSV-tagged 
PDE4D5 (lane A) were harvested in 3T3 lysis buffer and subject to 
immunoprécipitation with VSV affinity beads. The association of PDE4D with ERK2 
was detected by probing the immunoprecipitates with a specific anti-ERKl/2 antibody, 
which was followed by probing the same membrane with a specific VSV antibody to 
confirm the pull-down. Molecular weight markers are shown with sizes indicated in 
kDa.
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Figure 6.9 Probing PDE4D5 peptide array for ERK2 interaction sites.
PDE4D5 is shown schematically with its unique N-terminal region, UCRl, UCR2, 
catalytic region and C-terminal domain. Cellulose membrane containing overlapping 
peptides and representing the entire sequence of PDE4D5 was blocked in 5% milk 
before being overlaid with recombinant ERK2-GST. The detection was performed 
using immunoblotting with a specific anti-ERK2 antibody. Shown here are the only 
sections in the array that generate dark spots (positive interactions).
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Figure 6.10 The binding of ERK2 to sequential alanine substituted version of a 
FQF-containing peptide.
Here shows an array of peptides based on a 25mer parent peptide (Ctr, peptide 132 in 
Figure 6.9) of sequence Glu660-Glu685 in PDE4D5. Further spots reflect a scanning 
peptide array of this parent peptide where indicated amino acids were sequentially and 
individually substituted with alanine. Cellulose membrane was blocked before 
overlaid with GST-ERK2, followed by immunoblotting with a specific anti-ERK2 
antibody. Ctr, control.
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Figure 6.11 The binding of p-arrestin2 and ERK2 to sequential alanine 
substituted version of a FQF-containing peptide.
(a) Comparison of p-arrestin! and ERK2 binding to an alanine scan array of PDE4D5 
whose sequence reflects amino acids 660-685, as shown in Figure 6.6b and Figure 
6.10, by using ECL developing reagent, (b) As (a) but except that signals were 
detected with Odyssey system, the peptide array was screened for interaction with 
recombinant P-arrestin2-GST, or ERK2-GST as shown in black-and-white, and 
simultaneous interaction with recombinant p-arrestin2-GST and recombinant ERK2- 
GST as shown in color, (c) Shows the quantitative data from three independent 
experiments by using ECL reagent. Data were expressed as fold in control peptide 
signal. Red boxes indicated the most important amino acids that are essential for both 
P-arrestin2 and ERK2 binding to PDE4D5 within a peptide spanning from Glu660 to 
Glu 685. 670-680A is used as a negative control.
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Figure 6.12 Association of PDE4D with Ubc9 in HEKB2 cells.
Intact HEKB2 cells (control cells) and those transfected with siRNA specific to 
PDE4D were harvested in 3T3 lysis buffer and subject to immunoprécipitation with a 
specific anti-PDE4D antibody. The association of PDE4D with Ubc9 was detected by 
probing the immunoprecipitates with a specific anti-Ubc9 antibody. Lower panel 
shows the efficient ablation of PDE4D when a siRNA specific to PDE4D was 
transfected in. Lys, lysates; PI, pre-immune; IP, immunoprécipitation.
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Figure 6.13 Purification of recombinant protein of GST-Ubc9.
GST-Ubc9 was over-expressed at 37°C in E. Coli DH5a cells by induction with ImM 
IPTG Samples from different stages of the Glutathione Sepharose column purification 
process (see section 2.2.5) were separated on a 4-12% SDS-PAGE gel stained with 
Coomassie brilliant blue. Expression of GST-Ubc9 is indicated as arrows. Free GST 
present in the final elute is also indicated as arrows. Molecular weight markers are 
shown with sizes indicated in kDa. The listing numbers are indicated as follows: 1, 
before induction; 2, 5 hr after induction; 3, before elution with glutathione buffer; 4, 
after elution with glutathione buffer. The observed molecular weight of full-length 
GST-Ubc9 on SDS-PAGE is -43 kDa, which corresponds closely with its calculated 
molecular weight of 45 kDa.
i
218
73HTIFQERDLLKTnaPVDTLIT YLM(361-385)
74 ERDLLKTFKIPVDTUTYLMTLEDH(366-390)
75 KTFKIPVDTLITYLMTLEDHYHADV(371-395)
76 PVDTLnTLMTLEDHYHADVAYHNN(376-400)
77 rrYLMTLEDHYHADVAYHNNIHAAD(381-405)
78 TLEDHYHADVAYHNNIHAADWQST(386-410)
79 YHADVAYHNNIHAADWQSTHVLLS(391-415)
130SnPQSPSPAPDDPEEGRQGQTEKF(646-670)
131 SPSPAPDDPEEGRQGQTEKFQFELT(651-675)
132 PDDPEEGRQGQTEKFQFELTLEEDG(656-680)
133 EGRQGQTEKFQFELTLEEDGESDTE(661-685)
134 QTEKFQFELTLEEDGESDTEKDSGS(666-690)
135 QFELTLEEDGESDTEKDSGSQVEED(671-695)
136 LEEDGESDTEKDSGSQVEEDTSCSD(676-700)
PVDTLITYLMTLEDHYHADVA YHNN (376-400) 4D5 QTEKFQFELTLEEDGESDTEKDSGS (666-690) 4D5
regionl r%ion2• •  -  » # * .
73 74 75 76 77 78 79 130 131 132 133 134 135 136
361 415 646 700
N I  UCRl jUCR2h—4________ catalytic r^ io n  ^  C
PDE4D5
Figure 6.14 Probing PDE4D5 peptide array for Ubc9 interaction site.
PDE4D5 is shown schematically with its unique N-terminal region, UCRl, UCR2, 
catalytic region and C-terminal tail. The entire sequence of PDE4D5, represented by 
spots on cellulose membranes containing overlapping peptides, each shifted along by 
5 amino acids in the PDE4D5 sequence, was overlaid with recombinant Ubc9-GST 
protein, blocked prior to detection by immunoblotting. Shown are sections of 
membranes indicating positive interaction peptide spots (black) bounded by null 
interaction peptide spots (clear). The numbers associated with the peptides indicate 
their order in the array. The sequences of PDE4D5 that shows positive binding to 
Ubc9 are indicated in red.
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Figure 6.15 The binding of Ubc9 to sequential alanine substituted versions of 
Ubc9-interacting PDE4D5 peptides.
(a) Shows an array of peptides based on a parent peptide (spot 76) in original 
PDE4D5 peptide array) whose sequence reflects amino acids 376-400 of PDE4D5. 
This alanine substitution array was probed with recombinant Ubc9-GST and 
interaction was detected by immunoblotting with an anti-Ubc9 antibody. The wild 
type parent peptide (spot 76) was used as a control, (b) Shows an array of peptides 
based on a parent peptide (spot 134 in original PDE4D5 peptide array) whose 
sequence reflects amino acids 666-690 of PDE4D5. This alanine substitution array 
was probed with recombinant Ubc9-GST and interaction was again detected by 
immunoblotting with an anti-Ubc9 antibody. The wild type parent peptide (spot 134) 
was used as a control. Cont, control.
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Figure 6.16 Probing P-arrestin2 peptide array for Ubc9 interaction sites.
p-arrestin2 is shown schematically with its N-domain and C domain. Cellulose 
membrane containing overlapping peptides and representing the entire sequence of p- 
arrestin2 was blocked in 5% milk before being overlaid with recombinant Ubc9-GST. 
The detection was performed using immunoblotting with a specific anti-Ubc9 
antibody. Shown here are the only sections in the array that generate dark spots 
(positive interactions) bounded by clear spots (null interactions). The numbers 
associated with the peptides indicate their order in the array. The potential 
sumoylation site on p-arrestin2 is indicated on the p-arrestin2 schematic
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Figure 6.17 The binding of Ubc9 to sequential alanine substituted versions of 
Ubc9-interacting p-arrestin2 peptides.
(a) Shows an array of peptides based on a parent peptide (spot 38 in original p- 
arrestin2 peptide array) whose sequence reflects amino acids 186-210 of p-arrestin2. 
This alanine substitution array was probed with recombinant Ubc9-GST and 
interaction was detected by immunoblotting with an anti-Ubc9 antibody. The wild 
type parent peptide (spot 38) was used as a control, (b) Shows an array of peptides 
based on a parent peptide (spot 75 in original p-arrestin2 peptide array) whose 
sequence reflects amino acids 371-395 of p-arrestin2. This alanine substitution array 
was probed with recombinant Ubc9-GST and interaction was again detected by 
immunoblotting with an anti-Ubc9 antibody. The wild type parent peptide (spot 75) 
was used as a control. Cont, control.
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Figure 6.18 Predicted structure of catalytic domain in PDE4D.
The structure of PDE4D catalytic domain is modeled based upon the existence of its 
conserved counterpart in PDE4B, whose structure has been resolved, (a) Shows the 
derived 1XM6 structure in which the predicted a  helix-17 (^^^FQFELTL^^^) in 
PDE4D5 is indicated to fold across the opening of the catalytic site and in so doing 
occlude the surface implicated in p-arrestin2, ERK2 or Ubc9 interaction, (b) Shows 
the derived IFOJ structure in which the predictated a  helix-17 (^^^FQFELTL^^^) in 
PDE4D5 stays in the open area away from its core catalytic domain. Amino acids 
whose alanine substitution leads to loss of RACKl interaction are shown in red and 
those that leads to clear attenuation are shown in blue. Amino acids whose alanine 
substitution leads to loss of P-arrestin2 interaction are shown in yellow. The flexible 
linker region between helix 16 and 17 are shown in pink.
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General Discussion
The cAMP signaling pathway controls a wide range of cellular processes, the 
specificity of which is facilitated by thiee dimensional organization o f signaling 
proteins, such as ACs, AKAPs and PDEs within cells (Houslay and Adams 2003; 
Wong and Scott 2004; Tasken and Aandahl 2004). Pivotal in shaping and controlling 
intracellular cAMP gradients, PDEs provide the sole means to degiade cAMP.
PDE4 genes generate over 20 isoforms, each of which is characterized by 
their unique N-terminal region, which can mediate protein-protein interactions and 
confer intracellular targeting (Houslay et al. 2005). An emerging theme in PDE4 
action is that individual isofonns are sequestered to particular signaling complexes, 
therefore allowing regulation of the activity of the cAMP effector proteins, targeted 
PKA, pi asm a-membrane bound CNGCs or localized EPACs (Baillie et al. 2005).
It is well established that phosphorylation of P2 AR by two types of protein 
kinases, PKA and GRK can result in receptor desensitization (Kohout and Lefkowitz
2002). PKA phosphorylation of the P2 AR causes the receptor to switch from its 
predominant coupling to Gg, which activates adenylyl cyclase, to another G-protein 
protein, namely G j, thereby allowing for activation of the ERK pathway (Lefkowitz et 
al. 2002). GRK phosphorylated P2 AR binds with high affinity to membrane recruited 
p-arrestin. Such binding of p-arrestin to the P2 AR prevents further coupling to Gas 
and targets the p%AR for endocytosis (Lefkowitz and Shenoy 2005). Recently, a new 
facet of this desensitization system has been identified (Perry et al. 2002), in that p- 
an’estin, when translocated to the receptor in response to agonist stimulation, has been 
shown to be in complex with PDE4. This results in efficient P2 AR desensitization 
with concomitant interdiction of coupling, preventing cAMP synthesis and also 
increasing local cAMP degradation (Perry et al. 2002; Bolger et al. 2003).
In the course of this work, I have extended our knowledge of the properties 
of one particular long PDE4 isofoim, PDE4D5. PDE4B and PDE4D together 
contribute more than 90% of the total PDE4 activity in HEKB2 cells (Lynch et al. 
2005). However, it is PDE4D5 alone, which contributes only 24% of total PDE4
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activity in these cells, that has been identified, by RNA silencing and overexpression 
of catalytically inactive (dominant negative) PDE4D5, as the functionally relevant 
PDE interacting with p-an^estin to control PKA phosphorylation of the P2 AR and 
consequentially switching of its signaling to activation of ERK pathway (Lynch et al. 
2005; Bolger et al. 2003).
Using co-immunoprecipitation, I have shown that AKAP79 associates with 
the P2 AR in a constitutive manner in HEKB2 cells. In contrast to this, the AICAP 
gravin is only associated with the p%AR receptor subsequent to challenge o f cells with 
isoprenaline. Further studies using siRNA technology to achieve knockdown of 
specific AKAPs show that the ability o f isoprenaline to trigger PKA-mediated 
phosphorylation of the P2 AR, and consequential activation of ERK, is ablated upon 
knockdown of AKAP79 but not upon knockdown of gravin. Such data indicate that p- 
anestin-recruited PDE4D5 gates the potential of a discrete pool of AKAP79-tethered 
PKA to phosphorylate the associated P2 AR. It is this important process that is required 
for the switching of P2 AR coupling from Gs to Gi and the consequential ERK 
activation. Although the role of the recruited gravin is still not understood, the fact 
that selective knockdown of gravin did not have any effect on PKA phosphorylated 
P2 AR indicates that membrane-bound forms of gravin serve a role distinct from that 
of AKAP79 in regulating the PKA phosphorylation of the P2 AR, at least in HEKB2 
cells.
It has been established that engineering a single point mutation within the 
catalytic domain of PDE4D5 can generate a catalytically inactive fonn of PDE4D5 
that retains its ability to bind to p-ari'estin (Baillie et al. 2003), This catalytically 
inactive species is able to exert a dominant negative role, displacing the active 
endogenous counterpart and enhancing the isoprenaline-stimulated phosphorylation of 
ERK. Here I confirm this data, and also show that mutating Arg34 to Ala within this 
dominant negative PDE4D5 ablates its ability to bind p-arrestin thereby preventing its 
ability to enhance isoprenaline-stimulated ERK phosphorylation. This data indicates 
that p-aiTestin-mediated delivery o f PDE4D5 participates in a unique desensitization 
process. The localized rate of cAMP degiadation is increased, AKAP79-anchored 
receptor-bound PKA is deactivated and the P2 AR is uncoupled from Gi. Alterations in
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the expression and availability of both AICAP79 and p-an estin-bonnd PDE4D5 might 
confer cell-type specific remodeling of the switching of P2 AR signaling to ERK.
In contrast to the p-aiTestin-delivered PDE4D5 isofonn-specific regulation of 
P2AR phosphorylation by PKA (Lynch et al. 2005), I have suggested that the 
regulation o f GRK2 phosphorylation by PKA is, seemingly, regulated by a mixed pool 
of PDE4 activity rather than a single isoform. This may be because GRK2 is located 
through the cytosol and thus subject to phosphorylation by cytosolic PKA, thus being 
regulated by bulk cAMP levels. Using imunoprecipitation, I have shown that 
inactivation of PDE4 by the PDE4 selective inhibitor, rolipram enhances the 
isoprenaline-induced PKA phosphorylation of GRK2, leading to increased GRK2 
membrane recruitment. In addition, siRNA-mediated knockdown o f either PDE4B or 
PDE4D subfamilies, which provide 30% and 60% of the total PDE4 activity in 
HEKB2 cells, respectively, also enhanced the isoprenaline-induced PKA 
phosphorylation of GRK2. In contrast to this, inhibition of PDE3, which provides 
40% of the total PDE activity in HEKB2 cells failed to affect PKA phosphorylation of 
GRK2. This implies that, in response to isoprenaline, the actions of PDE4B and 
PDE4D may act synergistically on the same cAMP pool, indeed a combination of 
knockdown of both PDE4B and PDE4D, whilst not additive in effect, did achieve a 
similar increase in isoprenaline-induced PKA phosphoiylation of GRK2 to rolipram. 
This is however distinct from the pool of cAMP regulated by PDE3, implying its 
function may be to regulate a spatially discrete pool of cAMP. Indeed, PDE3 is 
exclusively membrane-bound, and in many cell types, it has been shown that selective 
inhibition of PDE3 and PDE4 leads to very different fiinctional outcomes (Maurice et 
al. 2003; Huang et al. 2001).
It has previously been shown by others that PKA phosphorylation of GRK2 
increases its ability to interact with GPy and, in consequence, increases the membrane 
recruitment of GRK2 (Cong et al. 2001; Lodowski et al. 2003). Here my data lends 
ffirther support to this. With further time and resources I would like to examine the 
role of Gpy in the rolipram enhanced isoprenaline-induced GRK2 membrane 
translocation either by engineering a Gpy mutant which would prevent its binding to 
GRK2, or by employing an engineered HEKB2 cell line that lacks endogenous Gpy.
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Interestingly, in the presence of rolipram, the isoprenaline-induced membrane 
recruitment of GRK was not only accelerated but was also transient in nature. Such 
transience was abolished when the cells were pretreated with the MEK inhibitor 
U0126, suggesting an enhanced ERK activation involved in releasing the membrane- 
bound GRK2. As discussed above, previous studies have shown that PDE4 inhibition 
promotes PKA phosphorylation of the P2 AR and the switching of its signaling to ERK 
(Lynch et ah 2005; Baillie 2003). Here I confinn these results and extend them in 
showing an increase in the membrane fraction of ERK phosphorylated GRK2 that is 
more transient when rolipram is present in addition to isoprenaline. This parallels the 
transient nature of the GRK2 membrane translocation in the presence of both 
isoprenaline and rolipram. Therefore, PDE4 appears to control the scope of the 
actions of GRK2 in the early stage of P2 AR desensitization. In the process of 
membrane recmitment of GRK2, PDE4 regulates PKA phosphorylation of GRK2 and 
the subsequent GRK2 translocation to the membrane. Once GRK2 fonns in complex 
with the receptor, the switching of P2 AR G-protein coupling from Gg to G,, regulated 
by FDE4D5 causes activation o f ERK that acts to phosphorylate and deactivate GRK2, 
promoting its release from the plasma membrane back to the cytosol. Following
,1S.membrane translocation of GRK2, P-an*estin/PDE4D complexes are recruited to the 
membrane (Perry et al. 2002) and desensitization commences. I show here that the 
time-dependent transient and concomitant membrane recruitment of both p-arrestin 
and PDE4D5 occur more rapidly in isoprenaline-challenged cells that have been 
pretreated with rolipram, consistent with the GRK2 membrane recruitment time 
course.
Interestingly, in the absence of isoprenaline, inhibition o f PDE4 alone by 
rolipram is sufficient to cause PKA phosphorylation of GRK2, with consequential 
effects on GRK2 membrane recruitment and GRK2-mediated phosphorylation of the 
P2 AR. In contrast however, rolipram alone had no effect on ERK activation nor was 
ERK phosphorylated GRK2 detected in the plasma membrane following rolipram 
treatment. I would suggest that GRK2 phosphorylation by PKA is initiated in the 
cytosol thus allowing its control by global changes in cAMP that can be regulated by 
PDE4 isoenzymes also located within the cytosol. Indeed, single PDE4B or PDE4D 
subfamily knockdown failed to elicit the PKA phosphorylation of GRK2. This
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indicates that the cAMP threshold to activate PKA is set such that it needs either 
stimulation of adenylyl cyclase or the ablation o f both PDE4B and PDE4D 
subfamilies in order to breach this thieshold to activate PKA. Indeed, knockdown of 
both PDE4B and PDE4D together did achieve an increase in the PKA phosphorylated 
status of GRK2 in resting (unstimulated) cells.
In contrast, activation of the ERK2 pathway requires agonist stimulated
AKAP79-tethered PKA phosphoiylation of PzAR at the plasma membrane. Following
agonist stimulation p-an-estin and PDE4D5, in complex, are recruited to the
membrane where PDE4D5 is able to control a localized pool o f cAMP thereby
regulating PKA phosphorylation of the receptor and consequential activation of the
ERK pathway. This hypothesis has been partially proved by Lynch et al. (2005), as in
resting HEKB2 cells, knockdown of either PDE4B or PDE4D in the absence of
agonist, by siRNA, failed to induce the PKA phosphorylation of the P2 AR (Lynch et
.al. 2005). This study, however did not examine the effect of knocking down both 
PDE4B and PDE4D on phosphorylation of the P2 AR by PKA in the absence of 
agonist and should be addressed in the future.
;
It is widely recognized that reversible post-translational modifications often 
regulate dynamic protein function. Previous studies have shown PDE4D5 to be 
phosphorylated both by PKA at Seri26, which serves to activate PDE4D5 (Sette et al.
1994; MacKenzie et al. 2002) and by ERK2 at Ser651, which, conversely, inlhbits 
enzyme activity (Hofhnann et al. 1999; MacKenzie et al. 2000; Baillie et al. 2001). 
Post-ti'anslational modifications of specific proteins often occur in response to 
extracellular stimuli. It has been established (Peny et al. 2002; Lynch et al. 2005) that 
PDE4D5, in complex with p-arrestin, is recruited to the plasma membrane in response 
to isoprenaline stimulation of the P%AR where it regulates localized cAMP levels. I 
therefore set out to examine if PDE4D5 underwent post-translational modification 
following agonist treatment. If this modification did occur I wished to examine its 
effect on downstream signaling and the interaction of PDE4D5 with other proteins, 
for example p-arrestin. Sequence analysis revealed a ubiquitin interaction motif (UIM 
domain) located within the extreme C-tenninus of PDE4D5, prompting my 
investigation. UIM domains have been suggested to direct ubiquitination as well as to
.
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interact with ubiquitin (Miller et al. 2004). I thus examined whether PDE4D5 was
ubiquitinated in response to isoprenaline treatment in HEKB2 cells. Indeed I show
here that PDE4D5 does indeed become ubiquitinated, in both HEKB2 cells in
response to isoprenaline stimulation and also in HBKV2 cells in response to
vasopressin stimulation. This ubiquitination o f PDE4D5 appears to be dependent upon
the integiity of its UIM domain as, when the critical acidic patch within this domain
was mutated, ubiquitination of PDE4D5 in response to agonist was severely
attenuated. In agreement with this, several isofonns of PDE4A, PDE4B and PDE4C,
which lack a UIM domain within their extreme C-termini, did not undergo
ubiquitination in response to isoprenaline challenge of HEK cells expressing these
species. Thus, it would appear that ubiquitination of PDE4 isoenzymes requires at
least the presence of one UIM domain, PDE4D3, however, which does contain an
. .UIM domain within its extreme C-terminus failed to undergo ubiquitination in 
HEKB2 cells in response to isoprenaline. This suggests that an UIM domain alone is 
insufficient to promote ubiquitination, as will be further discussed below.
P-arrestins are important adapter and scaffold proteins in GPCR signaling 
(Lefkowitz and Whalen 2004). It has been shown that p-anestin is involved in P2 AR 
and V 2 R ubiquitination processes and that it can act as an E3 ligase adapter (Shenoy et 
al. 2001; Martin et al. 2003). Meanwhile, p-arrestin itself has also been shown to 
undergo ubiquitination, via an action involving the E3 ligase Mdm2 (Shenoy et al.
2001), which plays an important role in controlling the ubiquitination o f p53 (Fang et 
al. 2000). My data here demonstrates that ablation of PDE4D5 binding to p-arrestin 
completely abolishes the deteetion of PDE4D5 ubiquitination in response to 
isoprenaline in HEKB2 cells. This suggests two possibilities. Firstly it is known that 
a percentage of PDE4D5 foims a complex with p-arrestin in HEKB2 cells. It may be 
that the ubquitination signal observed following immunoprécipitation of PDE4D5 
from agonist stimulated HEKB2 cells is in fact ubiquitinated p-aiTestin that has been 
pulled down in complex with PDE4D5. Secondly, it is possible that p-arrestin 
interacting with PDE4D5 is acting in its capacity as an E3 ligase adaptor protein and, 
as has been reported for its function in the ubiquitination of the P2 AR (Girnita et al.
2005), acts to locate E3 ligase in close proximity to PDE4D5 thereby enabling its 
ubiquitination. I have shown here that the ubiquitination of PDE4D5 and p-arrestin
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occurs with very disparate time courses. This, coupled to the lack of the ubiquitination 
signal seen in the PDE4D5 UIM mutant that is still able to bind to p-arrestin, suggests 
that it is ubiquitination of PDE4D5 and not p-arrestin that is observed. To further 
investigate the possibility that PDE4D5 is indeed ubiquitinated upon isoprenaline 
stimulation, I chose to evaluate first the key E3 ligase, Mdm2, which has been 
reported to interact with p-aiTcstin and function to ubiquitinate it, as well as various 
proteins including p53 (Fang et al. 2000; Girnita et al. 2005; Lin et al. 2002). The 
observation that a mutant of PDE4D5, which is unable to interact with airestin (E27), 
severely diminished ubiquitination o f PDE4D5 upon isoprenaline treatment, suggests 
that the presence of aiTestin is key. This might be because arrestin acts to deliver the 
E3 ligase, Mdm2 to act on complexed PDE4D5.
Indeed, in HEKB2 cells when Mdm2 is knocked down by specific siRNA, 
then wild type PDE4D5 failed to undergo ubiquitination in response to isoprenaline. 
This shows that Mdm2 is crucial for the ubiquitination of PDE4D5. Together, these 
data suggest that only PDE4D5 in complex with p-arrestin and therefore with Mdm2 
can be modified by Ub moieties. Interestingly, in PDE4D5 mutated in its UIM domain, 
which compromised its ability to undergo ubiquitination, the level of associated 
Mdm2 was much reduced in comparison to wild type PDE4D5. As Mdm2 binds to p- 
aiTestin (Shenoy et al. 2001) and this is the suggested mode of delivery to initiate 
PDE4D5 ubiquitination, it seems that mutation of the UIM domain of PDE4D5 might 
lower the amount of associated P-arrestin and hence reduce the amount of associated 
Mdm2. In order to address this hypothesis, I have checked the relative levels of p- 
arrestin that binds to the UIM mutated fonn to the wild type fonn of PDE4D5. The 
result that UIM mutated form of PDE4D5 binds to less p-arrestin than wild type 
PDE4D5 supports such a hypothesis.
In order to explore the effect of ubiquitination on PDE4D5 function, I 
explored the interaetion of wild type and the UIM mutated form of PDE4D5 with p- 
aiTestin. Using immunoprécipitation, I showed that more wild type PDE4D5 interacts 
with p-anestin than PDE4D5 UIM mutant which loses the ability to undergo 
ubiquitination. Additionally the interaction of PDE4D5 and p-arrestin was transient in 
nature, peaking at 10 minutes after isoprenaline stimulation. However this was not
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seen in the PDE4D5 UIM mutant transfected HEKB2 cells. These results imply that 
ubiquitination of PDE4D5 increases the proportion of the PDE4D5/p-arrestin 
complex within the cells, which might be of important in positively mediating the 
desensitization of pzARs. Thus, further work is required to define if ubiquitination is 
involved in the degree to which the PDE4D5/p-arrestin signaling complex is able to 
translocate to the plasma membrane and thereby attenuate Gs~> Gi switching. To 
answer this, I would first measure the ability of the UIM mutant PDE4D5 to 
translocate to the membrane fraction in complex with p-arr estin and compare this 
with wild type PDE4D5. Secondly I would propose to compare the degree of ERK 
activation in HEKB2 cells transfected with either wild type PDE4D5 or PDE4D5 
UIM mutant. As p-airestin-delivered PDE4D5 functions in attenuating ERK 
activation in response to isoprenaline in HEKB2 cells (Lynch et al. 2005), it would be 
expected that less ERK activation occurs in the UIM mutant transfected cells 
compared to wild type transfected cells.
Ubiquitin is a small molecule that contains seven lysine residues, each of 
which can be targeted by another ubiquitin in an iterative process to form distinct 
types of Ub chains (Pickart 2001). In vitro, K l l ,  K29, K48 and K63 all can form Ub- 
Ub linkages, Poly-ubiquitin chains fonned through K48 of two adjacent Ub are a 
well-characterized signal for targeting proteins for proteasomal degradation 
(Weissman 2001). Using HA-tagged Ub mutants, I show that PDE4D5 is modified 
largely by K48-linked Ub chains, as well as by a single Ub / mono-ubiquitination. 
This suggests that PDE4D5 might be targeted to proteasomes for degradation 
following ubiquitination. Indeed, I have demonstrated that wild type PDE4D5 
interacts with 19S regulatory subunit S2 and S5a in a time-dependent manner when 
p%AR is activated by isoprenaline. In the PDE4D5 UIM mutant that is unable to 
undergo ubiquitination, however, no interaction is obsei*ved. This supports the 
hypothesis that K48-linked Ub chain formed on PDE4D5 may target PDE4D5 to 
proteasomes. Further studies need to be done to confinn this. With further time, I 
would examine the half-life of PDE4D5 WT and UIM mutant foims by pulse-chase 
experiments.
I have demonstrated by in vitro ubiquitination that tlu*ee lysine residues in the
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unique N-terminal region of PDE4D5 are the putative ubiquitination sites. In order to 
examine their relative importance in conjugating ubiquitin, further work is required in 
which I would propose to examine the effect of single or combined selective mutation 
of these lysine residues on ubiquitination of PDE4D5. This in vitro data does, 
however, clearly explain the lack of ubiquitination in PDE4D3. This is because in the 
unique N-terminal regions of PDE4D3 and PDE4D5 it is only PDE4D5 which 
contains a putative ubiquitination site, explaining the inability of PDE4D3 to be 
ubiquitinated despite the presence of the UIM domain within its C-terminal region 
(Figure 6.1). Thus, in addition to funetioning in protein-protein interaction and 
targeting PDE4 isoforms to distinct subcellular compartments (Houslay and Adams
2003), the N-terminal region of PDE4 family also serves to gate the process of 
ubiquitination in the case of PDE4D5.
It could be argued that the difference in the ubiquitination signals between 
PDE4D5 and PDE4D3 might be due to the preferential binding of PDE4D5 to P- 
arrestin (Bolger et al. 2003), and the consequential presence of Mdm2 within the 
complex. However, the complete absence of the ubiquitination signal from PDE4D3 
abrogates this argument as at least the mono-ubiquitination signal or a faint poly- 
ubiquitination signal should be present as PDE4D3 is still binding to p-aiTestin albeit 
to a lesser extent, in HEKB2 cells (Bolger et al. 2003). It is likely therefore that there 
is threshold of minimal p-aiTestin binding for initiating ubiquitination. This would 
explain both the absence of ubiquitination o f the PDE4D5 UIM mutant compared to 
wild type PDE4D5 and also the lack of ubiquitination of PDE4D3 and PDE4D5 in the 
absence of agonist stimulation.
Mutation of the UIM domain in PDE4D5 results in no ubiquitination and 
reduced p-ancstin binding. Simply concluding from this coincidence that ablation of 
ubiquitination leads to the reduced p-airestin binding seems inappropriate because the 
reduced binding affinity might result from the consequential conformational changes 
in PDE4D5 when its UIM region is mutated, rather than the effect of lack of 
ubiquitination, albeit the latter might also be the case. In order to resolve this enigma, 
independent blockage of ubiquitination o f wild type PDE4D5 and subsequent 
investigation of the association between PDE4D5 and p-arrestin are needed. This
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could be done through three independent actions: (i) deploying the HA-tagged 3R 
ubiquitin mutant; (ii) knockdown of the crucial E3 ligase Mdm2 by virtue of siRNA
'
I 
,reagent; or (iii) mutation of the key K residues in the N-terminal region of PDE4D5 
that are responsible for accepting the ubiquitin moieties.
Following the ubiquitination, I investigated another similar molecule- 
mediated post-translational modification-sumoylation. Unlike ubiquitination, the 
conditions to detect sumoylation of PDE4D5 are highly stringent. Overexpression of 
E3 ligase PIASy together with WT PDE4D5 leads to sumoylation of PDE4D5, 
suggesting that E3 ligase PIASy is critical in fonuing PDE4D5-SUMO conjugates. 
Although there are a number of other isoforms (Hay 2005) within the PIAS family,
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my initial data suggests that it is only overexpression of the PIASy isofoim, which 
can cause sumoylation of PDE4D5. Sequential immunoprécipitation experiments have 
shown that p-arrestin, RACKl, ERK2 and AKAP18Ô bind to both non-sumoylated 
and sumoylated forms of PDE4D5 within cells, with preferential binding to the 
sumoylated form. To note, in contrast to this dual binding of p-an*estin in a cellular 
setting where sumoylation of PDE4D5 is gettable and this post-translational 
modification increases the binding of p-arrestin to PDE4D5, in a cell-free system 
where this post-translational modification of PDE4D5 is negated in the peptide array 
studies, GST-p-arrestin only interacts with non-sumoylated form of PDE4D5 (Figure 
6.5), which coiTcsponds to the interaction o f p-anestin with the 4D5 K323R mutant in 
the cell system. This suggest that p-anestin can interact with PDE4D5, regardless of 
its sumoylation status, however, it preferentially binds to the sumoylated foim of 
PDE4D5 that constitutes a portion, even though ~ 1%, of the total pool of PDE4D5.
Sumoylation has been shown to be a highly dynamic process and one that 
controls the intracellular targeting of modified proteins, often targeting the modified
protein to the nucleus. My hypothesis is that that wild-type PDE4D5 might shuttle 
between the cytosol and nucleus, dependent on its sumoylation status. To address this 
hypothesis, further work is required in examining localization of the protein by cell 
fractionation studies and confocal microscopy. From such studies I would hope to 
gain insight into the functional effect of sumoylated PDE4D5 on gene expression. In 
addition, SUMO-modified PDE4D5 sequestered in different signaling complexes may
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well disseminate the distinct signals upstream and relay these signals to distinct 
intracellular compartments.
Initial experiments undertaken to study sumoylation effects on the interaction 
between PDE4D5 with p-anestin, revealed an increased binding of p-arrestin to the 
sumoylated form of PDE4D5 (Figure 5.6 a), the fonn of which is about 1% of the 
total PDE4D5. However, in previous studies carried out by others, it has been 
suggested that ~ 7% of total PDE4D5 seems to interact with p-anestin. The disparity 
between these two percentages might be due to the cell system used. In the previous 
study, the authors used HEK293 cells and evaluated the endogenous PDE4D5 that is 
in complex with endogenous p-arrestin. However, in the cell context where PDE4D5- 
VSV and PIASy-HA were co-transfected in HEK293 cells, the proportion of PDE4D5 
that is sequestered by p-anestin has not been tested. Therefore, it would be very 
useful to verify the proportion of the PDE4D5 interacting with p-anestin under these 
conditions so as to reasonably compare the two proportions o f PDE4D5, one 
sumoylated, another bound to P-arrestin.
The function of the sumoylation of PDE4D5 is not understood. However, 
initial studies have shown that the sumoylation site is located within a catalytic 
domain of PDE4D5 that has been suggested to be involved in dimerization. This 
implies that a potential relationship between sumoylation and dimerization may exist. 
Therefore, it would be interesting to determine if they synergize or antagonize on a 
specific effect, such as subcellular distribution, or change of activity. It has also been 
reported that sumoylation can prevent ubiquitination in some cases (Desterro et al. 
1998), suggesting that this may be the case for PDE4D5. Thus, in the future work I 
would like to examine the relationship between the ubiquitination and sumoylation of 
PDE4D5.
Post-translational modification of PDE4D5, by ubiquitination and 
sumoylation, has been successfully shown through the experiments described here, 
however, caution with respect to the proportion of the PDE4D5 population actually 
subjected to these regulatory events need to be taken. Compared to the strong 
ubiquitin signals at 10 min after isoprenaline challenge with a specific ubiquitin
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antibody (Figure 4.4 a), signals above the natural size of PDE4D5-VSV at the same 
time point in the same immunoprecipitant with tlie VSV antibody were hardly 
observed (Figure 4.4 b). This may indicate that only a very small portion of PDE4D5 
underwent ubiquitination, and the reason that the ubiquitinated PDE4D5 was so 
robustly detected in Figure 4.4 a is perhaps due to the high sensitivity of the ubiquitin 
antibody used. Similarly, sumoylated forms of PDE4D5 may also only constitute a 
small subpopulation of total PDE4D5 (Figure 5.4 a). To further verify the functional 
importance of these two post-translational modifications on PDE4D5, experiments to 
identify the actual proportion of the total PDE4D5 modified are needed. This can be 
done by full immunoprécipitation of PDE4D5 in the cell system studied, followed by 
comparison of the modified form to the total PDE4D5.
Both ubiquitination and sumoylation of some proteins are involved in the 
pathology of neuronal diseases, such as Alzheimer’s disease (Seibenliener et al. 2004), 
Parkinson’s disease (Nakaso et al. 2004) and Huntington’s disease (Nagaoka et al. 
2004; Dohmen 2004). PDE4 has been implicated in impaired memory (Houslay and 
Adams 2003). Therefore, my finding with respect with the above two types of post- 
translational modification might add new insight relating PDE4 to the pathogenesis of 
neuronal diseases.
In support of the possible modification of PDE4D5 by SUMO, I show that, in 
addition to the existing PDE4D5-binding partners P-arrestin and ERK2, Ube9, which 
is known as a SUMO E2 conjugating enzyme and function to recognize target 
proteins and facilitate the SUMO attachment (Desterro et al. 1997; Johnson 2004; 
Melchior 2000), is able to interact with PDE4D5 in intact HEK293 cells under basal 
conditions. It would be very interesting, in the future, to examine if the interaction 
between PDE4D5 and Ubc9 can be changed by the alterations o f other parameters, 
such as an increase in intracellular cAMP levels.
In order to examine the binding meehanisms of interaeting proteins on 
PDE4D5 more closely, I have employed a novel peptide array methodology. I have 
mapped p-arrestin binding on PDE4D5 to two sites, one within the N-terminal region 
(T11-85A) and the second a ^^^FQFELTL^^^-spamiing catalytic domain. The N-
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terminal interaetion site overlaps the kno-wn RACK binding site, further supporting 
the hypothesis that p-aiTestin and RACKl exclusively interact with PDE4D5 (Bolger 
et al. 2006). Within the C-terminal binding site scanning alanine substitution an'ays 
identified F670, F672, E673, L674 and L676, located in subdomain-3 of the catalytic 
unit of PDE4D5 as crucial in p-arrestin binding. Within this motif is a FQF motif 
which has previously been implicated as an ERK2 docking site on PDE4 isoenzymes 
(Flouslay and Adams 2003). In addition to p-arrestin binding I show that this short 
motif is also crucial for Ubc9 binding to PDE4D5. In addition, Ubc9 has an additional 
interaction site (K371-D405) downstream of the SUMO consensus site (K323) of 
PDE4D5. Therefore, both p-arrestin and Ubc9 can straddle PDE4D5 at two distinct 
sites, one of which on the catalytic domain is identical. Like the exclusive interaction 
pattern of P-arrestin and RACKl on PDE4D5 (Bolger et al. 2006), my finding 
suggests that p-arrestin and Ubc9 are likely to perform a similar competitive binding 
to PDE4D5. If this binding is mutually exclusive then it would suggest that p-arrestin 
bound PDE4D5 can be ubiquitinated but not sumoylated. This is because 
ubiquitination would strengthen p-arrestin interaction, stopping Ubc9 binding and 
therefore preventing sumoylation. It would be interesting to see if this was indeed the 
case. Due to the shared FQF binding domain it is likely that ERK2 also competes with 
P-arrestin and Ubc9 to bind PDE4D5. Thus these various proteins likely sequester 
different pools of PDE4D5 and in so doing add to the complexity of 
compartmentalization of cAMP signaling in cells. It is highly likely that 
overexpression of ERK2 or Ubc9 in HEKB2 cells may reduce the extent of the p- 
arrestin-mediated pgAR desensitisation in response to p agonist as their 
overexpression might compete the endogenous P-aiTestin binding to PDE4D5.
Peptide array based analysis provides only initial identification of potential 
interaction sites between proteins, mutation studies need to be carried out in order to 
confirm the binding sites on PDE4D5. Further work is required in order to assess the 
inter-relationships between PDE4D5 and p-aiTestin, Ubc9 and ERK2.1 would propose 
to examine the binding of these proteins with PDE4D5 after eaeh of the others is 
knoeked down using siRNA. This would be very interesting as it could provide 
evidence as to whether endogenous levels of particular scaffolds have consequences 
for the signaling tlrrough other scaffolding proteins. It has been shown that Ubc9 is
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Iubiquitously expressed in both cytoplasm and nucleoplasm (Melchior 2000; Dohmen
2004), and p-arrestin2 shuttles between the cytosol and nucleus (Scott et al. 2002; 
Wang et al. 2003). It would be interesting to examine whether a dynamic association 
between these proteins with PDE4D5 exists and if this alters their role in signal 
transduction. It has been shown that Ubc9 directs sumoylation of many proteins (Hay
2005), and I have demonstrated PDE4D5 can undergo sumoylation. Therefore, a 
siRNA-mediated knockdown of Ubc9 in HEK293 cells would then be useful to 
confirm the importance of Ubc9 in mediating PDE4D5 sumoylation.
In the work presented in this thesis, I have extended the appreciation of the 
concept that PDE4D5 has multifunctional roles in cells each of which is associated 
with the ability of PDE4D5 to be sequestered in distinct signaling complexes via 
distinct scaffolding proteins. In addition to the existing binding partners p-arrestin, 
RACKl and ERK2, I have added Ubc9 to the PDE4D5 ‘partnership list’. It appears 
that distinct pools of PDE4D5 sequestered by particular scaffolds are exposed to 
different post-translational modifications and that control compartmentalized signal 
transduction. Thus, anchored PDE4D5 may be dynamically recmited to different areas 
of cells to provide cross-talk with other signaling pathways and reprogramme the 
signal transduction. For example, only when PDE4D5 is complexed to P-arrestin is it 
able to be ubiquitinated and this has potential to modify the regulation of P2 AR 
desensitization. Ubc9-sequestered PDE4D5, however, is subject to SUMO 
modification and consequential integration with other binding proteins. As such, my 
data highlight the necessity for better identification and characterization of these 
partnerships.
The design of peptide compounds that can sterically block these particular 
interactions is likely to be extremely useful to detemiine the functional importance of 
the distinct properties of PDE4D5. Furthermore, these peptides-derived compounds 
might be used as PDE4 isoform-specific inhibitors to block unwanted aspects of their 
in vivo functions, therefore achieving a major goal in dmg research to improve the 
therapeutic ratio while reduce the side effects seen in the cuirent available PDE4 
inhibitors.
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Figure 7.1 Schematic of PDE4D5.
N-terminal domain of PDE4D5 contains both p-arrestin binding site and RACK-1 
binding site. The catalytic domain of PDE4D5 possesses a potential SUMO lysine, 
two Ubc9 binding sites, one p-arrestin binding site and two ERK docking sites, 
whereas the extreme C-terminus of PDE4D5 contains a Ubiquitin Interaction Motif. 
All the binding units are indicated in open squares or arrows.
239
References
■'I
Abrahamsen H., Baillie G., Ngai J., Vang T., Nika K., Ruppelt A., Mustelin T., 
Zaccolo M., Houslay M. and Tasken K. (2004) TCR- and CD28-mediated recruitment 
o f phosphodiesterase 4 to lipid rafts potentiates TCR signaling. The Journal o f  
Immunology 173(8), 4847-4858.
Alrmed T., Frey S. and Frey J.U. (2004) Regulation of the phosphodiesterase 
PDE4B3-isotype during long-term potentiation in the area dentata in vivo. 
Neuroscience 124(4), 857-867.
Aizawa T., Wei H., Miano J.M., Abe J., Berk B.C. and Chen Yan. (2003) Role of 
phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular 
smooth muscle cells. Circulation Research 93(5), 406-413.
Antoni F.A. (2000) Molecular diversity o f cAMP signaling. Frontiers in 
Neuroendocrinology 21(2), 103-132.
Ariga M., NeitzertB., Nakae S., Mottin G, Bertrand C., Pruniaux M.P., Jin S.L. and 
Conti M. (2004) Nonredundant function of phosphodiesterases 4D and 4B in 
neutrophil recruitment to the site of inflammation. The Journal o f  Immunology 
173(12), 7531-7538.
Ai-p J., Kirchhof M.G., Baroja M.L., Nazarian S.H., Chau T.A., Strathdee C.A., Ball 
E.H. and Madrenas J. (2003) Regulation of T-cell activation by phosphodiesterase 
4B2 requires its dynamic redistribution during immunological synapse fonnation. 
Molecular and Cellular Biology 23(22), 8042-8057.
Arshavsky V.Y., Lamb T.D. and Pugh, E.N. Jr. (2002) G proteins and 
phototransduction Annual Review o f Physiology 64, 153-187.
Artemyev N.O., Arshavsky V.Y. and Cote R.H. (1998) Photoreceptor 
phosphodiesterase: interaction of inhibitory gamma subunit and cyclic GMP with
240
specific binding sites on catalytic subunits. Methods 14(1), 93-104.
Asirvatham A.L., Galligan S.G., Sehillace R.V., Davey M.P., Vasta V., Beavo J.A. and 
Carr D.W. (2004) A-kinase anchoring proteins interact with phosphodiesterases in T 
lymphocyte cell lines. Journal o f  Immunology 173(8), 4806-4814.
Attramadal H., Aniza J.L., Aoki, C., Dawson T.M., Codina J., Kwatra M.M., Snyder 
S.H., Caron M.G and Lefowitz R.J. (1992) Beta-aiTestin2, a novel member of the 
aiTestin/beta-aiTestin gene family. The Journal o f  Biological Chemistry 267(25), 
17882-17890.
Azzi M., Charest P.G., Angers S., Rousseau G, Kohout T., Bouvier M. and Pineyro G. 
(2003) Beta-airestin-mediated activation of MAPK by inverse agonists reveals 
distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U. S. 
A. 100(20), 11406-11411.
Babol K. and Blasiak J. (2005) Beta3-adrenergic receptor. Postepy Biochemii 51(1), 
80-87.
Baillie G.S. and Houslay M.D. (2005) Arrestin times for compartmentalised cAMP 
signalling and phosphodiesterase-4 enzymes. Current Opinion in Cell Biology 17(2), 
129-134.
Baillie G.S., Huston E., Scotland G, Hodgkin M., Gall I., Peden A.H., MacKenzie C., 
Houslay E.S., Currie R., Pettitt T.R., Walmsley A.R., Wakelam M.J., Warwicker J. and 
Houslay M.D.. (2002) TAPAS-1, a novel microdomain within the unique N-tenninal 
region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+- 
triggered membrane association with selectivity for interaction with phosphatidic acid. 
The Journal o f  Biological Chemistry 277(31), 28298-28309.
Baillie G.S., MacKenzie S.J. and Houslay M.D. (2001) Phorbol 12-myiistate 13- 
acetate triggers the protein kinase A-mediated phosphorylation and activation of the 
PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a 
route involving extracellular signal regulated kinase (ERK). Molecular Pharmacology
241
60(5), 1100-1111.
Baillie G.S., Mackenzie S.J., McPhee I. and Houslay M.D. (2000) Sub-family 
selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the 
activity of PDE4 c AMP-specific phosphodiesterases. British Journal o f  
Pharmacology 131(4), 811-819.
Baillie G.S., Scott J.D. and Houslay M.D. (2005) Compartmentalisation of 
phosphodiesterases and protein kinase A; opposites attract. FEBS Letter 579(15), 
3264-3270.
Baillie G.S., Sood A., McPhee I., Gall I., Peiry S.J., Lefkowitz R.J. and Houslay M.D. 
(2003) beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recmitment regulates 
beta-adrenoceptor switching fi'om Gs to Gi. Proc Natl Acad Sci U. S. A. 100(3), 940- 
945.
Bajpai M., Fiedler S.E., Huang Z., Vijayaraghavan S., Olson G.E., Livera G , Conti M. 
and C a iT  D.W. (2006) AKAP3 selectively binds PDE4A isoforms in bovine 
spermatozoa. Biology o f  Reproduction 74(1), 109-118.
Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E. and Naylor A.M. (1998) 
Effects of sildenafil on the relaxation of human coipus cavernosum tissue in vitro and 
on the activities of cyclic nucleotide phosphodiesterase isozymes. The journal o f  
Dra/ogy 159(6), 2164-2171.
Barber R., Baillie G.S., Bergmann R., Shepherd M.C., Sepper R., Houslay M.D. and 
Heeke GV. (2004) Differential expression of PDE4 cAMP phosphodiesterase 
isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and 
nonsmokers. American Journal o f  Physiology, Lung Cellular and Molecular 
Physiology 287(2), L332-343.
Barnes A.P., Livera G, Huang P., Sun C., O ’Neal W.K., Conti M., Stutts M.J. and 
Milgram S.L. (2005) Phosphodiesterase 4D foims a cAMP diffusion banier at the 
apical membrane of the aiiway epithelium. The Journal o f Biological Chemistry
242
280(9), 7997-8003.
B arnette M .S. and U nderw ood D.C. (2000) N ew  phosphodiesterase inhibitors as 
therapeutics for the treatm ent o f  chionic lung disease. Current Opinion in Pulmonary 
Medicine 6(2), 164-169.
Bayer P., A rndt A. M etzger S., M ahajan R., M elchior P., Jaenicke R. and Becker J. 
(1998) Structure determ ination o f  the small ubiquitin-related m odifier SUM O-1. 
Journal o f Molecular Biology 280(2), 275-286.
Baye w itch M .L., Avidor-Reiss T., Levy R., Pfeuffer T., N evo L, Sim onds W.F. and 
Vogel Z. (1998) Inhibition o f  adenylyl cyclase isoform s V and VI by various 
G betagam m a subunits. The FASEB Journal 12(11), 1019-1025.
Beard M .B., H uston E., Cam pbell L., Gall I., M cPhee I., Yaiivood S., Scotland G. and 
H ouslay M.D. (2002) In addition to the SH3 binding region, m ultip le regions w ithin 
the N -teim inal noncatalytic portion o f  the cA M P-specific phosphodiesterase, 
PD E4A5, contribute to its intracellular targeting. Cellular Signalling 14(5), 453-465.
Beard M .B., O ’Connell J.C ., Bolger G.B. and H ouslay M.D. (1999) The unique N- 
term inal dom ain o f  the cAM P phosphodiesterase PD E4D4 allows for interaction w ith 
specific SH3 domains. FEBS Letters 460(1), 173-177.
B eard M .B., O lsen A.E ., Jones R.E., Erdogan S., Houslay M .D. and Bolger G.B. 
(2000) U C R l and UCR2 dom ains unique to the cA M P-specific phosphodiesterase 
fam ily fonn  a discrete m odule via electrostatic interactions. The Journal o f Biological 
Chemistry 10349-10358.
Beavo J.A. (1995) C yclic nucleotide phosphodiesterases: functional im plications o f 
m ultiple isofoim s. Physiological Reviews 75(4), 725-748.
Beavo J.A. and Brunton L.L. (2002) Cyclic nucleotide research — still expanding after 
h a lf a centuiy. N ature reviews. Molecular cell biology 3(9), 710-8.
243
Bender A.T. and Beavo J.A. (2006) Cyclic nucleotide phosphodiesterases: m olecular 
regulation to clinical use. Pharmacological Reviews 58(3), 488-520.
B ennan D.M . and Gilm an A.G. (1998) M am m alian RGS proteins: barbarians at the 
gate. The Journal o f Biological Chemistry 273(3), 1269-1272.
Bernier-V illam or V , Sam pson D.A., M atunis M .J. and Lim a C.D. (2002) Stm ctural 
basis for E2-m ediated SUM O conjugation revealed by  a com plex betw een ubiquitin- 
conjugating enzym e U bc9 and R anG A P l. Cell 108(3), 345-356.
Bevan S., Porteous L., Sitzer M. and M arkus H.S. (2005) Phosphodiesterase 4D gene, 
ischem ic stroke, and asym ptom atic carotid atherosclerosis. Stroke 36(5), 949-953.
I
Bohren K.M ., N adkam i V., Song J.H ., G abbay K.H. and O w erbach D. (2004) A 
M 55V  polym orphism  in a novel SUM O gene (SUM O -4) differentially activates heat 
shock transcription factors and is associated w ith susceptibility to type I diabetes 
m ellitus. The Journal o f Biological Chemistry 279(26), 27233-27238.
Bolger G , M ichaeli T., M artins T., St. John T., Steiner B,, Rodgers L., Riggs M ., 
W igler M and Ferguson K. (1993) A fam ily o f  hum an phosphodiesterases hom ologous 
to the dunce learning and m em ory gene product o f  D rosophila m elanogaster are 
potential targets for antidepressant drugs. Molecular and Cellular Biology 13(10), 
6558-6571.
Bolger G.B., M cCahill A., H uston E., Cheung Y.F., M cSorley T., Baillie G S. and 
H ouslay M .D. (2003) The unique am ino-term inal region o f  the PD E4D5 cAM P 
phosphodiesterase iso fonn  confers preferential interaction w ith beta-arrestins. The 
Journal o f Biological Chemistry 278(49), 49230-49238.
Bolger G.B., M cCahill A., Yarwood S.J., Steele M .R., Wai'wicker J. and H ouslay M.D. 
(2002) D elineation o f  R A ID l, the R A C K l interaction dom ain located w ithin the 
unique N -term inal region o f  the cA M P-specific phosphodiesterase, PDE4D5. BMC 
Biochemistry 3, 24.
244
B um ouf C. and Pruniaux M.P. (2002) R ecent advances in PD E4 inliibitors as 
im m unoregulators and anti-inflam m atory drugs. Current Pharmaceutical Design 
8(14), 1255-1296.
B um s P., R odger I.W. and Pyne N.J. (1992) The catalytic subunit o f  protein kinase A 
triggers activation o f  the type V cyclic G M P-specific phosphodiesterase from  guinea- 
pig lung. Biochemical Journal 283(Pt 2), 487-91.
245
4B olger G.B., Peden A.H ., Steele M .R., M acK enzie C., M cEwan D.G., W allace D.A.,
H uston E., Baillie G S . and H ouslay M .D. (2003) A ttenuation o f  the activity o f  the 
cA M P-specific phosphodiesterase PDE4A5 by  interaction with the im m unophilin 
XA P2. The Journal o f Biological Chemistry 278(35), 33351-33363.
Bos J.L. (2003) Epac: a new  cAM P target and new  avenues in  cAM P research. Nature 
Reviews. Molecular CellBiology 4(9), 733-738.
■Bos J.L., De Bruyn K., Enserink J., Kuiperij B., Rangarajan S., R ehm ann H., Riedl J., 
de Rooij J., van M ansfeld F. A nd Zw artkm is F. (2003) The role o f  R ap l in integrin- 
m ediated cell adhesion. Biochemical Society Transactions 31(1), 83-86.
B rink C.B., H arvey B.H ., B odenstein J., Venter D.P. and O liver D.W. (2004) Recent 
advances in  drug action and therapeutics: relevance o f  novel concepts in G-protein- 
coupled receptor and signal transduction phaim acology. British Journal of Clinical 
Pharmacology 57(4), 373-387.
Broderick K .E., K ean L., D ow  J.A., Pyne N.J. and Davis S.A. (2004) Ectopic 
expression o f bovine type 5 phosphodiesterase confers a renal phenotype in 
Drosophila. The Journal o f  Biological Chemistry 279(9), 8159-8168.
B m nton L.L. (2003) PDE4: arrested at the border. Sciences STKE 204, PE44.
B iunton L.L., H ayes J.S. and M ayer S.E. (1998) Functional com partm entation o f 
cAM P and protein kinase in  heart. Advances in Cyclic Nucleotide Research 14, 391- 
397.
Busch C.J., Liu H., G raveline A.R. and B loch K.D. (2006) N itric oxide induces 
phosphodiesterase 4B expression in rat pulm onary artery sm ooth m uscle cells. 
American Journal o f Physiology. Lung Cellular and Molecular Physiology 290(4), 
L747-L753.
B uxton I.L., and B iunton L.L. (1983) Com partm ents o f  cyclic AM P and protein 
k inase in m am m alian cardiom yocytes. The Journal of Biological Chemistry 258(17), 
10233-10239.
Cali J.J., Zw aagstra J.C., M ons N ., Cooper D.M . and K iupinski J. (1994) Type VIII 
adenylyl cyclase. A  C a2+/calm odulin-stim ulated enzym e expressed in discrete regions 
o f  rat brain. The Journal o f Biological Chemistry 269(16), 12190-12195.
Card G.L., England B.P., Suzuki Y., Fong D., Pow ell B., Lee B., Luu C., Tabrizizad 
M ., G illette S., Ibrahim  P.N., Artis D .R ., Bollag G , M ilbum  M.V., K im  S.H., 
Schlessinger J. and Zhang K.Y. (2004) S tm ctural basis for the activity o f  dm gs that 
inhibit phosphodiesterases. Structure 12(12), 2233-2247.
Carlisle M ichel J.J., Dodge K.L ., W ong W., M ayer N.C., Langeberg L.K., Scott J.D. 
(2004) PK A -phosphorylation o f PDE4D3 facilitates recruitm ent o f  the m AKAP 
signaling complex. Biochemical Journal 381 (Pt 3), 587-592.
Castro A., Jerez M .J., Gil C. and M artinez A. (2004) Cyclic nucleotide 
phosphodiesterases and their role in im m unom odulatory responses: advances in the 
developm ent o f  specific phosphodiesterase inhibitors. Medical Research Reviews 
25(2), 229-244.
Chang B.Y., Harte R.A. and Cartw right C.A. (2002) R A C K l : a novel substrate for the 
Src protein-tyi'osine kinase. Oncogene 21(50), 7619-7629.
.
Chang L.K., Lee Y.H., Cheng T.S., H ong Y.R., Lu P.J., Wang J.J., W ang W .H., Kuo 
C.W., Li S.S. and Liu S.T. (2004) Post-translational m odification o f  Rta o f  Epstein- 
BaiT vim s by  SU M O -1. The Journal o f Biological Chemistry 279(37), 38803-38812.
246
Chau V., Tobias J.W., Baclim air A., M arriott D., Ecker D.J., G ouda D.K. and 
V arshavsky A. (1989)A niu ltiub iquitin  chain is confined to specific lysine in a targeted 
short-lived protein.et al. Science 243(4898), 1576-1583.
Choi E.J., X ia Z., S tonn D.R. (1992) Stim ulation o f  the type III olfactory adenylyl 
cyclase by  calcium  and calm odulin. Biochemistry 31(28), 6492-6498.
C hristianson J.C. and Green W.N. (2004) Regulation o f  nicotinie receptor expression 
by  the ubiquitin-proteasom e system. The EMBO Journal 23, 4156-4165.
C laing A., Laporte S.A, Caron M.G. and Lefkow itz R.J. (2002) Endocytosis o f  G 
protein-coupled receptors: roles o f  G protein-coupled receptor kinases and beta- 
arrestin proteins. Progress in N eurobiology 66(2), 61-79.
Cong M ., Perry S.J., Lin F.T., Fraser I.D., Flu L.A., Chen W., Pitcher J.A., Seott J.D. 
and Lefkow itz R.J. (2001) Regulation o f  m em brane targeting o f  the G protein-coupled 
receptor kinase 2 by  protein kinase A and its anchoring protein AKAP79. The Journal 
of Biological Chemistry 216{\'S), 15192-15199.
Conti M., R ichter W., M ehats C., L ivera G , Park J.Y. and Jin C. (2003) Cyclic AM P- 
specific PD E4 phosphodiesterases as critical com ponents o f  cyclic AM P signaling. 
The Journal o f Biological Chemistry 278(8), 5493-5496.
Cooper D.M . (2003) Regulation and organization o f adenylyl cyclases and eAMP. 
Biochemical Journal 375(Pt 3), 517-529.
Cooper D.M . and Crossthw aite A.J. (2006) H igher-order organization and regulation 
o f  adenylyl cyclases. Trends in Pharmacological Sciences 27(8), 426-31.
Cooper D.M ., Schell M .J., T hom  P. and Irvine R.F. (1998) R egulation o f  adenylyl 
cyclase by  m em brane potential. The Journal o f Biological Chemistry 273(42), 27703- 
27707.
Corbin J.D. and Francis S.H. (1999) Cyclic GM P phosphodiesterase-5: target o f
247
sildenafil. The Journal o f Biological Chemistry 214(20), 13729-13732.
Cote R.H. (2004) Characteristics o f photoreceptor PDE (PD E 6 ): sim ilarities and 
differences to PDE5. International Journal of Impotence Research 16 Suppl 1 :S28~33.
Crook T., Ludw ig R.L., M arston N.J., W illkom m  D, and Vous den K.H. (1996) 
Sensitivity o f  p53 lysine m utants to ubiquitin-directed degi'adation targeted by  hum an 
papillom avirus E 6 . Vwrogoly 217(1), 285-292.
D ’Sa C., Tolbert LM ., Conti M. and D um an R.S. (2002) Regulation o f  cA M P-specific 
phosphodiesterases type 4B and 4D (PDE4) splice variants b y  cAM P signaling in 
prim ary cortical neurons. Journal o f Neurochemistry 81(4), 745-757.
D aaka Y., Luttrell L.M ., Lefkow itz R.J. (1997) Sw itching o f  the coupling o f the beta2- 
adrenergic receptor to different G proteins by protein  kinase A. Nature 390(6655), 8 8 - 
91.
Dal P iaz V. and G iovannoni M.P. (2000) Phosphodiesterase 4 inhibitors, stiucturally 
unrelated to rolipram , as prom ising agents for the treatm ent o f  astlim a and other 
pathologies. European Journal o f Medicinal Chemistry 35(5), 463-480.
D anchin A. (1993) Phylogeny o f  adenylyl cyclases. Advances in Second Messenger 
and Phosphoprotein Research 27, 109-162.
De Rooij J., Rehm am i H., van Triest M , Cool R.H., W ittinghofer A. and Bos J.L. 
(2000) M echanism  o f  regulation o f  the Epac fam ily o f cA M P-dependent RapGEFs. 
The Journal o f Biological Chemistry. 275(27), 20829-20836.
D egerm an E., Belffage P. and M anganiello V C . (1997) Structure, localization, and 
regulation o f  cG M P-inhibited phosphodiesterase (PDE3). The Journal o f Biological 
Chemistry 272(11), 6823-6826.
Desten'o J.M ., Rodriguez M .S. and H ay R.T, (1998) SUMO-1 m odification o f  
IkappaB alpha inhibits N F-kappaB  activation. Molecular Cell 2(2), 233-239.
248
D everaux Q., U strell V., P ickart C. and Rechsteiner M. (1994) A  26 S protease subunit 
that binds ubiquitin conjugates. The Journal o f Biological Chemistry 269(10), 7059- 
7061.
Di F iore P.P., Polo S. and H oftnann K. (2003) W hen ubiquitin  m eets ubiquitin 
receptors: a signalling connection. Nature Reviews. Molecular Cell Biology 4(6), 491- 
497.
D ing B., Abe J., Wei H., H uang Q., W alsh R.A., M olina C.A., Zhao A., Sadoshim a J., 
B laxall B.C., Berk B.C. and Yan C. (2005) Functional role o f  phosphodiesterase 3 in 
cardiom yocyte apoptosis: im plication in heart failure. Circulation 111(19), 2469-2476.
Diviani D., B aisam y L. and A ppert-C ollin  A, (2006) AKAP-Lbe: A  m olecular scaffold 
for the integration o f  cyclic AM P and Rho transduction pathw ays European Journal 
of CellBiology 85(7), 603-610.
D odge K.L., ICiouangsathiene S., K ap ilo ff M .S., M outon R., H ill E.V., H ouslay M .D., 
Langeberg L.K. and Scott J.D. (2001) m A K A P assem bles a protein kinase A /PD E4 
phosphodiesterase cAM P signaling m odule. The EMBO Journal 20(8), 1921-1930.
Dolimen R.J. (2004) SUM O protein m odification. Biochimica et Biophysica Acta 
1695(1-3), 113-131.
D ryja T.P., Rucinski D.E., Chen S.H. and Berson E.L. (1999) Frequency o f  m utations 
in the gene encoding the alpha subunit o f  rod cG M P-phosphodiesterase in autosom al 
recessive retinitis pigm entosa. Investigative Ophthalmology and Visual Science 40(8), 
1859-1865.
Duda D.M . and Schulm an B.A. (2005) Tag-team  SUM O wrestling. Molecular Cell 
18(6), 612-614.
' Î:)!■ ;•
y.
Dum az N. and M arais R. (2005) Integiating signals betw een cAM P and the 
RAS/RAF/M EK7ERK signalling pathw ays. B ased on the amriversary prize o f  the 
G esellschaft fur B iochem ie und M olekularbiologie Lecture delivered on 5 July  2003
249
at the Special FEBS M eeting in Brussels. The FEBS Journal 272(14), 3491-3504.
D upre D .J., Rola-Pleszczynski M. and Stankova J. (2004) Inverse agonism : m ore than 
reverting constitutively active receptor signaling. Biochemistry and Cell Biology 82(6), 
676-680.
Eardley I. and C artledge J. (2002) Tadalafil (Cialis) for m en w ith erectile dysfunction. 
International Journal of Clinical Practice 56(4), 300-304,
Edm ondson SD, M astracchio A, He J, C hung CC, Foirest M J, H ofsess S, M acIntyre E, 
M etzger J, O ’Connor N, Patel K, et al. (2003) Benzyl vinylogous am ide substituted 
aryldihydropyridazinones and aryldim ethylpyrazolones as potent and selective 
PD E3B inhibitors. Bioorganic and Medicinal Chemistry Letters1 13(22), 3983—3987.
Elorza A., Sam ago S. and M ayor F. Jr. (2000) A gonist-dependent m odulation o f  G 
protein-coupled receptor kinase 2 by m itogen-activated protein kinases. Molecular 
Pharmacology 57(4), 778-783.
Elsasser S., Gali R.R., Schwickart M ., Larsen C.N., Leggett D .S., M üller B., Feng 
M.T., Tubing F., D ittm ar G  A. and Finley D. (2002) Proteasom e subunit R pnl binds 
ubi qui tin-like protein dom ains. Nature Cell Biology 4(9), 725-730.
Engels P., Sullivan M ., M uller T. and Lubbert H. (1995) M olecular cloning and 
functional expression in yeast o f  a hum an cA M P-specific phosphodiesterase subtype 
(PDE IV-C). FEBS Letters 358(3), 305-310.
Fagan K.A ., G raf R .A ., Tolman S., Schaack J. and Cooper D.M . (2000) Regulation o f 
a Ca2+-sensitive adenylyl cyclase in an excitable cell. Role o f  voltage-gated versus 
capacitative Ca2 + entry. The Journal o f  Biological Chemistry 275(51), 40187-40194.
Fan Chung K. (2006) Phosphodiesterase inhibitors in airways disease European 
Journal o f Pharmacology 533(1-3), 110-117.
Fang S., Jensen J.P., Ludw ig R .L., Vousden K.H. and W eissman A.M . (2000) M dm 2 is
250
251
a RIN G  finger-dependent ubiquitin  protein ligase for itse lf and p53. The Journal o f 
Biological Chemistry 21 S{\2), 8945-8951,
Faw cett L., B axendale R., Stacey R , M cG routher C., Harrow I., Soderling S., Hetm an 
J., Beavo J.A. and Phillips S.C. (2000) M olecular cloning and characterization o f  a 
distinct hum an phosphodiesterase gene family: PD E 11 A. Proc. Natl Acad. Sci. U.S.A. 
97(7), 3702-3707.
Ferguson, S. S. (2001) Evolving concepts in  G protein-coupled receptor endocytosis: 
The role in  receptor desensitization and signaling. Pharmacological. Reviews 53(1),
1-24.
Fesenko E.E., K olesnikov S.S. and Lyubarsky A.L. (1985) Induction by  cyclic GM P 
o f  cationic conductance in plasm a m em brane o f  retinal rod outer segm ent. Nature 
313(6000), 310-313.
Fidock M., M iller M. and Lanfear J. (2001) Isolation and differential tissue 
distribution o f  two hum an cDNAs encoding PD E l splice variants. Cell Signalling 
14(1), 53-60.
Fisher D .A ., Sm ith J.F., P illar J.S., St. Denis S.H. and Cheng J.B. (1998) Isolation and 
characterization o f  PD E 8 A, a novel hum an cAM P-specific phosphodiesterase. 
Biochemical and Biophysical Research Communications 246(3), 570-577.
Fisher R .D ., W ang B., A lam  S.L., H igginson D.S., Robinson H., Sundquist W.I. and 
Hill C.P. (2003) Structure and ubiquitin  binding o f  the ubiquitin-interacting m otif. The 
Journal o f Biological Chemistry 278(31), 28976-28984.
Flem ing Y.M., Fram e M .C. and H ouslay M .D. (2004) PD E4-regulated cAM P 
degradation controls the assem bly o f  integrin-dependent actin adhesion stm ctures and 
REF 5 2 cell m igration. Journal o f Cell Science 117(Pt 11), 2377-2388.
Fram e M., Wan K.F., Tate R., Vandenabeele P. and Pyne N.J. (2001) The gam m a 
subunit o f  the rod photoreceptor cGM P phosphodiesterase can m odulate the
proteolysis o f  two cGM P binding cG M P-specific phosphodiesterases (PD E 6  and 
PD E5) by  caspase-3. Cellular Signalling 13(10), 735-741.
Fram e M .J., Tate R., A dam s D.R., M organ K .M ., Houslay M .D., Vandenabeele P. and 
Pyne N.J. (2003) Interaction o f  caspase-3 w ith the cyclic GM P binding cyclic GM P 
specific phosphodiesterase (P D E 5al). European Journal o f Biochemistry 270(5), 962- 
970.
Francis S.H., Colbran J.L., M cA llister-Lucas L.M. and Corbin J.D. (1994) Zinc 
interactions and conserved m otifs o f  the cG M P-binding cGM P-specific 
phosphodiesterase suggest that it is a zinc hydrolase. The Journal o f Biological 
Chemistry 269(36), 22477-22480.
Francis S.H., Turko I.V. and Corbin J.D. (2001) Cyclic nucleotide phosphodiesterases:
■irelating structure and function. Progress in Nucleic Acid Research and Molecular 
Biology 65, 1-52.
Fraser I.D., Cong M ., K im  J., Rollins E.N., D aaka Y , Lefkow itz R.J. and Scott J.D.
(2000) A ssem bly o f  an A kinase-anchoring protein-beta(2)-adrenergic receptor 
com plex facilitates receptor phosphorylation and signaling. Current Biology 10(7),
409-412.
Freedm an N .J., L iggett S.B., D rachm an D.E., Pei G , Caron M. and Lefkowitz R.J. 
(1995) Phosphorylation and desensitization o f  the hum an beta 1-adrenergic receptor. 
Involvem ent o f  G protein-coupled receptor kinases and cA M P-dependent protein 
kinase. The Journal o f Biological Chemistry 270(30), 17953-17961.
Fujishige K., K otera J., M ichibata H., Yuasa K., Takebayashi S., O kum ura K. and 
Omori K. (1999) C loning and characterization o f  a novel hum an phosphodiesterase 
that hydrolyzes both cAM P and cGM P (PDE 10A). The Journal of Biological 
Chemistry 214(26), 18438-18445.
Gal A., Orth U., Baehi' W., Sehw inger E. and Rosenberg T. (1994) H eterozygous 
m issense m utation in the rod cGM P phosphodiesterase beta-subunit gene in autosomal
252
■ï"7
dom inant stationary night blindness. Nature Genetics 7(4), 551.
G ardner C, Robas N , Caw kill D and Fidock M  (2000) Cloning and characterization o f  
the hum an and m ouse PD E7B, a novel cA M P-specific cyclic nucleotide 
phosphodiesterase. Biochemical and Biophysical Research Communications 272(1), 
186-192.
G ardner L.A., Delos Santos N .M ., M atta S .G , W hitt M.A. and Bahouth S.W. (2004) 
Role o f  the cyclic A M P-dependent protein kinase in hom ologous resensitization o f  the 
beta l-ad renerg ic  receptor. The Journal o f Biological Chemistry 279(20), 21135-21143.
Geijsen N., Spaargaren M, Raaijm akers J.A ., Lam mers J.W., K oenderm an L. and 
Coffer P.J. (1999) A ssociation o f  R A C K l and PK Cbeta w ith the com m on beta-chain 
o f  the IL-5/IL-3/G M -CSF receptor. Oncogene 18(36), 5126-5130.
Giem bycz M. (2000) PD E4D -deficient m ice knock the breath out o f  asthm a. Trends in 
Pharmacological Sciences 21(8), 291-292.
Giem bycz M .A. (2000) Phosphodiesterase 4 inhibitors and the treatm ent o f  astluna; 
w here are w e now and w here do w e go from  here? Durgs 59(2), 193-212.
G iem bycz M .A. (2005) Life after PDE4: overcom ing adverse events with dual- 
speeificity phosphodiesterase inhibitors. Current Opinion in Pharmacology 5(3), 238- 
244.
G ilckm an M .H. and Ciechanover A. (2002) T he ubiquitin-proteasom e proteolytic 
pathw ay: destiuction for the sake o f  constm ction. Physiological Reviews 82(2), 373- 
428.
Gill G. (2004) SU M O and ubiquitin in the nucleus: different functions, sim ilar 
m echanism s? Genes and Development 18(17), 2046-2059.
Giorgi M ., M odica A., Pom pili A., Pacitti C. and Gasbarri A. (2004) The induction o f  
cyclic nucleotide phosphodiesterase 4 gene (PDE4D) im pairs m em ory in a w ater
253
m aze task. Behavioural Brain Research 154(1), 99-106.
G im ita L., Shenoy S.K., Sehat B, Vasilcanu R., G im ita A., Lefkow itz R.J. and 
Larsson O. (2005) (beta)-A rrestin  is crucial for ubiquitination and dow n-regulation o f  
the insulin-like grow th factor-1 receptor by acting as adaptor for the M D M 2 E3 ligase. 
The Journal o f Biological Chemistiy 280(26), 24412-24419.
G lickm an M .H. (2000) G etting in and out o f  the proteasom e. Siminars in Cell and 
Developmental Biology 11(3), 149-158.
Goraya T.A. and Cooper D.M . (2005) Ca2+-calm odulin-dependent phosphodiesterase 
(P D E l): current perspectives. Cell Signalling 17(7), 789-797.
G oraya T.A., M asada N., Ciruela A. and C ooper D.M . (2004) Sustained entry o f  Ca2+ 
is required to activate Ca2+-calm odulin-dependent phosphodiesterase lA . The 
Journal o f Biological Chemistry 279(39), 40494-40504.
G retarsdottir S., Thorleifsso G , Reynisdottir S.T. et al. (2003) The gene encoding 
phosphodiesterase 4D  confers risk o f  ischem ic stroke. Nature Genetics 35(2), 131-138.
Gu C. and Cooper D.M . (2000) Ca(24-), Sr(2+), and Ba(2+) identify distinct 
regulatory sites on adenylyl cyclase (AC) types VI and VIII and consolidate the 
apposition o f  capacitative cation entry channels and Ca(2+)-sensitive ACs. The 
Journal o f Biological Chemistry 275(10), 6980-6986.
Guipponi M., Scott H .S., K udoh J., K aw asaki K., Shibuya K., Shintani A., Asakaw a 
S., Chen H ., Lalioti M .D., R ossier C., M inoshim a S., Shim izu N. and Antonarakis S.E. 
(1998) Identification and characterization o f  a novel cyclic nucleotide 
phosphodiesterase gene (PD E9A ) that m aps to 21q22.3: alternative splicing o f  m RN A  
transcripts, genom ic structure and sequence. Human Genetics 103(4), 386-392.
H aglund K., Di Fiore P.P. and D ikic I. (2003) Distinct m onoubiquitin  signals in 
receptor endocytosis. Trends in Biochemical Sciences 28(11), 598-603.
254
H ansen G , Jin S. U m etsu D.T. and Conti M. (2000) A bsence o f  m uscarinic 
cholinergic airw ay responses in m ice deficient in the cyclic nucleotide 
phosphodiesterase PDE4D. Proc. Natl Acad. Sci. U.S.A. 97(12), 6751-6756.
H arding V.B., Jones L.R., Lefkow itz R .J., K och W.J. and Rockm an H.A. (2001) 
Cardiac beta A R K l inhibition prolongs survival and augm ents beta blocker therapy in 
a m ouse m odel o f  severe heart failure. Proc. Natl Acad. Sci. U.S.A. 98(10), 5809- 
5814.
H am dahl L., Jing X .J., Ivarsson R., D egerm an E., A hrén B., M anganiello V.C., 
R enstrom  E. and H olst L.S. (2002) Im portant role o f  phosphodiesterase 3B for the 
stim ulatory action o f cAM P on pancreatic beta-cell exocytosis and release o f  insulin. 
The Journal of Biological Chemistiy 277(40), 37446-37455.
H atakeyam a S. and N akayam a K.I. (2003) U biquitylation as a quality control system  
for intracellular proteins. Journal of Biochemistry (Tokyo) 134(1), 1-8.
H ay R.T. (2005) SUM O: a history o f  m odification. Molecular Cell 18(1), 1-12.
Hayashi, M ., M atsushim a, K., Ohashi, H ., Tsunoda, H., M urase, S., Kaw arada, Y. and 
Tanaka, T. (1998) M olecular cloning and characterization o f  hum an PD E 8 B, a novel 
thyroid-specific isozym e o f  3',5 '-cyelic nucleotide phosphodiesterase. Biochemical 
and Biophysical Research Communications 250(3), 751-756.
Hayes J.S. and Brunton L.L. (1982) Functional com partm ents in cyclic nucleotide 
aetion. Journal o f Cyclic Nucleotide Research 8(1), 1-16.
H eijink I.H., Vellenga E., O ostendorp J., de M onchy J .G , Postm a D.S. and K aufhnan
H.F. (2005) Exposure to TARC alters beta2-adrenergic receptor signaling in hum an 
peripheral blood T lym phocytes. American Journal o f Physiology. Lung Cellular and 
Molecular Physiology 289(1), L53-L59.
Hepler J.R. and Gilm an A .G . (1992) G proteins. Trends in Biochemical Sciences 
17(10), 383-387.
255
H ershko A. and C iechanover A. (1998) T he ubiquitin  system. Annual Review of 
Biochemistry 67, 425-479.
H icke L. (2001) Protein regulation by  m onoubiquitin. Nature Revews, Molecular Cell 
Biology 2(3), 195-201.
Hilgarth R.S., M uiphy L.A., Skaggs H .S., W ilkerson D.C., X ing H. and Sarge K.D. 
(2004) R egulation and function o f  SUM O m odification. The Journal o f  Biochem istry 
279(52), 53899-53902.
H ochstrasser M. (2000) Evolution and function o f  ubiquitin-like protein-conjugation 
system s. Nature Cell Biology 2(8), E l 53-E l 57.
H offm ann R., Baillie G.S., M acK enzie S.J., Yarwood S.J. and H ouslay M  D. (1999) 
The M AP kinase ERK2 inhibits the cyclic A M P-specificphosphodiesterase 
HSPDE4D3 by phosphorylating it at Ser579. The EMBO Journal 18(4), 893-903.
H ofhuann R., W ilkinson I.R., M CC A LLU M  J.F., Engels P. and H ouslay M.D. (1998) 
cA M P-specific phosphodiesterase HSPDE4D 3 m utants w hich m im ic activation and 
changes in rolipram  inhibition triggered by  protein  kinase A phosphorylation o f  Ser- 
54; generation o f  a m olecular m odel. Biochemical Journal 333(Pt 1), 139-149.
Hofiuam i H., Floss S., Stam m inger T. (2000) Covalent m odification o f  the 
transactivator protein IE2-p86 o f  hum an cytom egalovirus by  conjugation to the 
ubiquitin-hom ologous proteins SUMO-1 and hSM T3b. Journal o f Virology 74(6), 
2510-2524.
Hofm ann K. and Falquet L. (2001) A ubiquitin-interacting m o tif  conserved in 
com ponents o f  the proteasom al and lysosom al protein degradation system s. Trends in 
Biochemical Sciences 26(6), 347-350.
H orton Y.M., Sullivan M. and H ouslay M .D. (1995) M olecular cloning o f  a novel 
splice variant o f  hum an type I VA (PDE-IVA) cyclic AM P phosphodiesterase and 
localization o f  the gene to the p l3 .2 -q l2  region o f  hum an chrom osom e 19.
256 I
Biochemical Journal 308(Pt 2), 683-691.
H ou D., Cenciarelli C, Jensen J.P., N guygen H.B. and W eissm an A.M . (1994) 
A ctivation-dependent ubiquitination o f  a T  cell antigen receptor subunit on m ultiple 
intracellular lysines. The Journal o f Biological Chemistry 269{19), 14244-14247.
H ouslay M .D, (2001) PDE4 cA M P-specific phosphodiesterases. Progress in Nucleic 
Acid Research and Molecular Biology 69, 249-315.
H ouslay M .D. (2005) The long and short o f  vascular sm ooth m uscle 
phosphodiesterase-4 as a putative therapeutic target. Molecular Pharmacology 68(3), 
563-567.
H ouslay M .D. and A dam s D.R. (2003) PD E4 cAM P phosphodiesterases: m odular 
enzym es that orchestrate signalling cross-talk, desensitization and 
com partm entalization. Biochemical Journal 370(Pt 1), 1-18.
H ouslay M .D. and Baillie G.S. (2003) The role o f  ERK2 docking and phosphorylation 
o f  PD E4 cAM P phosphodiesterase isoform s in  m ediating cross-talk betw een the 
cAM P and ERK signalling pathw ays. Biochemical Society Transactions 31(Pt 6 )
1186-1190. '
H ouslay M .D. and K olch W. (2000) Cell-type specific integration o f  cross-talk 
betw een extracellular signal-regulated kinase and cAM P signaling. Molecular 
Pharmacology 58(4), 659-68.
H ouslay M .D. and M illigan G. (1997) Tailoring cA M P-signalling responses through 
isoform  multiplicity. Trends in Biochemical Sciences 22(6), 217-224.
H ouslay M .D., Schafer P. and Zhang K.Y. (2005) Keynote review: phosphodiesterase- 
4 as a therapeutic target. Drug Discovery Today 10(22), 1503-1519.
H ouslay M .D., Sullivan V. and Bolger, G.B. (1998) The m ultienzym e PD E4 cyclic 
adenosine m onophosphate-specific phosphodiesterase family: intracellular targeting,
257
' t
regulation, and selective inliibition by com pounds exerting anti-inflam m atory and 
antidepressant actions. Advances in Pharmacology 44, 225-342.
Huai Q., Colicelli J. and Ke H. (2003) T he crystal structure o f  A M P-bound PDE4 
suggests a m echanism  for phosphodiesterase catalysis. Biochemistry 42(45), 13220- 
13226.
Huai Q., W ang H., Sun Y , K im  H.Y., Liu Y. and Ke H. (2003) Three-dim ensional 
structures o f  PD E4D  in com plex w ith rolipram s and im plication on inhibitor 
selectivity. Structure 11(7), 865-873.
H uang C., H epler J.R., Chen L.T., G ilm an A.G., Anderson, R.G. and M um by S.M. 
(1997) O rganization o f  G proteins and adenylyl cyclase at the p lasm a m em brane. 
Molecular Biology o f the Cell 8(12), 2365-2378.
H uang Z., D ucharm e Y , M acdonald D. and Robichaud A. (2001) The next generation 
o f  PD E4 inhibitors. Current Opinion in Chemical Biology. 5(4), 432-438.
H unter T. (1995) Protein kinases and phosphatases: the yin and yang o f  protein 
phosphorylation and signaling. Cell 80(2), 225-236.
Iffland A. (2005) Structural deteim inants for inhibitor specificity and selectivity in 
PD E2A  using the w heat germ  in vitro translation system. Biochemistry 44(23), 8312- 
8325.
Jacoby E., Bouhelal R., G erspacher M ., S eu wen K. (2006) The 7 TM  G-protein- 
coupled receptor target family. ChemMedChem 1(8), 761-782.
Jahns R., Boivin V. and Lohse M .J. (2006) beta(l)-A drenerg ic receptor function, 
autoim m unity, and pathogenesis o f  dilated cardiomyopathy. Trends in Cardiovascular 
Medicine 16(1), 20-24.
Jesen O.N. (2004) M odification-specific proteom ics: characterization o f  post- 
translational m odifications by m ass spectrometry. Current Opinion in Chemical
258
Biology 8( 1), 33-41 .
Jin S.L. and Conti M. (2002) Induction o f  the cyclic nucleotide phosphodiesterase 
PD E4B is essential for LPS-activated T N F-alpha responses. Proc. Natl. Acad. Sci. 
U.S.A. 99(11), 7628-7633.
Jin S.L., Lan L., Zoudilova M. and Conti M, (2005) Specific role o f  
phosphodiesterase 4B in lipopolysaccharide-induced signaling in m ouse m acrophages. 
The Journal o f Immunology 175(3), 1523-1531.
Jin  S.L., R ichard F.J., Kuo W.P., D ’Ercole A.J. and Conti M. (1999) Im paired growth 
and fertility o f  cA M P-specific phosphodiesterase PD E4D -deficient m ice. Proc. Natl. 
Acad. Sci. U.S.A. 96(21), 11998-12003.
Jin  S.L., Sw innen J.V. and Conti M. (1992) Characterization o f  the structure o f a low 
Km , rolipram -sensitive cAM P phosphodiesterase. M apping o f  the catalytic domain. 
The Journal of Biological Chemistry 267(26), 18929-18939.
Joazeiro C.A. and W eissm an A.M . (2000) RIN G  finger proteins: m ediators o f  
ubiquitin  ligase activity. Cell 102(5), 549-552.
Jockers R., Angers S., Silva A .D ., Benaroch P., Strosberg A .D ., Bouvier M. and 
M arullo S. (1999) Beta(2)-adrenergic receptor down-regulation. Evidence for a 
pathw ay that does not require endocytosis. The Journal o f Biological Chemistry 
274(41), 28900-28908.
Johnson E.S. (2004) Protein m odification by  SUM O. Annual Review o f Biochemistry 
73, 355-382.
Johnson J.A , G ray M .O., Chen C.H. and M ochly-Rosen D. (1996) A protein kinase C 
translocation inhibitor as an isozym e-selective antagonist o f  cardiac function. The 
Journal o f Biological Chemistry 271(40), 24962—24966.
Johnson M . (2006) M olecular m echanism s o f  beta(2)-adrenergic receptor function.
259
response, and regulation. The Journal o f Allergy and Clinical Immunology 117(1), 18- 
24.
293(5538), 2204-2205.
K aupp U.B. and Seifert R. (2002) Cyclic nucleotide-gated ion channels. Physiological
260
Jolinston L.A., Erdogan S., Cheung Y.R, Sullivan M., Barber R., Lynch M .J., Baillie 
G.S., Heeke G.V., A dam s D .R ., H uston E. and H ouslay M .D. (2004) Expression, 
intracellular distribution and basis for lack o f  catalytic activity o f  the PDE4A7 
isofonn encoded by  the hum an PD E4A  cA M P-specific phosphodiesterase gene. 
Biochemical Journal 380(Pt 2), 371-384.
Kagey M .H., M elhuish T.A, and W otton D. (2003) The polycom b protein Pc2 is a 
SU M O  E3. Cell 113(1), 127-137.
K akiuchi S. and Yam azaki R. (1970) Calcium  dependent phosphodiesterase activity 
and its activating factor (PAF) from  brain studies on cyclic 3 ',5 '-nucleotide 
phosphodiesterase. Biochemical and Biophysical Research Communications 41(5),
1104-1110.
Kandel E.R. and Schwartz J.H. (1982) M olecular biology o f  learning: m odulation o f  
transm itter release. Science 218(4571), 433-443.
Kanelis V., R otin  D. and Form an-K ay J.D. (2001) Solution structure o f  a N edd4 W W  
dom ain-EN aC peptide com plex. N ature Stm ctural Biology 8(5), 407-412.
K apilo ff M .S., Jackson N. and A irhart N. (2001) m AKAP and the ryanodine receptor 
are part o f  a m ulti-com ponent signaling com plex on the cardiom yocyte nuclear 
envelope. Journal o f Cell Science 114(Pt 17), 3167-3176.
Karin M. (1995) T he regulation o f  AP-1 activity  by  m itogen-activated protein kinases. 
The Journal o f  Biological Chemistry 270(28), 16483-16486.
K arpen J.W. and R ich T.C. (2001) The fourth dim ension in cellular signaling. Science
f:
Reviews 82(3), 769-824.
K iely P.A., Leahy M ., O ’G onnan D. and O ’Connor R. (2005) R A C K l-m ediated  
integration o f adhesion and insulin-like growth factor I (IGF-I) signaling and cell 
m igration are defective in  cells expressing an IGF-I receptor m utated at tyrosines 
1250 and 1251. The Journal o f Biological Chemistry 280(9), 7624-7633.
K iely  P.A., Sant A. and O ’Connor R. R A C K l is an insulin-like growth factor 1 (IGF- 
1) receptor-interacting protein that can regulate IG F -Î -m ediated A kt activation and 
protection h o m  cell death. (2002) The Journal o f Biological Chemistry 277(25), 
22581-22589.
K ing R.W., G lotzer M. and K irscliner M.W. (1996) M utagenic analysis o f  the 
destruction signal o f  m itotic cyclins and structural characterization o f  ubiquitinated 
intennediates. Molecular Biology o f the Cell 7(9), 1343-1357.
K irsh O., Seller J.S., P ichler A ., G ast A ., M üller S., M iska E., M athieu M., Harel- 
B ell an A., K ouzarides T., M elchior F. and D ejean A. (2002) The SUM O E3 ligase 
RanBP2 prom otes m odification o f  the H D A C4 deacetylase. The EMBO Journal 
21(11), 2682-2691.
K itam ura T., K itam ura Y., K uroda S., H ino Y , Ando M ., Kotani K., Konishi H., 
M atsuzaki H., K ikkaw a U., O gaw a W. and Kasuga M. (1999) Insulin-induced 
phosphorylation and activation o f  cyclic nucleotide phosphodiesterase 3B by the 
serine-threonine kinase Akt. Molecular and Cellular Biology 19(9), 6286-6296.
K lapisz E., Sorokina I., Lem eer S., Pijnenburg M ., Verkleij A.J. and van Bergen en 
H enegouw en P.M. (2002) A  u b iq u itin - in te ra c tin g  m o tif  (U IM ) is e ssen tia l fo r 
E ps 15 an d  E p s l5 R  u b iq u itin a tio n . The Journal o f Biological Chemistry 277(34), 
30746-30753.
K lauck K .M ., Faux M .C., Labudda K., Langeberg L.K., Jaken S. and Scott J.D. (1996) 
C oordination o f  three signaling enzym es by  A K A P79, a m am m alian scaffold protein.
261
Science 271(5255), 1589-1592.
K lem ke M., Pasolli H. A., K ehlenbach R.H., O ffem ianns S., Schultz G. and Huttner 
W.B. (2000) Characterization o f  the extra-large G protein alpha-subunit XLalphas. II. 
Signal transduction properties. The Journal o f  Biological C hem istry 275(43), 33633- 
33640.
Kobayashi, T., G am anum a, M ., Sakaki, T., Yam ashita, Y , Yuasa, K., Kotera, J. and 
Om ori, K. (2003) M olecular com parison o f  rat cyclic nucleotide phosphodiesterase 8  
fam ily: unique expression o f  PD E 8 B in rat brain. Gene 319, 21-31.
Koegl M ., H oppe T., Schlenker S., U lrich H.D., M ayer T.U. and Jentsch S. (1999) 
novel ubiquitination factor, E4, is involved in  m ultiubiquitin chain assembly. Cell 
96(5), 635-44.
Kohout T.A. and Lefkow itz R.J. (2003) R egulation o f  G protein-coupled receptor 
kinases and arrestins during receptor desensitization. Molecular Pharmacology 63(1), 
9-18.
K otaja N ., Kaiwonen U., Jamie O.A. and Palvim o J.J. (2002) PIAS proteins m odulate 
transcription factors by  functioning as SUMO-1 ligases. Molecular and Cellular 
Biology 22(14), 5222-5234.
K ozasa T. (2004) The structure o f  G R K 2-G  beta gam m a complex: intim ate 
association o f  G -protein signaling m odules. Trends in Pharmacological Sciences 
25(2), 61-63.
K ram er A. and Schneider-M ergener J. (1998) Synthesis and screening o f  peptide 
libraries on continuous cellulose m em brane supports. M ethods in M olecular B iology 
87, 25-39.
Krasel C., D am m eier S., W instel R., Brockm ann J., M ischak H. and Lohse M.J. (2001) 
Phosphorylation o f  GRK2 by protein kinase C abolishes its inhibition by  calm odulin. 
The Journal o f Biological Chemistry 276(3), 1911-1915.
262
Krupinski J., Coussen R , Bakalyar H .A ., Tang W .J., Feinstein R G , Orth K,, Slaughter 
C., Reed R.R. and G ilm an A.G. (1989) Adenylyl cyclase am ino acid sequence: 
possible channel- or transporter-like structure. Science 244(4912), 1558-1564.
K ulkam i S.K. and Patil C.S. (2004) Phosphodiesterase 5 enzym e and its inhibitors: 
update on pharm acological and therapeutical aspects. Methods and findings in 
Experimental and Clinical Pharmacology 26(10), 789-799.
K um ar K.G., K rolew ski J.J, and Fuchs S.Y. (2004) Phosphorylation and specific 
ubiquitin acceptor sites are required for ubiquitination and degradation o f  the IFN A R l 
subunit o f  type I interferon receptor. The Journal o f Biological Chemistry 279(45), 
46614-46620.
Lam Y.A., Lawson T.G., Velayutham  M ., Zw eier J.L. and Pickart C.M . (2002) A 
proteasom al ATP as e subunit recognizes the polyubiquitin degradation signal. Nature 
416(6882), 763-767.
Lam  Y.A., Xu W., D em artino G.N. and Cohen R.E. (1997) Editing o f  ubiquitin 
conjugates by  an isopeptidase in the 26S proteasom e. Nature 385(6618), 737-740.
Lam ba S. and A braham  W.T. (2000) A lterations in  adrenergic receptor signaling in 
heart failure. Heart Failure Reviews 5(1), 7-16.
Laporte, S. A., Oakley, R. H., Holt, J. A., Barak, L. S. and Caron, M. G. (2000). The 
interaction o f  beta-an 'estin w ith the AP-2 adaptor is required for the clustering o f  beta
2-adrenergic receptor into clathrin-coated pits, The Journal o f Biological Chemistry 
275(30), 2312 0 -2 3 1 2 6 .
Law ler O.A., M iggin S.M. and K insella B.T. (2001) Protein kinase A -m ediated 
phosphorylation o f  serine 357 o f  the m ouse prostacyclin receptor regulates its 
coupling to G(s)-, to G(i)-, and to G (q)-coupled effector signaling. The Journal of 
Biological Chemistry 216(36), 33596-33607.
Layfield R., Cavey J.R. and Low e J. (2003) Role o f  ubiquitin-m ediated proteolysis in
263
the pathogenesis o f  neurodegenerative disorders. A geing R esearch Review s 2(4), 343- 
356.
Le Jeune I.R., Shepherd M ., Van H eeke G , H ouslay M .D. and Hall I.P. (2002) Cyclic 
A M P-dependent transcriptional up-regulation o f  phosphodiesterase 4D5 in hum an 
airw ay sm ooth m uscle cells. Identification and characterization o f  a novel PDE4D5 
promoter. The Journal o f Biological Chemistry 211(39), 35980-35989.
Lee M .E., M arkow itz J., Lee J.O. and Lee H. (2002) Crystal structure o f  
phosphodiesterase 4D and inhibitor com plex. FEBSLetters 530(1-3), 53-58.
Lee R., W olda S., M oon E., Esselstyn J., Hertel C. and Lem er A. (2002) PD E7A  is 
expressed in hum an B-lym phocytes and is up-regulated by  elevation o f  intracellular 
cAMP. Cell Signalling 14(3), 277-284.
Lefkow itz R.J. and Shenoy S.K. (2005) Transduction o f  receptor signals by  beta- 
arrestins. Science 308(5721), 512-517.
Lefkow itz R.J. and W halen E.J. (2004) beta-arrestins: traffic cops o f cell signaling. 
Current Opinion in Cell Biology 16(2), 162-168.
Lefkow itz R .J., Pierce K.L. and Luttrell L.M. (2002) D ancing w ith different partners: 
protein kinase a phosphorylation o f  seven m em brane-spaim ing receptors regulates 
their G protein-coupling specificity. Molecular Pharmacology 62(5), 971-974.
Lefkow itz R .J., Rockm an H.A. and K och W.J. (2000) Catecholam ines, cardiac beta- 
adrenergic receptors, and heart failure. Circulation 101(14), 1634-1637.
Lehnart S.E., W ehrens X.H., Reiken S., W arner S., Belevych A .E., Haiwey R.D., 
R ichter W., Jin S.L., Conti M. and M arks A.R. (2005) Phosphodiesterase 4D 
deficiency in the ryanodine-receptor com plex prom otes heart failure and airhythm ias. 
Cell 123(1), 25-35.
Leroy M .J., D egem ian E., Taira M., M urata T., W ang L.H., M ovsesian M .A., M eacci
264
E. and M anganiello V.C. (1996) C haracterization o f  two recom binant PDE3 (cGM P- 
inhibited cyclic nucleotide phosphodiesterase) isoform s, R cG IP l and HcGIP2, 
expressed in NIH  3006 m urine fibroblasts and Sf9 insect cells. Biochemistry 35(31), 
10194-10202.
Li S.J. and H ochstrasser M. (1999) A  new protease required for cell-cycle progi'ession 
in yeast. Nature 398(6724), 246-251.
Lim J., Pahlke G. and Conti M. (1999) A ctivation o f  the cA M P-specific 
phosphodiesterase PDE4D3 by  phosphorylation. Identification and function o f  an 
inliibitory dom ain. The Journal o f Biological Chemistry 274(28), 19677-19685.
Lin P., W ang H. and M albon C.C. (2000) G ravin-m ediated fonnation o f  signaling 
com plexes in beta 2 -adrenergic receptor desensitization and resensitization. The 
Journal o f Biological Chemistry 275(25), 19025-19034.
Lin H .K ., W ang L., H u Y.C., A ltuw aijri S. and Chang C. (2002) Phosphorylation- 
dependent ubiquitylation and degradation o f  androgen receptor by  A kt require M dm2 
E3 ligase. The EMBO Journal 21(15), 4037-4048.
Lin X., L iang M., Liang Y.Y., B m nicardi F.C. and Feng X.H. (2003) SU M 0~1/U bc9 
prom otes nuclear accum ulation and m etabolic stability o f  tum or suppressor Smad4. 
The Journal o f  Biological Chem istry 278(33), 31043-31048.
L ipw orth B.J. (2005) Phosphodiesterase-4 inhibitors for asthm a and chronic 
obstructive pulm onary disease. Lancet 365(9454), 167-175.
Liu H. and M aurice D.H. (1999) Phosphorylation-m ediated activation and 
translocation o f  the cyclic A M P-specific phosphodiesterase PDE4D3 by  cyclic AM P- 
dependent protein kinase and m itogen-activated protein kinases. A potential 
m echanism  allow ing for the coordinated regulation o f  PDE4D activity and targeting. 
The Journal o f Biological Chemistry 274(15), 10557-10565.
Lochhead A., N ekrasova E., A rshavsky V.Y. and Pyne N.J. (1997) The regulation o f
265
■TA
Luttrell L.M. (2006) Transm em brane signaling by  G protein-coupled receptors. 
Methods in Molecular Biology 332, 3-49.
266
the cG M P-binding cGM P phosphodiesterase by  proteins that are im m unologically 
related to gam m a subunit o f  the photoreceptor cGM P phosphodiesterase. The Journal 
o f Biological Chemistry 211(29), 18397-403.
Lodow ski D.T., Pitcher J.A., Capel W .D., Lefkow itz R.J. and Tesm er J.J. (2003) 
K eeping G proteins at bay: a com plex betw een G protein-coupled receptor kinase 2 
and Gbetagam m a. Science 300(5623), 1256-1262.
Luo X., Zeng W., X u X., Popov S., D avignon L, W ilkie T.M ., M um by S.M. and 
M uallem  S. (1999) A lternate coupling o f  receptors to Gs and Gi in pancreatic and 
subm andibular gland cells. The Journal o f Biological Chemistry 274(25), 17684- 
17690.
Luttrell L.M. and Lefkow itz R.J. (2002) The role o f  beta-arrestins in the term ination 
and transduction o f  G -protein-coupled receptor signals. Journal o f Cell Science 115(Pt 
3), 455-465.
Lynch M .J., Baillie G.S., M oham ed A., Li X., M aisonneuve C., K lussmam r E., Heeke 
V. G. and H ouslay M .D. (2005) RN A  silencing identifies PD E4D 5 as the functionally 
relevant cAM P phosphodiesterase interacting w ith beta arrestin to control the protein 
kinase A /A K A P79-m ediated sw itching o f  the beta 2 -adrenergic receptor to activation 
o f  ER K  in H EK 293B2 cells. The Journal o f  Biological Chemistry 280(39), 33178- 
33189.
M acK enzie S.J., Baillie G S ., M cPhee 1., B olger G B . and H ouslay M .D. (2000) ERK2 
m itogen-activated protein kinase binding, phosphorylation, and regulation o f  the 
PD E4D  cA M P-specific phosphodiesterases. The involvem ent o f  C O O H -tenninal 
docking sites and N H 2-tenninal U C R  regions. The Journal of Biological Chemistry 
275(22), 16609-16617.
M acK enzie S.J., Baillie G S ., M cPhee I., M acK enzie C., Seam ons R., M cSoiiey  T.,
ii..'
ïi-
Î'
a
M ill en J., Beard M .B., H eeke V.G and H ouslay M .D. (2002) Long PDE4 cAM P 
specific phosphodiesterases are activated by protein kinase A -m ediated 
phosphorylation o f  a single serine residue in U pstream  Conserved Region 1 (U C R l). 
British Journal o f Pharmacology 136(3), 421-433.
M acK enzie S.J., Yarwood S.J., Peden A.H., Bolger G.B., Vernon R.G. and H ouslay 
M .D. (1998) Stim ulation o f  p70S6 kinase v ia a growth hoim one-controlled 
phosphatidylinositol 3-kinase pathw ay leads to the activation o f  a PD E4A cyclic 
A M P-specific phosphodiesterase in  3T3-F442A  preadipocytes. Proc.Natl. Acad. Sci. 
U.S.A. 95(7), 3549-3554.
M albon C.C., Tao J. and W ang H.Y. (2004) A K A Ps (A-kinase anchoring proteins) and 
m olecules that com pose their G -protein-coupled receptor signalling complexes. 
Biochemical Journal 319(?i 1), 1-9.
M anganiello V.C., Taira M ., D egerm an E. and B elhage P. (1995) Type III cGM P- 
inhibited cyclic nucleotide phosphodiesterases (PDE3 gene fam ily). Cell Signalling 
7(5), 445-455.
M anza L.L., Codreanu S .G , Stam er S.L., Sm ith D.L., W ells K .S., Roberts R.L., 
Liebler D C. (2004) G lobal shifts in protein sum oylation in  response to electrophile 
and oxidative stress. Chemical Research in Toxicology 17(12), 1706-1715.
M archai C., H aguenauer-Tsapis R. and U rban-G rim al D. (2000) Casein kinase I- 
dependent phosphorylation w ithin a PEST sequence and ubiquitination at nearby 
lysines signal endocytosis o f  yeast uracil perm ease. The Journal o f Biological 
Chemistry 275(31), 23608-23614.
M arinissen M .J. and G utkind J.S. (2001) G -protein-coupled receptors and signaling 
netw orks: em erging paradigm s. Trends in Pharmacological Sciences 22(7), 368-376.
M artin N.P., Lefkow itz R.J. and Shenoy S.K. (2003) Regulation o f  V2 vasopressin 
receptor degradation by  agonist-prom oted ubiquitination. The Journal o f Biological 
Chemistry 278(46), 45954-45959.
267
M artin N.P., W halen E.J., Zam ah M .A., P ierce K.L. and Lefkow itz R J .  (2004) PKA- 
m ediated phosphorylation o f  the beta  1-adrenergic receptor prom otes Gs/Gi switching. 
Cell Signalling 16(12), 1397-1403.
M artinez S.E., Wu A.Y., Glavas N .A ., Tang X.B., Turley S., Hoi W .G  and Beavo J.A. 
(2002) The two GAP dom ains in phosphodiesterase 2A have distinct roles in 
dim erization and in  cGM P binding. Proc. Natl. Acad. Sci. U.S.A. 99(20), 13260-13265.
M arx S.O., R eiken S., H isam atsu Y., Jayaram an T., B urklioff D., R osem blit N. and 
M arks A.R. (2000) PK A  phosphorylation dissociates FK BP12.6 from the calcium  
release channel (ryanodine receptor): defective regulation in failing hearts. Cell 
101(4), 365-376.
M asciarelli S., H om er K., Liu C., Park S.H., H inckley M., H ockm an S., Nedachi T., 
Jin C., Conti M. and M anganiello V. (2004) Cyclic nucleotide phosphodiesterase 3A- 
deficient m ice as a  m odel o f  fem ale infertility. The Journal o f Clinical Investigation 
114(2), 196-205.
M astrandrea L.D., You J., N iles E.G. and Pickart C.M. (1999) E2/E3-m ediated 
assem bly o f  lysine 29-linked polyubiquitin  chains. The Journal o f Biological 
Chemistry 274(38), 27299-27306.
M atunis M .J. and Pickart C.M . (2005) B eginning at the end w ith SUMO. Nature 
Structural and Molecular Biology 12(7), 565-566.
M atunis M .J., Coutavas E. and Blobel G, (1996) A novel ubiquitin-like m odification 
m odulates the partitioning o f  the R an-G TPase-activating protein R anG A Pl betw een 
the cytosol and the nuclear pore complex. The Journal o f Cell Biology 135(6Pt 1), 
1457-1470.
M atunis M .J., W u J. and Blobel G. (1998) SUMO-1 m odification and its role in 
targeting the Ran G TPase-activating protein, R anG A P l, to the nuclear pore complex. 
The Journal o f Cell Biology 140(3), 499-509.
268
M audsley S., M artin B. and Luttrell L.M . (2005) The origins o f  diversity and 
specificity in g protein-coupled receptor signaling. The Journal o f Pharmacological 
and Experimental Therapeutics 314(2), 485-494.
M aurice D .H ., Palm er D ., T illey D .G , D unkerley H.A., N etherton S.J., Raym ond D R., 
E lbatam y H.S. and Jim m o S.L. (2003) Cyclic nucleotide phosphodiesterase activity, 
expression, and targeting in cells o f  the cardiovascular system . Molecular 
Pharmacology 64(3), 533-546.
M cCahill A., M cSorley T., Huston E., Hill E.V., Lynch M .J., Gall I., K eryer G , 
Lygren B., Tasken K., H eeke V.G. and H ouslay M .D. (2005) In resting C O Sl cells a 
dom inant negative approach shows that specific, anchored PD E4 cAM P 
phosphodiesterase isofoim s gate the activation, by  basal cyclic AM P production, o f  
A K A P-tethered protein kinase A type II located in the centrosom al region. Cell 
Signalling 11(9), 1158-1173.
M cCahill A., W arw icker J., Bolger G.B., H ouslay M .D. and Yarwood S.J. (2002) The 
R A C K l scaffold protein: a dynam ic cog in cell response m echanism s. Molecular 
Pharmacology 62(6), 1261-1273.
M cC onnachie G , Langeberg L.K. and Scott J.D. (2006) AKAP signaling complexes: 
getting to the heart o f  the matter. Trends in Molecular Medincine 12(7), 317-323.
M cPhee I., Cochran S. and H ouslay M .D. (2001) The novel long PD E4A 10 cyclic 
AM P phosphodiesterase shows a pattern  o f  expression w ithin brain that is distinct 
from  the long PD E4A5 and short PDE4A1 isoform s. Cell Signalling 13(12), 911-918.
M cPhee I., Pooley L., Lobban M ., B olger G , H ouslay M.D. (1995) Identification, 
characterization and regional d istribution in brain  o f  R PD E 6  (RN PD E4A 5), a novel
269
M cA llister-Lucas L.M ., H aik T.L., Colbran J.L., Som ienburg W .K., Seger D., Turko
I.V., Beavo J.A ., Francis S.H. and Corbin J.D. (1995) An essential aspartic acid at 
each o f  two allosteric cG M P-binding sites o f  a cG M P-specific phosphodiesterase. The 
Journal o f Biological Chemistry 270(51), 30671-30679.
.-i;
I ■ ■! =
J,
4
splice variant o f  the PD E4A  cyclic AM P phosphodiesterase family. Biochemical 
Journal 310(3), 965-974.
M cPhee L, Yarwood S.J., Scotland G., H uston E., Beard M .B., Ross A .H ., Houslay 
E.S. and H ouslay M .D. (1999) A ssociation w ith the SRC fam ily tyi'osyl kinase LYN 
triggers a  conform ational change in the catalytic region o f  hum an cA M P-specific 
phosphodiesterase HSPDE4A 4B. Consequences for rolipram  inhibition. The Journal 
of Biological Chemistry 274(17), 11796-11810.
M ehats C., Jin S.L., W ahlstrom  J., Law E., U m etsu D.T. and Conti M. (2003) PD E4D 
plays a critical role in the control o f  airw ay sm ooth m uscle contraction. The FASEB 
Journal \1 { \3 \  1831-1841.
M elchior F. (2000) SU M O —nonclassical ubiquitin. Annual Review o f  Cell and 
Developmenal Biology 16, 591-626.
M elchior F., Schergaut M ., Pichler A, (2003) SUMO: ligases, isopeptidases and 
nuclear pores. Trends in B iochem ical Sciences 28(11), 612-618.
M eschia J.F., Brott T.G., B row n R.D. Crook R., W orrall B.B., K issela B., B row n W.M., 
R ich S.S., Case L.D., Evans E.W., H ague S., Singleton A., H ardy J. et al. (2005) 
Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischem ic stroke. 
Annals ofNew'ology 58(3), 351-361.
M eyer H .H ., W ang Y. and W arren G. (2002) D irect binding o f  ubiquitin  conjugates by  
the m am m alian p97 adaptor com plexes, p47 and U fdl-N pl4 , The EMBO Journal 
21(21), 5645-5652.
M ichaeli T., B loom  T.J., M artins T., Loughney K., Ferguson K,, Riggs M ., Rodgers L., 
Beavo J.A. and W igler M. (1993) Isolation and characterization o f  a previously 
undetected hum an cA M P phosphodiesterase by com plem entation o f  cAM P 
phosphodiesterase-deficient Saccharom yces cerevisiae. The Journal o f  B iochem istry 
268(17), 12925-12932.
270
M ichel J.J. and Scott J.D. (2002) AK A P m ediated signal transduction. Annual Review 
o f Pharmacology and Toxicology 42, 235-257.
M illar J.K ., P ickard B.S, M ackie S., Jam es R., Christie S., Buchanan S.R., M alloy 
M.P., Chubb J.E., H uston E., Baillie G.S., Thom son P.A., Hill E.V., Brandon N.J., Rain 
J.C., Cam argo L.M ., W hiting P.J., H ouslay M .D ., B lackw ood D.H ., M uir W.J. and 
Porteous D.J. (2005) D ISC I and PD E4B are interacting genetic factors in 
schizophrenia that regulate cAM P signaling. Science 310(5751), 1187-1191.
M iller S.L., M alotky E. and O ’Bryan J.P. (2004) Analysis o f  the role o f  ubiquitin- 
interacting m otifs in  ubiquitin  binding and ubiquitylation. The Journal o f Biological 
Chemistry 219{32), 33528-33537.
M illigan G. (2003) Constitutive activity and inverse agonists o f  G protein-coupled 
receptors: a cuiTent perspective. Molecular Pharmacology 64(6), 1271-1276.
M im naugh E.G. and N eckers L.M. (2005) M easuring ubiquitin conjugation in cells. 
Methods in Molecular Biology 301, 223-241.
M iyauchi Y., Yogosawa S., H onda R., N ishida T. and Yasuda H. (2002) Sum oylation 
o f  M dm 2 by protein inhibitor o f  activated STAT (PIAS) and RanBP2 enzymes. The 
Journal o f Biological Chemistry 277(51), 50131-50136.
M ongillo M ., M cSorley T., Evellin  S., Sood A., L issandron V , Terrin A., Huston E., 
H annaw acker A., Lohse M .J., Pozzan T., H ouslay M.D. and Zaccolo M. (2004) 
Fluorescence resonance energy transfer-based analysis o f  cAM P dynam ics in live 
neonatal rat cardiac m yocytes reveals distinct functions o f  com partm entalized 
phosphodiesterases. Circulation Research 95(1), 67-75.
M oore A.R. and W illoughby D.A. (1995) The role o f cAM P regulation in controlling 
inflam m ation. Clinical and Experimental Immunology 101(3), 387-389.
M ovsesian M .A. (2002) PDE3 cyclic nucleotide phosphodiesterases and the 
com partm entation o f cyclic nucleotide-m ediated signalling in cardiac m yocytes. Basic
271
Research in Cardiology 97 Suppî 1,183-190.
Mueller T.D., Kamionka M. and Falquet L. (2004) Specificity of the interaction 
between ubiquitin-associated domains and ubiquitin. The Journal o f  Biological 
Chemistry 11926-11936.
Muller S., Hoege C., Pyi'owolakis G and Jentsch S. (2001) SUMO, ubiquitin's 
mysterious cousin. Nature Reviews. Molecular Cell Biology 2(3), 202-210.
Muller S., Ledl A. and Sclimidt D. (2004) SUMO: a regulator of gene expression and 
genome integi’ity. Oncogene 23(11), 1998-2008.
MuiTay F., MacLean M.R. and Pyne N.J. (2002) Increased expression of the cGMP- 
inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5). British 
Journal o f  Pharmacology 137(8), 1187-1194.
Nakagawa K. and Yokosawa H. (2002) PIAS3 induces SUMO-1 modification and 
transcriptional repression of IRF-1. FEBSLetters 530(1-3), 204-208.
Nakamura T. and Gold G.H. (1987) A cyclic nucleotide-gated conductance in 
olfactory receptor cilia. Nature 325(6103), 442-444.
Namekata K., Nishimura N. and Kimura H. (2002) Presenilin-binding protein forms 
aggresomes in monkey kidney COS-7 cells. Journal of Neurochemistry 82(4), 819- 
827.
Netherton S.J. and Maurice D.H. (2005) Vascular endothelial cell cyclic nucleotide 
phosphodiesterases and regulated cell migration: implications in angiogenesis. 
Molecular Pharmacology 67(1), 263-272.
Newlon M.G, Roy M., Morikis D., Hausken Z.E., Coghlan V, Scott J.D. and 
Jennings P. A. (1999) The molecular basis for protein kinase A anchoring revealed by 
solution NMR. Nature Structural Biology 6(3), 222-227.
I-
272
Nikolaev V.O., Bunemann M., Hein L., Hannawacker A. and Lohse M.J. (2004)Novel 
single chain cAMP sensors for receptor-induced signal propagation. The Journal o f  
Biological Chemistry 219(36), 37215-37218.
O’Donnell J.M, and Zhang H.T. (2004) Antidepressant effects of inhibitors of cAMP 
phosphodiesterase (PDE4). Trends in Pharmacological Sciences 25(3), 158-163.
Oakley R.H., Laporte S.A., Holt J.A., Caron M.G. and Barak L.S. (2000) Differential 
affinities of visual aiTestin, beta aiTestinl, and beta aiTestin2 for G protein-coupled 
receptors delineate two major classes of receptors. The Journal o f  Biological 
Chemistry> 215(22), 17201-17210.
Obemolte R., Ratzliff J., Baecker P.A., Daniels D.V., Zuppan P., Jamagin K. and 
Shelton E.R. (1997) Multiple splice variants of phosphodiesterase PDE4C cloned 
from human lung and testis. Biochemica et Biophysica Acta 1353(3), 287-297.
Oger S., Mehats C., Barnette M.S., Ferre R, Cabrol D. and Leroy M.J. (2004) Anti­
inflammatory and utero-relaxant effects in human myometrium of new generation 
phosphodiesterase 4 inhibitors. Biology o f Reproduction 70(2), 458-464.
Oldham C.E., Mohney R.P., Miller S.L.H., Hanes R.N. and O’Bryan J.P. (2002) The 
ubiquitin-interacting motifs target the endocytic adaptor protein epsin for 
ubiquitination. Current Biology 12(13), 1112-1116.
Ostrom R.S., Violin J.D., Coleman S. and Insel P.A. (2000) Selective enhancement of 
beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: 
colocalization of receptor and adenylyl cyclase in caveolae o f cardiac myocytes. 
Molecular Pharmacology 57(5), 1075-1079.
Owens R.J., Lumb S., Rees-Milton K., Russell A., Baldock D., Lang V , Crabbe T., 
Ballesteros M. and Peiry M.J. (1997)Molecular cloning and expression of a human 
phosphodiesterase 4C. Cell Signalling 9(8), 575-585.
Papa RR, and Hochstrasser M. (1993) The yeast DOA4 gene encodes a
273
1,!
deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature 
366(6453X 313-319.
Passmore L.A. and Barford D. (2004) Getting into position: the catalytic mechanisms 
of protein ubiquitylation. Biochemical Journal 379(Pt 3), 513-525.
Patrucco E., Notte A., Barberis L., Selvetella G, Maffei A., Brancaccio M., Marengo
S., Russo G, Azzolino O., Rybalkin S.D., Silengo L., Altruda F., Wetzker R., Wymann 
M.P., Lembo G. and Hirsch E. (2004) P13Kgamma modulates the cardiac response to 
chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 
118(3), 375-387.
Penn R.B., Pronin A.N. and Benovic J.L. (2000) Regulation of G protein-coupled 
receptor kinases. Trends in Cardiovascular Medicine 10(2), 81-89.
Perry S.J. and Lefkowitz R.J. (2002) Arresting developments in heptahelical receptor 
signaling and regulation. Trends in Cell Biology 12(3), 130-138.
Peny S.J., Baillie G.S., Kohout T.A., McPhee I., Magiera M.M., Ang K.L., Miller 
W.E., McLean A.J., Conti M., Houslay M.D, and Lefkowitz R.J. (2002) Science 
298(5594), 834-836.
Petrofski J.A. and Koch W.J. (2003) The beta-adrenergic receptor kinase in heart 
failure. Journal o f  Molecular and Cellular Cardiology 35(10), 1167-1174.
Pichler A., Gast A., Seeler J.S., Dejean A. and Melchior F. (2002) The nucleoporin 
RanBP2 has SUMOl E3 ligase activity. Cell 108(1), 109-120.
Pickart C.M. (2000) Ubiquitin in chains. Trends in Biochemical Sciences 25(11), 544- 
548.
Pickart C.M. (2001) Mechanisms underlying ubiquitination. Annual Review o f  
Biochemistry 70, 503-533.
274
Pickart C.M, and Eddins M.J. (2004) Ubiquitin: structures, functions, mechanisms.
Biochimica et Biophysica Acta 1695(1-3), 55-72.
Pierce K.L., Premont R.T. and Lefkowitz R.J. Seven-transmembrane receptors. (2002)
Nature Reviews. Molecular Cell Biology 3(9), 639-650.
Pitcher J.A., Tesmer J.J., Freeman J.L., Capel W.D., Stone W.C. and Lefkowitz R.J.
(1999) Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by 
extracellular signal-regulated kinases. The Journal o f  Biological Chemistry 274(49),
34531-34534.
Polo S., Sigismund S., Faretta M., Guidi M., Capua M.R., Bossi G , Chen H., De 
Camilli R and Di Fiore P.P. (2002) A single motif responsible for ubiquitin recognition 
and monoubiquitination in endocytic proteins. Nature 416(6879), 451-455.
Ponting C.R (2000) Proteins of the endoplasmic-reticulum-associated degradation 
pathway; domain detection and function prediction. Biochemical Journal 351(Pt 2),
527-535.
Pomillos O., Alam S.L., Rich R.L., Myszka D.G, Davis D.R, and Sundquist W.I.
(2002) Structure and functional interactions of the TsglOl UEV domain. The EMBO 
Journal 21(10), 2397-2406.
Pornillos O., Alam S.L., Rich R.L., Myszka D.G, Davis D.R. and Sundquist W.I.
Pronin A.N., Loudon R.R and Benovic J.L. (2002) Characterization of G protein- 
coupled receptor kinases. Methods in Enzymology 343, 547-559.
Qiu Y.H., Chen C.N., Malone T., Richter L., Beckendorf S.K. and Davis R.L. 
(1991)Characterization of the memory gene dunce of Drosophila melanogaster.
Journal o f  Molecular Biology 222(3), 553-565.
Rail T. W. and Sutherland E. W. (1958) Fractionation and characterization of a cyclic 
adenine ribonucleotide formed by tissue particles. The Journal o f  Biological :i
Chemistry 232(2), 1077-1091.
275
Rapacciuolo A., Suvama S., Barki-Harrington L., Luttrell L.M., Cong M., Lefkowitz 
R.J. and Rockman H.A. (2003) Protein kinase A and G protein-coupled receptor 
kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through 
different pathways. The Journal o f  Biological Chemistry 278(37), 35403-35411.
Rehmann H., Prakash B., Wolf E., Rueppel A., De Rooij J., Bos J.L. and Wittinghofer 
A. (2003) Structure and regulation of the cAMP-binding domains o f Epac2. Nature 
Structural Biology 10(1), 26-32.
Reiter E. and Lefkowitz R.J. (2006) GRKs and beta-arrestins: roles in receptor 
silencing, trafficking and signaling. Trends in endocrinology and metabolism 17(4), 
159-65.
Ren D., Navarro B., Perez G, Jackson A.C., Hsu S., Shi Q., Tilly J.L. and Clapham
D.E. (2001) A sperm ion channel required for sperm motility and male fertility. Nature 
413(6856), 603-609.
Rena G, Begg R, Ross A., MacKenzie C., McPhee I., Campbell L., Huston E., 
Sullivan M. and Houslay M.D. (2001) Molecular cloning, genomic positioning, 
promoter identification, and characterization of the novel cyclic amp-specific 
phosphodiesterase PDE4A10. Molecular Pharmacology 59(5), 996-1011.
Reneland R.H., Mali S., Kammerer S., Hoyal C.R., Marnellos G, Wilson S.G, 
Sambrook P.N., Spector T.D., Nelson M.R. and Braun A. (2005) Association between 
a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Medical 
Genetics 6, 9.
Reverter D. and Lima C.D. (2005) Insights into E3 ligase activity revealed by a 
SUMO-RanGAP 1 -Ubc9-Nup358 complex. Nature 435(7042), 687-692.
Rich T.C., Fagan K.A., Tse T.E., Schaack J., Cooper D.M. and Karpen J.W. (2001) A 
uniform extracellular stimulus triggers distinct cAMP signals in different 
compartments of a simple cell. Proc. Natl. Acad. Sci. U.S.A. 98(23), 13049-13054.
276
Richter W and Conti M. (2004) The oligomerization state determines regulatory 
properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. The 
Journal o f  Biological Chemistry 279(29), 30338-30348.
Richter W., Jin S.L. and Conti M. (2005) Splice variants of the cyclic nucleotide 
phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. 
Biochemical Journal 388(Pt 3), 803-811.
Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., MacDonald D., Laliberté F., Liu
S., Huang Z., Conti M. and Chan C.C. (2002) Deletion of phosphodiesterase 4D in 
mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral conelate of 
emesis. The Journal o f Clinical Investigation 110(7), 1045-1052.
Rochais F., Vandecasteele G , Lefebvre F., Lugnier C., Lum H., Mazet J.L., Cooper
D.M. and Fischmeister R, (2004) Negative feedback exerted by cAMP-dependent 
protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in 
intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of 
CNG channels. The Journal o f  Biological Chemistry. 279(50), 52095-52105.
Rockman H.A., Koch W.J. and Lefkowitz R.J. (2002) Seven-transmembrane-spanning 
receptors and heart function. Nature 415(6868), 206-212.
Ron D., Chen C.H., Caldwell J., Jamieson L., Orr E. and Mochly-Rosen D. (1994) 
Cloning of an intracellular receptor for protein kinase C: a homolog of the beta 
subunit of G proteins. Proc. Natl. Acad. Sci. U.S.A. 91(3), 839-843.
Ron D., Jiang Z., Yao L., Vagts A., Diamond I. and Gordon A. (1999) Coordinated 
movement of RACKl with activated betallPKC. The Journal of Biological Chemistry 
274(38), 27039-27046.
Rosman G.J., Martins T.J., Sonnenburg W.K., Beavo J.A., Ferguson K. and Loughney 
K. (1997) Isolation and characterization of human cDNAs encoding a cGMP- 
stimulated 3',5'-cyclic nucleotide phosphodiesterase. Gene 191(1), 89-95.
I l l
Roth A.R and Davis N.G. (2000) Ubiquitination of the PEST-like endocytosis signal 
of the yeast a-factor receptor. The Journal o f  Biological Chemistry 275(11), 8143- 
8153.
Rybalkin S.D., Rybalkina I., Beavo J.A. and Bomfeldt K.E. (2002) Cyclic nucleotide 
phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation.
Circulation Research 90(2), 151-157.
Rybin V.O., Xu X., Lisanti M.P. and Steinberg S.R (2000) Differential targeting of 
beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A 
mechanism to functionally regulate the cAMP signaling pathway. The Journal o f  
Biological Chemistry 275(52), 41447-41457.
■
Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior R and Grosschedl R. (2001)
PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEFl activity by 
sequestration into nuclear bodies. Genes and Development 15(23), 3088-3103.
Saenz de Tejada L., Angulo J., Cuevas P., Fernandez A., Moncada I., Alloua A., Lledo
E., Korschen H.G., Niewohner U., Haning H., Pages E. and Bischoff E. (2001) The 
phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the 
new PDE5 inhibitor vardenafil. International Journal o f  Impotence Research. 13(5),
282-290.
Saitoh H. and Hinchey J. (2000) Functional heterogeneity of small ubiquitin-related 
protein modifiers SUMO-1 versus SUMO-2/3. The Journal o f  Biological Chemistry 
275(9), 6252-6258.
Sampson D.A., Wang M. and Matunis M.J. (2001) The small ubiquitin-like modifier-1 
(SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 
modification. The Journal o f  Biological Chemistry 276(24), 21664-21669.
Sanz M.J., Alvarez A., Piqueras L., Cerda M., Issekutz A.C., Lobb R.R., Coitijo J. and 
Morcillo E.J. (2005) Rolipram inhibits leukocyte-endothelial cell interactions in vivo 
through P- and E-selectin downregulation. British Journal o f  Pharmacology 135(8),
278
1872-1881.
Scapin G , Patel S.B., Chung C., Vamerin, Edmondson S.D., Mastracchio A., Paimee
E.R., Singh S.B., Becker J.W., Van der Ploeg L.H. and Tota M.R. (2004) Crystal 
structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor 
specificity. Biochemistry 43(20), 6091-6100.
Scheffher M., Nuber U. and Huibregtse J.M. (1995) Protein ubiquitination involving 
an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373(6509), 81-83.
Schennuly R.T., Ghofrani H.A., Enke B., Weismman N., Grimminger R, Seeger W., 
Schudt C. And Walmrath D. (1999) Low-dose systemic phosphodiesterase inhibitors 
amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental 
pulmonary hypertension. American Journal o f  Respiratory and Clinical Care 
Medicine 160(5 Pt 1), 1500-1506.
Schmidt D. and Muller S. (2002) Members of the PIAS family act as SUMO ligases 
for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U.S.A. 99(5), 2872- 
2877.
Schnell J.D. and Hicke L, (2003) Non-traditional functions o f ubiquitin and ubiquitin- 
binding proteins. The Journal o f  Biological Chemistry 278(38), 35857-35860.
Scott A.I., Perini A.R, Shering P.A. and Whalley L.J. (1991) European Journal o f  
Clinical Pharmacology 40(2), 127-129.
Scott J.D. (2003) A-kinase-anchoring proteins and cytoskeletal signalling events. 
Biochemical Society Transactions 31(Pt 1), 87-89.
Scott J.D., DelPAcqua M.L., Eraser I.D., Tavalin S.J. and Lester L.B. (2000) 
Coordination of cAMP signaling events through PKA anchoring. Advances in 
Pharmacology , 175-207.
Sebastiani G, Morissette C, Lagace C., Boule M., Ouellette M.J., McLaughlin R.W.,
279
280
Lacombe D., Geiwais F. and Tremblay P. (2005) The cAMP-specific 
phosphodiesterase 4B mediates Abeta-induced microglial activation. Neurobiology o f  
Aging 21(5), 691-701.
Seeler J.S, and Dejean A. (2003) Nuclear and unclear functions of SUMO. Nature 
Reviews. Molecular Cell Biology 4(9), 690-699.
Seibenhener M.L., Babu J.R., Geetha T., Wong H.C., Krislina N.R. and Wooten M.W. 
(2004) Sequestosome l/p62 is a polyubiquitin chain binding protein involved in 
ubiquitin proteasome degi'adation. Molecular and Cellular Biology 24(18), 8055-8068.
Sette C. and Conti M. (1996) Phosphorylation and activation of a cAMP-specific 
phosphodiesterase by the c AMP-dependent protein kinase. Involvement of serine 54 
in the enzyme activation. The Journal o f  Biological Chemistry 271(28), 16526-16534.
Sette C., Vicini E. and Conti M. (1994) The ratPDE3/IVd phosphodiesterase gene 
codes for multiple proteins differentially activated by cAMP-dependent protein kinase. 
The Journal o f  Biological Chemistry 269{2S), 18271-18274.
Seybold J., Newton R., Wright L., Finney P.A., Suttorp N., Barnes P.J., Adcock I.M, 
and Giembycz M.A. (1998) Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 
4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo- 
cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor 
desensitization. The Journal o f Biological Chemistry 273(32), 20575-20588.
Sharma R.K. (1991) Phosphorylation and characterization of bovine heart calmodulin- 
dependent phosphodiesterase. Biochemistry 30(24), 5963-5968.
Sharrocks A.D., Yang S.H. and Galanis A. (2000) Docking domains and substrate- 
specificity detennination for MAP kinases. Trends in Biochemical Sciences 25(9), 
448-453.
Shenoy S.K. and Lefkowitz R.J. (2003) Multifaceted roles of beta-arrestins in the 
regulation of seven-membrane-spanning receptor trafficking and signalling.
Biochemical Journal 375(Pt 3), 503-515.
Shenoy S.K. and Lefkowitz R.J. (2003) Trafficking patterns of beta-arrestin and G 
protein-coupled receptors determined by the kinetics of beta-an'estin deubiquitination. 
The Journal o f  Biological Chemistry 278(16), 14498-14506.
Shenoy S.K., McDonald P.H., Kohout T.A. and Lefkowitz R.J. (2001) Regulation of 
receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta- 
anestin. Science 294(5545), 1307-1313.
Shepherd et al. (2004) Remodelling of the PDE4 cAMP phosphodiesterase isofonn 
profile upon monocyte-macrophage differentiation of human U937 cells. British 
Journal o f  Pharmacology 142(2), 339-351.
Shiina T., Kawasaki A., Nagao T. and Kurose H. (2000) Interaction with beta-anestin 
determines the difference in internalization behavor between betal- and beta2- 
adrenergic receptors. The Journal o f Biological Chemistry 275(37), 29082-29090.
Smith F.D., Langeberg L.K. and Scott J.D. (2006) The where's and when's o f 
kinase anchoring. Trends in Biochemical Sciences 31(6), 316-323.
Smith P.G., Wang R, Wilkinson K.N., Savage K.J., Klein U., Neuberg D.S, Bollag G, 
Shipp M.A. and Aguiar R.C. (2005) The phosphodiesterase PDE4B limits cAMP- 
associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 
105(1), 308-316.
Smith S.J., Cieslinski L.B., Newton R., Donnelly L.E., Fenwick P.S., Nicholson A.G, 
Barnes P.J., Barnette M.S. and Giembycz M.A. (2004) Discovery of BRL 50481 [3- 
(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of 
phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and 
CD8+ T-lymphocytes. Molecular Pharmacology 66(6), 1679-1689.
Snyder P.B., Florio V.A., Ferguson K. and Loughney K. (1999) Isolation, expression
281
and analysis of splice variants of a human Ca2+/calmodulin-stimulated 
phosphodiesterase (PDEl A). Cell Signalling 11(7), 535-544.
Soderling S.H., Bayuga S.J. and Beavo J.A. (1999) Isolation and characterization of a 
dual-substrate phosphodiesterase gene family: PDEIOA, Proc. Natl. Acad. Sci. U.S.A. 
96(12), 7071-7076.
Sondek J., Bohm A., Lambright D.G, Hamm H.E. and Sigler P.B. (1996)Crystal 
structure of a G-protein beta gamma dimer at 2.1 A resolution. Nature 379(6563), 369- 
374.
Souness J.E., Aldous D. and Sargent C. (2000) Immunosuppressive and anti­
inflammatory eflects of cyclic AMP phosphodiesterase (POE) type 4 inhibitors. 
Immunopharmacology 47(2-3), 127-162.
Spenee J., Gali R.R., Dittmar G, Sheiman F., Karin M. and Finley D. (2000) Cell 
cycle-regulated modification o f the ribosome by a variant multiubiquitin chain. Cell 
102(1), 67-76.
Spence J., Sadis S., Haas A.L. and Finley D. (1995) Aubiquitin mutant with speeific 
defects in DNA repair and multiubiquitination. Molecular and Cellular Biology 15(3), 
1265-1273.
Spengler M.L., Kurapatwinski K., Black A.R., Azizkhan-CIifford J. (2002) SUMO-1 
modification of human cytomegalovirus IE1/IE72. Journal o f  Virology 76(6), 2990- 
2996.
Stacey et al. (1998) Molecular cloning and expression of human cGMP-binding 
cGMP-specific phosphodiesterase (PDE5). Biochemical and Biophysical Research 
Communications 247(2), 2492-2454.
Steele M.R., McCahill A., Thompson D.S., MacKenzie C., Isaacs N.W., Houslay M.D. 
and Bolger G.B. (2001) Identification of a surface on the beta-propeller protein 
RACKl that interacts with the cAMP-specific phosphodiesterase PDE4D5. Cell
282
Signalling 13(7), 507-513.
Steiner A.A. and Branco L.G. (2003) Fever and anapyrexia in systemic inflammation: 
intracellular signaling by cyclic nucleotides. Frontiers in Bioscience 8, si 398-1408.
Steme-MaiT R., Gurevich V.V., Goldsmith R, Bodine R.C., Sanders C., Donoso L.A. 
and Benovic J.L. (1993) Polypeptide variants of beta-arrestin and an’estin3. The 
Journal o f  Biological Chemistry 268(21), 15640-15648.
Sturton G. and Fitzgerald M. (2002) Phosphodiesterase 4 inliibitors for the treatment 
of COPD. Chest 121(5 Suppl), 192S-196S.
Sullivan M., Olsen A.S. and Houslay M.D. (1999) Genomic organisation of the 
human cyclic AMP-specific phosphodiesterase PDE4C gene and its cliromosomal 
localisation to 19pl3.1, between RAB3A and JUND. Cell Signalling 11(10), 735-742.
Sullivan M., Rena G, Begg F., Gordon L., Olsen A.S. and Houslay M.D. (1998) 
Identification and characterization of the human homologue of the short PDE4A 
cAMP-speeific phosphodiesterase RDI (PDE4A1) by analysis of the human 
HSPDE4A gene locus located at chromosome 19pl3.2. Biochemical Journal 333(Pt 
3), 693-703.
Sun Y., Cheng Z., Ma L. and Pei G. (2002^ Beta-aiTestin2 is critically involved in 
CXCR4-mediated chemotaxis, and this is mediated by its enlrancement o f p38 MAPK 
activation. The Journal o f  Biological Chemistry 277(51), 49212-49219.
Sunahara R., Dessauer C. and Gilman A. (1996) Complexity and diversity of 
mammalian adenylyl cyclases. Annual Review o f  Pharmacology and Toxicology 36, 
461-480.
Sunahara R.K. and Taussig R. (2002) Isofonns of mammalian adenylyl cyclase: 
multiplicities of signaling. Molecular Interventions 2(3), 168-184.
Sutherland E.W. and Rail T.W. (1960) Fomiation of adenosine-3,5-phosphate (cyclic
283
adenylate) and its relation to the action of several neurohonnones or hormones. Acta 
Endocrinologica 34(Suppl 50), 171-174.
Swinnen J.V., Joseph D.R. and Conti M. (1989) The mRNA encoding a high-affinity 
cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. 
U.S.A. 86(21), 8197-8201.
Swiimen J.V., Tsikalas K.E. and Conti M. (1991) Properties and hormonal regulation 
of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. The 
Journal o f Biological Chemistry 266(27), 18370-18377.
Tachibana H., Naga Prasad S.V., Lefkowitz R.J., Koch W.J. and Rockman H.A. (2005) 
Level of beta-adrenergic receptor kinase 1 inhibition determines degree o f cardiac 
dysfunction after clii'onic pressure overload-induced heart failure. Circulation 111(5), 
591-597.
Tanaka K., Suzuki T., Hattori N. and Mizuno Y. (2004) Ubiquitin, proteasome and 
parkin. Biochimica et Biophysica Acta 1695(1-3), 235-247.
Tang K.M., Jang E.K. and Haslam R.J. (1997) Expression and mutagenesis of the 
catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned fr om human 
platelets. Biochemical Journal 323(Pt 1), 217-224.
Tao J., Wang H.Y. and Malbon C.C. (2003) Protein kinase A regulates AKAP250 
(gravin) scaffold binding to the beta2-adrenergic receptor. The EMBO Journal 22(24), 
6419-6429.
Tasken K. and Aandahl E.M. (2004) Localized effects of cAMP mediated by distinct 
routes of protein kinase A. Physiological Reviews 84(1), 137-167.
Tasken K.A., Collas P., Kemmner W.A., Witczak O., Conti M. and Tasken K. (2001) 
Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the 
centrosomal area. The Journal o f  Biological Chemistry 276(25), 21999-22002.
284
Tatham M.H. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to 
protein substrates by SAE1/SAE2 and Ubc9. The Journal o f  Biological Chemistry 276, 
35368-35374.
Tatham M.H., J affray E., Vaughan O.A., DesteiTO J.M., Botting C.H., Naismith J.H. 
and Hay R.T. (2001) Polymeric chains o f SUMO-2 and SUMO-3 are conjugated to 
protein substrates by SAE1/SAE2 and Ubc9. The Journal o f  Biological Chemistry 
276(38), 35368-35374.
Thornton C., Tang K.C., Phamluong K., Luong K., Vagts A., Nikanjam D., Yaka R. 
and Ron D. (2004) Spatial and temporal regulation of RACKl function andN-methyl- 
D-aspartate receptor activity tlnough WD40 motif-mediated dimerization. The 
Journal o f  Biological Chemistry 279(30), 31357-31364.
Tilley D. and Maurice D.H. (2005) Vascular smooth muscle cell phenotype-dependent 
phosphodiesterase 4D short form expression: role of differential histone acétylation 
on c AMP-regulated function. Molecular Pharmacology 68(3), 596-605.
Torras-Llort M. and Azorin F. (2003) Functional characterization of the human 
phosphodiesterase 7A1 promoter. Biochemical Journal 373(Pt 3), 835-843.
Tran T.M., Friedman J., Qunaibi E., Baameur F., Moore R.H. and Clark R.B. (2004) 
Characterization of agonist stimulation o f cAMP-dependent protein kinase and G 
protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor 
using phosphoserine-speeifrc antibodies. Molecular Pharmacology 65(1), 196-206.
Vandecasteele G, Rochais F., Abi-Gerges A. and Fisclimeister R. (2006) Functional 
localization of cAMP signalling in cardiac myocytes. Biochemical Society 
Transactior^s 34(Pt 4), 484-488.
Vandecasteele G, Verde L, Rucker-Martin C., Donzeau-Gouge P. and Fischmeister R.
(2001) Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial 
myocytes. The Journal o f Physiology 533(Pt 2), 329-340.
285
ï
VanDemark A.P. and Hill C.P. (2002) Structural basis of ubiquitylation. Current 
Opinion in Structural Biology 12(6), 822-830.
Varadan R., Walker O, Pickart C. and Fushnian D. (2002) Structural properties of 
polyubiquitin chains in soXuixon Journal o f  Molecular Biology 324(4), 637-647.
Verde I., Pahlke G, Salanova M., Zhang G, Wang S., Coletti D., Onuffer J., Jin S.L. 
and Conti M. (2001) Myomegalin is a novel protein of the golgi/centrosome that 
interacts with a cyclic nucleotide phosphodiesterase. The Journal o f  Biological 
Chemistry 11189-11198.
Verger A., Perdomo J. and Crossley M. (2003) Modification with SUMO. A role in 
transcriptional regulation. EMBO Reports 4(2), 137-142.
Voges D., Zwikl P. and Baunieister W. (1999) The 26 proteasome: a molecular 
machine designed for controlled proteolysis. Annual reviews in Biochemistry 68,
1015-1068.
von Zastrow M. and Kobilka B.K. (1994) Antagonist-dependent and antagonist- 
independent steps in the mechanism of adrenergic receptor internalization. The 
Journal o f  Biological Chemistry 269(2^)^ 18448—18452.
Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S. and Stork P.J. (1997) cAMP 
activates MAP kinase and Elk-1 thiough a B-Raf- and Rap 1-dependent pathway. Cell 
89(1), 73-82.
Wallace D.A., Johnston L.A., Huston E., MacMaster D., Houslay T.M., Cheung Y.F.,
Campbell L., Milieu J.E., Smith R.A., Gall I., Knowles R.G., Sullivan M. and Houslay 
M.D. (2005) Identification and characterization of PDE4A11, a novel, widely 
expressed long isofonn encoded by the human PDE4A eAMP phosphodiesterase gene.
Molecular Pharmacology 67(6), 1920-1934.
Wan K.F., Sambi B.S., Frame M., Tate R. and Pyne N.J. (2001) The inhibitory gamma 
subunit of the type 6 retinal cyclic guano sine monophosphate phosphodiesterase is a
286
a
novel intermediate regulating p42/p44 mitogen-activated protein kinase signaling in 
human embryonic kidney 293 cells. The Journal o f  Biological Chemistry 276(41), 
37802-37808.
Wang D., Deng C., Bugaj-Gaweda B., Kwan M., Gunwaldsen C., Leonard C., Xin X., 
Hu Y., Unterbeck A. and De Vivo M. (2003) Cloning and characterization of novel 
PDE4D isofonns PDE4D6 and PDE4D7. Cell Signalling 15(9), 883-891.
Wang G , Yang J. and Huibregtse J.M. (1999) Functional domains o f the Rsp5 
ubiquitin-protein ligase. Molecular and Cellular Biology 19(1), 342-352.
Wang H., Lee Y. and Malbon C.C. (2004) PDE6 is an effector for the 
Wnt/Ca2+/cGMP-signalling pathway in development. Biochemical Society 
Transactions 32(Pt 5), 792-796.
Wang P., Wu P., Egan R.W. and Billah M.M. (2003) Identification and characterization 
of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). 
Differential tissue distribution and subcellular loealization of PDE9A variants. Gene 
314, 15-27.
Waterman H., Levkowitz G, Alroy I. and Yarden Y. (1999) Ubiquitin ligase activity 
and tyi'osine phosphorylation underlie suppression of growth factor signaling by c- 
Cbl/Sli-l. Molecular Cell 4(6), 1029-1040.
Wechsler J., Choi Y.H., Krall J., Alimad F., Manganiello VC. and Movsesian M.A.
(2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. 
The Journal o f  Biological Chemistry 277(41), 38072-38078.
Wei H., Ahn S., Shenoy S.K., Kamik S.S., Hunyady L., Luttrell L.M. and Lefkowitz 
R.J. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for 
angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. 
Acad. Sci. U.S.A. 100(19), 10782-10787.
Weissman A.M. (2001) Themes and variations on ubiquitylation. Nature Rexdews.
287
Molecular Cell Biology 2(3), 169-178.
Westphal R.S., Tavalin S.J., Lin J.W., Alto N.M., Fraser I.D., Laiigeberg L.K., Sheng 
M. and Scott J.D. (1999) Regulation of NMDA receptors by an associated 
phosphatase-kinase signaling complex. Science 285(5424), 93-96.
Wilkinson K.D. (2000) Ubiquitination and deubiquitination: targeting o f proteins for 
degradation by the proteasome. Seminars in Cell and Developmental Biology 11(3), 
141-148.
Wilson V.G. and Rangasamy D. (2001) Intracellular targeting of proteins by 
sumoylation. Experimental Cell Research 271(1), 57-65.
Xia Z., Choi E.J., Wang F. and Storm D.R. (1992) The type III calcium/calmodulin- 
sensitive adenylyl cyclase is not specific to olfactory sensory neurons. Neuroscience 
Letters 144(1-2), 169-173.
Xiang Y., Naro F., Zoudilova M., Jin S.L., Conti M. and Kobilka B. (2005) 
Phosphodiesterase 4D is required for beta2 adrenoeeptor subtype-specific signaling in 
cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 102(3), 909-914.
Xiang Y , Rybin V.O., Steinberg S.F., Kobilka B. Xiang Y, Rybin V.O., Steinberg S.F. 
and Kolbilka B. (2002) The Jommal o f  Biological Chemistry 277(37), 34280-34286.
Xu R.X., Hassell A.M., Vanderwall D., Lambert M.FL, Flolmes W.D., Luther M.A., 
Rocque W.J., Milbum M.V., Zhao Y, Ke H. and Nolte R.T. (2000) Atomic stmcture of 
PDE4; insights into phosphodiesterase mechanism and specificity. Science 288(5472), 
1822-1825.
Yaka R., Thornton C., Vagts A.J., Phamluong K., Bonci A. and Ron D. (2002) NMDA 
receptor function is regulated by the inhibitory scaffolding protein, RACKl. Proc. 
Natl. Acad. Sci. U.S.A. 99(8), 5710-5715.
Yan C., Zhao A.Z., Bentley J.K. and Beavo J.A. (1996) The calmodulin-dependent
288
I
phosphodiesterase gene PDEIC encodes several functionally different splice variants 
in a tissue-specific manner. The Journal o f  Biological Chemistry 271, 25699-25706.
Yang Q., Paskind M., Bolger G , Thompson W. J., Repaske D. R., Cutler L. S. and 
Epstein P. M. (1994) A novel cyclic GMP stimulated phosphodiesterase from rat brain. 
Biochemical and Biophysical Research Communications 205(3), 1850-1858.
Yang S,H. and Sharrocks A.D. (2004 SUMO promotes HDAC-mediated 
transcriptional repression. Molecular Cell 13(4), 611-617.
Yang Y, Fang S., Jensen J.P., Weissman A.M. and Ashwell J.D. (2000) Ubiquitin 
protein ligase activity of TAPs and their degradation in proteasomes in response to 
apoptotic stimuli. Science 288(5467), 874-877.
Yarwood S.J., Steele M.R., Scotland G , Houslay M.D. and Bolger GB. (1999) The 
RACKl signaling scaffold protein selectively interacts with the cAMP-specific 
phosphodiesterase PDE4D5 isoform. The Journal o f Biological Chemistry 274(21), 
14909-14917.
Yedovitzky M., Moehly-Rosen D., Johnson J.A., Gray M.O., Ron D., Abramovitch E., 
Cerasi E. and Nesher R. (1997) Translocation inhibitors define specificity of protein 
kinase C isoenzymes in pancreatic beta-cells. The Journal o f  Biological Chemistry 
272(3), 1417-1420.
Young P., Deveraux Q., Beal R.E., Pickart C.M. and Rechsteiner M. (1998) 
Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. 
The Journal o f  Biological Chemistry 273(10), 5461-5467.
Yuasa K., Kotera J., Fujishige K., Michibata H., Sasaki T. and Omori K. (2000) 
Isolation and characterization of two novel phosphodiesterase PDEl 1A variants 
showing unique stmcture and tissue-specific expression. The Journal o f  Biological 
Chemistry 275(40), 31469-31479.
Zaccolo M. and Pozzan T. (2002) Discrete microdomains with high concentration of
289
cAMP in stimulated rat neonatal eardiac myocytes. Science 295(5560), 1711-1715.
Zaccolo M., Magalhaes P. and Pozzan T. (2002) Compaitmentalisation of cAMP and 
Ca(2+) signals. Current Opinion in Cell Biology 14(2), 160-166.
Zhang H.T., Huang Y., Suvarna N.U., Deng C., Crissman A.M., Hopper A.T., De Vivo 
M., Rose G.M. and O’Donnell J.M. (2005) Effects of the novel PDE4 inhibitors 
MEM 1018 and MEM 1091 on memory in the radial-arm maze and inliibitory 
avoidance tests in rats. Psychopharmacology 179(3), 613-619.
■:S,'
Zhang J., Ma Y, Taylor S.S. and Tsien R.Y. (2001) Genetically encoded reporters of 
protein kinase A activity reveal impact of substrate tethering. Proc. Natl. Acad. Sci 
U.S.A. 98(26), 14997-15002.
Zhang K.Y., Card G.L., Suzuki Y , Artis D.R., Fong D., Gillette S., Hsieh D., Neiman 
J., West B.L., Zhang C., Milburn M.V, Kim S.H., Schlessinger J. and Bollag G. (2004) 
A glutamine switch mechanism for nucleotide selectivity by 
phosphodiesterases .Mo/ecw/ar Cell 15(2), 279-286.
290
